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V Abstract 
Ovarian cancer is the deadliest gynaecological cancer, with less than half of 
patients surviving five years from diagnosis. The asymptomatic nature of the early 
disease commonly results in diagnosis at an advanced stage where peritoneal 
metastases are prevalent, and the disease rapidly develops resistance to platinum-
based agents. Innovative treatments are needed to combat this untreatable disease 
that has a poor prognosis.  
Adenoviruses (Ad) are versatile gene therapy vehicles that have been studied for 
six decades. Their wider clinical use has been limited by poor tumour-specificity, pre-
existing immunity, and toxicity-inducing off-target delivery. We have generated an 
Ad5.3D.A20 vector that is re-targeted to an epithelial cancer-specific marker, αvβ6 
integrin, and fully de-targeted from native interactions ‒ αvβ3/5 integrins, coxsackie 
and adenovirus receptor (CAR), and human coagulation factor 10 (FX). Ad5.3D.A20 
selectively transduced αvβ6+ epithelial ovarian cancer (EOC) cells in vitro and clinical 
ovarian ascites-derived EOC cells ex vivo, including in the presence of neutralising 
anti-Ad antibodies. In vivo, Ad5.3D.A20 exhibited significantly reduced off-target 
accumulation and transduction of the liver, spleen and lungs, relative to Ad5. Efficacy 
studies are underway to investigate its oncolytic potential. Furthermore, we explored 
the potential use of alternative serotypes from the rare seroprevalence subgroup D. 
A novel Ad10 vector showed improved resistance from neutralisation and lack of FX 
binding. Chimaeric Ad5 vectors pseudotyped with Ad10, -15, -24, -29, -48 or -53 fiber 
had reduced interactions with CAR, but no binding to CD46.  
Our strategy for translation initially is via intraperitoneal delivery of oncolytic 
vectors, bypassing many of the barriers presented by systemic delivery, but enabling 
transduction of disseminated metastases. These exquisitely tumour-targeted vectors 
may be further modulated to carry therapeutic moieties to complement their direct 
cell-killing activity via the stimulation of anti-cancer immunity. The generated tropism-
modified vectors have significant therapeutic potential for a wide range of immuno-
oncolytic applications. 
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CHAPTER 1. Introduction 
Ovarian cancer is the deadliest gynaecological cancer and fifth leading cause of 
cancer-related death in women, leading to 4500 annual mortalities in the UK alone 
(CRUK, 2012). According to the World Cancer Research Fund (WCRF), 
approximately 240 000 new cases are diagnosed every year worldwide (WCRF, 
2012), with a 5-year survival rate of 46 % (NCI, 2012). Despite advantageous 
progress in the cancer therapy field and introduction of new chemotherapeutic agents, 
the survival rates have seen only minor improvements in the past decades. Current 
chemo- and radiotherapy regimens not only cause major adverse effects, but are also 
ineffective against metastatic tumours that often result in high mortality rates, 
particularly in patients with late diagnosis. One of the major hurdles is combating the 
aggressive, platinum-resistant forms of ovarian cancer that commonly develop in the 
advanced stage of the disease. Oncolytic virus therapy offers an innovative treatment 
strategy for the eradication of the resistant cell populations, and has potential for use 
as adjunct therapy in combination with conventional regimens. Ovarian cancer 
presents an excellent avenue for local therapies as viral vectors can be locally 
administered into the peritoneal cavity.  
Adenoviruses (Ad) were originally isolated from a human adenoid tissue sample in 
1953 (Rowe et al., 1953), and since then they have been extensively studied and 
utilised for clinical cancer applications. Ads are obligate intracellular parasites that can 
infect a wide variety of cell types and tissues in the human body, and generally cause 
mild common cold-like illnesses. Certain viruses such as Ads are inherently lytic, as 
host cell infection leads to cell destruction accompanied with a burst of progeny 
viruses. This further infects the neighbouring cells and amplifies the therapeutic effect. 
Vigorous research into viral gene therapy has provided compelling evidence of the 
oncolytic potential of Ad-based vectors, which infect both dividing and non-dividing 
cells and can be manipulated to incorporate large transgenes (up to 105 % of genomic 
size) (Bett et al., 1993) into their genome without the risk of integration into the host 
genome, and are therefore not considered to be intrinsically oncogenic. Due to the 
generally mild nature of the disease manifestation and long clinical history with 532 
clinical trials conducted up to date (Abedia, 2016), Ads are widely considered to be 
safe delivery vectors for gene therapy applications. The Ad genome is well-
characterised, compact and largely permissive for a plethora of genetic modifications. 
Ad serotype 5 (Ad5) has been the most commonly used delivery vector for 
experimental and clinical purposes, and comprises the majority of gene therapy trials 
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worldwide (clinicaltrials.gov, 2016). The first Ad5-based, oncolytic vector ONYX-015 
was approved for therapeutic use for head and neck cancers in China in 2005 (Ganly 
et al., 2000, Nemunaitis et al., 2001a) but has not been licensed elsewhere. The latest 
trends in oncolytic Ad gene therapy have included Ads with a variety of cancer-
specificities, tumour vaccines, cancer immunotherapies and modulation of immune 
checkpoint control mechanisms [for reviews on oncolytic Ad-based therapies, see 
(Kanerva and Hemminki, 2005, Vähä-Koskela et al., 2007, Choi et al., 2012, Ribas, 
2012, Russell et al., 2012, Uusi-Kerttula et al., 2015a)]. Significant existing limitations 
of viral cancer gene therapies include the low level of cancer cell -specificity due to 
lack of a cancer-specific cell receptor, toxic adverse effects due to off-target 
sequestration, and poor target delivery due to tumour heterogeneity and vector 
inactivation by innate immune responses. Vectors based on common human 
pathogens typically exhibit high seroprevalence rates in the population. Native viral 
infection elicits serotype-specific neutralising antibodies (nAbs) that, upon systemic 
administration of a therapeutic vector, rapidly opsonise and eliminate the virus based 
on highly specific humoral immune recognition. Below, we discuss the strategies for 
Ad vector development and suggests novel approaches for improving therapeutic 
targeting for ovarian cancer applications. 
1.1 Ovarian cancer biology 
Ovarian cancer is challenging to diagnose. Its symptoms are very non-specific, and 
may include pain in the abdomen or pelvis, bloating, changes in digestive functions, 
nausea, feeling of fullness, fluid or lump in the abdomen, fatigue, loss or appetite and 
weight loss (ACS, 2016). Unfortunately, ovarian cancer commonly remains 
asymptomatic ‒ more than 75 % of ovarian cancers are diagnosed in the late 
advanced stages (Salani et al., 2011), which significantly contributes to its poor 
prognosis. The median age at the time of diagnosis is 63 years, and 70 years at the 
time of death (NCI, 2012). Ovarian cancer biology, classification, treatment and 
common features are discussed in the following sections. 
1.1.1 Classification, treatment and survival statistics 
Ovarian cancer progression is classified into four main stages according to the 
location and spread of the tumour, while grading is based on cell morphology (Figure 
1–1). The majority (90 %) of ovarian cancers arise from transformation of the ovarian 
epithelium (Koonings et al., 1989, Holschneider and Berek, 2000) that covers the 
surface of ovaries. This leads to the development of epithelial ovarian cancer (EOC) 
– the most common and deadliest ovarian cancer type (Wefers et al., 2015). It can be 
classified into five types ‒ serous, endometrioid, clear cell, mucinous and 
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undifferentiated / unclassifiable ‒ based on the histology (CRUK, 2012). Germ cell 
ovarian cancer originates from the eggs residing in the ovaries and is extremely rare, 
comprising only 1‒2 % of all ovarian cancers. Borderline ovarian tumours have low 
malignant potential and are responsible for 10 % of ovarian cancers. This type of 
cancer grows slowly and is typically diagnosed early, and therefore is commonly 
treatable with surgery alone. 
 
Figure 1–1. Ovarian cancer classification and grading. Classification scale (I‒IV) is based on 
International Federation of Gynaecological Oncologists (FIGO) system (CRUK, 2012). Ovarian cancer 
grading (GX‒G4) is based on cell morphology (CRUK, 2012, ASCO, 2015). i.p., intraperitoneal. 
 
In healthy tissues, tumour antigen p53 is the guardian of DNA damage and stress, 
and activates DNA repair mechanisms, initiates apoptosis, prevents angiogenesis 
and controls excessive cell proliferation by cell division arrest at G1/S stage of the cell 
cycle [reviewed in (Vogelstein et al., 2000)]. Mutations in p53 can lead to uncontrolled 
cell division and carcinogenesis due to aberrant apoptotic signalling pathways. 
Sequencing revealed an abnormal expression or a complete loss of p53 function, 
determined from six human ovarian carcinoma cell lines (PA-1, Caov-3 and -4, 
OVCAR3, SKOV3, and Kuramochi) (Yaginuma and Westphal, 1992). The analysis 
exposed variable mutations in p53, ranging from six-fold increased expression in PA-
1 cell line, in contrast with complete loss of function in SKOV-3 cell line that had a 
rearrangement of the p53 gene. Caov-3, OVCAR3 and Kuramochi cell lines all had 
point mutations in highly conserved domains, leading to single amino changes and 
undetectable p53 protein expression. High-throughput genomic analyses have shown 
Classification
I) One or both ovaries
II) One or both ovaries 
and spread to pelvis
III) One or both ovaries, spread below pelvis 
& surrounding lymph nodes and/or i.p.
IV) Spread beyond abdomen with 
distant metastases
Grading
GX) Grade cannot be evaluated
GB) Tissue borderline cancerous 
/ low malignant potential
G1) Well-differentiated
G2) Moderately differentiated
G3−G4) Poorly differentiated 
/ undifferentiated
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up to 96 % of high-grade serous ovarian carcinomas (HGS-OC) to have mutations in 
TP53 (Bell et al., 2011, Patch et al., 2015). 
The standard method of care for ovarian cancer is the combination of aggressive 
removal of the tumour by surgery and chemotherapy. Neo-adjuvant chemotherapy 
may be given to patients prior to surgery to reduce the size of the tumour and to 
facilitate its removal. The affected tissue is removed, which often means the removal 
of one or both ovaries, Fallopian tubes and the womb (including the cervix). This is 
followed by adjuvant chemotherapy, except for stage 1a cancers that do not require 
additional treatment. The first-line chemotherapy agents for ovarian cancer are 
commonly platinum-based, including cisplatin, carboplatin and oxaliplatin. These 
drugs are neutral platinum agents whose mechanism of action is based on the 
disruption of cell cycle regulation and the resulting apoptosis (Chen et al., 2013). They 
are often given in combination with taxanes, such as paclitaxel and docetaxel for a 
more pronounced response. Chemotherapy for EOC is given either intravenously 
(i.v.) or intraperitoneally (i.p.) through a catheter, every 3–4 weeks in a total of 3–6 
cycles. There are reports of i.p. delivery of anti-cancer agents being more effective 
but also causing more intolerable adverse effects than i.v. delivery, which causes 
some patients to withdraw early from treatment (ACS, 2016). The reason for 
abdominal discomfort has been linked to the use of phosphate-buffered saline (PBS) 
as a carrier (Hosie et al., 2001), which led to the use of renal dialysis fluids, such as 
4 % icodextrin, that have proven better tolerated with favourable pharmacokinetics 
(Hosie et al., 2003, McArdle et al., 1994). 
Chemotherapy can be used in conjunction with targeted biological treatments that 
cause minimal harm to healthy cells. Commonly used agents include poly (ADP-
ribose) polymerase (PARP-1) inhibitors and an angiogenesis inhibitor bevacizumab, 
a monoclonal antibody (mAb). Patients with advanced EOC who have breast cancer 
1/2 (Brca1/Brca2) mutations may receive olaparib, which is a PARP-1 inhibitor 
designed to inhibit DNA repair mechanisms in cancer cells with defective BRCA-
pathways. Other approaches include hormone treatments such as luteinizing-
hormone-releasing hormone (LHRH) agonists, tamoxifen (anti-oestrogen) and 
aromatase inhibitors. Chemo- and biological therapies may also be combined with 
external beam radiation therapy that resembles diagnostic X-ray. More information on 
the treatment of ovarian cancer can be found on the American Cancer Society website 
(ACS, 2016). In 2010‒2011 the 1-, 5- and 10-year overall survival (OS) from ovarian 
cancer was 73 %, 46 % and 3 %, respectively (CRUK, 2012). Holschneider and 
colleagues determined the stage-dependent survival from ovarian cancer as 93 % for 
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stage I, 70 % for stage II, 37 % for stage III and 25 % for stage IV disease 
(Holschneider and Berek, 2000). The authors also state that 80‒90 % of ovarian 
cancers are diagnosed in women older than 40 years of age, and that 2/3 of the 
diagnosed cases have reached an advanced, metastasised stage. Up to 70 % of 
ovarian cancer-related deaths are caused by advanced stage HGS-OC (Koonings et 
al., 1989, Seidman et al., 2004). Improvement of treatment regimens and attempts for 
better ovarian cancer screening are vital for earlier diagnosis and improved survival 
of these patients. 
1.1.2 Tumour microenvironment (TME), ascites and metastasis 
One of the major hurdles in all cancer therapies is the poor accessibility of the 
tumour by therapeutic agents. This is not only due to physical barrier formed by the 
extremely complex architecture within the bulky tumour mass, but also due to 
acquired drug resistance and uneven angiogenesis within the tumour. Biologically, 
TME forms a highly complex structure consisting of numerous different immune cell 
types, vasculature, fibroblasts, stromal cells, immune infiltrates, cancer-associated 
fibroblasts (CAFs), lymphocytes and the extracellular matrix (ECM), in addition to the 
primary neoplastic cells (Figure 1–2). TME presents three main threats to anti-cancer 
treatment: fibroblast-, immune- and vasculature-mediated resistance [reviewed in 
(Junttila and de Sauvage, 2013)]. Angiogenesis is often unevenly distributed within 
the tumour mass, leaving poorly vascularised areas hypoxic and out of reach of 
systemically-delivered therapeutics. 
Figure 1–2. Tumour microenvironment (TME) in ovarian cancer. Female reproductive system: 1) 
vagina, 2) cervix, 3) ovary, 4) Fallopian tube, 5) womb. DC, dendritic cell; M, macrophage; NK, natural 
killer cell; CAF, cancer-associated fibroblast; TIL, tumour-infiltrating lymphocyte; TAA, tumour-
associated antigen. Figure based on reviews (Junttila and de Sauvage, 2013, Wefers et al., 2015). 
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Ovarian cancer TME is typically immunosuppressive and pro-tumourigenic 
[reviewed in (Zou, 2005, Wefers et al., 2015)], meaning that immune responses are 
effectively dampened down while the environment is tumour-promoting, both in favour 
of uncontrollable tumour growth. It is commonly rich in tumour-infiltrating lymphocytes 
(TILs), CD8+ T-cells, pro-angiogenic factors, such as vascular endothelial growth 
factor (VEGF), and immunosuppressive cytokines, such as IL-10 and TGF-β 
[reviewed in (Jakeman et al., 2015)]. HER/neu, MAGE-A1, folate-binding protein 
(FBP), p53, NY-ESO-1, EpCAM and CA-125 are examples of ovarian cancer-specific 
tumour-associated antigens (TAA) that are expressed during malignant 
transformation and could therefore be used as targets for immunotherapies [reviewed 
in (Wefers et al., 2015, Ren et al., 2016)]. CD44 and CD133 have been described as 
markers of cancer stem cell (CSC) phenotype (Chen et al., 2011b). The role of CSCs 
in chemoresistant ovarian cancer is discussed in a review by Ren and colleagues 
(Ren et al., 2016). 
Ascites is the accumulation of serous or lymphatic fluid in the peritoneal cavity 
(Figure 1–3). Malignant ascites contains tumour cells and high concentrations of 
lactate dehydrogenase enzyme (Runyon et al., 1988), contrary to ascites that occurs 
due to other pathologies, most commonly found in liver diseases. A third of ovarian 
cancer patients have malignant ascites at the time of diagnosis, while the fluid is found 
in nearly all ovarian cancer patients with advanced disease. Ascites characterises the 
chemo-resistant and recurrent disease with a very poor prognosis. Large volumes of 
fluid cause problems with respiratory, gastrointestinal and urinary systems, abdominal 
pain, as well as general discomfort in the patients. Routine drainage (paracentesis) is 
required to temporarily ease the patients’ symptoms (CRUK, 2012). For a 
comprehensive review on the characteristics and biology of malignant ovarian ascites, 
see excellent reviews (Ahmed and Stenvers, 2013, Kipps et al., 2013). Ascites 
contains diverse cell populations that have either originated from the surface 
epithelium of the ovaries by shedding or from the lymphatic system. EOC cells can 
either exist as free-floating single cells or spheroids that can form secondary lesions 
and distant metastases. Other cell types include CAFs, stromal cells, infiltrating 
MΦs/monocytes, myeloid cells, mesenchymal stem cells, T-cells and ECM fragments 
[reviewed in (Ahmed and Stenvers, 2013)].  
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Figure 1–3. Ascites in ovarian cancer. A) Peritoneal membrane (peritoneum) consists of five layers and surrounds all major organs, including the ovaries, in the peritoneal 
cavity. B) Peritoneal membrane consists of mesothelial cells and basement membrane, supported by fibroblasts and collagen fibers residing below the membrane. C) Ascites 
formation and leakage into the peritoneal cavity occurs as a result of increase in oncotic pressure, leaky capillaries and disruptions in the endothelium. MΦ, macrophage. Modified 
from (Kipps et al., 2013).
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Ascites has a tumour-promoting environment that contributes to the inhibition of 
chemotherapy agents, promotes tumour cell motility and growth, and facilitates cell 
spread across the peritoneum. The fluid contains a plethora of inflammatory cytokines 
and chemokines, including angiogenin, angiopoietin, GRO, ICAM-1, IL-6/-6R/-8, 
leptin, MCP-1, MIF, NAP-2, osteoprotegerin (OPG), RANTES, TIMP-2, and urokinase 
plasminogen activating receptor (uPAR). These and multiple other factors may have 
a critical role in facilitating the tumour to evade immunosurveillance and enabling 
unrestricted cancer cell growth. Cancer metastasis is a complex process that involves 
coordinated changes in cancer cell structure, adhesion and motility (Figure 1–4). 
Ovarian cancer presents an appealing target for virotherapies due to the potential for 
direct i.p. vector administration, thus having access to both primary and metastatic 
tumours, as well as other tumour-associated cell types residing in ascites. It is also 
desirable route to circumvent of many of the dose-limiting vector:host interactions that 
are encountered via the i.v. route. Unfortunately however, ascites has a protein 
content similar to serum, including frequently substantial levels of anti-Ad5 nAbs 
(Hemminki et al., 2002), which makes it a highly neutralising environment for Ad5-
based vectors (Blackwell et al., 2000, Stallwood et al., 2000). In a study by Hemminki 
and colleagues, levels of nAbs in ovarian cancer patients were compared in both 
serum and ascites following i.p. delivery of Ad5. Induction of nAb production was rapid 
in both serum and ascites, and nAb titres were not affected by the administered dose. 
Surprisingly, Ad transgene expression was relatively unaffected by ascites, which 
may be due to 4-fold lower nAb titres in ascites as compared to serum nAb titres 
(Hemminki et al., 2002). Removal of the fluid prior to Ad virotherapy may help reduce 
vector neutralisation and improve bioavailability for active tumour targeting. 
1.1.1 Chemo-resistance in ovarian cancer 
Ovarian cancers often show a good initial response to chemotherapies. 
Unfortunately, relapse is common, as aggressive, CSC-rich resistant cell populations 
develop over the course of prolonged drug regimens. Cisplatin-resistance has been 
linked to loss of p53 function, even in the absence of a gene mutation (Eliopoulos et 
al., 1995, Righetti et al., 1996). Multidrug resistance (MDR) is a common reason for 
therapeutic failure in ovarian cancer, and involves both intrinsic and acquired factors. 
Clinical attempts to reverse MDR have included small molecule inhibitors and small 
interfering RNAs (siRNAs) that target mdr1 gene encoded by P-glycoprotein (Pgp) 
(Penson et al., 2004, Wang et al., 2015), however without significant success due to 
low efficacy and high toxicity. Other factors contributing to chemo-resistance include 
CSCs, autophagy, de-regulated non-coding RNAs (ncRNAs) and tumour 
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heterogeneity that could be targeted therapeutically. CSCs have been shown to 
express distinct cell surface markers, including CD44, CD133, CD117 (c-kit) and 
aldehyde dehydrogenase isoform 1 (ALDH1), which could be targeted in attempt to 
eradicate chemo-resistant cell populations. Other markers flagged up in 
chemoresistant EOCs are EpCAM, as well as Wnt/β-catenin, Sonic Hedgehog (Shh), 
TGF-β, phosphatase and tensin homologue (PTEN)/Akt and Notch signalling 
pathways. Zhang and colleagues also suggested that high human epidermal growth 
factor receptor 2 (HER2) expression, high KRAS expression and low PTEN 
expression could be associated with higher platinum chemoresistance (Zhang et al., 
2015). 
Up-regulation of long non-coding (lnc) RNAs such as HOX transcript antisense 
intergenic RNA (HOTAIR), plasmacytoma variant translocation 1 (PVT1) and 
urothelial carcinoma associated 1 (UCA1), and down-regulation of BC200, are also 
associated with chemoresistant ovarian cancer. The contributing factors of 
chemoresistance in ovarian cancer are further discussed in a recent excellent review 
by Ren and colleagues (Ren et al., 2016). There is a severe lack of second-line 
options for patients with resistant tumours, which drives the vigorous research on 
novel strategies. Powerful approaches include modulation of anti-cancer immunity by 
therapeutic antibodies, antibody-drug conjugates, adoptive cell transfer therapies 
(ACT), DC-based vaccines [reviewed in (Wefers et al., 2015)] and viral oncolytic 
vectors. 
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Figure 1–4. Mechanisms of ovarian cancer metastasis. (A) Passive dissemination: 1) Accumulation of ascites within the peritoneal cavity, 2) peritoneal dissemination of 
cancer cells from the primary tumour, 3) adhesion of cancer cells to the surface of metastatic cells, 4) enhanced cancer cell motility and invasiveness facilitate the establishment 
of tumour metastases, 5) metastases generate new supportive microenvironment. (B) Hematogenous metastasis: 1) Epithelial-to-mesenchymal transition (EMT) of cancer cells, 
2) cancer cells enter circulation via intravasation at the primary tumour site, 3) cancer cells leave circulation via extravasation at metastatic site, 4) establishment of metastases. 
Primary tumour is shown in purple, metastases in dark red, and ascites circulation in orange arrows. Modified from (Yeung et al., 2015)
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1.1.2 Tumour models of ovarian cancer 
The importance of representative tumour models is vital for the clinical translation. 
It is often impossible to mimic the physiological conditions of the human tissues in 
murine models that have variable cell phenotypes. Fortunately, there have been 
improvements in the human tumour models that aim at replicating the complex TME 
by utilising clinical specimens that can be adapted to laboratory conditions and 
tailored for each tumour type. A recent review by Jakeman and colleagues lists 
improvements in human tumour models developed for in vitro research applications 
(Jakeman et al., 2015). The current models include conventional cell culture 
monolayers, 3D cultures of spheroids and ex vivo tumour slice techniques of clinical 
tumour biopsies. These methods can be utilised to create a model that represents the 
tumour biology as accurately as possible, by preservation of the tumour architecture 
and TME. 
Primary EOC cells can be readily cultured ex vivo from clinical patient-derived 
ascites (Shepherd et al., 2007, Thériault et al., 2013). These cultures can be obtained 
as a product of paracentesis, and represent a valuable model for functional analyses 
of EOC properties (O'Donnell et al., 2014). EOC cells have the characteristic 
‘cobblestone’ monolayer phenotype (Dunfield et al., 2002) that distinguish EOC cells 
from other cell types residing in the fluid. Several groups have investigated the 
molecular phenotype of ascites-residing EOC cells. O’Donnell and colleagues report 
over-expression of EpCAM, pancytokeratin/cancer antigen 125 (CA125), epithelial-
related antigen (MOC-31), D2-40 and vimentin, while HGS-OC was the most common 
histological phenotype (O'Donnell et al., 2014). EpCAM (O'Donnell et al., 2014) or 
tumor-associated glycoprotein 72 (TAG-72) (Barker et al., 2001) have also been used 
as selective markers for immunomagnetic separation methods of EOC cells, although 
these markers may not be exclusive for EOC separation (O'Donnell et al., 2014). 
Systematic EOC cell enrichment prior to subsequent ex vivo assessment is likely to 
improve assay integrity and reproducibility. 
Spheroids are small (up to 500 μm) or large scale (> 500 μm) 3D cultures of tumour 
cells that can be grown to mimic the phenotype and TME of biological tumour masses. 
Small tissue biopsies can also be preserved on microscope slides, a technique that 
allows culture of primary tumour tissue for several days in oxygenated atmosphere. 
By examining multiple tissue sections throughout the primary mass, a comprehensive 
picture can be formed of the tumour stroma, including CAFs, tumour-associated 
immune cells and vasculature (Bremnes et al., 2011). Animal tumour models often 
lack the genetic variability that human tumours present. A potent gene editing 
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technology has recently been utilised to create improved murine models of the most 
widely used transplantable model of ovarian cancer, ID8 (Walton et al., 2016). In this 
study, the whole exome of ID8 was sequenced and shown to have functional Trp53, 
RB, Brca1/2 or Nf1 genes. This prompted the group to generate single Trp53‒/‒ and 
double Brca2‒/‒ knockout mice by CRISPR/Cas9 to mimic the genotype of HGS-OC. 
The authors also showed ID8 to have mutations in Adamts3, indicating its sensitivity 
to platinum-based agents and improved progress-free survival (Liu et al., 2015).  
Potent in vivo and ex vivo models are desperately needed to better replicate 
different clinical scenarios. Study of the later stages of ovarian cancer that are 
characterised by the build-up of large amounts of ascites fluid will be very important 
for gaining knowledge of the progression of ovarian cancer and development of 
resistance. Fortunately, clinical EOC samples provide an excellent source of primary 
ex vivo cultures that can be utilised as a model for therapeutic assessment, both for 
viral and non-viral agents. Understandably, ex vivo cultures lack the complex TME, 
surrounding organs, vasculature and lymphatic system, and are therefore only one 
step closer to reliable pre-clinical systems. Future human tumour models are likely to 
be powered by novel innovations in tissue engineering and regenerative medicine to 
better resemble tumour biology. 
1.2 Molecular virology of adenoviruses 
Ads belong to the Adenoviridae virus family. Human Ads were historically classified 
into species A−G based on their DNA homology, haemagglutination, oncogenic and 
neutralisation properties, with species D containing the largest number of different Ad 
serotypes [for a comprehensive review, see (Russell, 2009)]. Systematic sequence 
analyses have yielded detailed information on the evolutionary relationships between 
different Ad serotypes and enabled the classification of the 57 human Ad serotypes 
(Figure 1–5) based on alignment of the main capsid proteins – fiber, hexon and penton 
base. Recent sequencing of 20 species D Ads revealed great diversity in the 
hypervariable regions (HVRs) of the capsid proteins hexon, fiber and penton 
(Robinson et al., 2013). The extensive variability within the species D is likely a result 
of natural homologous recombination, which is a common mechanism responsible for 
viral diversity and immune escape. Recombination occurs due to selective immune 
pressure in the human host, which results in novel variants with altered tropism and 
virulence (Robinson et al., 2013). 
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Figure 1–5. All known 57 serotypes of human adenoviruses. Species B viruses belong to 
haemagglutination group I (complete agglutination of monkey erythrocytes), species D viruses in group 
II (complete agglutination of rat erythrocytes), species C, E and F in group III (partial agglutination of rat 
erythrocytes) and species A viruses in group IV (little agglutination) [reviewed in (Young and McNeish, 
2009)]. Figure modified from (Geisbert et al., 2011, Robinson et al., 2013). 
 
Ads are circulating in the human population with small seasonal fluctuations. They 
infect individuals of all ages, although young children are most affected due to lack of 
adaptive immunity. Infections commonly result in mild upper and lower respiratory 
tract infections, gastroenteritis, cystitis or keratoconjunctivitis, but can in rare cases 
produce manifestations with high morbidity and mortality such as hepatitis, 
pneumonia, meningoencephalitis and myocarditis. Opportunistic infections are seen 
in severely immunosuppressed patients and allogeneic stem cell or organ transplant 
recipients, in whom the consequences can be fatal due to severe inflammatory host 
responses, cytokine ‘storm’, extensive immune attack and multi-organ failure due to 
viremia. Ad infections in immunocompetent and -compromised patients are discussed 
in detail in a recent review by Lion and colleagues (Lion, 2014). In 1999 a young gene 
therapy volunteer received intravascular delivery of a large dose (3.8 × 1013 viral 
particles) of Ad5 for ornithine transcarbamylase deficiency, and died as a result of 
cytokine storm (Lehrman, 1999). This case was a significant low point in the clinical 
development of Ad as a gene therapy, and highlighted the requirement to better 
understand and refine the interactions that limit efficacy and promote toxicity.  
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1.2.1 Adenovirus life cycle 
Ads infect a wide variety of vertebrate hosts via aerosol droplets in the respiratory, 
urinary or gastrointestinal tract [reviewed in (Russell, 2009)]. ECM and the glycocalyx 
lining tissue surfaces form a physical barrier and the first line defence against intruding 
pathogens. They consist of various glycoproteins, proteoglycans, polysaccharides 
and tethered mucins that trap the Ad virions and limit infection (Pickles et al., 2000, 
Stonebraker et al., 2004). The viral replication cycle (Figure 1–6) is rapid, as the early 
phase takes 6‒8 h and the late phase only another 4‒6 h until mature virions are 
released. Ad5 recognises its primary entry receptor coxsackie and adenovirus 
receptor (CAR) (Kirby et al., 2000) via the fiber protein on the surface of the virion 
(Figure 1–7), while other serotypes use other primary attachment receptors (Table 1-
1).  
This initial attachment is accompanied by binding of the widely conserved Arg-Gly-
Asp (RGD) motif (Ruoslahti, 1996) in the penton base protein to αvβ3/5 integrins on 
the cell surface. Integrins are structural proteins that are connected to ECM via 
laminin, collagen IV, leukocyte-specific ligands and fibronectin, but also mediate cell-
to-cell interaction (Ganguly et al., 2013). They belong to a large family of heterodimers 
that consist of non-covalently linked α and β subunits, a transmembrane helix and a 
short cytoplasmic tail (Arnaout et al., 2007). Integrin changes from an inactive (low-
affinity) form into an active (high-affinity) stage when it binds to its ligand (Cantor et 
al., 2015). The role of integrins in signalling pathways, cell migration, growth, 
differentiation and apoptosis are further discussed in a number of excellent reviews 
(Ruoslahti, 1996, Giancotti and Ruoslahti, 1999, Arnaout et al., 2007).
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Figure 1–6. Adenovirus life cycle. (1) Virus binding to cellular receptors and endosomal entry, (2) endosomal acidification, (3) partial disassembly of the virion, (4) virus 
trafficking into the nuclear pore complex (NPC) via microtubules, and release of viral DNA, (5) transcription of early genes, (6) translation of early proteins, (7) DNA replication, 
(8) transcription of late genes, (9) transcription of late proteins, (10) virus assembly, (11) release of mature viruses by cell lysis. Figure adapted from (Russell, 2009, Russell, 
2000, Coughlan et al., 2010). 
           
           Chapter 1 
34 
 
 
Figure 1–7. Structural components of the adenovirus capsid. Penton base, hexon and fiber 
(shown here as monomers) are the main building blocks of the eicosahedral capsid, but also contain the 
major immunogenic epitopes (highlighted in colours). 
 
The coordinated interaction results in reorganisation of the actin cytoskeleton, 
which allows viral entry into the cell by phagocytosis via clathrin-coated pits (Figure 
1–8). The acidification of the endosomes leads to disassembly of the virion as fiber 
proteins are cleaved by the activated virus-encoded protease and detached from the 
penton base (Nakano et al., 2000). Detached free fibers facilitate escape from the 
endosome and promote viral spread by opening up CAR-dependent, intracellular tight 
junctions (Walters et al., 2002). Excessive fiber production seems to be essential for 
epithelial permeability and viral spread. Fiber binding to CAR enables viral motility 
between cells, facilitating basolateral-to-apical trafficking and viral escape from the 
apical surface (Walters et al., 2002). The length of the fiber is dependent on the 
number of pseudorepeats (3‒23) in the shaft domain, and varies between serotypes. 
Optimal fiber length (Roelvink et al., 1998, Shayakhmetov and Lieber, 2000) and 
flexibility (Wu et al., 2003) seems be crucial for entry of CAR-utilising Ads, for the 
geometrically challenging penton-integrin interaction to take place simultaneously 
with fiber-CAR interaction [reviewed in (Zhang and Bergelson, 2005)].  
The partially disassembled virus is trafficked to the nucleus via microtubule 
network, either by direct binding to microtubule-associated motor proteins, such as 
dynamin, or by remaining in organelles that interact with microtubules and 
microtubule-associated motor proteins (Bremner et al., 2009) [reviewed in (Leopold 
and Crystal, 2007)]. The virion binds to the nuclear pore complex (NPC) and releases 
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its genome into the nucleus. Early viral regulatory proteins aid the late viral DNA 
replication, as well as transcription and translation of late structural proteins. Viral 
assembly takes place in the nucleus. Mature virions are released from the cell surface 
by lysis, leading to host cell death. The entry pathways and life cycle are discussed 
in great detail in the excellent reviews (Russell, 2000, Russell, 2009, Coughlan et al., 
2010). 
 
Figure 1–8. Adenovirus attachment and internalisation. (1) Primary attachment of adenovirus to 
the cell membrane occurs via coxsackie and adenovirus receptor (CAR) (Kirby et al., 2000). (2) Penton 
binding to αvβ3/5 integrins is required for viral internalisation (Wickham et al., 1993) via phagocytic 
clathrin-coated pits. Membrane permeabilisation is dependent on penton-mediated activation of 
phosphoinositide-3-OH kinase (PI3K) and ERK1/ERK2 mitogen pathways (Li et al., 1998) and excessive 
production of the fiber protein (Walters et al., 2002). (3) Viral components detach in the low pH endosome 
and are released to the cytosol. (4) The stripped virion is trafficked to the nucleus for DNA synthesis. 
 
1.2.2 Viral structure 
Ads are non-enveloped viruses that contain a linear, non-segmented, double-
stranded 26−46 kb DNA genome that is transcribed in early and late phases of the 
viral life cycle (Figure 1–9A). Hexon (II), penton base (III), and fiber (IV) constitute the 
viral eicosahedral capsid (Figure 1–9B) and are responsible for viral tropism and 
immunogenicity. The minor proteins ‒ IIIa, VI, VIII, IX and IVa2 ‒ are associated with 
the capsid and have structural roles in the virion. The core proteins V, VII, μ peptide, 
terminal protein (TP) and are associated with the DNA, and the virus-coded protease 
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(Pr) is essential for viral assembly. The 5’ terminus of the DNA is attached covalently 
to the TP and the molecule carries inverted terminal repeats (ITRs) at both termini. 
The early genes are organised in gene transcription cassettes, E1‒E4, while L1‒5 
cassettes code for the late genes. Ad genome also codes for a set of VA RNAs that 
are not translated but are involved in cellular defence mechanisms. The genomic 
structure and roles of Ad proteins are discussed in detail in comprehensive reviews 
(Russell, 2000, Russell, 2009).  
Main capsid proteins contain the major antigenic epitopes of the Ad particle (Figure 
1–10). The Ad5 fiber is a homotrimeric ~ 62 kDa protein, each monomer containing 
581 amino acids, and it is located on the 12 vertices of the eicosahedral capsid. It 
consists of a globular knob domain containing the receptor-binding domain that 
mediates binding to the native receptor CAR. Residues Ser408, Pro409, Tyr477 and 
Leu485 are known to be the key amino acid residues for CAR binding (Kirby et al., 
2000). The fiber knob has a distinct electropotential in different Ad serotypes (Arnberg 
et al., 2002), which is likely to be crucial for their receptor binding properties. Distinct 
protruding loop structures with the 9 main antigenic epitopes (A‒I) are involved in 
elicitation of serotype-specific nAbs (Xia et al., 1994). The C terminus of the fiber is a 
flexible shaft structure, mediating contact to the underlying penton protein that plays 
a central role in endosome-mediated entry into host cells via αvβ3/5 integrins [entry 
pathway reviewed in (Russell, 2009)].  
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Figure 1–9. Adenovirus structural components. (A) Viral genomic structure. The early transcripts 
are in blue, late transcripts in green and protein products in italics. Pr, protease; MLP, major late 
promoter; ITR, internal terminal repeat. (B) Silver staining of adenoviral capsid proteins. 5 × 1010 
denatured virus particles/lane run on a 9 % SDS-PAGE gel and stained using Pierce silver staining kit 
(Thermo Scientific). Lane 1) Ad5-CMVLacZ, 2) Ad5-CMV-LacZ with hexon hypervariable region 5 
(HVR5) mutations, 3) Ad5-CMV-LacZ with hexon hypervariable region (HVR7) mutations. Reproduced 
with permission from (Parker et al., 2014). 
 
Fiber plays a key role in mediating viral endosome-cytoplasm transition through 
the detachment of the fiber protein and its membrane lytic activity in the low pH 
endosome. Ad serotypes have fiber shafts of variable lengths. Both the length and 
flexibility of the fiber protein are central in viral cellular uptake. This has been 
demonstrated by pseudotyping the long Ad5 shaft with short shafts from other 
serotypes, which resulted in reduced infectivity and attachment (Wu et al., 2003). 
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Introduction of point mutations into the KKTK motif within the fiber shaft showed 
impaired flexibility and drastically reduced cell transduction (Wu et al., 2003, Bayo-
Puxan et al., 2006, Kritz et al., 2007). The KKTK motif was previously considered to 
be involved in Ad5-mediated hepatic delivery via heparan sulfate proteoglycan 
(HSPG) interactions (Smith et al., 2003, Bayo-Puxan et al., 2006). However, more 
recent studies demonstrate it to be non-essential for the interaction and rather to exist 
at an essential ‘hinge region’ within the shaft protein, where modification of this motif 
renders the fiber inflexible and unable to interact with cellular αvβ3/5 integrins (Bayo-
Puxan et al., 2006, Di Paolo et al., 2007, Kritz et al., 2007, Corjon et al., 2011).  
The homotrimeric hexon is the largest (~ 130 kDa) and most abundant capsid 
component, with 240 pseudo-hexagonal trimers lining the 20 facets of the virion 
surface. Hexons are classified into H1‒H4 based on their interactions with 
neighbouring penton proteins. The hexon harbours the main neutralising epitope ε 
that can be utilised for serotyping by neutralisation tests, while the γ determinant in 
the fiber knob is responsible for hemagglutination properties. However, diagnostic 
typing is often non-exclusive due to cross-reactivity, resulting from extensive intra- 
and interspecies recombination (Madisch et al., 2005). They have up to nine HVRs 
(Khare et al., 2012) (dependent on the serotype) on the surface-exposed epitopes of 
the molecule (Figure 1–10B), which represent major antigenic targets for nAbs 
following virus challenge (Sumida et al., 2005, Roberts et al., 2006). Anti-hexon nAbs 
can act at both the extracellular level to sterically limit cellular association, or at the 
intracellular level to prevent virus uncoating and nuclear entry of viral DNA (Varghese 
et al., 2004). It has also been suggested that innate anti-Ad5 immune responses can 
be triggered by recognition of coagulation factor 10 (FX; Stuart-Prower factor) bound 
on the hexon protein (Doronin et al., 2012). On the contrary, a recent study reports 
the role of FX in shielding the Ad5 capsid from immune attack and subsequent 
neutralisation by natural IgM and complement proteins (Xu et al., 2013). Ad5 hexon 
HVRs have been suggested to be the specific sites determining sensitivity to the 
innate immune neutralisation (Ma et al., 2015), particularly following intramuscular 
(i.m.) vaccination or vector challenge (Bradley et al., 2012a, Bradley et al., 2012b). 
The exact target of anti-fiber nAbs remains a hot topic of debate, with compelling 
evidence that the antigenic loops within the fiber knob form the major 
immunodominant domains (Myhre et al., 2007, Bradley et al., 2012a), at least 
following a native Ad5 infection (Särkioja et al., 2008). Ad entry into the airway 
epithelia results in over-expression of the fiber protein (Walters et al., 2002) and thus 
directly exposes the fiber to the innate immune recognition mechanisms as it is the 
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most abundant viral component in the early stage of infection. There remains 
significant controversy surrounding the determination of primary antigenic 
determinants of the Ad5 virion, as earlier reports suggest that the fiber protein does 
not play a central role in nAb production (Gall et al., 1996), while more recent studies 
have demonstrated its involvement in eliciting the majority of anti-Ad5 nAbs following 
a natural inoculation (Särkioja et al., 2008). The role of anti-hexon and -fiber nAbs is 
discussed further in following sections.  
The third major capsid building block is the penton base, a homopentameric ~82 
kDa protein (Figure 1–10C) located on the base of each fiber trimer. The penton base 
protein is involved in viral internalisation, mediated by binding to αvβ3/5 integrins on 
the cell surface (Wickham et al., 1993) via the conserved integrin-binding RGD 
epitope (amino acid residues 485‒488 (Neumann et al., 1988, Zubieta et al., 2005)). 
A number of integrin ligands involved in cell adhesion, such as fibronectin, vitronectin, 
fibrinogen, vWF, thrombospondin, laminin, entactin, tenascin, osteopontin and some 
collagens, have been shown to carry the RGD motif that mediates the attachment to 
a variety of integrin subtypes [reviewed in (Ruoslahti, 1996)]. The penton has three 
immunodominant neutralising epitopes ‒ one of which overlaps with the RGD motif ‒ 
that may contribute to virus neutralisation mainly at the internalisation step of the 
infectious cycle (Hong et al., 2003). Anti-RGD antibodies have been suggested to 
have a non-neutralising role in Ad infection (Hong et al., 2003). Ad5 binding to cellular 
αvβ3 integrins on marginal zone macrophages (MZMΦ) in the spleen (area between 
the red and white pulp) via the penton RGD motif has been shown to contribute to 
innate immune activation by triggering the IL-1α activation and subsequent IL-1RI-
dependent induction of cytokine and chemokine C-X-C motif 1 (CXCL1) and CXCL2 
production, as was demonstrated in a study utilising an Ad5 vector with RGD motif 
deletion (Ad5ΔRGD) (Di Paolo et al., 2009). Ad5ΔRGD vectors with an Ad35-
pseudotyped short fiber (Chroboczek et al., 1995) were shown to have retained 
cellular attachment but an impaired internalisation, which may indicate role for this 
motif in endosomal escape and the importance of penton-integrin interactions for 
CD46-utilising species B Ads (Shayakhmetov et al., 2005a). Additionally, using Ad5 
vectors with a point mutation that abolishes integrin-binding (RGD > RGE) resulted in 
reduced splenic uptake and attenuated inflammatory responses in mice (Bradshaw et 
al., 2012). These observations suggest a central role for RGD motif not only in the 
viral internalisation, but also in the activation of anti-Ad innate immune responses. 
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Figure 1–10. The major antigenic proteins of adenovirus. (A) Side and top view of the Ad5 fiber monomer. Main antigenic epitopes are highlighted in distinct 
colours (see legend) and CAR-binding site is indicated in blue (Xia et al., 1994), PDB ID: 1KNB. CAR, coxsackie and adenovirus receptor. (B) The Ad2 penton base 
monomer. The three main antigenic sites (Hong et al., 2003) are highlighted in blue, integrin-binding motif Arg-Gly-Asp (RGD) in red (Zubieta et al., 2005, Cao et al., 
2012); PDB ID: 1X9P. (C) Top view of the Ad5 hexon monomer with the major antigenic epitopes. Hypervariable regions (HVRs) 1‒7 shown in different colours; the 
site for point mutation (E451Q) central for ablation of human coagulation factor 10 (FX) binding is shown in yellow; TET motif central for the high affinity interaction with 
FX shown in orange (Irons et al., 2013). Modified from (Khare et al., 2012); PD ID: 3TG7. All models were constructed in PyMol version 1.1eval. 
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1.2.3 Cell and tissue tropism 
Ads utilise multiple cellular entry receptors (Figure 1–11) in a serotype-dependent 
manner (Table 1–1). The most widely used cell attachment receptor for all, except 
species B, Ads is CAR. It belongs to the family of immunoglobulin-like surface 
molecules and co-localises in the tight junctions with zonula occludens-1 (ZO-1) 
protein on polarised epithelial cells [reviewed in (Coyne and Bergelson, 2005)]. It is 
ubiquitously expressed in all human organs, including erythrocytes and platelets 
(Carlisle et al., 2009, Seiradake et al., 2009).  
 
Figure 1–11. Adenovirus receptor tropism in vitro and in vivo. Adenoviruses utilise CAR as their 
main entry receptor in vitro, while in vivo entry is dictated by FX-mediated binding to HSPGs. CAR, 
coxsackie and adenovirus receptor; CD46, membrane co-factor protein; CR1, complement receptor 1; 
DSG-2, desmoglein 2; GD1a, disialoganglioside; HSPG, heparan sulphate proteoglycan. 
 
Table 1–1. Human adenovirus classification, receptor usage and tissue tropism. CAR, 
coxsackie and adenovirus receptor; DSG-2, desmoglein-2; HSPG, heparan sulfate proteoglycan; VCAM-
1, vascular cell adhesion molecule 1; SR, scavenge receptor; MHC1, major histocompatibility complex 
class 1; SA, sialic acid; nd, not determined. Table modified from (Uusi-Kerttula et al., 2015a). 
Species Serotypes Receptors Tropism 
A 12, 18, 31 CAR 
Cryptic (enteric, 
respiratory) 
B1 16, 21, 35, 50 
CD46 (Wang et al., 2007), CD80, 
CD86 
Respiratory, ocular 
B2 3, 7, 14, 34, 35 
DSG-2 (Wang et al., 2011), CD80, 
CD86 
Renal, ocular, 
respiratory 
B1/2 11 CD46, DSG-2 (Wang et al., 2011) Ocular, respiratory 
C 1, 2, 5, 6 
CAR (Kirby et al., 2000), HSPG, 
VCAM-1, SR, MHC1-α2 
Respiratory, 
ocular, lymphoid 
D 
8‒10, 13, 15, 17, 19, 20, 
22‒30, 32, 33, 36‒39, 42‒
49, 51, 53 
SA (Burmeister et al., 2004), CD46 
(Chen et al., 2010, Li et al., 2012), 
CAR (Chen et al., 2010), GD1a 
glycan (Nilsson et al., 2011) 
Ocular, Enteric 
E 4 CAR Ocular, respiratory 
F 40, 41 CAR Enteric 
G 52 nd Enteric 
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Following a natural respiratory tract infection with wild type Ad5, an early event 
involves the over-expression of the Ad fiber protein which disrupts tight junctions, thus 
facilitating viral translocation from the basolateral to apical surface of the epithelial 
cells and enabling onward virus spread (Walters et al., 2002). Ad3/7/11 binding to 
DSG-2 has been shown to stimulate epithelial-to-mesenchymal transition (EMT) that 
is a central event in carcinogenesis (Wang et al., 2011). This may hinder their use as 
anti-cancer vectors. Ads primarily utilise the fiber knob-CAR -mediated pathway for 
cell entry in vitro. Tropism in vivo however, appears to be dictated by a variety of other 
factors including the high affinity interaction between human coagulation factors (FX 
in particular) that largely determines their hepatic tropism following contact with the 
blood (Waddington et al., 2008, Alba et al., 2009) [reviewed in (Coughlan et al., 
2010)]. These ‘adapter molecules’ ‒ multiple vitamin K ‒dependent coagulation 
factors, play a central role in Ad5 hepatotropism (Parker et al., 2006, Waddington et 
al., 2007). FX is a serine endopeptidase that is part of the coagulation cascade (Figure 
1–12A) and is activated upon vascular injury. 
 
Figure 1–12. Proteins of the coagulation pathway. (A) The coagulation cascade. TF, tissue factor. 
Modified from (Davie et al., 1991). (B) The structure of human coagulation factor 10 (FX). The light N-
terminal chain consists of 11 γ-carboxyglutamic acid (GLA) residues that are responsible for Ca2+-
mediated binding to cellular domains, and two epidermal growth factor (EGF) homology domains. The 
heavy C-terminal chain has a 52-amino acid activation peptide (AP) that is enzymatically cleaved by the 
FXase, and a latent serine protease domain (Davie et al., 1979, Jackson and Nemerson, 1980). 
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FX is a two-chain molecule that consists of several domains with specialised 
functions (Figure 1–12B) and circulates freely in the blood at a concentration of 
approximately 8 μg/ml. The high affinity, Ca2+-dependent interaction between hexon 
and hepatocyte HSPGs is effectively ‘bridged’ by FX (Waddington et al., 2008, Parker 
et al., 2009). Ad5 HVR5, HVR7 (and possibly HVR3), located on the top of the hexon 
trimer (Kalyuzhniy et al., 2008, Waddington et al., 2008), bind to the γ-carboxylated 
glutamic acid (GLA) domain of FX, guiding the extensive liver sequestration of Ad5-
based vectors (Waddington et al., 2008). A recent study has shed light on the role of 
HSPGs in the FX-mediated Ad hepatocyte transduction, suggesting the involvement 
of additional or auxiliary receptors (Zaiss et al., 2015). The FX:hexon interaction may 
have a potentially critical role that protects the Ad5 capsid from complement-mediated 
immune attack and destruction by natural antibodies. This recent finding casts further 
doubt over the role of FX as a hepatotropic adaptor or in protection of the Ad5 virion 
from immune attack (Xu et al., 2013). Notably, species D Ads have been shown to 
exhibit low or abolished affinity to FX (Figure 1–13) and subsequently reduced liver 
transduction relative to Ad5 (Waddington et al., 2008). This is likely to have important 
implications for design of novel vector candidates based on these rare serotypes. 
 
Figure 1–13. Classification of adenovirus serotypes based on affinity to human coagulation 
factor 10 (FX). Modified from (Waddington et al. 2008). Species D viruses are attractive vector 
candidates due to their low affinity to FX. 
 
1.3 Adenovirus vectors for cancer therapy 
The Ad5 genome has been extensively studied over the past six decades, following 
their initial discovery in the 1950’s. Ads are popular gene therapy vectors because 
their genome can easily be altered by a number of well-described cloning and 
recombineering (Stanton et al., 2008) methods [first-generation vectors reviewed in 
(Danthinne and Imperiale, 2000)]. This involves deletions of genes essential for viral 
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replication and insertions of heterologous transgenes and targeting peptides into 
permissive regions in the capsid proteins. The fiber knob HI loop (Krasnykh et al., 
1998, Krasnykh et al., 1996, Belousova et al., 2008, Belousova et al., 2002, Nicklin et 
al., 2001, Kritz et al., 2007, Coughlan et al., 2009a, Uusi-Kerttula et al., 2015b, Uusi-
Kerttula et al., 2016), penton (Wickham et al., 1995) and hexon HVRs (Vigne et al., 
1999) are frequently studied locations for peptide insertions. Ads are inherently lytic 
in their host cells, and release virus progeny to infect neighbouring cells. Their 
compact genome can be modified to incorporate large therapeutic transgenes up to 
105 % of genomic size (Bett et al., 1993), which allows for the unique possibility of 
drug amplification in the TME, at the point of need. The therapeutic effect is amplified 
as the virus goes through repeated replication cycles and spreads through the tumour 
tissue. Another benefit is the good safety of Ad-based vectors as the pathogenicity of 
the wild type virus is low in immunocompetent individuals. Ads are able to infect both 
non-replicating and replicating cells (Barnes et al., 2002, Hawkins et al., 2002), which 
is an excellent feature for therapeutic purposes in a variety of tissue types. Delivery 
and expression of therapeutic transgenes into the nucleus makes Ads an attractive 
gene therapy vector. The advantages of Ads as gene therapy vectors are discussed 
further in comprehensive reviews (Russell, 2009, Russell, 2000, Coughlan et al., 
2010). 
1.3.1 Oncolytic & conditionally-replicative adenoviruses 
Viruses often exploit the similar cell cycle aberrations as cancer cells for hijacking 
the host cell’s replication machinery, and it is this overlap that makes viruses great 
cancer-attacking vectors. Ads are not inherently tumour-selective, unlike some other 
viruses such as reoviruses, some measles strains and vesicular stomatitis virus (VSV) 
(Hawkins et al., 2002). However, oncolytic Ads can be engineered by a number of 
genetic engineering strategies, including control mechanisms that target 
transductional (viral entry) and transcriptional (replication) processes and render the 
virus cancer-selective. Generally, this involves the combination of attenuation of 
genes essential for viral replication to achieve high selectivity and safety, and 
incorporation of genes that are expressed only in neoplastic cells. Substitution of the 
deleted gene regions in replication-deficient vectors with cancer-selective promoters 
can be utilised to generate conditionally-replicative Ad vectors (CRAds), which 
promotes restricted lysis of cancer cells with defective signalling pathways and/or 
characteristic TME.  
Ad vectors have undergone three generations of development, involving the 
deletion of early genes E1‒E4 that are central for viral replication, viral DNA 
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transcription/replication of late genes, modulation of immune responses and 
metabolism of virus mRNA/host protein synthesis, respectively. The first generation 
Ads had a E1/E3 mutation, a basic attenuating mutation for generation of replication-
deficient vectors, while second generation Ads had E4 deletion in addition to E1 
and/or E3 deletion [reviewed in (Bauerschmitz et al., 2002, Kanerva and Hemminki, 
2005)]. So called ‘gutless’ helper-dependent Ad vectors that lack all viral genes can 
be produced efficiently in a co-infection with a helper plasmid that complements 
missing genes (Ehrke-Schulz et al., 2016). The main benefits of these vectors are 
their high packaging capacity (up to 35 kb), low toxicity and low immunogenicity. 
However, their production is relatively cumbersome compared to AdEasy (Zeng, 
2001) and other  homologous recombineering methods that involve zero cloning steps 
(Stanton et al., 2008). 
1.3.2 Clinical history 
U.S. National Institutes of Health (NIH) has records of 123 completed or ongoing 
clinical trials (clinicaltrials.gov, 2016) for adenovirus therapies for cancer between 
2006‒2016 worldwide (Figure 1–14). Ad vectors have been modified to selectively 
replicate in cancer cells, mainly via introduction of selected deletions in viral genes 
E1A and E1B that are responsible for viral replication, to target cells with defective 
p53 and retinoblastoma protein (pRB) pathways (Table 1–2). 
 
Figure 1–14. Clinical trials involving adenovirus vectors for cancer treatment during the past 
decade. Trials were searched using terms “adenovirus AND cancer” between 01 Jan 2006 and 24 Oct 
2016. The search returned 123 completed or ongoing trials worldwide (clinicaltrials.gov, 2016). 
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The pRB tumor-suppressor pathway may be defective in all human cancer types 
(Sherr, 1996), which indicates its feasibility for cancer targeting (Fueyo et al., 2000). 
Wild type Ad E1A protein inactivates cellular pRB, which reverses transcriptional 
repression and enables transition from G1 to S phase (Sherr, 1996), allowing viral 
replication. One of the earliest attempts of an Ad therapy for ovarian cancer was a 
replication-deficient Ad (SCH 585000) expressing a wild type p53 under a 
cytomegalovirus (CMV) immediate early promoter (Buller et al., 2002). I.p. delivery of 
the vector in phase I and II trials resulted in elevated levels of p53 targets, such as 
Bax and p21, but with a very high inter-patient variance, and a multitude of adverse 
events. Phase III trial combining surgery and conventional chemotherapy with or 
without Ad gene therapy was commenced but soon halted due to unexpectedly low 
efficacy in the treatment arm ‒ the results from this study were never reported (Zeimet 
and Marth, 2003). Oncolytic Ad vectors tailored for ovarian cancer treatment are 
discussed in an excellent review (Young and McNeish, 2009). 
Table 1–2. Selected oncolytic Ads involved in pre-clinical and clinical studies. Ad, adenovirus; 
EnAd, enadenotucirev; ER, endoplasmic reticulum; GM-CSF, granulocyte-macrophage colony 
stimulating factor; HIF, hypoxia-inducible factor; pRB, retinoblastoma protein; Δ, deletion. For a list of 
vectors from early 2000, see (Chu et al., 2004). 
Name 
(serotype) 
Gene 
controlled 
Target Mutations References 
ONYX-015 
(Ad5) 
E1B 55kD 
p53 dl1520 (Ganly et al., 2000) 
ICOVIR-5 
(Ad5) 
E1A 
pRB 
Δ24; dl922‒947 
(Fueyo et al., 2000) 
(Cascallo et al., 2007, 
Nokisalmi et al., 2010) 
HYPR-Ad5 
(Ad5) 
E1A 
hypoxic 
cells 
HIF (Post and Van Meir, 2003) 
ORCA-010 
(Ad5) 
E3/19K ER 
retention 
domain 
T1 (Dong et al., 2014a) 
ONCOS-102 
(Ad5/3) 
E1A 
pRB 
Δ24 +  
GM-CSF + chimaera 
(Koski et al., 2010, Vassilev et 
al., 2015, Kuryk et al., 2016, 
Targovax, 2016) 
EnAd 
(Ad3/11p) 
ΔE1A/E1B 
(E4orf4) 
not 
known 
chimaera 
(Kuhn et al., 2008, Tedcastle 
et al., 2015, PsiOxus, 2016) 
The first oncolytic Ad5-based vector ONYX-015 was approved more than a decade 
ago by the Chinese authorities for treatment of head and neck cancers (Ganly et al., 
2000). The product of the Ad E1B 55 kD gene binds to and ‘neutralises’ p53, 
preventing p53-induced cell death and apoptosis, and allowing viral replication 
(Wiman, 2007). ONYX-015 vector has a complete deletion of E1B (dl1520) that 
renders it capable of selectively infecting p53-defective cells (Bergh et al., 1995). 
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However, since the treatment is only effective on p53-deficient tumours ‒ an 
estimated 50 % of all cancer patients (Vogelstein et al., 2000) ‒ complementing 
strategies are needed. However, ~ 97 % of ovarian cancer patients with HGS-OC 
have been tested positive for defective p53 pathways in large scale genomic analyses 
(Ahmed et al., 2010, Bell et al., 2011), highlighting the potential of targeting this 
pathway in ovarian cancer. Contradicting data indicates that ONYX-015 may not be 
as p53-specific as was previously thought. The vector has been shown to replicate in 
some cancer cells with an intact p53-pathway, which may come down to the 
involvement of Mdm2 and p14ARF pathways [reviewed in (McCormick, 2000)]. 
Clinical Ad applications based on the p53-pathway are reviewed in (Chen et al., 2014). 
The C-X-C chemokine receptor 4 (CXCR4) is over-expressed in EOC cells and 
primary cultures, but not detected in healthy ovarian epithelium (Scotton et al., 2001). 
Double-targeting approach combining the insertion of CXCR4 promoter and Ad5 fiber 
pseudotyping from Ad3 (Ad5-CXCR4-F5/3) showed increased replication in ovarian 
cancer cell lines but decreased replication in normal tissues, indicating beneficial 
selectivity and oncolytic efficacy for this virus (Rocconi et al., 2007). A 24-base pair 
deletion (Δ24; dl922‒947) in the pRB-binding domain of E1A efficiently restricts viral 
replication into proliferating, pRB-defective cells (Fueyo et al., 2000). A triple-targeted 
Ad5 with an epithelial cancer-induced cyclo-oxygenase (Cox2) promoter (Kanerva et 
al., 2004) driving the E1A mutation Δ24 and pseudotyped fiber knob from Ad3 (Cox2- 
Δ24-Ad5/3), showed up to 100 000-fold increased transduction compared to Ad5 wild 
type (Bauerschmitz et al., 2006). Unfortunately, neither of these EOC-specific vectors 
have been tested in clinical studies. An Ad5-based ICOVIR-5 vector combines E1A 
transcriptional control by EF2 promoter mutation with Δ24 mutation and an RGD-4C 
modification in the fiber HI loop (Cascallo et al., 2007, Nokisalmi et al., 2010), and has 
shown promising safety and anti-tumour efficacy in phase I trials for advanced 
melanoma (Nokisalmi et al., 2010). A HYPR-Ad5 vector developed by Post and 
colleagues utilises hypoxia-dependent E1A expression and selective lysis of hypoxic 
cells that dominate in chemo- and radiotherapy-resistant in solid tumours (Post and 
Van Meir, 2003). 
ORCA-010 vector carrying a novel ‘T1’ mutation has shown enhanced oncolytic 
efficacy and safety in pre-clinical in vivo studies, and seems to be significantly more 
potent than the licensed ONYX-015 (Dong et al., 2014a). T1 mutation is an insertion 
of a single adenine base at position 445 within the endoplasmic reticulum (ER) 
retention domain of the E3/19K gene that has been shown to greatly enhance 
oncolytic potency of Ad5, presumably due to increased release of the virus progeny 
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from the ER and efficient spread within the tumour mass (Gros et al., 2008). Ad5/3-
Δ24-GMCSF (ONCOS-102) ‒ a chimaeric Ad5/kn3 vector armed with a potent 
immunostimulatory granulocyte-M colony stimulating factor (GM-CSF) ‒ has 
completed phase I clinical studies with increased cancer-specific CD8+ T-cell 
responses and good safety profile in heavily pre-treated patients with injectable solid 
advanced tumours (Vassilev et al., 2015), and is ready to enter four new phase I/II 
trials (Targovax, 2016). Phase I studies demonstrated enhanced immunologic 
response, good safety and a significant correlation between anti-viral and anti-tumour 
T-cells, while safety nor efficacy were affected by the Ad5/kn3 fiber pseudotyping 
(Kanerva et al., 2013). Recently, immunogenic cell death and a synergistic anti-
cancer effect was observed using ONCOS-102 in combination with chemotherapy 
(pemetrexed and cisplatin or carboplatin) for the treatment of malignant mesothelioma 
in a mouse xenograft model (Kuryk et al., 2016). 
A novel ‘directed evolution’ approach was used to create the first wholly non-Ad5-
based oncolytic species B vector, enadenotucirev (EnAd; previously ColoAd1). EnAd 
is a complex and highly potent chimaeric Ad3/Ad11p virus that was generated on 
several tumour cell lines through forced recombination between a pool of Ads from 
different subgroups. EnAd has a small 24-bp deletion in the region encoding E4orf4 
that, in the context of Ad5, induces protein phosphatase 2A (PP2A)-mediated, p53-
independent apoptosis (Branton and Roopchand, 2001). However, the oncolytic 
mechanism of EnAd is entirely apoptosis-independent and its enhanced potency may 
be related to the chimeric E4 region that may alter the expression of additional, yet 
unknown genes (Kuhn et al., 2008). EnAd has shown significantly improved selectivity 
and cancer-killing as compared to ONYX-015 (Kuhn et al., 2008), as well as superior 
blood persistence and oncolysis in the highly neutralising environment of the whole 
human blood (Di et al., 2014). EnAd is being developed by PsiOxus Therapeutics 
(Oxfordshire, UK) and is currently (autumn 2016) undergoing a number of phase I and 
II trials (PsiOxus, 2016). SPICE, a phase I clinical trial evaluates its use in combination 
with pembrolizumab for metastatic or advanced epithelial tumours. EVOLVE is a 
phase I/II trial assessing the safety, tolerability and efficacy of intravenously (i.v.) 
administered EnAd in patients with epithelial, colorectal or bladder solid tumours. 
OCTAVE is a phase I/II clinical trial in patients with platinum-resistant EOC, and 
assesses i.p. or i.v. delivery of EnAd, either alone or in combination with paclitaxel.  
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Table 1–3. Adenovirus vectors in clinical trials for ovarian cancer. Search was limited to years 2006‒2016 and performed using Boolean operators “adenovirus 
AND ovarian cancer” and “oncolytic virus AND ovarian cancer”. CR, complete resolution; EnAd, enadenotucirev; EOC, epithelial ovarian cancer; i.p., intraperitoneal; 
MTD, maximum tolerated dose; NA, not available; NCI, National Cancer Institute; PFS, progress-free survival; RR, response rate; SD, stable disease. 
 
Trial 
Vector  
(+ chemotherapy) 
Indications Route 
Primary 
endpoint 
Stage Best outcome 
NCT00562003 Ad5Δ24RGD recurrent ovarian i.p. MTD completed 
14/21 patients with stable disease (Kimball et 
al., 2010) 
NCT00964756 
Ad5.SSTR/TK.RGD 
(ganciclovir) 
recurrent ovarian / other 
gynaecologic 
i.p. toxicity completed 
5/12 patients with SD, 1 patient with CR (Kim 
et al., 2012) 
NCT02435186 
rec. Ad human p53 
(cisplatin/paclitaxel) 
recurrent EOC, Fallopian 
tube, primary peritoneal 
i.p. RR, PFS not open yet NA 
NCT02028117 
(OCTAVE) 
Ad3/11p, EnAd 
(paclitaxel) 
recurrent, platinum-
resistant EOC 
i.p. MTD recruiting NA 
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A recent review further discusses the administration schedule and compares 
single-shot regimens with triple-hit courses for oncolytic Ad and other anti-cancer 
vectors (Ruf and Lauer, 2015). The efficacy of Ad vectors as monotherapies remains 
frustratingly low (Ganly et al., 2000, Nemunaitis et al., 2001b), which is why 
combination therapies are now gaining ground in Ad therapies for ovarian (Table 1–
3) and other cancers. Khuri and colleagues showed that intratumoural ONYX-015 
injection in combination with cisplatin and 5-fluorouracil (5-FU) in patients with 
recurrent squamous cell carcinoma of the head and neck (SCCHN) showed objective 
response (63 %), with 27 % complete and 36 % partial responses (Khuri et al., 2000), 
which is significantly higher that phase I monotherapy trial outcomes with ONYX-015, 
where no objective responses were observed by conventional criteria (Ganly et al., 
2000). Modest anti-tumoural activity was observed in a phase II study in SCCHN 
patients receiving i.t. ONYX-015 delivery, with reported 10 % complete response, 62 
% stable disease, and 29 % progressive disease rates (Nemunaitis et al., 2001b). 
Combination of potent Ad vectors with existing gene-, chemo- and radiotherapies is 
likely to result in better therapeutic responses due to multiple mechanisms of cancer 
cell killing, viral sensitisation and long-lasting anti-tumour immune responses 
[reviewed in (Chu et al., 2004, Jiang et al., 2011, Russell et al., 2012)].  
1.3.3 Immuno-oncolytic applications & cancer vaccines 
The persistent dilemma in Ad cancer therapies is tackling evasion of immune 
recognition whilst simultaneously stimulating long-term immunity against TAAs. 
Cancer immunotherapy is a currently a hot research topic in the cancer therapy field, 
and Ad-based vectors have great promise within this arena. Novel viral vectors 
commonly utilise two main mechanisms for host immune activation: (A) immune 
priming or cancer vaccination ‒ lysis of infected tumour cells that leads to innate and 
adaptive immune responses against TAAs, and (B) localised expression of 
immunoregulatory agents that modulate signalling pathways defective in different 
cancer types (Figure 1–15) [reviewed in (Lichty et al., 2014)]. TAAs are derived from 
proteins synthesised by the tumour cell, and may be either membrane-bound, 
secreted, cytoplasmic or nuclear-localized (Zarour et al., 2003). For an excellent 
review on the use of Ad vector for immuno-oncolytic applications, see (Jiang et al., 
2015). Recent years have seen the development and approval of multiple therapeutic 
mAbs called immune checkpoint inhibitors, that aim to break the cancer-driven 
immune tolerance. Suppressors of immune signalling pathways ‒ cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4; CD152) and programmed cell death 
protein 1 / programmed cell death protein ligand 1 (PD-1/PD-L1) ‒ are currently the 
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most commonly targeted molecules for mAbs. Ipilimumab and tremelimumab are anti-
CTLA-4 antibodies, while an anti-PD1 mAbs nivolumab and pembrolizumab dampen 
down the PD-1 pathway, and atezolizumab targets PD-L1. They have already been 
approved for several indications by U.S. Food and Drug Administration (FDA) and 
European Medicines Agency (EMA), and are undergoing extensive clinical evaluation 
in various cancer types. Immune checkpoint blockade strategies for cancer 
immunotherapies are further discussed in an excellent review (Postow et al., 2015).  
 
Immuno-oncolytic Ad vectors can potentially be used in combination with 
conventional chemo- and radiotherapies in order to target both primary and metastatic 
tumours, and to achieve an enhanced and long-lasting therapeutic effect. Combining 
the oncolytic activity of the virus with an immunostimulatory agent is likely to result in 
improved tumour eradication. Oncolytic Ads can be modified to carry ‘cargo’ 
molecules ‒ to express mAbs directed towards TAAs, T-cell receptors, immune 
checkpoint inhibitors, cytokines, and programmed to target DCs and TILs.  Ads infect 
cells in a receptor-dependent manner, and elicit subtle innate and adaptive immune 
responses, which makes them feasible cancer vaccine vectors for priming and 
stimulation of the host’s immune system [reviewed in (Majhen et al., 2014)]. Ads can 
be rendered tumour-selective, in situ cancer vaccines, providing higher cancer-
specificity and better safety margin. Additionally, they are able to kill cancer cells 
through a range of mechanisms from direct virus-mediated cytotoxicity, cell death due 
to anti-angiogenesis and vasculature targeting, to cytotoxic immune effector-induced 
cytotoxicity by apoptosis, necrosis, and autophagy (Woller et al., 2014). In an ideal 
situation, the strong elicited immune memory will be able to recognise and attack the 
tumour cells in the event of a relapse or development metastatic tumours at any 
anatomical location later in the patient’s life. Immuno-oncolytic applications are 
discussed in greater depth in the recent review by our group (Uusi-Kerttula et al., 
2015a). 
  
Figure 1–15. The dual mechanism 
of oncolytic virotherapy. (1) Tropism-
modified adenoviruses (Ad) infect cells 
via cancer-specific cell receptors (X). (2) 
Viral replication occurs in the nucleus of 
cancer cells with aberrant retinoblastoma 
protein (RB) or p53 signalling pathways. 
(3) Viruses are released via autophagy, 
leading to bursting of the cell membrane. 
(4) Cytolysis activates pathogen-
associated molecular patterns (PAMPs) 
and damage-associated molecular 
patterns (DAMPs) that (5) activate 
immune responses and antigen 
presentation. Viral oncolysis may cause 
(6a) anti-viral immunity without tumour 
regression. Ideally, oncolysis leads to 
(6b) anti-tumoural immunity and tumour 
progression, enhanced by the viral-
encoded checkpoint inhibitors such as 
anti-programmed cell death protein 1 
(PD1) monoclonal antibodies. ATP, 
adenosine triphosphate; HMGB1, high 
mobility group box protein 1; HSP, heat 
shock protein. Modified from (Jiang et al., 
2015). 
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1.3.4 Future directions 
Promising clinical outcomes (Kaufman and Bines, 2010, Andtbacka et al., 2014) 
from the OPTiM phase III clinical trial of a herpes simplex type 1-based immuno-
oncolytic vector talimogene laherparepvec (T-VEC; trade name Imlygic) helped to re-
energise the field of oncolytics. T-VEC was licenced for the treatment of advanced, 
unresectable melanoma by FDA in October 2015 (FDA, 2015) and by EMA in 
December 2015 as the first oncolytic immunotherapy in Europe. There is now clear 
evidence that virotherapies are finally coming of age in the clinical field. Technologies 
based on Ad are likely to be heavily represented among clinical virotherapies due to 
their ease of scale up, amenable genomes, long clinical history and potential to 
achieve tumour-selectivity. It is clear that a wide variety of safety and efficacy 
considerations must be addressed with regards to Ad-based delivery systems. 
Thorough molecular knowledge of the basic underpinning biology to delineate the 
virus: host interactions that determine off-target tropism and toxicity, is needed. Firstly, 
Ads must be re-engineered and optimised to evade pre-existing immunity and other 
dose-limiting interactions that promote uptake into a wide variety of non-tumour sites. 
Secondly, to ensure selectivity of transduction, tumour-selective targeting ligands are 
to be inserted into the viral capsid. Thirdly, “safety nets” must be integrated into the 
viral genome to ensure replication/transgene expression is unique to cancerous cells, 
for example, through the inclusion of tumour-specific promoter elements or miRNA 
silencing elements. Finally, the delivery of a suitable payload must be incorporated 
into the viral genome, whether a gene that directly or indirectly induces cell suicide in 
the tumour cells, or one that helps to stimulate a suitable host anti-tumour immune 
response. The relationships between cancer biomarkers and oncolytic viral vectors is 
likely to become increasingly important and warrants thorough investigation. 
Tookman and colleagues recently showed increased cytotoxicity using a oncolytic 
Ad5 in Brca2-positive HGS-OC cells that have an intact homologous recombination 
(HR) function (Tookman et al., 2016). This is a remarkable finding as cancers with 
intact HR commonly have a low response rate to platinum chemotherapy and PARP-
inhibitors, accompanied with a poor prognosis. Evidently, innovative strategies for Ad 
vector design, coupled with cancer biomarker evaluation and selective immune 
stimulation within the TME, hold significant promise for effective cancer eradication. 
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1.4 Limitations of adenoviral cancer therapies 
Despite decades-long investigations of Ad utilisation for therapeutic purposes, 
severe limitations to its potent and safe clinical use remain (Figure 1–16). 
Improvement strategies for therapeutic Ad vector design are discussed in section 1.6. 
 
Figure 1–16. Limitations of adenoviral (Ad) cancer therapies. (1) Ad vectors are sequestered by 
multiple circulating proteins and cells in the blood, and end up taken up by the liver and spleen. (2) Pre-
existing anti-Ad neutralising antibodies and complement proteins opsonise and inactivate the virus. (3) 
Anti-tumour efficacy is low due to down-regulation of the native coxsackie and adenovirus receptor (CAR) 
in progressive cancers and poor accessibility of the tumour mass. 
 
1.4.1 Native CAR down-regulation & inaccessibility in cancer 
The native receptor of Ad5, CAR, is ubiquitously expressed on the apical surface 
of healthy polarised epithelial cells [reviewed in (Coyne and Bergelson, 2005)]. Early 
reports documented decreased CAR expression among various cancer types, such 
as bladder (Li et al., 1999b), lung (Pearson et al., 1999), pancreatic (Pearson et al., 
1999) and ovarian cancer (You et al., 2001, Kim et al., 2002b, Kim et al., 2002a), as 
well as SCCHN (Li et al., 1999a) and malignant gliomas (Asaoka et al., 2000). In a 
recent large study (Reeh et al., 2013) involving 3714 specimens from 100 
malignancies and from 273 normal control tissues the frequency of CAR expression 
was widely varied, based on immunohistochemical staining from tissue microarrays 
(Table 1–4). The observations of this study largely agree with previous findings, with 
the exception of bladder cancer that has shown CAR down-regulation in previous 
studies (Li et al., 1999b, Sachs et al., 2002, Matsumoto et al., 2005, Buscarini et al., 
2007). The absence of CAR in the target tissue has a great impact on Ad transduction, 
and hampers therapeutic efficacy. 
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Table 1–4. Coxsackie and adenovirus receptor (CAR) expression level in human tissues. * = 
CAR tissue distribution based on a large study involving 3714 samples (Reeh et al., 2013), unless 
indicated otherwise. Expression in neoplastic tissues in grey; expression in normal tissues in italics. 
Range indicates the variation between different cancer types in the specified organ. 
Organ % of positives Organ % of positives 
adrenal cortex 
0 
ovary 
0 
25‒60.5 31.6‒100 
anal skin 
20 
pancreas 
80 
46.7 72.2‒82.1 
bone tumours 
nd 
parotis 
50 
50 11.7‒85.2 
brain 
0 
penis 
40 
10‒54.2 45.7 
breast 
18.2 
platelets 
positive  
(Carlisle et al., 2009, 
Seiradake et al., 2009) 
4.3‒24.1 nd 
cervix 
25 
prostate 
69.2 
50‒82.5 7.9 
colon 
92.3 
renal cell cancer 
73.7 
50‒80 5.9‒78.6 
endometrium 
21.1 
skin 
41.2 
75.5‒91.7 0‒91.3 
erythrocytes 
positive  
(Carlisle et al., 2009, 
Seiradake et al., 2009) small intestine 
42.9 
nd 50 
gall bladder 
88.9 
stomach 
80 
45.7‒60 37‒87.1 
heart 
low in adults (Noutsias 
et al., 2001) tendon sheat 
50 
nd 12.5‒72.7 
larynx 
0 
testis 
40 
63.6 26.1‒29.5 
liver 
100 
thymus 
0 
84.9 36.4 
lung 
45.8 
thyroid 
25 
20‒84.2 0‒90.3 
lymph node 
25 
urinary bladder 
0 
12.5‒13.2 30‒88.3 
muscle 
35.7 
vagina 
40 
0‒28.6 70 
naevus 
60 
vulva 
75 
41.2‒48.9 90 
oesophagus 
80   
67.8‒85.7   
 
In earlier reports, CAR and αvβ3/5 integrin expression were highly variable 
between five analysed ovarian cancer cell lines, resulting in variation in the Ad vector 
transduction efficiency (You et al., 2001). Similarly, Kim and colleagues demonstrated 
that the efficacy of Ad cancer therapies was severely hampered by the absence of 
CAR receptors in tumours (Kim et al., 2002b), while transient expression of CAR in 
ovarian cancer cells enhanced Ad transduction (Kim et al., 2002a). Highlighting the 
importance of cell sensitivity to oncolytic Ads, a recent study by Ingemarsdotter and 
colleagues showed that paclitaxel-induced CAR up-regulation enhanced oncolytic 
Ad5 vector efficacy in paclitaxel-resistant ovarian cancer cells via aberrant cell cycle 
control mechanisms (Ingemarsdotter et al., 2015). 
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Another obstacle is the localisation of the cellular target receptors within cancer 
tissue (Figure 1–17). CAR is localised in tight junctions between the epithelial cells 
within the epithelium and is therefore not directly accessible on the surface of the 
tumour.  In order to infect the cancerous tissue, the virus has to be able to break its 
way through the ECM into the tumour mass. The process of breaking through the first-
line barriers of infection may be facilitated by using tight junction openers and ECM-
degrading proteases that help the virus to penetrate deep into the tissues [reviewed 
in (Vähä-Koskela et al., 2007). Once inside the tissues the virus can process into 
oncolysis and release more helper proteases that boost virus spread. The loss of CAR 
expression in advanced cancers necessitates the development of alternative cellular 
receptors for cancer targeting. In an ideal situation, an optimal cancer marker would 
be over-expressed on the surface of cancer cells but virtually absent in healthy adult 
tissues. This feature is crucial for enabling the high level of cancer-selectivity and to 
avoid undesired adverse effects. 
 
 
Figure 1–17. Strategies for improving receptor accessibility for therapeutic viruses. ECM 
restricts Ad entry into the epithelium, which can be facilitated by matrix-degrading proteases (MDP) that 
degrade the extracellular matrix (ECM). TJOs can be utilised to open tight junctions and facilitate Ad 
access to CAR. Ad, adenovirus; TJO, tight junction opener. Modified from (Vähä-Koskela et al. 2007). 
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1.4.2 Sequestration by blood factors and off-target delivery 
Intravascular delivery of Ad5 vectors results in rapid recognition and opsonisation by 
various blood cells such as MΦs, platelets (Othman et al., 2007, Gupalo et al., 2011) 
and erythrocytes (Carlisle et al., 2009) [reviewed in (Coughlan et al., 2010)]. Vitamin 
K–dependent coagulation factors FVII, FIX, FX and protein C have been shown to 
enhance vector transduction in vitro (Parker et al., 2006). FX has been shown to be 
able to rescue liver transduction in mice that had been treated with warfarin to deplete 
vitamin K‒dependent zymogens (Waddington et al., 2007, Waddington et al., 2008). 
Ad5 is trapped from the bloodstream and trafficked into the liver (Smith et al., 2002) 
within the first hour of systemic administration (Green et al., 2004). Ad vectors (via 
HVR1, 2, 5 and 7) are rapidly sequestered by Kupffer cells (KCs) that hijack Ad via 
scavenger receptors (Khare et al., 2012), leading to viral saturation and destruction 
of the KCs. The FX-decorated virus is then taken up by hepatocytes ‒ the major cell 
type of the liver parenchyma ‒ and tissue-resident MΦs (Wolff et al., 1997) via 
HSPGs. The high affinity interaction between Ad5 hexon HVRs and FX is well-
characterised and further discussed in sections 1.2.2 and 1.2.3. Up to 98 % of 
systemically administered Ad5 seems to end up in the liver (Green et al., 2004), which 
triggers the production of chemokines/interferons (INF) and leads to recruitment of 
neutrophils. In severe cases, the extensive innate inflammatory attack may also result 
in hepatic necrosis and apoptosis [reviewed in (Russell, 2000, Russell, 2009), which 
together contribute to the development of acute transaminitis, vascular damage and 
severe toxicities (Shayakhmetov et al., 2005b). Extended blood availability and 
decreased hepatotoxicity have been described for Ad5 vectors whose surface was 
masked with poly(N-(2-hydroxypropyl)methacrylamide) (HPMA) polymer (Green et 
al., 2004).  
Spleen is the secondary off-target site for systemically-administered Ad5 vectors 
(Di Paolo et al., 2009). It is a central part of the lymphatic system and the main factory 
for cytokine and antibody production. Scavenging marginal zone MΦ (MARCO+) and 
marginal metallophilic MΦ (CD169+) within the marginal zone are the primary target 
cells of systemically-delivered Ad5 vectors in the spleen (Di Paolo et al., 2009). In this 
study, Di Paolo and colleagues showed that Ad5 binding via RGD motif to αvβ3 
integrins on the surface of marginal zone MΦ triggers IL-1α production, thus 
contributing to innate anti-viral immune responses. Substitution of Ad5 HVRs 1‒7 with 
the corresponding regions from non-FX binding Ad48 serotype (AdHVR48(1‒7)) did 
not result in significantly increased vector uptake in the spleen but did increase 
production of inflammatory chemokines (interferon γ-induced protein 10 (IP-10), 
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MCP-1, and MIP-1α) and cytokines (IL-5, IL-6, MCP-1, and IP-10) (Coughlan et al., 
2012). In the same study, Ad5 and Ad5HVR48 were also associated with ER-TR7+ 
reticular fibroblasts and MAdCAM-1+ cells in the spleens of MΦ-depleted animals. 
Based on these observations the splenotropism of pseudotyped Ads appears 
unpredictable, involving penton-independent mechanisms and may be dictated by 
various interactions between multiple cell types. Further investigating the 
splenotropism of different Ad serotypes will be crucial in future vector development 
strategies. 
1.4.3 Innate & adaptive immune responses 
The three major capsid proteins, early proteins E1A, E1B, E2 and E4, and virus-
associated non-coding RNAs VA-I and VA-II, are central in the synergistic activation 
of innate immune responses that lead to inflammation and vector clearance [reviewed 
in (Hartman et al., 2008, Hendrickx et al., 2014)]. Following systemic Ad5 vector 
administration, the virus is rapidly recognised and coated by proteins of the 
complement cascade (Figure 1–12) (Cichon et al., 2001, Appledorn et al., 2008) and 
IgM antibodies that readily recognise repetitive pathogen structures such as virus 
capsids (Ochsenbein et al., 1999) [in vivo blood interactions reviewed in (Coughlan et 
al., 2010)]. Human (but not murine) erythrocytes express CAR and complement 
receptor 1 (CR1) and are can rapidly coat and inactivate the Ad5 particles following 
systemic delivery (Carlisle et al., 2009). Ad5-based vectors are efficiently opsonised 
by complement factors ‒ even in the absence of nAbs ‒ which indicates central 
involvement of this pathway in both innate and adaptive arms of anti-Ad immunity 
(Cichon et al., 2001). Rapid chemokine and cytokine production, as well as Ad5-
induced thrombocytopenia mediated by p-selectin and von Willebrand factor (vWF) 
(Othman et al., 2007), are all elicited in a C3-dependent manner, with the help of other 
complement factors (Appledorn et al., 2008) such as C2 and C1q [reviewed in 
(Coughlan et al., 2010)]. Innate activation of IFN production by viral infection boosts 
production of chemokines, attracting neutrophils, mononuclear and natural killer (NK) 
cells. 
Systemic Ad delivery results in vector binding to β3 integrins via penton RGD motif 
on marginal zone macrophages (MZMΦ)  leading  to accumulation in the spleen, 
which initiates IL-1α-mediated activation of chemokine- and complement cascade, 
promoting polymorphonuclear leukocyte (PMN) activation and local inflammation (Di 
Paolo et al., 2009). Recent publications have also reported novel roles for the non-
inflammatory factor of the coagulation pathway, namely FX, indicating its involvement 
in Ad5 virus shielding from neutralisation by natural IgM antibodies and subsequent 
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activation of the complement cascade (Xu et al., 2013). Conversely, decoration of the 
virus particle with host FX has also been suggested to function as a pathogen-
associated molecular pattern (PAMP), triggering innate immune responses via Toll-
like receptor / nuclear factor κB (TLR/NF-κB) pathway (Doronin et al., 2012). 
Therapeutic Ad vector delivery results in long-lasting humoral and cellular immune 
responses in the human host (Juillard et al., 1995). Antigen-presenting cells (APCs) 
‒ DCs and immature MΦs ‒ recognise PAMPs and direct DC maturation and T-cell 
activation, leading to subsequent adaptive immune responses [reviewed in (Jooss 
and Chirmule, 2003, Thaci et al., 2011)]. Ad infection elicits NK cell (Tomasec et al., 
2007), cytotoxic CD8+ T-cell (Sumida et al., 2004) and memory CD4+ T-cell activation 
(Olive et al., 2002). In addition to containing major nAb epitopes as described earlier 
(Sumida et al., 2005, Sumida et al., 2004, Roberts et al., 2006), the highly conserved 
regions of the hexon protein contain at least three major CD4+ T-cell epitopes (Olive 
et al., 2002, Onion et al., 2007). Systemic production of serotype-specific IgM, IgA 
and IgG (Ariyawansa and Tobin, 1976) and nAb seroconversion has been reported to 
occur within 2‒4 weeks of the primary virus exposure (Crawford-Miksza and Schnurr, 
1996). There is evidence that the intensity of humoral immune responses may be 
determined by vector administration site and pre-existing nAb titres rather than the 
therapeutic dose (Harvey et al., 1999). Different human and animal serotypes have 
been shown to have minimal levels of cross-reactivity, as nAbs seem to be specific to 
the homologous virus (Sharma et al., 2010). 
Anti-Ad nAbs comprise primarily fiber-, penton- and hexon-specific IgG1, IgG4 and 
IgA antibodies [reviewed in (Jooss and Chirmule, 2003)] that can inactivate the virion 
at different points of its infectious cycle (Gall et al., 1996, Sumida et al., 2005). Anti-
fiber nAbs seem to contribute to blocking the initial virus attachment to the cell surface 
by extracellular virion aggregation (Wohlfart et al., 1985), while anti-penton nAbs may 
be responsible for inhibiting the internalisation step (Hong et al., 2003) and a 
proportion of anti-hexon nAbs potentially account for intracellular, post-entry 
neutralisation (Varghese et al., 2004), although this remains controversial. It has been 
demonstrated that 1.4 individual serotype-specific anti-hexon nAbs are needed for full 
neutralisation of Ad2 (Wohlfart, 1988). Intriguingly, this study also describes how the 
neutralisation efficiency of anti-penton nAbs can be increased from 50 % to 100 % 
efficiency by lowering the pH from 7 to 5, which is presumably due to the exposure of 
the penton antigenic epitopes and subsequent interaction with anti-penton nAbs. 
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1.4.4 Pre-existing humoral immunity 
Ad5 is a common respiratory virus, and the majority of human populations have 
anti-Ad5 nAbs that are highly capable of neutralising the virus upon a secondary 
infection or re-exposure to a therapeutic vector. The highest seroprevalence rates are 
reported in the developing world, sub-Saharan Africa in particular (Nwanegbo et al., 
2004), while pre-existing nAbs levels against rare human serotypes from subgroups 
B and D are substantially lower in the studied populations (Nwanegbo et al., 2004, 
Abbink et al., 2007, Mast et al., 2010). The prevalence of nAbs against subgroup C 
viruses Ad5 and Ad6, and subgroup D viruses Ad26 and Ad36 was evaluated in an 
international study (Mast et al., 2010) that revealed overall high prevalence of pre-
existing anti-Ad5 immunity (85.2 %), Thailand having close to 100 % prevalence (Mast 
et al., 2010). Both subgroup D viruses had remarkably lower seroprevalence, overall 
values being 58 % for Ad26 and 46.4 % for Ad36. In paediatric populations in sub-
Saharan Africa, maternally-derived anti-Ad5 Ab titres were high until 6 months of age, 
then remained low until the age of two years the increasing rapidly until 
seroprevalence rates reached adult levels by seven years of age (Thorner et al., 
2006). It is thus crucial to take into account the variable seroprevalence rates between 
different Ad serogroups when selecting new Ad vector candidates for patients from 
different age groups, particularly when intended for i.v. delivery. 
Anti-fiber nAbs emerge first after the delivery of therapeutic Ad vector, followed by 
generation of anti-penton nAbs and anti-hexon nAbs, suggesting that all three are 
needed for a full synergistic neutralising effect (Gahéry-Ségard et al., 1998). However, 
there has been considerable controversy surrounding the specificity and 
immunogenicity of the capsid protein-induced nAbs that seem to vary based on the 
inoculation route. Reports have suggested a primary role for anti-hexon nAbs in 
vaccine-induced immunity (Sumida et al., 2005) and anti-fiber nAbs in natural 
infection (Särkioja et al., 2008, Parker et al., 2009, Cheng et al., 2010). According to 
Parker and colleagues, nAbs elicited by replication-deficient Ad5 vaccine vectors in 
seronegative individuals were directed against capsid components other than the 
fiber, while nAbs elicited by natural infection mainly were directed against the fiber 
(Parker et al., 2009). Previously seropositive individuals had nAbs against both fiber 
and other capsid components after vaccine challenge (Cheng et al., 2010). On the 
contrary, a recent study reports only subtle differences between the specificity of nAbs 
relative to the infection type (vaccination vs. natural), suggesting the 
immunodominance of hexon and subdominant assisting role for anti-fiber nAbs in 
neutralising immunity (Bradley et al., 2012a). 
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1.5 αvβ6 integrin ‒ an epithelial cancer marker 
Cancer cells often express a variety of cell surface markers that can give cues to 
the origin, metastatic spread, stage and prognosis of the primary tumour they originate 
from. EOC cells have been shown to express various markers including CD326 
(EpCAM), HER2 (Zhang et al., 2015), BRCA1/2 (Zhang et al., 2015), murine sarcoma 
viral oncogene homolog B (BRAF) (Zhang et al., 2015), Kirsten rat sarcoma viral 
oncogene homolog (KRAS) (Zhang et al., 2015), epidermal growth factor receptor 
(EGFR) (Zhang et al., 2015) and tumor protein 53 (TP53) (Zhang et al., 2015). CSC 
markers CD44 and CD133 have been suggested to be prevalent in tumour-initiating 
cells (TICs) (Garson and Vanderhyden, 2015), while endometrioid and HGS-OC has 
been shown to exhibit high EGFR expression (Zhang et al., 2015). Importantly, for 
any biomarker to be specific enough for successful cancer therapeutic applications, it 
has to be virtually absent in healthy adult tissues but significantly up-regulated 
throughout the process of carcinogenesis. Many of the markers mentioned above are 
expressed across various different cell types, and are thus not strictly EOC-specific. 
αvβ6 integrin however, is a highly cancer-specific marker and therefore has significant 
potential to be utilised for highly selective therapeutic cancer targeting.  
1.5.1 Structure and function of αvβ6 integrin 
Integrins play a central role in cell adhesion, cell motility and signalling processes, 
as discussed in section 1.2.3 of this thesis. Interestingly, RGD-binding integrins ‒ 
including αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5v1 ‒ also play central roles in cancer 
metastasis (Ganguly et al., 2013, Cantor et al., 2015). The integrin β6 subunit was 
originally identified from human pancreatic carcinoma epithelial cells in the early 
1990s, and shown to share 43, 38, and 47 % sequence homology with other β 
subunits 1, 3 and 5, respectively (Sheppard et al., 1990). αvβ6 is heterodimer that 
consists of an αv subunit (681 aa; GenPept GI: 720063178) and a β6 subunit (788 
aa; GenPept GI: 720063179) that contains an EGF-like motif (Dong et al., 2014b). 
The receptor has an open conformation on the membrane, and assumes a closed 
conformation when bound to its native ligands. Sheppard and colleagues identified 
an 11-amino acid extension in its C-terminus, absent in other β subunits, that has 
unique cytoplasmic interaction with extracellular signal-regulated kinase (ERK2) and 
activates ERK/MAPK pathway [mentioned in (Sowmya et al., 2014)]. αvβ6 integrin 
binds to fibronectin but not to vitronectin or collagen I, unlike other αvβx integrins 
(Busk et al., 1992). The β6 subunit pairs exclusively with αv and no other alpha 
subunits (Hynes, 2002). Alpha v integrins are the main up-stream regulators of 
transforming growth factor β1 (TGF-β1) ‒ a pleiotropic tumour suppressor cytokine 
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involved in control of epithelial cell division, whose activation is tightly controlled. In 
addition to TGF-β1, αvβ6 binds to TGF-β3 with high affinity (Dong et al., 2014b). In 
cancer cells, resistance to TGF-β1 suppression is orchestrated by an αv integrin-
mediated activation of the latent form of TGF-β1, which directly contributes to cancer 
metastasis (Figure 1–18). The role of TGF-β1 in tumour development is further 
discussed in an excellent recent review (Khan and Marshall, 2016). Compared to 
other integrins, αvβ6 has an extraordinarily high affinity to its ligands, which may be 
indicative of its specialised role in TGF-β activation rather than cell migration (Dong 
et al., 2014b). 
In addition to its cellular ligands, functional binding studies have shown αvβ6 
integrin to have natively high affinity to a structural VP1 protein from a single-stranded 
positive-strand RNA virus, type O1 foot-and-mouth virus (FMDV) (Dicara et al., 2008, 
Slack et al., 2016). This interaction is mediated via the integrin-binding RGD motif 
within a 20-amino acid peptide (A20, NAVPNLRGDLQVLAQKVART) in the VP1 
protein (DiCara et al., 2007) (Figure 1–19) that contains the viral major antigenic 
epitopes and is responsible for attachment of FMDV to host epithelial cells (Acharya 
et al., 1989). The A20-αvβ6 interaction has recently been characterised into great 
pharmacological and kinetic detail (Slack et al., 2016). According to the detailed 
evaluation by this group, αvβ6 binding to A20 peptide is equally strong as it is to its 
cellular ligand, TGF-β1. Interestingly, the RGD motif and its surrounding amino acid 
residues in TGF-β1 seem to form a similarly protruding hairpin loop structure (Dong 
et al., 2014b) as does the A20 peptide in FMDV in context of αvβ6 receptor binding 
(DiCara et al., 2007). The A20 peptide interaction is highly stable and EDTA-resistant, 
similar to the complex that an infectious FMDV forms with αvβ6 (Dicara et al., 2008). 
DiCara and colleagues also demonstrated that the αvβ6-mediated interaction is 
dependent on the presence of a conserved DLXXL motif in a post-RGD α-helical loop. 
In line with the observation, Dong and colleagues showed that αvβ6 recognises an 
LXXL/I motif in TGF-β3 that folds into an amphipathic α-helix, fitting snugly to the 
hydrophobic pocket in β6 subunit (Dong et al., 2014b). 
 
                                                                   
      
 
Figure 1–18. Activation of transforming growth factor β1 (TGF-β1) by αvβ6 integrin and its role in carcinogenesis. Mutations in the TGF-β1 signalling pathway promote 
carcinogenesis. (1) Latency associated peptide (LAP) together with latent TGF-β1 forms the small latent complex (SLC). (2) Binding of SLC to latent TGF-β-binding protein (LTBP) 
forms the large latent complex (LLC). (3) The LLC is secreted to the extracellular matrix (ECM), where αvβ6 binds LAP via its Arg-Gly-Asp (RGD) motif, thereby triggering 
activation of TGF-β1 either by a conformational change pathway or proteolytic cleavage pathway. Figure based on the comprehensive review by Khan and Marshall (Khan and 
Marshall, 2016).
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Figure 1–19. Foot-and-mouth disease virus (FMDV) capsid protein VP1. A20 peptide 
(NAVPNLRGDLQVLAQKVART) highlighted in green, integrin-binding motif (RGD, Arg-Gly-Asp) 
highlighted in red. GenPept GI: CAA00045.1, PDB ID: 1FOD1. Generated in PyMol version eval 1.1. 
 
αvβ6 is strictly epithelial-restricted and undetectable in healthy adult tissues 
(Weinacker et al., 1994, Ahmed et al., 2002b). αvβ6 is an intriguing member of the 
integrin family, as it has been linked to various tissue re-modelling, developmental 
and neoplastic events. In addition to carcinogenesis, these include foetal tissue 
development, wound healing (Haapasalmi et al., 1996), acute lung injury and 
idiopathic pulmonary fibrosis in the lung (Breuss et al., 1995, Horan et al., 2008), and 
fibrosis in the kidney and liver (Peng et al., 2016). Its over-expression correlates with 
cancer progression (Allen et al., 2014) and extremely poor survival. αvβ6 upregulation 
has also been linked to respiratory pathogen-induced pathogenesis (Meliopoulos et 
al., 2016). β6 knockout (KO) mice with normal lung morphology exhibited increased 
survival upon influenza infection, with high levels of CD11b+ alveolar MΦ and type I 
IFN, due to loss of TGF-β. β6 KO mice have also been shown to present with juvenile 
baldness, immune cell infiltration to the skin and airway epithelia, and 
hyperresponsiveness to acetylcholine, indicative of asthma (Huang et al., 1996). 
Female endometrium during menstrual cycle (Busk et al., 1992), and subclinical 
inflammation in the lung and skin (Huang et al., 1996) are the only known exceptions 
of its exclusive role in pathological tissue remodelling events. Low level of αvβ6 
expression has been observed in healthy basal keratinocytes, and in few cells in the 
kidney and trophoblastic cells in placenta (Professor John F Marshall, Barts Cancer 
Institute, London; personal communication).  
1.5.2 αvβ6 integrin expression in different cancers 
The initiation process for αvβ6 over-expression is not well established, although it 
is likely to be connected to changes in TGF-β1 signalling pathways. αvβ6 expression 
seems to be activated following an interaction between stromal border close to basal 
membrane, starting from just a couple of cells and then spreading around the tissue. 
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A patchy and non-uniform coverage is often observed within the tumour mass 
(Professor John F Marshall, Barts Cancer Institute, London; personal 
communication). αvβ6 integrin expression has been documented in a plethora of 
different cancer types (Table 1–5), including breast (Allen et al., 2014, Koopman Van 
Aarsen et al., 2008), cervical (Koopman Van Aarsen et al., 2008), skin (Koopman Van 
Aarsen et al., 2008), ovarian (Ahmed et al., 2002b, Koopman Van Aarsen et al., 2008), 
colorectal (Yang et al., 2008, Koopman Van Aarsen et al., 2008), prostate (Dutta et 
al., 2014), head and neck (Nothelfer et al., 2009), and cancer of the oral cavity 
(Thomas et al., 2006).  
Table 1–5. αvβ6 integrin expression in different cancer types. Modified 
from (Koopman Van Aarsen et al., 2008). N, number of analysed samples. 
Tumour site Positive expression % N 
Cervix 92 46 
Skin 84 49 
Oesophagus 68 56 
Head & neck 64 100 
Breast 43 145 
Lung 35 54 
Ovarian 33 52 
Kidney 21 103 
Colorectal 12 60 
Hepatocellular < 2 59 
Evaluation of 66 ovarian epithelial tissues revealed that αvβ6 was absent in all 
healthy ovarian tissues but expressed on all 45 carcinomas, of which 14 were 
borderline (low malignant potential) and 31 malignant tumours (Ahmed et al., 2002b). 
Additionally, the expression of αvβ6 correlated with cancer progression, observed as 
increased staining intensity on histological ovarian tissue samples, while no significant 
difference was observed between serous, endometrioid and mucinous tumour 
subtypes. Ahmed and colleagues also showed grade III tumours to have strong αvβ6 
expression throughout the tissue, while benign tumours expressed αvβ6 expression 
only at the epithelial edge of the tumour. The reports suggest an important role for 
αvβ6 in EOC progression, which implies it could be a promising target for ovarian 
cancer therapies. However, another study showed αvβ6 to be expressed in only a 
third of ovarian cancers (Koopman Van Aarsen et al., 2008), and therefore patient 
stratification may be required. Dutta and colleagues identified αvβ6 integrin up-
regulated in human prostate cancer bone metastases (Dutta et al., 2014). The authors 
also suggest its involvement in regulation of osteolysis by promoting matrix 
metalloproteinase 2 (MMP2) in an androgen receptor-independent manner, and co-
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localisation with parathyroid hormone-related protein (PTHrP) that is an inducer of 
osteoclastogenesis. It has also been shown to be involved in thyroid carcinoma 
colorectal cancer metastasis via activation of transcription factors and cell migration 
(Cantor et al., 2015). This excellent review highlights the role of the β6 subunit in 
activation of ERK2 and SDF-1/CXCR4, TGF-β1 and uPAR, which in turn is thought 
to contribute to metastasis. In prostate cancer cells, αvβ6 integrin is localised in focal 
contacts and binds to fibronectin and latency-associated peptide (LAP)-TGF-β1, thus 
mediating  attachment and migration (Dutta et al., 2014). Binding to LAP-TGF-β1 
promotes the activation of TGF-β1, leading to pro-metastatic and pro-invasive 
signalling pathways (Sheppard, 2000). Additionally, the role of αvβ6 in cancer 
progression has been demonstrated by using a function-blocking anti-αvβ6 antibody 
on head and neck cancer xenografts, which led to TGF-β-mediated inhibition of 
tumour growth (Koopman Van Aarsen et al., 2008). Taken together, αvβ6 may be a 
promising therapeutic target in cancers with a disrupted TGF-β activation. 
1.5.3 αvβ6 in cancer diagnostics, imaging and therapeutic targeting 
αvβ6 integrin presents a good molecular target for cancer therapies. Direct binding 
of ERK to β6 subunit is responsible for increase in cytosolic MAP kinase activation 
upon EGF stimulation (Ahmed et al., 2002a). In this study the deletion of ERK-binding 
domain from β6 inhibited tumour growth in vivo. A U.S. patent 7150871 claims that 
treatment with a function-blocking mAb anti-αvβ6 antibody 10D5 reduced the number 
of cancer cells in lung metastasis (USPTO, 2004). Furthermore, by blocking αvβ6 
using this antibody, apoptosis was induced in αvβ6-positive colon cancer cells (Zhao-
Yang et al., 2008), which is an interesting finding with therapeutic potential. A 
humanised single-chain Fv (scFv) antibody B6-2 was constructed by inserting a 17-
mer specificity-determining domain of FMDV A20 peptide 
(NAVPNLRGDLQVLAQKVART) into a murine scFv that is reactive with 
carcinoembryonic antigen (Kogelberg et al., 2008). The B6-2 antibody was shown to 
inhibit αvβ6-mediated cell migration and adhesion, and could potentially be used as 
a delivery vehicle of tumour-toxic agents. An αvβ6-blocking antibody 264RAD has 
shown great efficacy in HER2+/αvβ6+ breast cancers in combination with a mAb 
trastuzumab (Herceptin) in vivo (Moore et al., 2014). It is currently being developed 
for phase I clinical trials (BCI, 2015) and has great promise for the treatment of 
aggressive and resistant forms of breast cancer. The potential use of αvβ6 as a target 
for chimaeric antigen receptor (CAR) T-cell immunotherapies is reviewed in (Whilding 
et al., 2016). 
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The A20 peptide has also been evaluated for use in diagnostic applications for 
αvβ6 integrin-positive cancers. These cancers are known to present with an extremely 
poor prognosis and highly invasive and metastatic disease [reviewed in 
(Bandyopadhyay and Raghavan, 2009)], which underlines the necessity for their 
accurate and timely diagnosis. Hausner and colleagues have described conjugation 
of A20 peptide to a radiotracer for positron emission tomography (PET) imaging of 
αvβ6high pancreatic tumour model (Hausner et al., 2009). The authors demonstrate 
this to be a highly specific method with potential implications for non-invasive 
detection of pancreatic metastases. The A20 peptide can be used as an informative 
functional accessory for pre-clinical assessment of cancer and other disease models. 
By using a radiolabelled form of A20 ([3H]A20FMDV2), Slack and colleagues showed 
its affinity and selectivity for αvβ6 to be at least 85-fold higher than for other members 
of the integrin family (Slack et al., 2016). The authors also showed that the 
concentration-dependent and fast ligand-induced internalisation of αvβ6 receptor was 
followed by a relatively slow recycling of αvβ6 back to the cell surface, which may be 
due to the unique interaction between the RGD-motif with its binding site. Additionally, 
the ligand-receptor interaction was shown to be dependent on bivalent cations, Mn2+, 
Mg2+ and Ca2+. This study is the first one reporting comparable ability for the 
radioconjugated A20 peptide and LAP1 ‒ the endogenous ligand of αvβ6 ‒ to 
internalise the αvβ6 receptor (Slack et al., 2016). In a study by Liu and colleagues, a 
21-mer αvβ6-targeting peptide RGDLATLRQLAQEDGVVGVRK conjugated with 6-
hydrazinonicotinyl and radiolabelled with technetium-99m (99mTc) showed promising 
usability for non-invasive single-photon emission computed tomography (SPECT) 
imaging of αvβ6+ cancers (Liu et al., 2014). 
Due to its cancer-specificity, αvβ6 presents a highly cancer-specific cell surface 
marker and a potential cellular target for cancer gene therapies. Pameijer and 
colleagues successfully generated primary human T cells that carried a 12-mer αvβ6-
specific peptide (screened by phage display) as a CAR-targeting domain (Pameijer et 
al., 2007). In this study, cytotoxic T cells were successfully shown to kill αvβ6-
expressing ovarian cancer cells. Coughlan and colleagues reported the first attempt 
of targeting Ad5 vectors to αvβ6-positive cancer cells by an insertion of the A20 
peptide in the viral fiber knob (Coughlan et al., 2009a). In the current doctoral thesis, 
the approach validated by Dr Coughlan was taken further by incorporating additional 
de-targeting mutations in the αvβ6-targeted vector background in order to improve its 
off-target delivery profile.  
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1.6 Adenovirus vector design: de-targeting and re-targeting 
Systemic vector delivery remains the ‘Holy Grail’ for Ad therapies for cancer 
applications. To this end, the vectors require extensive genetic modifications to allow 
effective and safe therapies (Figure 1–20). Successful vector targeting to the liver, 
however, demands effective alteration of the viral tropism. These strategies all aim at 
avoidance of vector delivery into the liver, spleen and other organs, improving its 
availability for therapeutic function. Genetic modification strategies, including point 
mutations in the tropism-dictating viral proteins and swapping of capsid proteins from 
rare Ad serotypes, are discussed in the following sections. For an extensive review 
on chemical and physical de-targeting strategies, see our recent review (Uusi-Kerttula 
et al., 2015a). 
 
Figure 1–20. Transductional strategies for improved adenoviral vectors. Adenoviruses (Ad) can 
be modified by swapping the fiber knob domain or the whole fiber protein from other serotypes. 
Heterologous targeting peptide moieties can be genetically inserted in the viral capsid proteins. The 
vectors can also be directed away from the native receptors by introduction of de-targeting mutations in 
fiber, penton and hexon. The fourth option is utilisation of alternative serotypes that have novel receptor 
tropisms and low levels of pre-existing immunity. 
 
1.6.1 Ablation of native tissue tropisms 
The first, and the most important, step for improvement of vector blood-availability 
for the tumour tissue is the ablation of the three major tropism-determining interactions 
(Figure 1–21). Several CAR-binding mutations have been described for Ad vectors, 
including residues in AB (S408E, P409A) and CD (ΔV441, ΔK442) loops. CAR-
interaction is commonly knocked out by the introduction of two amino acid 
substitutions in fiber knob AB loop, Ser408Glu and Pro409Ala. This double 
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substitution was named ‘KO1’ by Smith and colleagues (Smith et al., 2002) ‒ the 
name is used for all CAR-binding-ablated Ad vectors throughout the thesis. In a 
pioneering study by Smith and colleagues, KO1 mutation abrogated fiber-mediated 
Ad transduction into CAR-expressing A549 (lung adenocarcinoma) cells (Smith et al., 
2002). No negative impact was observed from the mutation for fiber protein production 
or viability of the virions. To the authors’ surprise, the KO1-modified vectors were still 
capable of transducing hepatocytes at equal or even increased levels compared to 
the parental Ad5. This was a very important observation that prompted scientists in 
the Ad field to study the involvement of alternative receptors in in vivo Ad entry. 
Rigorously implemented studies on Ad tissue tropism subsequently revealed that Ad5 
hexon protein binds to hepatocytes via FX, leading to vector uptake and liver infection 
in vivo (Waddington et al., 2008). A point mutation E451Q in HVR7 has been 
dominated as the central for ablating the interaction, and has been introduced as a 
common method for de-targeting Ad5 from FX.  Alba and colleagues performed an 
extensive comparison of a panel of hexon HVR mutations, assessing their impact on 
binding affinity to FX (Alba et al., 2009). A combination of five mutations ‒ I421G, 
T423N, E424S, L426Y and E451Q ‒ in hexon HVR7 showed superior ability to 
completely block binding to FX. Based on this comprehensive assessment, this 
combination of HVR7 mutations was chosen to be incorporated into our Ad vectors, 
and is called ‘HVR7’ mutation for simplicity throughout this thesis. 
 
Figure 1–21. Tropism-ablating amino acid substitutions in adenovirus capsid proteins. KO1 
mutation in fiber knob ablates binding to coxsackie and adenovirus receptor (CAR) (Smith et al., 2002), 
HVR7 mutation in hexon ablates binding to coagulation factor X (FX) (Alba et al., 2009), and RGE 
mutation in penton ablates binding to αvβ3/5 integrins (Wickham et al., 1993). HVR7, hypervariable 
region 7; RGD, integrin-binding motif. 
 
Ad penton base mediates viral internalisation into the host cells, and plays a role 
in induction of innate immune responses against the Ad virion. A single amino acid 
point mutation D342E within the RGD motif (RGD > RGE) has been characterised to 
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ablate vector internalisation into αvβ3/5 integrin-expressing cells (Wickham et al., 
1993). Additionally, this motif has a secondary role in the induction of innate immune 
and anti-Ad5 inflammatory responses (Di Paolo et al., 2009), which emphasises the 
importance of mutating this site for an ablated vector backbone. In a previous study 
by Bradshaw and colleagues, the combination of FX-binding ablation and RGD > RGE 
mutation led to decreased splenic uptake and attenuated antiviral responses as 
compared to the wild type Ad5 (Bradshaw et al., 2012). This mutation has been 
incorporated into the vectors generated in this thesis study, and is referred to as ‘RGE’ 
mutation. It is likely that a combination of the described tropism-ablating mutations is 
needed for successful deterioration of therapeutic Ad vector entry into the main off-
target sites, namely the liver, spleen and lungs. As the Ad field is geared towards 
designing systemically-delivered therapeutic anti-cancer agents, it is important that 
these mutations and their clinical significance is comprehensively assessed. The 
experimental part of this thesis discusses the evaluation of these de-targeted 
mutations in vitro and in vivo settings. 
1.6.2 Serotypes with alternative tropisms 
The utilisation of alternative Ad serotypes for cancer therapies is intriguing for two 
reasons: (A) anti-Ad5 humoral immunity may be circumvented by using less common 
serotypes that have low natural seroprevalence in the general human population, and 
(B) tumour-targeting may be improved due to their variable (non-CAR) receptor and 
tissue tropisms. Ad vectors have been extensively modified by exchanging specific 
capsid components with those from less seroprevalent or immunogenic serotypes 
[virus chimaeras reviewed in (Kaufmann and Nettelbeck, 2012)]. Chimaeric or 
pseudotyped vectors with altered cell selectivity, antigenicity and tissue tropism have 
been successfully tested in both pre-clinical (Gall et al., 1996, Ophorst et al., 2004, 
Roberts et al., 2006, Abbink et al., 2007, Särkioja et al., 2008, Penaloza-MacMaster 
et al., 2013) and clinical trials (Kuhn et al., 2008, Nokisalmi et al., 2010, Vassilev et 
al., 2015) over the past decades. 
Ad subgroup D has the largest diversity of viruses, coupled with other advantages 
such as low seroprevalence rates (Abbink et al., 2007) and low affinity to FX 
(Waddington et al., 2008). The members can infect their host cells via multiple surface 
receptors, such as CD46 (Chen et al., 2010, Li et al., 2012), CAR (Chen et al., 2010), 
SA (Burmeister et al., 2004) and GD1a glycan (Nilsson et al., 2011), whilst the 
involvement of additional receptors has not yet been ruled out. In a recent study Ad9 
was the most efficient at infecting both CAR+ and CAR‒ cells out of 16 different species 
D Ads (Uchino et al., 2014). Ad35, -26 and -48 vaccine vectors have been 
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demonstrated to be more immunogenic in rhesus monkeys than Ad5 (Teigler et al., 
2012). An interesting study compared the replication efficacy and oncolytic potency 
of 15 different species B, C, D and F viruses on B-cell cancer cell lines and primary 
cancers (Chen et al., 2011a). Species D viruses were overall most oncolytic in vitro, 
while serotypes Ad26, -45 and -48 showed markedly improved oncolysis compared 
to all other viruses, including Ad5. Mastrangeli and colleagues demonstrated no 
cross-reactivity between Ad4 (species E) and Ad30 (species D) with Ad5 (species C) 
(Mastrangeli et al., 1996), showing that Ad4 and Ad30 were capable of efficiently 
transducing the airway the epithelium, regardless of a prior exposure to Ad5. Another 
subgroup C vector, Ad2, indicated circumvention of pre-existing immunity but 
compromised transgene expression (Mack et al., 1997). 
One of the selection criteria for a good anti-cancer virus is its potent replication and 
oncolysis. Accelerated evolution is a novel technique that has been introduced into 
the field of Ad vector design. It may be utilised for generation of potent recombinant 
viruses with altered virulence, tropism and immunogenic properties that are deviant 
from the properties of their parent serotypes. This strategy mimics the inherent 
random recombination occurring between different Ad serotypes in human 
populations. In a study by Kuhn and colleagues, multiple Ad serotypes from various 
subgroups were passaged on a panel of cancer cell lines, directing the emergence of 
a chimaeric Ad3/11p serotype vector (Kuhn et al., 2008). EnAd (discussed in section 
1.3.2) has shown superior oncolytic properties on colon cancer cell lines as compared 
to the previously developed oncolytic Ads (Kuhn et al., 2008). The vector carries a 
large deletion in E3 region, a small 24 bp deletion in E4 region and a chimaeric 
Ad3/Ad11p E2B region such that the pTP and DNA pol regions have been swapped 
to those from a species B1 virus Ad3. Its major capsid proteins appear to originate 
from a species B2 virus Ad11p. EnAd has a superior blood persistence as compared 
to Ad5 (Di et al., 2014) ‒ a highly advantageous feature for an oncolytic vector 
intended for i.v. treatment of disseminated solid tumours. The use of non-human or 
‘xeno’ Ads as cancer vectors is discussed in a recent review by our group (Uusi-
Kerttula et al., 2015a).  
1.6.3 Immune-naïve vectors: rare species D and non-human Ads 
Commonly utilised Ad5 vectors can be ‘pseudotyped’ by switching the major 
immunodominant regions into domains from less seroprevalent or immunogenic 
serotypes [for a review, see (Kaufmann and Nettelbeck, 2012)]. Exchange of Ad5 
hexon HVRs with low seroprevalence, species D Ad48 HVRs (Ad5HVR48) resulted 
in altered vector immunogenicity. In one study Ad5HVR48 efficiently escaped anti-
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Ad5 nAb responses and showed comparative immunogenicity to the parental Ad5 
(Roberts et al., 2006), while in vivo studies by Coughlan and colleagues showed 
significantly increased splenotoxicity and immunogenicity for Ad5HVR48 in mice 
following i.v. delivery, despite favourably decreased hepatotropism (Coughlan et al., 
2012). More recently, Teigler and colleagues showed that Ad5HVR48 could evade 
pre-existing anti-Ad5 nAbs with reduced hepatotoxicity and comparable T-cell 
responses with Ad5 (Teigler et al., 2014). These conflicting observations highlight the 
unpredictable nature of chimeric Ad vectors and reinforce the importance of rigorous 
preclinical evaluation of recombinant vectors. 
Another widely exploited genetic modification approach is the swapping of either 
the Ad5 fiber knob domain or complete fiber protein with rare Ad serotypes. Fiber 
pseudotyping results in altered innate (Schoggins et al., 2005) and adaptive immune 
activation (Rogee et al., 2010, Parker et al., 2009), which implicates an important role 
for this genetic modification strategy. However, Ad5 fiber replacement with Ad7 
(species B) fiber did not change vector immunogenicity, despite successfully altered 
tropism (Gall et al., 1996). Similarly, Ophorst and colleagues have reported increased 
DC transduction and T-cell activation in vivo using an Ad35 fiber-substituted Ad5 
vector, but no protection from anti-Ad5 immunity (Ophorst et al., 2004). In contrast, 
Särkioja and colleagues showed increased gene delivery in mice treated with an Ad5 
vector with fiber knob domain pseudotyped with Ad3 fiber knob (Ad5/3) in presence 
of low and high nAb titres, in comparison to Ad5 (Särkioja et al., 2008). However, 
higher nAb titres induced by triple immunisation with Ad5/3 were capable of cross-
neutralisation of Ad5, which indicates the involvement of other neutralising epitopes 
either within fiber shaft or other capsomers.  
Denby and colleagues pseudotyped Ad5 with fibers from a species B virus Ad16 
and two species D viruses Ad19p and Ad37, showing equal or improved cell 
transduction, as compared to Ad5 (Denby et al., 2004).  Parker and colleagues 
evaluated a panel of pseudotyped Ad5 vectors with fiber derived from subgroup D 
Ads Ad17, -24, -30, -33, -45 and -47 and showed these vectors to directly interact with 
FX and to efficiently transduce the liver, demonstrating that hepatotropism is not fiber-
mediated (Parker et al., 2007). Pre-existing immunity was partially bypassed by 
pseudotyping Ad5 with fiber from a species D virus Ad45 (Ad5/F45) (Parker et al., 
2009) that had previously shown high levels of FX-mediated cell binding and 
transduction (Parker et al., 2007). The study demonstrated greatly improved 
protection for Ad5/F45 from highly neutralising anti-Ad5 nAbs, indicating that nAbs 
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are at least partially directed against the fiber protein and may contribute to 
extracellular neutralisation (Wohlfart, 1988).  
An Ad5-based Ad35 (species B) fiber-chimaeric virus (Ad5T*F35++) showed 
improved cell transduction and protection from anti-Ad5 nAbs in human sera (White 
et al., 2013). In addition to having the fiber protein from Ad35, Ad5T*F35++ has a 
mutation (T*) that ablates FX interactions (Alba et al., 2010), for combining potential 
immune evasion with efficient liver de-targeting. Coupled with penton pseudotyping, 
Ad5/F35/P35 vector transduced in vitro cultures, mouse CD46-transgenic ex vivo 
cultures, and human ex vivo cultures at significantly higher levels than either Ad5 or 
Ad/F35 (Parker et al., 2013). The observations suggest potential utility of this vector 
for targeting CD46high cancers. The comparative immunogenicity of different Ad 
serotypes is further discussed in our extensive review (Uusi-Kerttula et al., 2015a). 
1.6.4 Enhancement of tumour-tropism by targeting peptide insertion  
Ad vectors do not preferentially infect cancer cells, and therefore various strategies 
have been implemented to enhance their tumour-tropism. Modification of the main 
capsid proteins by genetic engineering to incorporate short heterologous targeting 
peptide sequences has been widely investigated within the field [reviewed in (Reetz 
et al., 2014, Coughlan et al., 2010)]. Peptide ligands could potentially serve for dual 
purposes, as the insertion of peptides may favourably shift antigenic recognition away 
from the major antigenic epitopes, in addition to efficient targeting to cancer markers. 
The fiber protein has been the most frequently modified for these purposes (Särkioja 
et al., 2008, Uusi-Kerttula et al., 2015b), due to the location of major antigenic 
epitopes within the knob domain (Xia et al., 1994), its native role in primary cell 
tethering, and its tolerance of genetic manipulation. 
Pre-existing anti-Ad nAbs present in the blood and bodily fluids rapidly recognise 
and eliminate systemically- or locally administered Ad vectors. For ovarian cancer 
applications, vector neutralisation by ascites may be circumvented by genetic 
masking of the fiber. Blackwell and colleagues reported successful evasion of nAbs 
in ascites using a tropism-modified Ad5 vector with an integrin-binding RGD motif 
insertion in the fiber knob (Blackwell et al., 2000). Our research has utilised a similar 
masking approach by genetically inserting short high affinity peptides targeted to 
receptors over-expressed on various tumours into the Ad5 fiber knob (Uusi-Kerttula 
et al., 2015b, Uusi-Kerttula et al., 2016). We genetically incorporated a short GE11 
peptide (YHWYGYTPQNVI) targeting cellular EGFR, or two peptides M* (MQLPLAT) 
(Maruta et al., 2002) and LS (LSPPRYP) (Wu et al., 2013) targeting FGFR1, into a 
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replication-deficient Ad5 vector (Uusi-Kerttula et al., 2015b). Although cancer 
targeting was not markedly improved, these vectors exhibited improved protection 
from anti-Ad5 nAb-mediated neutralisation. 
αvβ6 integrin is a particularly interesting cellular target receptor due to its over-
expression in progressive cancers (discussed in section 1.5.2). Several reports have 
described genetic incorporation of the A20 peptide from FMDV into viral vectors for 
targeting into αvβ6 integrin-expressing cancer cells (Coughlan et al., 2009b, 
Coughlan et al., 2014, Uusi-Kerttula et al., 2016). In a study by Coughlan and 
colleagues, A20 was genetically incorporated into the fiber knob HI loop within a 
recombinant enhanced green fluorescent protein (EGFP)-expressing Ad5 vector 
background (Ad5EGFPA20) (Coughlan et al., 2009a). This vector exhibited ~50-fold 
increased CAR-independent transduction and greatly enhanced cytotoxicity in 
αvβ6high cancer cells as compared to the parent vector Ad5EGFPWT, confirming 
successful A20-mediated cancer-targeting. Importantly, the safety of this vector was 
greatly improved relative to the natively hepatotropic Ad5EGFPWT, with significantly 
reduced liver uptake following systemic delivery. In this thesis we aim to utilise a 
similar approach for Ad vector targeting to αvβ6-expressing EOC.  
1.7 Hypotheses of this thesis 
The three experimental aims are: (1) Generation of de-targeted Ad5-based vectors 
with mutations in fiber knob, hexon and penton proteins to ablate native interactions 
with CAR, FX and αvβ3/5 integrins, respectively; (2) Generation of novel pseudotyped 
Ad5-based vectors with fiber or fiber knob from species D serotypes to study 
alternative receptor tropisms in vitro; (3) Generation of de-targeted, tropism-modified 
vectors by a genetic incorporation of the A20 peptide ligand from FMDV, targeting an 
epithelial-specific cancer marker αvβ6 integrin.  
We hypothesise that the combination of de-targeting mutations (‘3D’) will lead to 
strictly selective vectors that fail to transduce normal, healthy cells in the liver, spleen 
and other off-target sites, thus improving their toxicity profile. The A20 peptide-
modified vectors are expected to selectively transduce αvβ6+ cancer cells in vitro, 
primary clinical ascites-derived EOC cultures ex vivo and tumour xenograft models in 
vivo. The combination of A20 peptide insertion and fiber-pseudotyping is expected to 
facilitate vector protection from neutralisation by anti-Ad5 nAbs present in malignant 
ovarian ascites. Local i.p. delivery for the treatment of ovarian cancer is our proposed 
route to clinical translation.
                                                                   
   
CHAPTER 2. Materials and methods 
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2.1 Phenotyping of cell lines, primary cells and ovarian ascites  
This section describes the phenotyping and validation of suitable ovarian cancer 
model cell lines and primary EOC cell ex vivo cultures from clinical ovarian ascites. 
Ovarian ascites cell-free supernatants were also characterised for their anti-Ad vector 
neutralising properties and for the concentration of free FX. 
2.1.1 Basic cell culture techniques 
All cells were grown in a Human Tissue Act (HTA) certified cell culture incubator 
(HERA Cell, Thermo Scientific) at 37oC in a humidified atmosphere with 5 % CO2. All 
reagents and materials used for cell culture were sterile, disposable and individually 
packed. Cell lines were sourced either from American Type Culture Collection (ATCC) 
or collaborators, and cultured in a cell line-specific media and supplements (Table 2–
1). 
Table 2–1. Cell culture media. Basic cell culture media was used for culture of cell lines and primary 
cells. All media were supplemented with P/S, L-Glut and FBS. 
Abbreviation Full name Supplier Cat. # 
α-MEM 
Minimum Essential Medium Eagle 
alpha modification with 
Sigma, Gillingham, UK M8042 
DMEM Dulbecco’s Modified Eagle’s Medium  Sigma, Gillingham, UK D5796 
DMEM/F12 DMEM with F12 modification Sigma, Gillingham, UK D6421 
FBS 
Foetal Bovine Serum, heat 
inactivated 
Gibco, Paisley, UK 10500-064 
L-Glutamine L-Glutamine, stock 200 mM Gibco, Paisley, UK 25030-024 
DPBS 
Dulbecco’s Phosphate Buffered 
Saline 
Sigma, Gillingham, UK D8537 
P/S 
Penicillin 100 U/mL, streptomycin 100 
μg/mL 
Gibco, Paisley, UK 15070-063 
RBC lysis Red blood cell lysis buffer Sigma, Gillingham, UK R7757 
RPMI 1640 Roswell Park Memorial Institute 1640 Gibco, Paisley, UK 21875-034 
Trypsin 0.05 % Trypsin-EDTA, phenol red Gibco, Paisley, UK 25300-054 
Mammalian cell lines (Table 2–2) were regularly sub-cultured once or twice weekly 
by passaging into new sterile flasks when they reached 80‒100 % confluency. Slowly 
growing cells were generally cultured in T75 flasks (Corning, UK) and not split with 
higher ratio than 1:3, while very rapidly growing cells were split even 1:10 twice weekly 
into T150 flasks (Corning, UK). Sub-culture of cells growing in T150 flasks involved 
aspirating the cell culture medium and washing the cells with 10 mL (T75) or 20 mL 
(T150) of PBS. 2.5 % (T75) or 5 mL (T150) of 0.05 % trypsin was then added to the 
cells, swirled around to cover the entire monolayer, and incubated for ~ 5 min at 37°C. 
The side of the flask was then gently tapped until the cells were completely detached, 
as observed under the light microscope. BT-20 and SKOV3 cells attached to the flask 
more firmly than other cell types, and therefore detachment required two washes with 
PBS and scraping the bottom of the flask with a sterile single-use cell scraper (Greiner 
Bio-One, #82050-468, VWR) to collect all the cells. The cell suspension was then 
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divided into new flasks with an appropriate ratio (1:2‒1:10), depending on their 
subsequent usage. 10 mL (T75) or 20 mL (T150) of fresh cell culture medium was 
added into each flask and the cells incubated until appropriate level of confluency was 
reached. The cells were then sub-cultured once or twice a week for maintenance or 
used for in vitro assays. 
Table 2–2. Mammalian cell lines and growth conditions. collab., collaborators at Cardiff 
University; DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, foetal bovine serum; LC, Dr Lynda 
Coughlan (Oxford University, UK); puro, puromycin; RPMI, Roswell Park Memorial Institute. 
Cell line Cell origin Medium % FBS Suppl. Source 
A549 Human lung carcinoma RPMI1640 10 ‒ collab. 
BT-20 Human breast cancer α-MEM 20 ‒ LC 
CHO-K1 
Chinese hamster ovarian 
epithelial 
DMEM/F12 10 ‒ collab. 
CHO-CAR 
CHO transfected to express 
hCAR 
DMEM/F12 10 ‒ collab. 
HEK293 Human embryonic kidney DMEM 10 ‒ LC 
IGROV-1 
Human ovarian 
adenocarcinoma 
RPMI1640 10 ‒ collab. 
HEK293-β6 
HEK293 expressing β6 
integrin 
DMEM 10 
5 μg/mL 
puro 
LC 
OVCAR3 Ovarian cancer RPMI1640 20 ‒ collab. 
SKOV3 
Human ovarian 
adenocarcinoma 
DMEM 10 ‒ LC 
SKOV3-β6 
SKOV3 expressing αvβ6 
integrin 
DMEM  
5 μg/mL 
puro 
in-house 
T24 
Human urinary bladder 
transitional cell carcinoma 
DMEM 10 ‒ collab. 
T-REx 293 Human embryonic kidney DMEM 10 ‒ Invitrogen 
 
2.1.2 Generation of SKOV3-β6 ovarian cancer cell line 
A pBABE puro plasmid with human itgb6 gene (2400 bp; GenBank ID: 
NM_000888) from (pBABE-β6 puro; #13596, Addgene) (Figure 2–1) was received as 
a bacterial stab in DH5-α E. coli cells. This plasmid expresses the human integrin β6 
subunit that pairs in cells with αv subunit only, forming the αvβ6 heterodimer (Hynes, 
2002). The bacteria were amplified in an O/N culture of 250 mL low-salt powder (LB; 
#L1703, Melford Laboratories, Suffolk, UK) supplemented with 100 μg/mL Amp and 
plasmid was purified using NucleoBond BAC 100 purification kit (#740579, Macherey-
Nagel, Duren, Germany). DNA concentration was determined using NanoDrop ND-
1000 (Thermo Scientific, UK) and transfected into a packaging cell line 293Phoenix 
in a confluent T25 flask using Effectene transfection reagent (#301425; Qiagen, 
Manchester, UK) according to manufacturer’s instructions. After 48 h, the retrovirus-
containing supernatant was harvested and filtered through a 0.4 μm syringe filter to 
ensure complete removal of the 293Phoenix cells. The virus was snap-frozen in dry 
ice and stored at ‒80°C for subsequent use.  
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Figure 2–1. pBABE-puro plasmid backbone. The plasmid was purchased from Addgene with itgb6 
gene coding for the β6 integrin subunit cloned in (Snapgene, 2016). The plasmid carries ampicillin and 
puromycin resistance genes. 
 
In the following step the retrovirus was transfected into the target cell line, SKOV3. 
A 6-well plate was coated with RetroNectin reagent (#T100B, Takara Bio Europe SAS, 
France) O/N at 4ºC, washed with PBS. 1.5 mL of virus (supernatant from step above) 
was added in the coated well, the plate sealed in a bag and centrifuged at 2800 rpm 
at 30°C for 2 h to bind the virus to the bottom of the dish. The virus was removed, the 
bottom of the well was washed once with PBS and SKOV3 cells seeded at ~ 70 % 
density (1 × 105 cells/mL). After 48 h, the cells were detached from the plate using 
trypsin and seeded into a T25 tissue culture flask in DMEM medium supplemented 
with 5 μg/mL puromycin (#P8833, Sigma Aldrich, Gillingham, UK). After 3‒4 days the 
only surviving cells were cells expressing αvβ6 integrin. 
2.1.3 Ex vivo primary epithelial ovarian cancer (EOC) cell culture 
Permission for the collection and cultivation of EOC cells from ovarian ascites was 
granted through a Wales Cancer Bank application for biomaterials, reference WCB 
14/004. All patients gave written informed consent for the use of their samples prior 
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to collection.  A 400‒600 mL total volume of clinical ovarian ascites (OAS) was 
drained from ovarian cancer patients using an intraperitoneal (i.p.) catheter 
(paracentesis) as part of routine cancer care by trained nurses at Velindre Cancer 
Centre, Cardiff. OAS samples were received in sterile 500 mL containers generally 
within 3 hours from paracentesis. Samples were assigned into treatment groups 
according to the stage of chemotherapy (1, pre-treatment/chemo naïve; 2, 1st line 
chemo; 3, relapsed disease/platinum sensitive; 4, relapsed disease/platinum 
resistant). Samples were given ‘OAS’ codes to retain anonymity.  
Fluids were stored at 4oC following paracentesis and processed fresh within 24 h. 
Ex vivo cultures were established essentially according to a protocol by Dr Sandra 
Bell (Leeds Institute of Biomedical & Clinical Sciences, St James's University Hospital 
Leeds) and previously described methods (Shepherd et al., 2007, Thériault et al., 
2013). Initially, 100 mL of the original sample was aliquoted into five T75 tissue culture 
flasks (20 mL each) and 20 mL RPMI 1640 medium supplemented with 1 % 
Glutamax/L-Glutamin, 10 % FBS, 100 U/mL penicillin and 100 μg/mL streptomycin 
was added into each flask. The cells were allowed to attach for 3 days undisturbed. 
Media was then removed, cells washed with PBS and grown in complete EOC 
medium additionally supplemented with 10 % of cell-free autologous fluid 
supernatant. Medium was then changed twice a week and cells sub-cultured when 
they reached confluency (2‒4 weeks from culture initiation). Cell morphology of the 
established ex vivo cultures was monitored several times a week by visual 
examination under light microscope throughout cell passages. The cultures that were 
heavily contaminated with fibroblasts, were partially trypsinised for 1 min to remove 
fibroblasts that were more loosely attached to the plastic than EOC cells. Primary 
EOC cells in the remaining OAS sample (~ 400 mL) were pelleted by centrifugation 
at 1000 rpm for 5 min. Ascites supernatant was decanted into 50 mL falcon tubes and 
stored at −70oC. Cell pellets were pooled and treated twice with 2 mL of RBC lysis 
buffer according to the manufacturer’s protocol, in case of a heavy erythrocyte 
contamination. The cell pellet was washed with PBS and re-suspended in freezing 
medium (10 % dimethyl sulfoxide (DMSO) in 90 % FBS) and stored in liquid nitrogen 
tanks at −130oC (passage 0) for long term stocks.  
2.1.4 Long-term storage and recovery of cell lines 
Mammalian cell lines and primary EOC cell cultures were grown until confluent, 
washed with PBS and detached with trypsin. They were neutralised with complete 
medium and pelleted at 1200 rpm for 3 min, supernatant discarded and the pellet re-
suspended into 3 mL of 10 % DMSO in FBS. Cell suspensions were aliquoted into 1 
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mL and stored long-term in 1.5 mL cryovials (Corning, UK) in ‒130°C liquid nitrogen 
tanks. Primary EOC cell stocks were always established at passage 0 and 1. Passage 
numbers were not recorded for other cell lines. When cell culture was initiated, a vial 
of each cell type was removed from the tank, placed immediately on dry ice and 
rapidly thawed in a pre-warmed 37°C water bath for ~ 2‒3 min until no ice was visible. 
The contents of the vial were then removed with a 1 mL pipette into a T25 flask with 
10 mL of pre-warmed complete cell line-specific medium and left undisturbed for 24 
h. On the following day medium was aspirated and replaced with 5 mL of fresh 
complete medium, and cultured until a confluent cell monolayer was reached. Cells 
were sub-cultured as described in section 2.1.1. 
2.1.5 Direct ELISA for detection of anti-adenovirus antibodies in ascites 
Anti-Ad antibodies were detected from ascites according to a previously published 
protocol (Stallwood et al., 2000) (Figure 2–2). Viruses were diluted at 200 ng 
protein/ml in coating buffer (NaHCO3/Na2HCO3, pH 9.6) and heat-inactivated at 56ºC 
for 30 min. 96-well flat-bottom ELISA plates (#44-2404-21, MaxiSorp, Nunc; 
Affymetrix eBioscience) were coated with 100 μL of virus / well and incubated O/N at 
4ºC. Each well was washed six times with 200 μL of PBS-T (0.01 % Tween-20 in 
PBS). 2-fold dilutions (1:50‒1:51 200) of ascites samples and serum control were 
prepared in 1 % BSA/PBS-T and 100 μl of added into each well in duplicate for 2 h at 
room temperature (RT). The wash was repeated and wells incubated with 100 μL of 
anti-human IgG-HRP (1:10 000; goat α-human IgG-HRP, sc-2907, #J0914, Santa 
Cruz) in 1 % BSA/PBS-T for 1 h at RT. After a wash, 100 μL of substrate (1:1 mix of 
BD OptEIA TMB substrate reagents; #555214, Benkton Dickinson, Oxford, UK) was 
added into each well and incubated for 20 min at RT. The reaction was then stopped 
with 100 μL of 0.2 M H2SO4 and absorbance measured immediately at λ450 nm. 
 
Figure 2–2. Direct enzyme-linked immunosorbent assay (ELISA) for the quantification of anti-
adenovirus (Ad) antibodies in ovarian ascites. The order of reagents is depicted in numbers (1‒3). 
After adding the TMB substrate, absorbance was measured at λ490 nm. HRP, horse radish peroxidase. 
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2.1.6 Sandwich ELISA for detection of coagulation factor X in ascites 
An ELISA protocol was developed in-house for the detection of FX from ascites 
(Figure 2–3). Each well on a 96-well flat-bottom ELISA plates (MaxiSorp, Nunc; #44-
2404-21, Affymetrix eBioscience) was coated with 100 μL of a sheep anti-human 
coagulation factor X (FX) capture antibody (#ab110138, Abcam) at 2 μg/mL and 
incubated O/N at 4ºC. The wells were washed four times with 200 μL of PBS-T (0.01 
% Tween-20 in PBS) and plate dried on an absorbent tissue between each wash. 2-
fold dilutions (neat, 1:2 and 1:4) of ascites samples and serum control were prepared 
in 1 % milk/PBS-T and 100 μL added into each well in duplicate for 2 h at 37ºC on a 
rocker. Purified human FX (#HCX0050, Haematologic Technologies, Cambridge 
Bioscience, Cambridge, UK) was diluted (0‒10 μg/ml) in sample buffer and assayed 
on the same plate to generate a standard curve. After washing the wells four times 
with wash buffer as before, they were incubated with 100 μL of rabbit anti-human FX 
detection antibody (#ab80345, Abcam, Cambridge, UK) for 2 h at RT. The wash was 
repeated, and wells incubated with 100 μL of goat anti-rabbit IgG (H + L)-HRP 
conjugate (1:3000; #1706515, BioRad, Hertfordshire, UK) in 1 % milk/PBS-T for 1 h 
at RT. After serial washes, 100 μL of substrate (1:1 mix of BD OptEIA TMB substrate 
reagents; #555214, Benkton Dickinson, Oxford, UK) was added into each well and 
incubated for 20 min at RT. The reaction was then stopped with 100 μL of 0.2 M 
H2SO4 and absorbance measured immediately at λ450 nm. 
 
Figure 2–3. Sandwich enzyme-linked immunosorbent assay (ELISA) for the quantification of 
human coagulation factor 10 (FX) in ovarian ascites. The order of reagents is depicted in numbers 
(1‒3). After adding the TMB substrate, absorbance was measured at λ490 nm. HRP, horse radish 
peroxidase. 
 
2.1.7 Western blot for qualification of anti-Ad antibodies in ascites 
Viruses were run in a pre-cast NuPAGE Novex® 10 % Bis-Tris SDS-PAGE gels 
(#WG1201BOX; Life Technologies, Loughborough, UK) at 0.625, 1.25, 2.5 and 5 μg 
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of protein/well (1 μg of protein corresponding to 4 × 109 viral particles (Von Seggern 
et al., 1998)) in a total volume of 40 μl (including 2 μl of DTT and 10 μl of 4 x NuPAGE 
LDS sample buffer) for 1 h 20 min at 150 V. The proteins were transferred onto an 
Amersham Protran 0.45 μm nitrocellulose blotting membrane (#10600002; GE 
Healthcare Life Science, Little Chalfont, UK) by semi-dry blotting in a Trans-blot SD 
Semi-dry Transfer Cell (Bio-Rad, Hertfordshire, UK) for 1 h at 20 V. The membrane 
was blocked in 5 % milk/TBS-T for 90 min at RT or O/N at 4ºC on a rocker and 
incubated in ascites or serum at 1:500 in 5 %/TBS-T for 90 min at RT on a rocker. It 
was then washed three times for 10 min in TBS-T on a rocker at RT and incubated in 
secondary anti-human IgG-HRP (goat α-human IgG-HRP sc-2907 #J0914, Santa 
Cruz) at 1:2000 in 5 %/TBS-T for 1 h at RT on a rocker, and washed again three times 
for 10 min in TBS-T at RT on a rocker. The proteins were then visualised by incubating 
the membrane in 1:1 mixture of West Pico SuperSignal (#34078; Thermo Scientific, 
Paisley, UK) reagents for 10 min, and membrane imaged in G:BOX Chemi XX6 
imager (Syngene, Cambridge, UK). 
2.1.8 Flow cytometry for cell line receptor profiling 
Receptor expression profiles were determined for each cell line and EOC ex vivo 
culture by flow cytometry. A sufficient number of sub-cultured cells were detached 
from the flasks using 0.05 % trypsin, washed with complete DMEM at 1200 rpm for 3 
min and then re-suspended into 10 mL of ice-cold wash buffer (0.5 % FBS in PBS). 
Cells were counted on a haemocytometer and 1 × 105 cells added into each well in 
duplicate on a U-bottom 96-well plate (#268200, Nunc, Thermo Scientific, UK). Cells 
were then washed in 200 μL of ice-cold wash buffer, pelleted at 1500 rpm for 3 min 
at 4°C and kept on ice for the remainder of the protocol. Cells were incubated in 100 
μL of diluted primary antibodies (Table 2–3) on ice for 1 h and mixed well. The cells 
were re-pelleted, washed three times in 200 μL of ice-cold wash buffer, re-pelleted 
and incubated with 100 μL of diluted secondary antibody F(ab')2-goat α-mouse IgG 
(H+L) IgG AlexaFluor 647 (#A21237, Life Technologies, Paisley, UK) for 30 min on 
ice in the dark. After three washing steps the cells were re-pelleted and fixed in 200 
μL of ice-cold 4 % paraformaldehyde (PFA) for a minimum of 10 min (or O/N). Cells 
were analysed on a BD Accuri C6 version 1.0.264.21 (BD Biosciences, Oxford, UK) 
flow cytometer with pre-run washing steps according to the manufacturer’s 
instructions. Initially, the measurement was gated with unstained cells, and 2 × 104 
gated events were recorded per sample. The results were analysed using the BD 
Accuri software. 
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Table 2–3. Mouse anti-human primary antibodies used in flow cytometry. CAR, coxsackie and 
adenovirus receptor; EGFR, epidermal growth factor receptor. 
Target Clone Dilution Cat # Supplier 
αvβ6 10D5 1:100 MAB2077Z Millipore, Watford, UK 
CAR RmcB 1:500 05-644 Millipore, Watford, UK 
EGFR H11 1:200 MA5-13070 Thermo Scientific, Paisley, UK 
CD44 F10442 1:100 ABIN135705 antibodies-online 
CD46 MEM258 1:100 MA1-82140 Thermo Scientific, Paisley, UK 
normal IgG 
‒ 
1:200 
sc-2025 Santa Cruz Biotechnologies, Heidelberg, 
Germany 
2.1.9 Fluorescence activated cell sorting (FACS) 
SKOV3-β6 cells were sorted into high αvβ6 expressing populations prior to in vitro 
assays. Cells were stained with primary anti-αvβ6 antibody 10D5 (1:100) and 
secondary AlexaFluor 647 according to the flow cytometry protocol (section 2.1.8), 
except that the cells were left non-fixed. Cell sorting was performed on BD FACSAria 
II multicolour cell sorter (BD Biosciences) by Dr Kristin Ladell, Institute of Infection 
and Immunity, Cardiff University. Data were analysed in BD FACSDiva 8.0.1 software 
(BD Biosciences). Cells with the highest 10 % fluorescence intensity were selected, 
propagated and used for assays. SKOV3-β6 cell sorting prior to implantation of in vivo 
ovarian cancer xenografts was performed at the Microscopy and Cytometry Core at 
Mayo Clinic, Rochester, MN, USA. 2 × 107 cells were stained with a primary anti-αvβ6 
antibody 10D5 (1:100) and a secondary anti-mouse IgG/IgA/IgM-FITC conjugate 
(1:100; #0855499; MP Biomedicals, USA). The population with 10 % highest αvβ6 
expression was sorted and propagated in the presence of 5 μg/mL of puromycin 
selection antibiotic prior to implantation into mice. 
2.2 Recombinant fiber knob protein engineering 
Recombinant, soluble Ad fiber knob proteins were produced for competition 
inhibition assays for the assessment of pseudotyped vector tropism. The production 
and purification method has been previously validated and optimised elsewhere by 
Dr Lynda Coughlan [Oxford University, UK, (Coughlan et al., 2014)]. The pQE30 
expression plasmids contain a 6 x His tag at the C terminus of the knob sequence to 
enable efficient and rapid protein purification by nickel ion nitrilotriacetic acid (Ni2+-
NTA) affinity chromatography. The method is based on high affinity binding to the 
Ni2+-NTA agarose matrix between the polyhistidine tag (Figure 2–4) in the 
recombinant protein and increasing concentrations of imidazole present in the elution 
buffer. Histidine and imidazole have very similar ring structures that forms the basis 
for competitive binding into the agarose matrix. 
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Figure 2–4. Interactions between polyhistidine tag (left) and nickel–nitrilotriacetic acid (Ni2+-
NTA) matrix. The Ni2+ ion lies in octahedral coordination relative to two histidine side chains and four 
matrix ligands (Bornhorst and Falke, 2000). 
 
2.2.1 Predictive structural modelling of knob domains 
The potential knob protein structures with targeting peptide insertions were created 
to assess the spatial conformation of the inserted peptides in the context of the 
homotrimeric knob structure to predict their feasibility as complete virus particles. Ad5 
(GenPept: AAP31231.1), Ad48 (GenPept: ABO61306.1) and Ad35 (GenPept: 
AP_000601.1) fiber amino acid sequences were downloaded from the National 
Center for Biotechnology Information (NCBI) database and aligned in BioEdit (Hall, 
1999) version 7.2.5 using the ClustalW Multiple Alignment command. Knob domains 
were edited to contain the A20 peptide amino acid sequence and the sequences were 
submitted to the predictive online 3D modelling software SWISS-MODEL (Arnold et 
al., 2006, Bordoli et al., 2009, Biasini et al., 2014) (Biozentrum, Basel, Switzerland) in 
an automated mode. Previously crystallised Ad knob structures with the highest 
homology (%) were chosen to be used as templates, and the models were saved as 
Protein Data Bank (PDB) files for further manipulation. Ad5 knob models were based 
on PDB structure 1KNB, species D knob models were based on either Ad19p knob 
(PDB ID: 1UXB) or Ad37 knob (PDB ID: 2WGU). Crystallisation data is currently not 
available for other species D Ad knobs. Molecular graphics and analyses were 
performed using the UCSF Chimera package (Pettersen et al., 2004) version 1.10.2 
(Resource for Biocomputing, Visualization, and Informatics; University of California, 
San Francisco, USA).  
2.2.2 Generation of pQE30 expression plasmids 
Recombinant fiber knob proteins were produced in E. coli essentially as described 
previously (Coughlan et al., 2009b, Coughlan et al., 2014). The pQE30knob48 
expression plasmids were a kind gift from Dr Lynda Coughlan (Oxford University, UK), 
and readily contained the knob48 sequence and the A20 peptide sequence in the four 
different locations (loops CD, DG, HI, IJ). These plasmids carry an ampicillin (Amp) 
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resistance gene. Plasmid sequences were received as Whatman paper preparations, 
and were first dissolved into 50 μL of TE buffer. The DNA were then transformed into 
commercially available chemically competent, high copy number E. coli strain JM109 
(#L1001, Promega, Southampton, UK) for plasmid amplification. In brief, 50 μL cells 
were mixed with 10 ng of plasmid DNA on ice, incubated for 30 min on ice and 
transferred into 42oC water bath for exactly 45 seconds. Cells were then recovered 
on ice for 2 min and incubated at 37oC for 1 h, after which they were plated on LB (+ 
100 μg/mL Amp / 50 μg/mL Kan) plates and incubated at 37oC for 24‒48 h. Individual 
colonies were then picked and inoculated into 5 mL of LB + Amp for O/N incubation 
at 37oC. On the following day the DNA was purified by using a miniprep kit and DNA 
concentration verified by Nanodrop. The Kan-resistant E. coli strain SG13009 was 
utilised for knob protein production from the pQE30 plasmids (Figure 2–5). Initially, 
the SG13009 bacteria were made chemically competent by a rubidium chloride 
method (QIAexpressionist 06/2003 protocol). 
 
Figure 2–5. Schematic presentation of the pQE30 plasmid. The plasmids were based on pQE30 
plasmids (Qiagen) and were kindly gifted by Dr Lynda Coughlan, Oxford University. 
 
A single colony of SG13009 was first inoculated into 10 mL of LB (+ Kan) and 
grown O/N. On the following day 1 mL of the culture was incubated in 100 mL of LB 
(+ Kan) until optical density (OD) reached 0.5 (λ600 nm). The culture was then 
pelleted at 4000 x g at 4oC for 5 min in a sterile round-bottomed tube and re-
                                                                                                                                     
                                                                                                              Chapter 2 
86 
 
suspended into 30 mL of sterile-filtered (0.22 μm) ice-cold TFB1 buffer (100 mM RbCl, 
50 mM MnCl2, 30 mM KAc, 10 mM CaCl2, 15 % glycerol, pH 5.8), incubated on ice 
for 90 min and pelleted as previously. The pellet was then re-suspended into 4 mL of 
sterile-filtered, ice-cold TFB2 buffer (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15 
% glycerol, pH 6.8), divided into 200 μL aliquots in 1.5 ml cryovials and stored at ‒
80oC. For protein production, 10 μg of each pQE30 plasmid DNA was transformed 
into 50 μL of the competent SG13009 bacteria by heat shock method as described 
earlier, and grown on selective LB (+Amp/Kan) plates for 48 h. 
2.2.3 Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced protein 
production 
Protein production was initiated by culturing a pre-culture that served as a seed 
culture for protein induction. For preparation of a pre-culture, multiple colonies of each 
pQE30 plasmid-containing SG13009 cells were picked from the LB (+Amp/Kan) 
plates and grown in 100 mL of LB (+Amp/Kan) O/N at 37oC with aeration (250 rpm). 
On the following day the cells were pelleted at 4000 x g for 10 min, re-suspended into 
20 mL of LB, divided into five 4 mL aliquots, pelleted again and frozen down at ‒20 
oC for subsequent protein induction. For induction of protein production, a “4 mL” 
aliquot was thawed in a 37oC water bath and inoculated into 1 L of Terrific Broth 
(#T0918, Sigma Aldrich, Gillingham, UK) supplemented with 0.8% glycerol, 100 
μg/mL Amp and 50 μg/mL Kan in a 2 L flask. The culture was incubated at 37 oC (250 
rpm) until OD reached 0.6 (λ600 nm). Protein expression was then induced by adding 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM at 
20oC for 16 h. The optimisation of knob protein induction conditions has previously 
shown that these conditions are preferable to a shorter (4 h) induction at 37oC 
(Coughlan et al., 2009a). The culture was then harvested at 4000 × g for 15 min and 
the pellet was washed with 50 mL of PBS, re-pelleted at 4000 × g for 10 min and 
frozen at ‒80oC if not used immediately. 
2.2.4 Protein purification by nickel-nitrilotriacetic acid (Ni-NTA) affinity 
chromatography 
A 1 mL aliquot was taken from each pre-purification and purification step for 
analysis by SDS-PAGE. The pellet from a 1 L culture was re-suspended in 50 mL of 
lysis buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole, 1 % NP40 substitute, 1 
mg/mL lysozyme, 1 mM β-merkaptoethanol, pH 8.0 in H2O) and agitated on roller for 
1 h at 4oC in the cold room. The suspension was transferred into 2 x 25 ml high speed 
centrifuge tubes, balanced with equal volumes and spun at 30 000 x g for 20 min at 4 
oC in a high speed centrifuge (rotor JA 25.50). The cleared lysate was divided into 2 
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x 50 mL clean tubes and agitated on a roller with 0.5 mL of high binding capacity Ni-
NTA Agarose (#30210, Qiagen, Manchester, UK) for 1 h at 4oC. The matrix was then 
collected by spinning at 1000 x g for 10 min and the supernatant was carefully 
removed (but kept in case protein had not bound to matrix) and loaded into a 
disposable plastic chromatography column (#7321010, Biorad, Hertfordshire, UK). 
The column was washed with 50 mL of wash buffer (50 mM Tris, 300 mM NaCl, 1 mM 
β-merkaptoethanol, 10 mM imidazole, pH 8.0 in H2O). 5 x 1.0 mL fractions were then 
eluted for each concentration for a gradient of 50‒300 mM imidazole (50 mM Tris, 
300 mM NaCl, 1 mM β-merkaptoethanol, 50/100/200/300 mM imidazole, pH 8.0 in 
ddH2O) by allowing it to flow through, collecting each 1 mL fraction manually in a 1.5 
mL tube. The aliquots were stored short term at 4˚C prior to analysis by SDS-PAGE. 
2.2.5 Coomassie brilliant blue staining for protein 
All SDS-PAGE analyses were performed using the NuPAGE Novex® (Life 
Technologies, Loughborough, UK) systems and buffers. 14 μL of eluted protein 
fractions were mixed with 1 μL of DTT and 5 μL of NuPAGE LDS sample buffer (4 x 
concentrated, Thermo Scientific), boiled at 95 oC for 10 min and loaded into pre-cast 
midi NuPAGE Novex® 10 % Bis-Tris SDS-PAGE gels (#WG1201BOX, Life 
Technologies, UK). The samples were run along with 10 μL Novex® Sharp Pre-
stained protein standard (#LC5800, Thermo Fisher Scientific, UK) for 1 h 15 min at 
150 V and stained in Coomassie stain (0.25% Coomassie brilliant blue, 50 % 
methanol, 10 % acetic acid in H2O) for 30 min, after which they were de-stained (30 
% methanol, 10 % acetic acid in H2O) with multiple changes of buffer O/N or until no 
background staining was visible. The gels were then visualised in gel imager 
(GelDocIt, Ultra-Violet Products Ltd, Cambridge, UK or G:BOX Chemi XX6 imager, 
Syngene, Cambridge, UK).  
 
2.3 Virus engineering by homologous recombination (AdZ recombineering) 
All viral vectors produced in this thesis were generated by rapid AdZ 
recombineering techniques (Figure 2–6). 
 
2.3.1 Generation of bacterial artificial chromosomes (BACs) 
The wild type Ad5 virus was originally gifted by Vivien Mautner at University of 
Birmingham, UK. The viral genome was captured within a bacterial artificial 
chromosome (BAC) and has since been vectorised and heavily genetically modified 
in our laboratory (Stanton et al., 2008). Generated recombinant Ad5 genomes are 
based on luciferase (Luc) or green fluorescent protein (GFP) -expressing Ad5 vector 
                                                                                                                                     
                                                                                                              Chapter 2 
88 
 
genome (Figure 2–7). This vectors have been made replication-deficient by deleting 
the E1 and E3 gene regions (ΔE1/ΔE3) that are responsible for viral replication. 
Oncolytic viruses contain the E1 and E3 gene regions, making them replication-
competent. These vectors were made cancer-selective by an insertion of a 24-base 
pair deletion (dl922‒947, Δ24) in the retinoblastoma protein (pRB) binding domain of 
E1A gene (Fueyo et al., 2000), which restricts viral replication into cancer cells with 
aberrant pRB signalling pathways. Additionally, T1 mutation ‒ a single adenine 
insertion at position 445 within the endoplasmic reticulum (ER) retention domain of 
the E3/19K gene (Gros et al., 2008) ‒ was inserted to enhance viral release from the 
ER.  
 
 
 
 
 
 
                                                                                                                                     
                                                                                                               
 
 
Figure 2–6. Complete production cycle of Ad5 vectors from AdZ recombineering to purified virus particles. (1) Transformation by electroporation, (2) & (3) temperature-
induced recombineering (42˚C), (4) purification of BAC DNA and transfection into T-Rex-293 cells, (5) propagation of high titre stocks in T-Rex-293 cells, (6) purification of viral 
particles by CsCl gradient ultracentrifugation, (7) titration by microBCA and/or rapid plaque assay. 
  
Figure 2–7. Plasmid map of the bacterial artificial chromosome (BAC) containing green fluorescent protein-expressing adenovirus serotype 5 (Ad5.GFP) sequence. 
This BAC contains the sacB selection cassette, chloramphenicol and ampicillin resistance genes (image created in Genome Compiler). 
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Selection cassettes and de-targeting mutation (Table 2–4) encoding DNA 
fragments with ~70 bp homology arms were generated by PCR using Expand High 
Fidelity PCR system (#11732650001, Roche Applied Science, East Sussex, UK). 
Gene synthesis of the complete species D whole fiber and fiber knob sequences for 
pseudotyping Ad5 was ordered from GeneArt (Invitrogen; Regensburg, Germany). To 
allow a straightforward insertion into the Ad5 BAC, these sequences were designed 
to contain homologous overlapping sequences at either end to match the Ad5 
sequence. The Ad5 genome was modified by temperature-induced AdZ homologous 
recombination (‘recombineering’) in E. coli strain SW102 in a two-step process by 
using autoclaved-sterilised reagents and disposable plastic ware. First an RPSL/neo 
selection cassette (‘cassette in’) was inserted into the region of interest, and then 
replaced with a DNA oligo containing the appropriate sequence (‘cassette out’). The 
first step involved growing the bacteria containing the correct target BAC O/N in 5 mL 
of LB in a 30-mL universal tube (#128B/FS, Sterilin, Thermo Scientific, UK) in a shaker 
at 32oC. This was done by streaking the ‒70 oC glycerol stock of the target strain with 
a pipette tip and inoculating into the medium containing selective antibiotics. 
Table 2–4. Primer sequences for insertion of de-targeting mutations. CAR-binding ablating KO1 
mutation (S408E, P409A) (Smith et al., 2002) was inserted into the AB loop of Ad5 fiber knob. A 
combination of five FX-binding mutations (HVR7; I421G, T423N, E424S, L426Y and E451Q) (Alba et al., 
2009) was inserted into the HVR7 region, and integrin-binding ablation (RGE; D342E) in penton base 
(Wickham et al., 1993). Homology arms.  
Primer Sequence 
RGD>RGE cass in F 
GGCGCGGAAGAGAACTCCAACGCGGCAGCCGCGGCAATGCAGCCGGTGGAGG
ACATGAACGATCATGCCATTCGCGGCCCTGTGACGGAAGATCACTTCG 
RGD>RGE cass in R 
CGGGTTGCGCAGCGGGGGCGGCAGCTTCGGCCGCTGCTTCGGCCTCAGCGCG
CTTCTCCTCAGCCCGTGTGGCAAAGGTCTGAGGTTCTTATGGCTCTTG 
RGD>RGE cass out 
CGCGGCAATGCAGCCGGTGGAGGACATGAACGATCATGCCATTCGCGGCGAAA
CCTTTGCCACACGGGCTGAGGAGAAGCGCGCTGAGGCCGAAGCAGCG 
KO1 fiber cass in F 
AGTTTTGACAGCACAGGTGCCATTACAGTAGGAAACAAAAATAATGATAAGCTAA
CTTTGTGGACCACACCAGCTCCACCTGTGACGGAAGATCACTTCG 
KO1 fiber cass in R 
CTGTAGCAAGTATTTGACTGCCACATTTTGTTAAGACCAAAGTGAGTTTAGCATCT
TTCTCTGCATTTAGTCTACAGTTCTGAGGTTCTTATGGCTCTTG 
KO1 fiber cass out 
GAAACAAAAATAATGATAAGCTAACTTTGTGGACCACACCAGCTCCAGAGGCCAA
CTGTAGACTAAATGCAGAGAAAGATGCTAAACTCACTTTGGTCTT 
HVR7 cass in F 
GATCCAGATGTTAGAATTATTGAAAATCATGGAACTGAAGATGAACTTCCAAATTA
CTGCTTTCCACTGGGAGGTGTGCCTGTGACGGAAGATCACTTCG 
HVR7 cass in R 
TTATTTCATTTTTATCTGAAAATTCTGTAGCATCTTTTTCCCATCCATTTTCCTGACC
TGTTTTAGGTTTTACCTTGGTCTGAGGTTCTTATGGCTCTTG 
HVR7 cass out 
AAGATGAACTTCCAAATTACTGCTTTCCACTGGGAGGTGTGGGCAATAACTCCAC
TTACACCAAGGTAAAACCTAAAACAGGTCAGGAAAATGGATGGGA 
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On the following morning 2 mL of the O/N culture was inoculated into 50 mL of LB 
and grown until log phase was reached (OD ~ 0.6 at λ600 nm). Lambda genes were 
induced by incubating 25 mL of the culture in a 42oC water bath for exactly 15 min, 
after which the cultures were cooled down on a shaker on ice for 15‒20 min. The cells 
were then pelleted at 4000 rpm in a pre-cooled centrifuge for 5 min at 0oC and washed 
with 25 ml of ice-cold H20. The pellet was re-suspended first into 1 mL of ice-cold H20 
by gently swirling and tapping the tube, and adding further 25 mL of H20. Cells were 
then re-pelleted and wash repeated once. Supernatant was decanted and cells re-
suspended into the remaining H20 (~ 400 μL). 25 μL of the suspension was added 
into pre-cooled 0.5 mL Eppendorf tubes with 3 μL of the RPSL/neo or sacB cassette 
and mixed gently by flicking the tube. The mix was added into pre-cooled disposable 
2 mm electroporation cuvettes (#71-2020, HiMaX, Isogen Life Science, The 
Netherlands) and incubated on ice for 5 min. The cuvette was briefly dried with tissue 
and cells electropermeabilised (MicroPulser Electroporator, Bio-Rad, Hertfordshire, 
UK) using a pre-set program “Ec2” for bacterial electroporation. The cells were then 
recovered in 1 mL of LB for 1 h in a shaker at 32oC. The recombineering technology 
relies on blue/white selection based on IPTG-inducible expression of the lacZ gene. 
The selection for the cassette was performed using Kan (15 µg/mL) while the selection 
against the cassette was performed using Strep (400 µg/mL). After the recovery step 
following the first round of recombineering, 150 μL of cells were plated on LB-agar 
(1.5 %) plates containing IPTG, Kan/Strep, X-Gal and Chlor and incubated for 48‒72 
h until blue colonies appeared. Three blue colonies per construct were then picked 
and re-suspended into 10 μL of H20 and each divided into two cultures: 5 μL was 
inoculated into 5 mL of LB (+ Kan, Chlor) and 5 μL into 5 mL of LB (+ Strep, Chlor). 
This was done to verify the Kan-resistance and Strep-sensitivity of the selected 
colonies in order to proceed into the second round of recombineering.  
 Table 2–5. A20 peptide insertion sites within the Ad5, Ad10 and Ad48 knob. Insertion sites in 
Ad5 (Krasnykh et al., 1998, Coughlan et al., 2009a) and Ad48 had been previously determined (Coughlan 
et al., 2014). The flanking sequences and amino acid (aa) numbers indicate the insertion site within the 
knob domain. A20, NAVPNLRGDLQVLAQKVART. aa, amino acid; F, whole fiber pseudotyped; kn, knob 
domain pseudotyped. 
 
Vector Flanking 
sequence 
preceding 
aa 
following 
aa 
Flanking 
sequence Ad5.HI.A20 QETG 546 547 DTTP 
Ad10.DG SKKY 304 305 ARDI 
Ad10.Δ5aaDG.A20 KPSN 300 306 RDIV 
Ad10.HI.A20 QETG 334 335 CEYS 
Ad5/kn48.CD.A20 MINN 232 233 KVNG 
Ad5/kn48.Δ13aaDG.A20 KPPT 297 311 AKNK 
Ad5/kn48.HI.A20 KETG 340 341 CTYS 
Ad5/kn48.IJ.A20 FAWN 352 353 KTYE 
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On the following morning, 2 mL of one Kan-resistant colony of each construct was 
inoculated into 50 mL of LB and the following recombineering steps performed as 
described for the first round of recombineering. In the second round, oligonucleotides 
containing DNA sequences coding for the modified target sequence (de-targeting 
mutations and/or targeting peptide insertions) were generated by PCR and inserted 
into the respective gene location. The generated vector backbones were further 
modified by insertion an αvβ6-targeting A20 peptide within the fiber knob domain ‒ in 
HI loop in Ad5 (Krasnykh et al., 1998, Coughlan et al., 2009a), in CD, Δ13aa.DG (a 
13-aa deletion), HI and IJ loops in Ad48 (Coughlan et al., 2014) and in DG, Δ5aa.DG 
(a 5-aa deletion) and HI loops in Ad10 knob (Table 2–5). Primers that were used for 
the insertion are in Table 2‒6. 
 Table 2–6. Primers used for the A20 peptide insertion. Overlapping sequence for the A20 is in green, and overlapping sequence for the RPSL cassette is shown in blue. 
Primer Sequence 
A20 peptide AATGCTGTGCCCAACTTGAGAGGTGACCTTCAAGTGTTGGCTCAAAAGGTGGCACGGACG 
RPSL neo_kn5 F CCTGTGACGGAAGATCACTTCG 
RPSL neo_kn5 R CTGAGGTTCTTATGGCTCTTG 
Ad5.HI.A20 F TCAGTCAAGTTTACTTAAACGGAGACAAAACTAAACCTGTAACACTAACCATTACACTAAACGGTACACAGGAAACAAATGCTGTGCCCAACTTGAGAG 
Ad5.HI.A20 R CAAATATTTCATTAATGTAGTTGTGGCCAGACCAGTCCCATGAAAATGACATAGAGTATGCACTTGGAGTTGTGTCTCCCGTCCGTGCCACCTTTTGAG 
RPSL_kn48.CD F ATGTGGGAGTCAGATTTTGGCTAATATGTCTTTGCTGGTAGTTAAAGGAAAATTTTCCATGATAAATAA CCCTGTGACGGAAGATCACTTCG 
RPSL_kn48.CD R ATAAAACACCCTTTTCATCAAATAATAACTTTATTGTAAATTTTTTATAATCATCAGTTCCATTTACTTTCTGAGGTTCTTATGGCTCTTG 
RPSL_kn48.DGΔ13aa F TGTTGGAAGTGCATATGAAGAAGCTGTTGGTTTTATGCCAAGTACAACAGCTTATCCTAAACCACCTACTCCTGTGACGGAAGATCACTTCG 
RPSL_kn48.DGΔ13aa R TAACAGTTGTGGCAACTGGGTTGCCTGCTTGTCCGCCAAGGTAGACGTTACTTACGTATTTATTTTTTG CCTGAGGTTCTTATGGCTCTTG 
RPSL_kn48.HI F TAACGTCTACCTTGGCGGACAAGCAGGCAACCCAGTTGCCACAACTGTTAGTTTTAATAAGGAAACGGGGCCTGTGACGGAAGATCACTTCG 
RPSL_kn48.HI R AGGAGGAATCAAACTGCACATTTTCATAAGTTTTGTTCCAAGCAAAGTCAATGTAATCGAATAAGTACACTGAGGTTCTTATGGCTCTTG 
RPSL_kn48.IJ F TGCCACAACTGTTAGTTTTAATAAGGAAACGGGGTGTACTTATTCGATTACATTTGACTTTGCTTGGAA CCCTGTGACGGAAGATCACTTCG 
RPSL_kn48.IJ R AAGCTTATTCTTGGGCAATATAGGAGAAAGTTAAAAAGGAGGAATCAAACTGCACATTTTCATAAGTTTTCTGAGGTTCTTATGGCTCTTG 
kn48.CD_A20 F ATGTGGGAGTCAGATTTTGGCTAATATGTCTTTGCTGGTAGTTAAAGGAAAATTTTCCATGATAAATAACAATGCTGTGCCCAACTTGAGAGGTGAC 
kn48.CD_A20 R ATAAAACACCCTTTTCATCAAATAATAACTTTATTGTAAATTTTTTATAATCATCAGTTCCATTTACTTTCGTCCGTGCCACCTTTTGAGCCAAC 
kn48.DGΔ13aa_A20 F TGT TGG AAG TGC ATA TGA AGA AGC TGT TGG TTT TAT GCC AAG TAC AACAGCTTATCCTAAACCACCTACTAATGCTGTGCCCAACTTGAGAGGTGAC 
kn48.DGΔ13aa_A20 R TAACAGTTGTGGCAACTGGGTTGCCTGCTTGTCCGCCAAGGTAGACGTTACTTACGTATTTATTTTTTGCCGTCCGTGCCACCTTTTGAGCCAAC 
kn48.HI_A20 F TAACGTCTACCTTGGCGGACAAGCAGGCAACCCAGTTGCCACAACTGTTAGTTTTAATAAGGAAACGGGGAATGCTGTGCCCAACTTGAGAGGTGAC 
kn48.HI_A20 R AGGAGGAATCAAACTGCACATTTTCATAAGTTTTGTTCCAAGCAAAGTCAAATGTAATCGAATAAGTACACGTCCGTGCCACCTTTTGAGCCAAC 
kn48.IJ_A20 F TGC CAC AAC TGT TAG TTT TAA TAA GGA AAC GGG GTG TAC TTA TTC GATTACATTTGACTTTGCTTGGAACAATGCTGTGCCCAACTTGAGAGGTGAC 
kn48.IJ_A20 R AAGCTTATTCTTGGGCAATATAGGAGAAAGTTAAAAAGGAGGAATCAAACTGCACATTTTCATAAGTTTTCGTCCGTGCCAC CTTTTGAGCCAAC 
RPSL_kn10.DG F TTATGAAAAAGCAATTGGTTTTATGCCTAATTTGGTAGCGTATCCGAAACCCAGTAATTCTAAAAAATATCCTGTGACGGAAGATCACTTCG 
RPSL_kn10.DG R TAGTTTTAATGACTGCTGGCTGATCAGGTTTTCCACCAAGATATATAGTTCCATAAACTATGTCTCTTGC CTGAGGTTCTTATGGCTCTTG 
RPSL_kn10.DGΔ5aa F TGTTTCGACAGCTTATGAAAAAGCAATTGGTTTTATGCCTAATTTGGTAGCGTATCCGAAACCCAGTAAT CCTGTGACGGAAGATCACTTCG 
RPSL_kn10.DGΔ5aa R AGGTAGTTTTAATGACTGCTGGCTGATCAGGTTTTCCACCAAGATATATAGTTCCATAAACTATGTCTCT CTGAGGTTCTTATGGCTCTTG 
RPSL_kn10.HI F AACTATATATCTTGGTGGAAAACCTGATCAGCCAGCAGTCATTAAAACTACCTTTAACCAAGAAACTGGA CCTGTGACGGAAGATCACTTCG 
RPSL_kn10.HI R AGGTGGTTTCAAATTCAACATTTTCATAGGTTTTGGACCAACTAAAGTCAAATGTTATAGAGTATTCACA CTGAGGTTCTTATGGCTCTTG 
kn10.DG.A20 F TTATGAAAAAGCAATTGGTTTTATGCCTAATTTGGTAGCGTATCCGAAACCCAGTAATTCTAAAAAATAT AATGCTGTGCCCAACTTGAGAGGTGAC 
kn10.DG.A20 R TAGTTTTAATGACTGCTGGCTGATCAGGTTTTCCACCAAGATATATAGTTCCATAAACTATGTCTCTTGC CGTCCGTGCCACCTTTTGAGCCAAC 
kn10.DGΔ5aa.A20 F TGTTTCGACAGCTTATGAAAAAGCAATTGGTTTTATGCCTAATTTGGTAGCGTATCCGAAACCCAGTAAT AATGCTGTGCCCAACTTGAGAGGTGAC 
kn10.DGΔ5aa.A20 R AGGTAGTTTTAATGACTGCTGGCTGATCAGGTTTTCCACCAAGATATATAGTTCCATAAACTATGTCTCT CGTCCGTGCCACCTTTTGAGCCAAC 
kn10.HI.A20 F AACTATATATCTTGGTGGAAAACCTGATCAGCCAGCAGTCATTAAAACTACCTTTAACCAAGAAACTGGA AATGCTGTGCCCAACTTGAGAGGTGAC 
kn10.HI.A20 R AGGTGGTTTCAAATTCAACATTTTCATAGGTTTTGGACCAACTAAAGTCAAATGTTATAGAGTATTCACA CGTCCGTGCCACCTTTTGAGCCAAC 
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2.3.2 Verification of genome modifications by sequencing 
The correct construction of Ad5 BAC genomes was confirmed by sequencing 
across the modified region by using either internal or external sequencing services. 
BigDye® Terminator v3.1. Cycle Sequencing Kit (Life Technologies) was used to 
prepare the samples for sequencing [95oC – 5 min, 100 x (95oC – 30 s, 55oC – 10 s, 
60oC – 4 min), 4oC − ∞] and PCR products were purified using Performa DTR columns 
(Edge Biosystems, Gaithersburg, MD, USA). Sequencing based on this method was 
performed at Central Biotechnology Services (School of Medicine, Cardiff University). 
Alternatively, sequences were prepared by PCR using primers (Table 2–7), PCR 
products purified using columns and 150 ng of DNA samples sent to sequencing in 
pre-coded sequencing tubes with 2 μL sequencing primers in a total volume of 17 μL 
(Eurofins, Ebersberg, Germany). Forward (F) and reverse (R) primers were used in 
separate reactions to sequence both strands of the generated DNA. The correct 
sequence modifications were verified using CLC Main Workbench 6 software 
(Qiagen) or Genome Compiler (Los Altos, CA, USA) software. Permanent glycerol 
stocks were prepared of the verified correct clones by mixing 700 μL of the bacterial 
culture with 300 μL of glycerol (30 %) and stored at ‒70°C.  
Table 2–7. Primers for verification of correct mutation by sequencing. F, forward primer; HVR7, 
coagulation factor 10-binding mutation; KO1, coxsackie and adenovirus-binding mutation; R, reverse 
primer; RGE, αvβ3/5 integrin-binding mutation. 
Primer Sequence 
Sequencing RGE GCACTGTTGGATGTGGACGC 
Sequencing KO1 GTTCACCTAATGCACCAAACAC 
Sequencing HVR7 TCCATTGGTGATAGAACCAGG 
  
PCR for seq around Ad5 fiber F GCAAATTTCTGTCCAGTTTATTCAGCAGCA 
PCR for seq around Ad5 fiber R GCCAGCCGGGGAGAAAGGACT 
PCR for seq knob swap F CTACAGCCATAGCCATTAATGCAGGAGAT 
  
Seq Ad5 fiber swap F CTCCTTGCCCTCCTCCCAGCT 
Seq Ad5 fiber swap R GTACTCTGTGTGTTGGGAGGGAGGT 
Seq knob swap F GGCTTGAATTTGGTTCACCTAATGCACCA 
  
PCR for seq within Ad10 knob F AACACCAGACACTTCTCCAAACTGCAC 
PCR for seq within Ad10 knob R TACACTGTGAAATGGGCTGGTGGTGG 
  
Seq of Ad10 knob F ATTGCTCAGGATAAGGACTCTAAACTAACTC 
Seq of Ad10 knob R AGACTGACTACCCGTGCTGGTGTAAAAATC 
  
Seq Ad48 fiber CACTGCCAAGGGGTTGATG 
Seq Ad48 fiber CCAGCCGGGGAGAAAGG 
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2.3.3 Amplification and purification of virus genomes 
Viral genomic BACs were purified using the commercial NucleoBond BAC 100 kit 
(#740579, Macherey-Nagel, Duren, Germany). All materials and reagents were 
sterilised by autoclaving prior to DNA purification. The BACs containing correct 
insertions (as verified by sequencing) were amplified in 5 mL of LB (+ Strep, Chlor) in 
a shaker for 8 h at 32oC. In the evening, the 5 mL pre-culture was inoculated into 250 
mL of LB (+ Strep, Chlor) in a 1 L conical flask and incubated in a shaker O/N at 32oC. 
The culture was pelleted at 6000 rpm for 15 min at 4oC in a high-speed centrifuge 
(Avanti J-20 XP, Beckman Coulter, USA) and pellet re-suspended into 24 mL of S1 
buffer (+ RNAse) by using a 5 mL stripette. 24 mL of S2 lysis buffer was added, mixed 
by inverting the tube 6‒8 times and incubated for exactly 5 min at RT. To neutralise 
the suspension, 24 mL pre-cooled S3 buffer was added, suspension mixed by 
inverting and incubated for 5 min on ice. The lysed suspension was then pelleted at 
6000 rpm for 15 min at 4oC. Meanwhile, the purification column was equilibrated by 
adding 6 mL of N2 buffer and the flow-through discarded. The separated lysate was 
then bound to the column through a funnel covered with a filter, and the column 
washed twice with 18 mL of wash buffer N3. The flow-through was discarded and the 
column was taped onto a 15-mL centrifuge tube. The DNA was eluted by adding 15 
mL of pre-heated (50oC) N5 elution buffer, and the eluate mixed with 11 mL of RT 
isopropanol. The DNA was pelleted at 15 000 rpm for 30 min at 4oC and supernatant 
discarded. The pellet was washed with 70 % ethanol, mixed briefly on a vortex, and 
re-pelleted at 15 000 rpm for 10 min at RT. Ethanol was decanted and pellet dried in 
a 37oC incubator for ~1 h. DNA was re-suspended into 100 μL of H20 by allowing it to 
stand for ~15 min, scraping the pellet and collecting the liquid by a brief spin. DNA 
concentration was consistently verified to be ~ 100‒600 ng/μL as estimated in 
Nanodrop ND-1000 (Thermo Scientific, UK). Maxiprep DNAs were stored at ‒20oC 
for subsequent cell transfection. 
2.3.4 Virus rescue and propagation for high titre stocks 
T-REx-293 cells were generally used for virus propagation and titration, while A20 
peptide-containing viruses were rescued in HEK293-β6 cells that express αvβ6 
integrin. On the previous day prior to DNA transfection, cells were seeded on T25 
tissue culture flasks (Corning CellBIND, Amsterdam, The Netherlands) at 5.0 × 105 
cells/flask and allowed to adhere O/N. Cell monolayers were washed in 5 mL of PBS 
and 1 μg of purified DNA was transfected into in a total volume of 5 mL complete 
medium using Effectene transfection reagent (#301425; Qiagen, Manchester, UK) 
according to the manufacturer’s instructions. A control plasmid pmaxGFP (SiRNA test 
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kit, #VSC-1001; Lonza, Slough, UK; Figure 2–8) was used for evaluating the 
transfection efficiency of the Effectene reagent by transfecting cells with 1 μL of the 
reagent and quantifying the proportion of GFP-positive cells in flow cytometer after a 
48 h incubation. Rescue of de-targeted Ad5 vectors containing native receptor-
binding KO1 and RGD > RGE mutations was facilitated by addition of 8 μL/mg of FX 
(#HCX0050, Haematologic Technologies, Cambridge Bioscience, Cambridge, UK) 
into the growth medium. Cells were left untouched for 24 h, after which they were 
washed in 5 mL of PBS and 5 mL of fresh complete DMEM was changed. Media were 
replaced every 1−2 days until cytopathic effect (CPE) was visible and the whole 
monolayer was rounded up in grape-like structures. The cells were observed daily 
under inverted microscope (Nikon TMS; Surrey, UK) until CPE was complete, ~10‒
14 days post-transfection. Cell pellets were then collected at 1500 rpm for 5 min and 
re-suspended into 1 mL of medium. The viruses were crude-extracted from the 
infected host cells by addition of an equal amount (1 mL) of tetrachloroethylene (TCE; 
Fisher Scientific, Loughborough, UK) by vigorous shaking for 30 s and centrifugation 
at 2000 rpm for 10 min. The upper layer containing the virus particles was then 
carefully extracted by decanting with a 1-mL pipette into a fresh 1.5 mL cryo vial. This 
was marked as the passage 1 virus stock (P1 stock) that was either stored at ‒80oC 
long-term or immediately proceeded into propagation of P2 high titre stocks.  
 
Figure 2–8. Plasmid map of the transfection control pmaxGFP. Green fluorescent protein (GFP)-
expressing plasmid pmaxGFP was used as a negative control to assess transfection efficiency of 
Effectene transfection reagent in T-REx-293 cells (Amaxa, 2017). 
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For generation of high titre P2 stocks, cells were seeded in five T150 tissue culture 
flasks (Corning CellBIND, Amsterdam, The Netherlands) per virus, and allowed to 
attach O/N to obtain 60‒70 % confluent monolayer. Medium was replaced with 20 mL 
of fresh complete DMEM into each flask prior to infection. The cells were infected with 
TCE crude-extracted P1 stocks by mixing 100 μL of virus with 900 μL of complete 
DMEM in a 1.5 mL Eppendorf and by adding 200 μL into each confluent T150 flask. 
Cells were observed daily and medium changed approximately every two days, when 
it turned acidic (yellow). When the cells were getting close to full CPE, ~ 200 μL of 
sterile 7.5 % sodium bicarbonate (#S8761; Sigma Aldrich, Gillingham, UK) was added 
into each flask to turn the medium back to red in order to disturb the monolayer as 
little as possible and to keep the infection progressing. Cell pellets were collected at 
1200 rpm for 5 min when CPE was complete (3−8 days post-infection), after which 
they were re-suspended in 5 mL of PBS. Pellets could be frozen ‒70ºC at this point if 
virus purification didn’t immediately follow. The P2 virus stocks were thawed in 37ºC 
water bath and crude-extracted by adding 5 mL of TCE, followed by centrifugation at 
2000 rpm for 20 min. Upper layer containing the virus particles was decanted into a 
clean 15 mL tube by using a 1 mL pipette and proceeded into ultracentrifugation. 
2.3.5 Virus purification by CsCl gradient ultracentrifugation 
Virus particles were purified by two-step ultracentrifugation. Cesium chloride 
(CsCl) gradients were prepared into UltraClear 14 × 89 mm tubes (#344059, Beckman 
Coulter) tubes holding a total volume of 13.2 mL. Initially, 2.5 mL of 1.40 g/mL density 
CsCl was pipetted to the tube, followed by 2.5 mL addition of 1.25 g/mL density CsCl 
on the top and addition of 5 mL of P2 virus stock as the uppermost layer. The gradients 
were prepared with extreme care, by expelling the liquid very slowly and by using a 5 
mL disposable stripette. The tubes were then balanced with sterile PBS on a scale in 
the hood in order to achieve equally balanced counter tubes. The viruses were 
subjected to 35 600 rpm for 1.5 h at RT in swinging bucket Sw41Ti rotor in Optima 
XPN-80 Ultracentrifuge (Beckman Coulter). As a result, the mature virus particles 
could be seen as a distinct grey band on the lower quarter of the tube, with a faint 
band on the top consisting of empty virus capsids (Figure 2–9). The virus band was 
extracted by using a 19-gauge needle and 1 mL syringe into a sterile 15 mL tube. The 
second gradient was prepared by adding 5 mL of 1.34 g/mL density CsCl on the 
bottom of an ultracentrifuge tube and 1 mL of the purified virus stock from the first 
step was carefully added on the top by using a 1 mL pipette. 
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Figure 2–9. Adenovirus purification by caesium chloride (CsCl) ultracentrifugation. (A) Poorly 
purified preparation with a very small proportion of mature virions. (B) Well purified virus preparation with 
a very strong band of mature virions. 
 
The viruses were then subjected to 35 600 rpm centrifugation for 18 h (O/N) in the 
same rotor as in the first centrifugation step. The visible virus band was then extracted 
as before and transferred into a sterile 15 mL tube. One ~ 20 cm piece of dialysis 
tubing (#DTV12000.01.15, Visking 6.3 mm, MWCO 12‒14 000 Daltons; MediCell 
Membranes Ltd, London, UK) was cut for each virus with EtOH-sterilised scissors and 
sterilised in 500 mL of dialysis buffer (10 % glycerol, 10 mM Tris-HCl (pH 7.8), 135 
mM NaCl and 1 mM MgCl2 × 6H2O) by heating in the microwave until boiling. One 
end of the tubing was tied with a single knot and the purified virus was carefully added 
into the tube by using a 1 mL pipette. The tubing was carefully depleted of air and 
closed with a single knot; both ends were also tied with Mediclips (MediCell 
Membranes Ltd, London, UK) to prevent accidental leakage. Each virus was dialysed 
in a separate 1 L conical flask in dialysis buffer for 24 h with a single change of buffer 
on the following day.  
2.3.6 Viral titration 
Viral titres were determined using a micro-BCA assay kit (#23235; Pierce, Thermo 
Fisher Scientific, Loughborough, UK) according to the manufacturer’s protocol. 
Briefly, 1, 3 and 5 μL of purified virus stocks was added on a sterile flat-bottom 96-
well plate (#163320; Nunc Microwell, Thermo Fisher Scientific, Loughborough, UK) in 
triplicate and the volume adjusted to 150 μL with PBS. On the same plate, 150 μL of 
bovine serum albumin (BSA) standards (0, 0.5, 1, 2.5, 5, 10, 20, 40, 200 μg/ml in 
PBS) were assayed in duplicate. Working solution was prepared by mixing reagents 
A, B and C in the ratio of 25:24:1 and 150 μL of the solution added into each well and 
mixed briefly on a shaker. The plate was incubated at 37oC for 2 h and absorbance 
measured at λ570 nm on an iMark™ Microplate Absorbance Reader (BioRad, 
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Hertfordshire, UK). The values of the blank (PBS only) were subtracted from all values 
and standard curve was prepared of the OD values of the BSA standards. Protein 
concentration in each sample well was deducted from the equation of the standard 
curve and normalised to the corresponding sample volume. The viral particle titres 
per ml (vp/mL) were determined by assuming that 1 µg protein equals 4 × 109 vp (Von 
Seggern et al., 1998).  
Rapid plaque assay (Bewig and Schmidt, 2000) was used for titering the CsCl-
purified viruses based on expression of the Ad hexon protein. T-REx-293 cells were 
seeded at 1 × 106/well in 12-well plates and allowed to adhere O/N. Cells were 
infected with 100 μL of 10‒3, 10‒4 and 10‒5 dilutions of virus stocks for 1 h at 37C, 
complete medium changed and cells incubated for further 48 h. Medium was 
aspirated and cells allowed to air dry. 1 mL of ice-cold 50/50 acetone/methanol was 
added for 10 min at ‒20C, aspirated and cells washed three times in wash buffer 
(1% BSA in PBS). Polyclonal goat anti-Ad2 antibody (1:5000; #AB1056, Millipore, 
Watford, UK) was added for 1 h at 37C on a rocker and cells washed then three 
times with the wash buffer. Cells were incubated with 500 μL of secondary antibody 
anti-goat (#sc-2056, Biotechnologies, Heidelberg, Germany) for 1 h at 37C on a 
rocker. Cells were then stained with 500 μL of 3, 3’-diaminobenzidine (DAB) substrate 
(#SK-4100; Vector Laboratories Ltd, Peterborough, UK) for 10 min at RT, after which 
the substrate was removed and 1 mL PBS added into each well. The number of 
positive cells was counted in three separate fields of view using an objective that gave 
5‒50 positive cells/field. The average number of positive cells/well was then 
calculated and plaque forming units (pfu)/mL determined (Figure 2–10).  
 
Figure 2–10 Calculation of viral plaque-forming units per mL (pfu/mL). 
 
2.4 In Vitro characterisation of recombinant vectors 
The generated vectors were assessed in multiple well-documented in vitro assays 
to validate their structural and functional integrity.  
2.4.1 Sequencing of the fiber protein from viral DNAs 
Viral DNA of Ad5-based pseudotyped viruses was sequenced to exclude the 
possibility of incorporated accidental mutations post-virus production. Viral DNA was 
first precipitated from CsCl-purified high titre virus stocks by ethanol precipitation. 50 
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μL of purified virus was mixed with 5 μL of 3 M sodium acetate (pH 5.2) and 150 μL 
of 100 % molecular grade ethanol (Fisher Scientific, UK). The mixtures were 
incubated on dry ice for 15 min and DNA pelleted by centrifugation for 30 min at 4ºC. 
The pellets were washed with 70 % ethanol, air-dried and re-suspended in 30 μL of 
H2O. This DNA was then used as a template for PCR to amplify the fiber protein. 
Primers specific for Ad5 sequence immediately outside of the exchanged fiber region 
were used for the PCR reactions (Table 2–7). Sequencing was performed by Eurofins 
Genomics (Ebersberg, Germany). 
2.4.2 Fiber integrity assessment by Western blot 
The structural integrity of the Ad fiber proteins was assessed by Western blotting. 
5 × 109 vp/virus stock were run on pre-cast NuPAGE Novex® 10 % Bis-Tris SDS-
PAGE gels (#WG1201BOX; Life Technologies, Loughborough, UK) with 1 μL of DTT 
and 5 μL of 4 x NuPAGE LDS sample buffer (#NP0008; Life Technologies, 
Loughborough, UK) in a total volume of 20 μL. Proteins were transferred to Amersham 
Protran 0.45 μm nitrocellulose blotting membrane (#10600002; GE Healthcare Life 
Science, Little Chalfont, UK) by semi-dry blotting in a Trans-blot SD Semi-dry Transfer 
Cell (Bio-Rad, Hertfordshire, UK). Nitrocellulose membranes were prepared by 
treating with 5 mL of Pierce Miser antibody extender (#32110; Thermo Scientific, 
Paisley, UK) for 10 min and washing seven times with H20. Membranes were blocked 
in 5 % milk in Tris-buffered saline containing 0.05 % TWEEN-20 and 0.05 % Triton X-
100 (TBS-T) O/N at 4oC. The membrane was then incubated in primary anti-Ad 
antibody 4D2 (1:2000) at 37oC for 1 h, then washed 5 times for 5 min in TBS-T, and 
incubated in anti-mouse IgG-HRP conjugate (1:2000; Insight Biotechnology Ltd, 
Wembley, UK) for 1 h at RT. After washing a further 5 times for 5 min in TBS-T, the 
membrane was incubated for 5 min in SuperSignal West Pico Chemiluminescent 
substrate (#34078; Thermo Scientific, Paisley, UK), and analysed on GelDoc 
autoChem camera (Ultra-Violet Products Ltd, Cambridge, UK) or G:BOX Chemi XX6 
imager (Syngene, Cambridge, UK). 
2.4.3 Silver staining of viral proteins 
The presence of viral proteins in the recombinant pseudotyped vectors was verified 
by silver staining. 1 × 1010 vp of each purified virus stock was diluted in PBS in a total 
volume of 14 μL and loaded into each well with 5 μL of loading buffer and 1 μL of 
DTT. The samples were first run for 1 h 20 min at 150 V. The viral proteins were 
stained by using the Pierce Silver Stain kit (#24612; Thermo Scientific). 
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Figure 2–11. Silver staining of adenovirus particles. Figure reproduced from (Parker et al., 2014). 
 
The gel was washed twice in ultrapure H2O for 5 min and fixed in 30 % ethanol:10% 
acetic acid for 30 min. It was then washed twice in 10 % ethanol and twice in ultrapure 
H2O for 5 min, and incubated in sensitiser working solution for 1 min at RT. After 
washing in ultrapure H2O twice for 1 min, the gel was stained in stain working solution 
for 30 min at RT and then washed twice for 20 s in ultrapure H2O. The gel was then 
developed for 5 min at RT, reaction stopped with 5 % acetic acid and bands 
documented in G:BOX Chemi XX6 imager (Syngene, Cambridge, UK). 
2.4.4 Transduction assay for quantification of luciferase expression  
The assay was performed using the Luciferase Assay System kit, essentially 
according to the manufacturer’s protocol (#E1501; Promega UK Ltd, Southampton, 
UK). Cells were seeded on a sterile 96-microwell Nunc delta surface plate (#163320; 
Thermo Scientific, Paisley, UK) in 200 μL of complete growth medium at a density of 
2 × 104 cells / well in triplicate 24 h prior to the experiment and allowed to adhere at 
37oC in order to reach ~ 60−70% confluency. Medium was then removed, cells 
washed with 200 μL of PBS and viruses were added at doses of 1 × 103, 5 × 103 and 
1 × 104 vp/cell in serum-free RPMI1640 for 3 h. After this, media were replaced with 
cell line-specific complete growth media. 48 h post-infection the cells were lysed with 
1 × Cell Culture Lysis Buffer diluted in H2O (#E1531, Promega UK Ltd, Southampton, 
UK) and plates frozen at −70oC. The cells were then thawed and prepared for the 
analysis by Luciferase Assay System (#1501, Promega UK Ltd, Southampton, UK) 
according to manufacturers’ protocol.  
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10 or 20 μL of cell suspensions were mixed with 100 μL of luciferase assay reagent 
on a white 96-well Nunc microwell plate (#236105; Thermo Fisher Scientific, 
Loughborough, UK) and the luciferase activity in relative light units (RLU) was then 
immediately measured on a multimode plate reader (FLUOstar Omega, BMG 
Labtech, Aylesbury, UK). Protein concentration (mg/mL) in each well of the sample 
plate was determined using a bicinchoninic acid (BCA) protein assay according to 
manufacturer’s protocol (#23227; Pierce™ BCA Protein Assay Kit, Thermo Scientific, 
Loughborough, UK). Bovine serum albumin (BSA) was used as a protein standard at 
concentrations 2.0, 1.5, 1.0, 0.75, 0.5, 0.25, 0.125, 0.025 and 0 mg/mL in PBS in 
duplicate. Samples and standards were incubated with the working reagent (A:B = 
50:1) for 30 min, after which absorbance was measured at λ570 nm on an iMark™ 
Microplate Absorbance Reader (BioRad, Hertfordshire, UK). Blank OD (PBS only) 
was subtracted from all values and standard curve was prepared of the OD values of 
the BSA standards. Protein concentration in each sample well was deducted from the 
equation of the standard curve and normalised to the corresponding sample volume. 
RLU values in each sample well were normalised for total cellular protein (RLU/mg). 
2.4.5 The effect of FX on transduction efficiency 
For assessment of the impact of physiological concentrations of human 
coagulation FX on transduction efficiency, the assays were performed essentially as 
described for the luciferase assay above. Virus dilutions were prepared in serum-free 
medium that was supplemented with 10 μg/mL of FX (#HCX0050, Haematologic 
Technologies, Cambridge Bioscience, Cambridge, UK) for 3 h. Volumes were scaled 
down to a total volume of 100 μL / well to save valuable reagents. FX can be depleted 
from blood or transduction medium by the addition of a two-chain heterogeneous 
anticoagulant X-bp that binds to GLA-domain and depletes FX (Waddington et al., 
2008). The venom was originally extracted from the hundred pace snake 
(Deinagkistrodon acutus) (Atoda, 1998). X-bp was used for depletion of FX from 
serum or ascites at a ratio of 3:1 (X-bp:FX). 
2.4.6 Transduction assays on β-galactosidase-expressing vectors 
Transduction assay for β-galactosidase (β-Gal)-expressing viruses was performed 
using Galacto-Light Plus System according to manufacturer’s instructions (Applied 
Biosystems, Bedford, Massachusetts, USA). Cells were seeded on 96-well Nunc delta 
surface plates (#236105; Thermo Scientific, Loughborough, UK) and infected as 
described in section 2.4.4. Infected cells were lysed 48 h post-infection in 100 μL of 
home-made lysis buffer (0.2 % Triton X-100 in PBS) and plate frozen at ‒70°C for a 
minimum of 1 h. Cells were thawed and 10 μL of suspension was mixed with 70 μL of 
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Galacton Plus Tropix reagent (1:100 in 100 mM NaH2PO4 / 1 mM MgCl2 diluent, pH 
8.0) on a black 96-well microwell plate (#237105 Thermo Scientific, Loughborough, 
UK), covered with foil and incubated for 1 h at RT. 100 μL of Tropix II accelerator was 
added into each well and β-Gal activity in RLU) was then immediately measured on 
luminescence mode on a multimode plate reader (FLUOstar Omega, BMG Labtech, 
Aylesbury, UK). Protein concentration (mg/mL) in each well of the sample plate was 
determined using microBCA assay kit and BSA as a protein standard. RLU values in 
each sample well were then normalised for total cellular protein (RLU/mg). 
2.4.7 Neutralisation assays in the presence of ovarian ascites 
Cell-free ascites samples were used for neutralisation assays to assess the effect 
of pre-existing anti-Ad nAbs on viral transduction efficiency. Working stocks of freshly 
isolated fluids were stored as 1 mL aliquots at ‒20°C for further use (section 2.1.2). 
Prior to in vitro assays, a vial of each fluid was rapidly thawed in a 37ºC and kept on 
ice. Neutralisation assays were performed essentially as described in section 2.4.4, 
with the exception that cells were pre-incubated with 2-fold serial dilutions (1:40‒
1:2.5, corresponding to final concentration of 2.5‒40 %) of ascites. The dilutions were 
prepared in serum-free medium (RPMI 1640) by mixing equal amounts of the previous 
dilution with medium in 1.5 mL Eppendorf tubes. The cells in each well were washed 
with 200 μL of sterile PBS and 100 μL of ascites dilutions added on the cells for 1 h 
at 37oC, prior to virus addition for 2 h at 37oC. After this the cells were washed with 
200 μL of PBS, 100 μL cell lysis reagent added and the plate frozen at ‒70oC for a 
minimum of 1 h. The plate was thawed in RT for a minimum of 1 h and 10‒20 μL of 
cell suspension analysed for luciferase activity, as described in section 2.4.4. Ascites 
supernatant that exhibited > 90 % inhibition of transduction was considered to be 
neutralising, as described and validated previously for serum neutralisation assays 
(Parker et al., 2009). 
2.4.8 Competition inhibition assays 
Vector tropism for cellular receptors CAR, CD46 and αvβ6 integrin was assessed 
in competition inhibition assays, which is a variation of a standard luciferase 
transduction assay described above. 20 000 cells were seeded in each well on a 96-
well tissue culture plate and pre-incubated with Ni-NTA purified recombinant His-
tagged knob proteins (section 2.2) ‒ kn5.wt, kn5.hCAR‒, kn5.HI.A20, kn48.wt and 
kn48.DG.A20 at a final concentration of 10 μg/105 cells in triplicate. For binding 
inhibition with function-blocking antibodies, cells were pre-incubated anti-αvβ6 
antibody clone 10D5 (Abcam, Cambridge, UK), anti-CD46 clone MEM-258 (Abcam, 
Cambridge, UK) or normal anti-mouse control IgG (Santa Cruz Biotechnologies, 
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Heidelberg, Germany) for 30 min on ice (all 10 μg/mL). Total sample volume was 100 
μL/well. The viruses were then added on the top at 5000 vp/cell and the mixture 
incubated for further 1 h on ice. Viruses were then removed, and cells incubated in 
complete medium for further 47 h at 37ºC. Cells were then washed with 200 μL of 
PBS, lysed with 100 μL of cell culture lysis buffer and plates frozen at ‒70ºC. RLU 
values were measured from 20 μL of cell lysate at 48 h post-infection and normalised 
to total cellular protein (mg/mL) as described above. 
2.4.9 Cytotoxicity assays 
The cytotoxicity of the oncolytic vectors was assessed using a semi-quantitative, 
colorimetric CellTiter 96 Aqueous One Solution Cell Proliferation Assay (#G3580; 
Promega, Madison, WI, USA) according to the manufacturer’s instructions. A 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] together with an electron coupling 
reagent phenazine ethosulfate (PES) is reduced into a coloured formazan product by 
NADPH/NADH produced by dehydrogenase enzymes in metabolically active cells 
(Figure 2–12). Cells were infected at 1000, 5000 and 25 000 vp/cell in triplicate in a 
total volume of 100 μL for 3 h, as described in section 2.4.4. Medium was then 
replaced with 100 μL of complete medium, and cells incubated at 37ºC in a closed 
humidified container. Cell viability was assessed by addition of 20 μL of assay reagent 
in each well (5 % final concentration) at pre-determined 24 h time-points. Absorbance 
was measured at λ490 nm in an iMark™ Microplate Absorbance Reader (BioRad, 
Hertfordshire, UK) following a 2 h incubation at 37ºC covered in the dark. The number 
of live cells is directly proportional to the intensity of the produced dark brown colour. 
The absorbance from uninfected cells was used as a reference of 100 % cell viability. 
 
Figure 2–12. The cell viability assay is based on a colorimetric reaction.  3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) is reduced to a coloured 
product formazan by dehydrogenase enzymes in live cells (Promega, 2017). 
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2.4.10 Haemagglutination assays 
Ethics permission was obtained for collection of blood from healthy volunteers 
(Cardiff University School of Medicine Research Ethics committee (SMREC) 
reference number: 16/45). Recombinant Ad vector tropism was assessed in standard 
haemagglutination assays (Dooley et al., 1982, Cichon et al., 2003, Nicol et al., 2004). 
The assay is based on erythrocyte agglutination and the formation of a characteristic 
erythrocyte network on the surface of the well, due to Ad binding to CAR on 
erythrocytes (Nicol et al., 2004). Non-CAR-binding Ads fail to agglutinate blood and 
therefore characteristic erythrocyte pellet forms at the bottom of the well. Leftover 
erythrocytes were received from other researchers who had separated the blood by 
serial centrifugation and removed plasma to be used for other assays. The erythrocyte 
cell pellet was transferred to a fresh 15-mL tube and washed two times with 5 mL of 
PBS by centrifugation for 8 min at 1000 rpm. The erythrocytes were then diluted to 1 
% (v/v) in PBS, and virus dilutions were prepared at 1 × 109, 7.5 × 108 and 5 × 108 vp 
in PBS. 50 μL of erythrocyte suspension was added in each well of V-bottom 96-well 
plate, 50 μL of virus dilutions added on the top and mixed gently. After a 2 h incubation 
at 37ºC haemagglutination was graded as ‒, no haemagglutination, +, partial, ++, 
midrange, +++, complete haemagglutination (Cichon et al., 2003). 
2.5 In vivo characterisation of recombinant vectors 
All in vivo experiments were performed at Professor Richard Vile’s laboratory at 
the Department of Immunology/Molecular Medicine (Mayo Clinic, Minnesota, USA). 
All procedures were approved by the local Mayo Foundation Institutional Animal Care 
and Use Committee (IACUC). Permissions for the international export and use of 
replication-deficient and oncolytic Ad vectors were requested from Centers for 
Disease Control (CDC, USA). Animal experiments were funded from Mayo Clinic PAU 
funding #91939 and International Collaboration Seedcorn grant awarded to Dr Alan 
Parker by School of Medicine, Cardiff University, UK (#AH1170A001; £10 000). 
Cancer Research Wales (CRW) charity funded part of the research done in this thesis 
but did not allow funding of animal experiments. The Seedcorn grant was therefore 
obtained for the purposes of funding the in vivo experiments that were considered 
pivotal for the successful completion of this thesis. The completion of in vivo studies 
involved a 2-month collaborative visit to Prof Richard Vile’s laboratory. In order to 
achieve consistency of results, all animals were sex-matched; female mice were 
chosen due to the ease of housing. Mice were allowed to acclimatise for a minimum 
of 48 h prior to experiments. All injections and animal handling were performed by a 
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highly qualified veterinary technologist Jill M. Thompson (Mayo Clinic, Rochester, MN, 
USA). 
2.5.1 Biodistribution profile following systemic vector delivery 
 
Figure 2–13. Treatment schedule for in vivo biodistribution study. Mice were challenged with 
viruses and blood collected for cytokine screening. The animals were sacrificed on day 3 post-infection 
(p.i.). i.v., intravenous; IVIS, In Vivo Imaging System; vp, viral particle. 
 
The biodistribution of replication-deficient vectors was assessed in wild type B6 
albino mice (B6N-Tyrc-Brd/BrdCrCrl) that is a spontaneous albino mutant co-isogenic 
C57BL/6 strain with an MHC haplotype H2b. This immunocompetent strain was 
chosen due to its white coloured coat, which makes luciferase tracking much more 
feasible compared to the commonly used black C57BL/6 phenotype. 6-week-old mice 
(n = 5/group) were ordered from Charles River Laboratories International (USA) and 
allowed to acclimatise for one week prior to experiments (Figure 2–13). Viruses were 
diluted in PBS at 1 × 1011 vp in a total volume of 100 μL and injected into the lateral 
tail vein. Animals were monitored daily for distress and vector-induced toxicities. All 
mice were sacrificed immediately after IVIS imaging at 72 h by inhalation of CO2 and 
organs harvested to assess vector distribution by ex vivo imaging, 
immunohistochemical staining of paraffin-embedded tissues (IHC-P) and 
quantification of viral copy number. 
 Table 2–8. Treatment groups in the biodistribution study. All viruses were replication-deficient. 
A20, peptide NAVPNLRGDLQVLAQKVART (DiCara et al., 2007); KO1, CAR-binding mutation (Smith et 
al., 2002). 
 
 
 
 
 
 
 
Group Replication-deficient vector Insert N 
A PBS ‒ 5 
B Ad5.Luc ‒ 5 
C Ad5.KO1 ‒ 5 
D Ad5.A20 A20 peptide 5 
E Ad5.KO1.A20 A20 peptide 5 
F Ad5.HVR7 ‒ 5 
G Ad5.HVR7.A20 A20 peptide 5 
H Ad5.3D.A20 A20 peptide 5 
 TOTAL  40 
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2.5.2 IVIS imaging for temporal and spatial luciferase expression 
All viruses express Firefly luciferase, which allowed us to track their temporal and 
spatial distribution in real time by using the non-invasive, semi-quantitative In Vivo 
Imaging System (IVIS), Xenogen IVIS-200 Bioluminescent Imager (PerkinElmer, 
Hopkinton, MA, USA). Live mice were imaged at 72 h time-point to assess vector 
trafficking to peripheral tissues. The bioluminescence of luciferase is activated by its 
substrate, D-luciferin. For IVIS imaging, mice were anaesthetised using 2 % isoflurane 
(1.5 % for maintenance) and 200 μL of D-luciferin at 15 mg/mL (#LUCK; potassium 
salt, Gold Biotechnology, St. Louis, MO, USA) was injected i.p. and allowed to 
disseminate for 5 min prior to imaging. Mice were placed in the IVIS imager one group 
(n = 5) at a time, and bioluminescence recorded with 1 min exposure time. Mice were 
then sacrificed by inhalation of CO2, organs harvested and each organ placed in a 
separate well on a 12-well plate with 1 mL of PBS to prevent them from drying out. Ex 
vivo luminometry was performed on tissue blocks immediately after harvesting of the 
organs to correlate with the observations from IVIS imaging. 1 mL of D-luciferin was 
added on top of each organ at a final concentration of 300 μg/mL and image taken 
immediately with 1 min exposure time. Images were further evaluated in Living 
Image® software version 4.5 (Perkin Elmer, Hopkinton, MA, USA).  
2.5.3 Viral genome number by quantitative polymerase chain reaction (qPCR) 
Viral and total genomic DNA was obtained from non-fixed murine tissues (~ 10 mg 
of spleen and ~ 25 mg of other organs) using DNeasy Blood & Tissue DNA extraction 
kit according to the manufacturer’s protocol (#69506; Qiagen, Germantown, MD, 
USA). The concentration of purified DNA was determined using a NanoDrop ND-1000 
photospectrometer (NanoDrop Technologies). 40 ng of total DNA was subjected to 
fluorogenic quantitative PCR using Fast SYBR Green Master Mix system (#4385612; 
Applied Biosystems, Life Technologies, Paisley, UK). Reactions were performed in 
triplicate, using primers for the hexon region of the genome, Forward: 5′-
CGCGGTGCGGCTGGTG-3′ and Reverse: 5′-TGGCGCATCCCATTCTCC-3′ (Sigma 
Aldrich, Gillingham, UK). Negative controls were run to ensure that no amplification 
occurred in the absence of DNA. Cycling conditions were as follows; 50°C for 2 min, 
95°C for 10 min, 40 cycles of 95°C for 15 s, followed by 60°C for 1 min. Total 
adenoviral genomes were calculated using a standard curve of 101‒107 viral 
genomes; separate standard curve was prepared for each virus. 
2.5.4 Immunohistochemical staining of paraffin-embedded tissues (IHC-P) 
Lungs, liver, spleen, heart, ovaries and tumour tissues were harvested from mice 
post-mortem. Immediately after ex vivo imaging, organs were immersed in 10 mL 
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volume of 10 % formalin (#032-059; Protocol®, Fisher Scientific, MI, USA). Livers 
were sent to Histology Core Laboratory, Mayo Clinic Arizona, Scottsdale, AZ, USA for 
preparation of formalin-fixed paraffin-embedded and haematoxylin/eosin (H&E) 
stained tissue slides. The presence of Ad particles in liver tissues was visualised by 
IHC staining. Tissues were first re-hydrated by incubating in three changes of xylene 
for 5 min. They were then washed twice in 100 % industrial methylated spirit (IMS) for 
3 min, once in 90 % IMS for 3 min, distilled H2O for 5 min and rinsed in PBS. The 
tissues were circled with ImmEDGE pen (#H-4000; Vector Laboratories, 
Peterborough, UK), and treated with proteinase K (#4333793; AB, Foster City, CA, 
USA) at 20 μg/mL in Tris/EDTA (TE) buffer for 10 min at RT. Tissues were then 
washed in PBS for 5 min and blocked in 2.5 % horse serum (#MP-7401; 
ImmPRESS™ HRP anti-rabbit IgG-HRP polymer detection kit; Vector Laboratories, 
Peterborough, UK) for 1 h. After a 5-min wash in PBS, endogenous hydrogen 
peroxide activity was quenched by treating the tissues with 3 % H2O2 (#21,676-3; 
Sigma Aldrich, Gillingham, UK) in PBS for 10 min, after which the tissues were 
washed in PBS for 5 min. Tissues were then incubated with primary polyclonal rabbit 
anti-adenovirus type 5 antibody (1 μg/mL; #ab6982, Abcam, Cambridge, UK), anti-
ITGB6 antibody (1:10; #ab197672, Abcam, Cambridge, UK) or anti-CAR antibody 
(1:100; #ab153740, Abcam, Cambridge, UK) O/N at 4ºC in a humidified container. A 
rabbit IgG isotype control antibody (1 μg/mL; #GTX35035; GeneTex, Wembley, UK) 
was included as a negative control to detect any non-specific staining. Tissues were 
washed in 1 mL of PBS for 5 min and incubated with anti-rabbit secondary (#MP-
7401; ImmPRESS™ HRP anti-rabbit IgG-HRP polymer detection kit, made in horse; 
Vector Laboratories, Peterborough, UK) for 30 min at RT. Tissues were washed in 
PBS for 5 min and incubated with DAB substrate for 3 min. They were then rinsed in 
tap water, counterstained in haematoxylin for 15 s and rinsed in running water for 15 
min until the water was completely clear. The tissues were then de-hydrated by 
repeating the re-hydration sequel in reverse, starting from 90 % IMS and proceeding 
to the xylene washes. Tissues were mounted using DPX Mountant for histology 
(#06522; Sigma Aldrich, Gillingham, UK), coverslip added on the top, and images 
acquired at 10 x, 20 x and 40 x magnification using a light microscope (Leica DMC 
2900; Leica Microsystems Ltd, CH-9435 Heerbrugg, Switzerland).  
2.5.5 Cytokine screening 
Elicitation of innate immune mediators was assessed in immunocompetent mice 
as a part of the biodistribution study, as cytokine/chemokine assessment provides 
important information on vector toxicity and tolerability. Cytokine screening was 
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performed in its entirety by Dr Angela Bradshaw, BHF Glasgow Cardiovascular 
Research Centre, UK. Approximately 100 μL of blood was collected from mice at 6 h 
and 24 h post-injection from the submandibular (cheek) vein into lithium heparin tubes 
(#365965; BD Microtainer, Becton Dickinson, New Jersey, USA). Whole blood was 
transferred to 1.5 mL Eppendorf tubes and plasma was separated by centrifugation 
at 1000 x g for 10 min at 4ºC in a table top centrifuge and stored at ‒80ºC. Cytokines 
and chemokines were assessed in a magnetic bead-based Bio-Plex Pro™ Mouse 
Cytokine 23-plex assay (#M60009RDPD; Bio-Rad Laboratories Ltd, Herts, UK) and 
Pro reagent kit (#171-304070M; Bio-Rad Laboratories Ltd, Herts, UK) per 
manufacturer’s instructions. The panel assesses the levels of common markers of 
acute innate immune response activated upon (viral) infections: granulocyte colony-
stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-
CSF), interferon γ (IFN-γ), interleukin (IL) 1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-
10, IL-12 (p40/p70), IL-13, IL-17A, tumour necrosis factor α (TNF-α), chemokine 
ligand 5 (RANTES), keratinocyte-derived cytokine (KC), monocyte chemoattractant 
protein 1 (MCP-1; MCAF), macrophage inflammatory protein-1 α (MIP-1α), MIP-1β 
and eotaxin (CC subfamily of eosinophil chemotactic proteins). 30 μL of plasma was 
mixed with 90 μL Bio-Plex sample diluent (1:4) and incubated with the magnetic beads 
on ice. Following an O/N vortexing at 4ºC, the coupled beads were incubated with the 
secondary detection antibody for 30 min on a shaker. Serial washes were performed 
in wash buffer between each incubation step. The beads were then mixed with assay 
buffer and analysed in a fluorescence-based Bio-Plex® 200 plate reader with high-
throughput fluidics (#171000205; Bio-Rad Laboratories Ltd, Herts, UK). Protein 
concentration was quantified by BCA assay using 10 μL of the original plasma 
samples that were diluted 1:10 in PBS and absorbance measured at λ560 nm; values 
were normalised to total protein in each well (pg/mg). Data were analysed in Bio-Plex® 
200 Manager™ software with 5-point log curve fitting and statistical analyses 
performed in GraphPad Prism.  
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2.5.6 Generation of a SKOV3-β6 ovarian cancer xenograft model 
 
Figure 2–14. Schedule for the SKOV3-β6 pilot study. Intraperitoneal (i.p.) SKOV3-β6 tumour 
xenografts were established in NOD/SCID mice. Two mice were sacrificed on days 7, 14, 21 and at the 
final endpoint. 
 
A pilot study (Figure 2–14) was set up to establish a timeline for the tumour take 
rate, and to set up an optimal time point for OAd treatment for a subsequent efficacy 
study. Prior to implantation to mice, 2 × 107 SKOV3-β6 cells were sorted into a highly 
αvβ6-positive cell population by FACS by staining with primary anti-αvβ6 antibody 
10D5 (1:100; #MAB2077Z, Millipore, Watford, UK) and secondary anti-mouse-FITC 
IgG conjugate (1:100; #0855499, MP Biomedicals, USA). Cell sorting was performed 
on FACSAria cell sorter by trained professionals at Microscopy and Cytometry Core 
at Mayo Clinic, Rochester, MN, USA. A total number of 3.1 × 106 positive cells were 
recovered and sub-cultured for 8 days prior to implantation. Cells in log phase 
(monolayer ~ 70 % confluent) were rapidly trypsinised and washed twice with PBS 
immediately prior to implantation. Immunocompromised non-obese diabetic severe 
combined immune deficiency (NOD/SCID) mice homozygous for the SCID 
spontaneous mutation (Prkdcscid) (Jackson Laboratories, Bar Harbor, Maine, USA) 
were allowed to acclimatise for a week prior to handling.  
On day 0, 1 × 107 SKOV3-β6 cells were implanted i.p. in eight animals (n = 
2/group). Mice were monitored daily for the onset of malignant ascites build-up, and 
weighed every 7 days. At 7-day intervals two mice were sacrificed, and their peritoneal 
cavity rinsed with 10 mL of DMEM to collect floating cancer cells. Visible tumours 
were dissected into a homogenous solution and cells cultured in a T75 tissue culture 
flask. For flow cytometry, cells were stained with primary anti-CAR RmcB (1:500; #05-
644, Millipore, Watford, UK) and anti-αvβ6 10D5 (1:100) antibodies, and a secondary 
anti-mouse IgG (H+L) Alexa Fluor 647 (#A-21235, Invitrogen). In vitro grown SKOV3-
β6 cells were used for gating to distinguish the EOC cells from other cell types present 
in the ascites. A minimum of 10 000 events were recorded for each mouse on 
FACSCanto at Microscopy and Cytometry Core at Mayo Clinic, Rochester, MN, USA.  
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2.6 Statistical analysis and software used 
2.6.1 Statistical analyses 
All figures were created and statistical analyses performed in GraphPad Prism 
version 4.03 (GraphPad Software Inc., La Jolla, CA, USA). Unless otherwise stated, 
data show the mean  standard deviation (SD) or standard error of the mean (SEM) 
of n = 2–5 (specific n numbers are indicated in each figure legend). P values were as 
follows: ns, not statistically significant, p > 0.05; *, p < 0.05; ** p < 0.01; ***, p < 0.001; 
****, p < 0.0001. 
2.6.2 Sequence analyses 
All viral BAC sequences were verified by sequencing after mutation by AdZ 
recombineering. DNA sequences were analysed in CLC Main (Qiagen) or Genome 
Compiler (Genome Compiler Corporation, CA, USA) software.  
2.6.3 Protein alignments and structural analyses 
All sequences of adenovirus structural proteins were downloaded from National 
Center for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/protein). Sequences were aligned in BioEdit software 
(Hall, 1999) using the ClustalW multiple alignment tool. The alignments were then 
saved as rich text format and further edited in Microsoft Word and PowerPoint. 
2.6.4 Flow cytometry and fluorescence-activated cell sorting (FACS) 
FACS of SKOV3-β6 cells for in vitro studies was performed by Dr. Kristin Ladell, 
Cardiff University. FACS of SKOV3-β6 cells for in vivo xenograft study was performed 
in Aria cell sorter at Microscopy and Cytometry Core at Mayo Clinic, Rochester, MN, 
USA. Analyses of flow cytometry data were performed in BD Accuri software (BD 
Biosciences). FACS data were analysed in FACSDiva 8.0.1 software (BD 
Biosciences). 
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CHAPTER 3. Characterisation of model cell lines and ovarian 
ascites 
This chapter discusses the characterisation of model cell lines for the assessment 
of recombinant cancer-targeted Ad vectors. We sought to find suitable cells that would 
express variable levels of CAR, CD46 and αvβ6 integrin. The second major objective 
was the establishment of successful ex vivo cultures of EOC cells from clinical 
malignant ascites that had been derived from patients who were receiving 
chemotherapy for advanced ovarian cancer. The ascitic fluids were also characterised 
for their presence of anti-Ad antibodies and FX, both of which are likely to play an 
important role in the efficacy of Ad vector-based therapies that are intended for local 
i.p. delivery. 
3.1 Phenotyping of cancer cell lines 
3.1.1 Receptor expression profile 
Epithelial cell lines were assessed for the surface receptor expression profile of 
αvβ6, CAR, CD44, CD46 and EGFR by flow cytometry (Table 3–1) in order to screen 
and evaluate suitable candidates for preliminary in vitro transduction studies. The 
native receptor of species C Ads ‒ CAR ‒ was expressed at highly variable levels, 
while the level of native receptor of species B Ads ‒ CD46 ‒ was consistently high in 
all cell lines. Levels of a CSC marker CD44 and a common cancer cell marker EGFR 
were consistently high in all tested human cell lines. BT-20 breast cancer cell line was 
shown to express natively high levels of αvβ6 integrin.  
Table 3–1. Receptor expression profile of epithelial cell lines. 100 000 cells were stained in 
duplicate with primary antibodies (αvβ6, 10D5; CAR, RmcB; CD44, F10442; CD46, MEM258; EGFR, 
H11) for 1 h on ice, and with secondary AlexaFluor 647 for 30 min on ice. Data were recorded for 10 
000‒20 000 events in BD Accuri C6 flow cytometer and analysed in BD Accuri software. αvβ6, αvβ6 
integrin; CAR, coxsackie and adenovirus receptor; CD46, cluster of differentiation 46 receptor; EGFR, 
epidermal growth factor receptor; SKOV3-β6, SKOV3 cell line expressing β6 subunit (generated in-
house); *, primary cell line; nd, not determined. 
Cell line Organ αvβ6 CAR CD44 CD46 EGFR 
A549 Human lung carcinoma 7 100 nd 100 100 
BT-20 Human breast cancer 87 40 93 97 96 
CHO-K1 Hamster ovary 0 0 nd 0 0 
CHO-CAR Hamster ovary 0 100 nd 0 0 
CHO-BC1 Hamster ovary 0 0 nd 100 nd 
D007-SFi* Human skin fibroblast 0 0 100 nd nd 
HeLa Human cervical cancer 0 3 nd 40 50 
HepG2 Human liver cancer 0 100 nd 90 100 
MDA-MB-231 Human breast cancer 0 13 98 nd nd 
MDA-MB-361 Human breast cancer 72 87 18 nd nd 
OVCAR3 Human ovarian cancer 18 18 0 96 84 
SKOV3 Human ovarian cancer 9 44 nd 98 nd 
SKOV3-β6 Human ovarian cancer 100 90 nd 98 nd 
T24 Human bladder cancer 0 9 nd 100 nd 
T-REx-293 Human embryonic kidney 0 87 77 nd nd 
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3.1.2 Selection of model cell lines for transduction assays 
This thesis is focused on the characterisation of vectors targeted to ovarian cancer, 
which is why we focused on assessing the phenotype of several different ovarian 
cancer cell lines. Cell lines with high levels of αvβ6 expression were selected as model 
cell lines for the in vitro assessment of αvβ6-targeted vectors. BT-20 is a breast cancer 
cell line that expresses high levels of αvβ6 and low levels of CAR (Figure 3–1A). In 
the absence of a suitable CARlow/αvβ6high EOC model cell line, BT-20 was used as a 
αvβ6high control cell line, despite its non-ovarian origin. Chinese hamster ovarian cell 
lines CHO-K1 (Figure 3–1B), CHO-CAR (Figure 3–1C) and an ovarian ascites-
derived cell line SKOV3 (Figure 3–1D), were the main cell lines used for transduction 
assays in this thesis. CHO-K1 cell line, being devoid of all primary native Ad receptors 
and the assessed cancer cell markers, was used as a clean negative control cell line 
for Ad transduction in this thesis. CHO-CAR cell line was chosen as a representative 
positive control cell line for all in vitro studies assessing vector CAR-tropism, due to 
its high level of CAR-expression. Another ovarian cell line, OVCAR3 (Figure 3–1E), 
was shown to lack expression of αvβ6 and was therefore not readily suitable for these 
studies. The CARhigh T-REx-293 cell line was shown to lack αvβ6 expression but to 
express high levels of CAR (Figure 3–1F), and was used routinely for propagation of 
replication-deficient vectors due to its expression of Ad E1 and E3 genes that have 
been removed from the Ad5 vector backbone.  
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Figure 3–1. Selected cell lines for transduction studies based on their αvβ6 integrin and CAR 
expression. (A) BT-20 breast cancer, (B) CHO-K1 hamster ovarian, (C) CHO-CAR hamster ovarian, (D) 
SKOV3 ovarian cancer, (E) OVCAR3 ovarian cancer and (F) T-REx-293 kidney cells were stained with 
primary antibodies (αvβ6, 10D5; CAR, RmcB) for 1 h on ice and with secondary AlexaFluor 647 for 30 
min on ice. 10 000‒20 000 events were recorded in BD Accuri C6 flow cytometer and data analysed in 
BD Accuri software. CAR, coxsackie and adenovirus receptor. 
 
The second main part of this thesis is focused on the generation and in vitro 
characterisation of novel pseudotyped vectors based on species D serotypes. We 
therefore sought to assess the receptor tropism of these vectors on cell lines that 
would have variable levels of both CAR and CD46 expression, since these receptors 
are potential entry receptors for viruses from subgroup D. We chose to use CHO-K1 
cells as a negative control cell line, since they have no CD46 expression (Figure 3–
2A). CHO-BC1 cells (Figure 3–2C) that stably express an isoform BC1 of the CD46 
receptor, as previously described by Prof Lieber’s research group (Gaggar et al., 
2003), were used for all assays evaluating CD46 tropism of Ad serotypes in this 
thesis. This is a clean model cell line as it does not express CAR or other Ad receptors 
(data not shown). Model cell lines for αvβ6 targeting, SKOV3 and BT-20, were also 
shown to express very high levels of CD46 (Figure 3–2D, E). 
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Figure 3–2. CD46 receptor expression on selected model cell lines. (A) CHO-K1 Chinese 
hamster ovarian, (B) CHO-BC1 Chinese hamster ovarian expressing an BC1 isoform of CD46, (C) 
SKOV3 ovarian cancer and (D) BT-20 breast cancer cell lines were stained with primary CD46 antibody 
MEM258 for 1 h on ice, and with secondary AlexaFluor 647 for 30 min on ice. 10 000‒20 000 events 
were recorded in BD Accuri C6 flow cytometer and data analysed in BD Accuri software. 
 
3.1.3 Generation of an αvβ6-positive model cell line ‒ SKOV3-β6  
SKOV3 ovarian cancer cells were used as a cell line counterpart for ascites-
derived primary EOC ex vivo cultures assessed in this thesis. SKOV3 cells were 
originally derived from clinical ascites from an ovarian cancer patient donor and further 
propagated into a permanent cell line (source: ATCC, American Type Culture 
Collection), which is why they are an optimal cell line for our purposes. These were 
used as the parent cell line to generate SKOV3-β6 cell line by stable transfection 
using a pBABE puro β6 retrovirus plasmid expressing the human β6 integrin subunit. 
Cell line was generated in a week’s time, and transduced cells were further 
propagated for assays for a minimum of several weeks in the presence of puromycin 
selection marker, until any in vitro assays were carried out. The generated SKOV3-
β6 cells were propagated through serial passages in the presence of 5 μg/mL of 
puromycin selection marker in complete DMEM medium. The cells were then sorted 
into high αvβ6-expressing populations prior to subsequent in vitro assays, to ensure 
that they were highly permissive to viral infection. At the time of the first sort the cells 
were ~ 88 % positive for αvβ6 (Figure 3–3A). The top 8 % most positive population of 
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these cells was sorted by FACS, and expanded in subsequent culture in the presence 
of 5 μg/ml of puromycin until a desired cell number was achieved for second FACS 
sort. The sorted cells were assessed by flow cytometry and shown to be 100 % 
positive for αvβ6 (Figure 3–3B). The SKOV3-β6 cells were then further propagated 
and second round of FACS performed to ensure high proportion of αvβ6-positive cells 
for transduction assays. At this stage the cells were still 94 % positive for αvβ6 (data 
not shown). Of this positive population, the top 10 % most αvβ6-positive SKOV3-β6 
cells were sorted (Figure 3–3C), further sub-cultured, used for in vitro assays, and 
frozen down for permanent stocks. 
 
Figure 3–3. Fluorescence-activated cell sorting (FACS) of SKOV3-β6 cells. Cells were stained 
with primary αvβ6 antibody 10D5 for 1 h on ice, and with secondary AlexaFluor 647 for 30 min on ice. 
(A) In the first round the top 10 % most αvβ6-positive cell population (red) was sorted and further 
propagated. (B) The level of αvβ6 and CAR expression on SKOV3-β6 cells was assessed by flow 
cytometry after the first round of FACS, recording 20 000 events. (C) Second round of FACS for SKOV3-
β6 cells. Cells were sorted into a 10 % most αvβ6-positive population (red). αvβ6, αvβ6 integrin; CAR, 
coxsackie and adenovirus receptor. 
 
3.2 Characterisation of clinical ovarian ascites 
Twenty clinical ovarian ascites samples were received from Velindre Cancer 
Centre (Cardiff, UK) between December 2014 and August 2016. Ascites samples 
arrived to our lab in a 500 mL plastic disposable container, generally within ~ 3 h of 
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isolation from the patient. In few cases samples were stored in the original container 
O/N in the fridge at 4°C and processed on the following morning. Up to 24 h storage 
at 4°C did not have a notable effect on the survival of EOC cells, while cell survival 
was notably decreased in samples that were stored beyond this period. The samples 
were processed according to established protocols (Thériault et al., 2013, Shepherd 
et al., 2007, O'Donnell et al., 2014) with a satisfactory success rate. Considerable 
variation was observed in the colour, thickness and consistency of the clinical ovarian 
ascites samples. One sample was extremely thick and creamy (Figure 3–4A), which 
is likely to be a result of lymphatic obstruction by a tumour mass, causing leakage of 
protein-rich lymphatic fluids into the peritoneal cavity. The parenthesis procedure itself 
can cause leakage of blood into the peritoneum from the catheter pass, causing 
bloody appearance in the fluid (Figure 3–4B and C). Most commonly however, the 
fluid was a shade of dark yellow straw, reminiscent of the colour of serum (Figure 3–
4D). Very frequently there were ~ 1‒2 cm pieces of connective tissue and/or adipose 
tissue present in the fluid, which were discarded at the time of sample processing and 
not included in the EOC ex vivo cultures. 
 
Figure 3–4. Physical appearance of ovarian ascites samples. Huge variation was seen in the 
appearance of ovarian ascites. Some fluids were (A) extremely creamy and thick, (B) contaminated with 
blood, (C) heavily contaminated with haemolysed blood. (D) Summary of all 20 samples on a 96-well 
plate showing the range of colour variation; neat ascites, diluted 1:2 and 1:4 in 1 % milk/PBS-T for ELISA; 
S, serum control (first row). 
 
Cells were isolated from the fluid by centrifugation, and sub-cultured in general T75 
cell culture flasks at 37ºC for up to several months. The cell-free fluids were stored as 
50 mL aliquots at ‒70ºC for permanent long-term stocks, and 1 mL working stocks 
were stored at ‒20ºC. Two cryovials of cells of each sample were stored at passage 
0 in ‒130ºC liquid nitrogen tanks for long term storage and future use. At the time of 
subsequent use, a vial was rapidly thawed in 37ºC water bath and cells sub-cultured 
in complete EOC growth medium for up to several months until they turned senescent. 
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Cells were frozen back at passage 1 to establish long-term stocks for future use. 
Proliferating primary EOC ex vivo cultures were successfully established for 13 out 
20 ascites samples, corresponding to a 65 % success rate (Table 3–2). Successful 
culture establishment seemed to be independent on the chemotherapy treatment 
stage and on the level of blood contamination in the received sample. 
Table 3–2. Clinical ovarian ascites sample summary. Samples were received from Velindre 
Cancer Centre (Cardiff, UK) and processed within 24 h. Successful epithelial ovarian cancer (EOC) cell 
ex vivo cultures are shown in black. The level of blood contamination: ‒, absent/low; +, medium; ++ 
high/very high. Stage indicates the extent of previous chemotherapies: 1, pre-treatment/chemo naïve; 2, 
first-line chemo; 3, relapsed disease/platinum-sensitive; 4, relapsed disease/platinum-resistant. 
Sample 
ID 
Date 
received 
Vol. 
(mL) 
Stage Blood Remarks 
000 3/12/14 500 2 ++ ‒ 
001 15/12/14 500 2 + ‒ 
002 26/2/15 500 3 ++ lots of cells present in the initial sample 
003 1/4/15 650 1 ++ ‒ 
004 1/4/15 500 4 ++ ‒ 
005 27/4/15 500 nd ++ 
heavy bacterial contamination (extremely 
cloudy); sample not used for any assays 
006 28/4/15 500 nd ++ ‒ 
007 7/5/15 500 3 ‒ ‒ 
008 3/6/15 600 3 + ‒ 
009 25/6/15 625 1 ‒ ‒ 
010 4/8/15 500 4 ++ ‒ 
011 3/2/16 500 4 ‒ 
very creamy and thick - lymphatic 
obstruction? 
012 6/7/16 400 nd ++ ‒ 
013 12/7/16 500 4 ‒ yellow colour 
014 12/7/16 500 2 ++ good cell growth 
015 15/7/16 450 4 ‒ 
yellow colour; lots of connective/fat tissue - 
stored 48 h until processed 
016 15/7/16 500 4 + brownish yellow colour 
017 11/8/16 550 4 ‒ ‒ 
018 17/8/16 550 nd ‒ 
nice yellow colour, some fat/connective 
tissue; pretty cobblestone cells 
019 24/8/16 450 3 ++ extremely dark brown colour and thick texture 
 
3.2.1 Epithelial ovarian cancer (EOC) cell morphology and senescence 
The EOC primary cells were generally sturdy to culture and tolerated freeze-thaw 
cycles very well. There was no significant cell loss when cells were revived from 
frozen. The cells were generally cultured for up to four weeks until a suitable cell 
confluency was achieved. They were then either sub-cultured or seeded in 96-well 
tissue culture plates for ex vivo assays. In general, primary EOC cells grew very slowly 
and reached senescence at passage 2‒4, after which their morphology changed 
remarkably, and they stopped dividing. At this stage the cells grew considerably in 
size and the cells formed outward-reaching elongated structures. Sample 005 was 
completely unusable due to its thick, creamy appearance and an extremely heavy 
bacterial contamination. All in all, early senescence and low number of EOC cells 
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greatly limited the usability of the clinical ascites samples. Ascites contains a variety 
of cell types, and therefore verification for epithelial origin it was essential. Cultures 
were monitored approximately three times a week under a general light microscope 
and images taken at different growth stages to verify that cells were of the typical 
‘cobblestone’ morphology (Figure 3–5). Cultures that appeared to have spider-like 
elongated cells, were treated as contaminated with fibroblasts. In this case, the cells 
were briefly trypsinised for 2 min to remove more loosely attached fibroblasts and to 
enrich the culture with firmly-attached epithelial-type cells. Partial trypsinisation was 
repeated as many times as required to completely remove fibroblasts from the culture. 
 
Figure 3–5. Epithelial ovarian cancer (EOC) cell morphology. A representative example of the 
typical ‘cobblestone’ morphology of EOC cells. Cells were imaged at 5 x and 10 x magnification. SKOV3 
cell line is a positive control EOC cell line that was originally derived from ovarian ascites. 
 
3.2.2 Phenotyping of epithelial ovarian cancer (EOC) cultures 
Ex vivo EOC cultures were established from freshly-isolated ovarian ascites, 
generally within a month of paracentesis. After sufficient propagation, the cells were 
stained for five different cell surface markers and assessed for their receptor 
expression profile at passage 1–2 by flow cytometry (Table 3–3). 
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Table 3–3. Receptor expression profile of epithelial ovarian cancer (EOC) cells. Cultures were 
classified according to their chemotherapy stage: 1, chemo naïve/pre-treatment; 2, first-line chemo; 3, 
relapsed disease/platinum-sensitive; 4, relapsed disease/platinum-resistant. Only samples for which 
successful EOC cultures were established, are included in this table. CAR, coxsackie and adenovirus 
receptor; EGFR, epidermal growth factor receptor. αvβ6-positive cultures highlighted in purple; nd, not 
determined. 
EOC # Stage αvβ6 CAR CD44 CD46 EGFR 
001 2 0 98 98 96 78 
002 3 0 70 99 100 99 
003 4 19 34 nd 100 nd 
004 1 94 30 93 100 nd 
006 nd nd 89 92 99 98 
008 3 nd 81 87 88 87 
009 1 nd 99 99 99 99 
011 4 0 46 99 99 99 
013 4 0 90 93 100 98 
014 2 0 100 100 100 100 
016 4 40 50 98 100 95 
018 nd 0 38 91 98 98 
019 3 46 65 68 100 96 
 
Four out of fourteen EOC cultures (31 %) were shown to be positive for αvβ6 
integrin, with expression ranging between 19 and 94 % (Figure 3–6). These cultures 
were selected to be assessed for transduction efficiency by αvβ6-targeted vectors. 
Expectedly, the EOC cells were found to express greatly variable levels of CAR (range 
0–100 %). However, CAR expression levels did not seem to be dependent on the 
chemotherapy treatment stage. The level of CD44 expression was very high in all 
EOC cultures (range 68‒100 %). Similarly, all EOC cultures exhibited very high levels 
of CD46 (range 88‒100 %) and EGFR expression (range 78‒100 %). Four EOC 
cultures were positive for both αvβ6 and CD46, while CAR expression in these cells 
was variable (Figure 3–6) but relatively lower than in the cultures that did not express 
αvβ6 integrin. 
 
Figure 3–6. Epithelial ovarian cancer (EOC) cultures positive for αvβ6 integrin. EOC cultures 
were stained with primary anti-αvβ6, -CAR and -CD46 antibodies for 1 h on ice, and a secondary 
AlexaFluor647 antibody for 30 min on ice. 10 000 events were analysed on BD Accuri C6 flow cytometer 
and data analysed in BD Accuri software. 
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3.2.3 Quantification of coagulation factor 10 (FX) concentration in ascites 
The concentration of FX present in cell-free ovarian ascites was evaluated using 
an in-house developed sandwich ELISA protocol. Sheep anti-FX capture antibodies 
were bound on a high binding ELISA plate and soluble FX present in ascites was 
allowed to bind to the capture antibodies. Secondary rabbit anti-human FX antibodies 
were then bound and complexes detected with a goat anti-rabbit IgG-HRP conjugate 
antibody. Purified human FX was used for generation of a standard curve, from which 
the FX concentrations in ascites were extrapolated. Sixty-three per cent of ascites (n 
= 12) samples had lower, and 37 % of samples (n = 7) higher levels of FX than sera 
on average (8‒10 μg/mL) ( 
Table 3–4). The exact FX concentration could not be determined from nine 
samples, because eight samples had too low and one had too high FX concentration 
that gave optical readings outside the detection limits of this assay.  
Table 3–4. Concentration of coagulation factor 10 (FX) in patient-derived ascites. FX 
concentration was measured by sandwich ELISA on a 96-well plate from 100 μL of neat, 1:2 and 1:4 
dilutions of cell-free ascites samples in duplicate. Polyclonal anti-FX antibody was used as a capture 
antibody, and bound FX was detected using a rabbit anti-human FX antibody and a secondary anti-rabbit 
IgG HRP-conjugate. Complexes were detected with TMB substrate and reaction stopped using 0.02 M 
H2SO4; absorbance was measured at λ450 nm. Sample values were extrapolated from a standard curve 
of purified human FX (0‒10 μg/mL). +, above detection limit; ‒, below detection limit. 
OAS sample FX (μg/mL) Relative to serum 
000 5.7  
001 ‒  
002 3.8  
003 0.4  
004 +  
006 32.4  
007 142  
008 ‒  
009 ‒  
010 4.4  
011 ‒  
012 ‒  
013 ‒  
014 ‒  
015 ‒  
016 36.2  
017 88.3  
018 61.9  
019 76.6  
 
3.2.4 Quantification of anti-Ad antibodies in ascites 
The level of anti-Ad5 and anti-Ad10 antibodies was quantified from 19 cell-free 
ovarian ascites samples and an anonymous control serum from an adult male 
volunteer by a direct ELISA assay (Figure 3–7). Unfortunately, sample OAS005 was 
unusable due to heavy bacterial contamination and had to be disposed of. For the 
quantification of anti-Ad antibodies present in ascites, heat-inactivated replication-
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deficient Ad5.Luc or Ad10.Luc virus particles (generated in-house) were bound on 
highly absorbent 96-well plates, incubated with serial 2-fold dilutions of cell-free OAS 
and bound anti-Ad antibodies detected with anti-human IgG-HRP conjugate. The 
levels of anti-Ad5 Abs in OAS that were capable of binding to the heat-inactivated 
particles, were substantially higher than the levels of anti-Ad10 Abs in the same 
samples. Half (n = 9) of the OAS samples had higher and half (n = 10) had lower 
levels of anti-Ad5 antibodies than the control serum, judging from the 1:1600 dilution 
that gave ~ 50 % binding for the control serum (Figure 3–8A). Similarly, eight ascites 
samples had higher and 11 samples had lower levels of anti-Ad10 antibodies than the 
control serum at dilution 1:800 that gave 50 % of the maximum binding for the control 
serum (Figure 3–8B). Sample OAS008 contained the highest concentration of anti-
Ad5 antibodies (Figure 3–8A), while sample OAS019 had the most anti-Ad10 
antibodies of all samples (Figure 3–8B). OAS001 had very similar levels of both anti-
Ad5 and anti-Ad10 antibodies as the control serum, and was therefore chosen to be 
used in the subsequent in vitro and ex vivo vector neutralisation assays. 
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Figure 3–7. Anti-adenovirus 5 (Ad5) and anti-Ad10 antibodies in ovarian ascites. Maxisorp 96-
well plates were coated with heat-inactivated adenoviruses in carbonate/bicarbonate buffer overnight at 
4ºC. Cell-free ascites was added for 2 h and a secondary anti-human IgG-HRP conjugate incubated for 
1 h at room temperature. Bound antibodies were detected in a colorimetric reaction using TMB substrate 
for 20 min. Reaction was stopped using 0.02 M H2SO4 and absorbance (OD) measured at λ450 nm. 
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Figure 3–8. An overview of (A) anti-adenovirus 5 (Ad5) and (B) anti-Ad10 antibodies detected 
from cell-free ovarian ascites. 50 % and 100 % of the maximum binding is shown for the control serum 
as dotted lines. OAS, ovarian ascites; OD, optical density was quantified at λ450 nm. 
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3.2.5 Antigen-specificity of anti-Ad antibodies 
The serotype-specificity, cross-reactivity and neutralising potential of pre-existing 
anti-Ad antibodies present in ovarian ascites was further assessed by luciferase-
based neutralisation assays and Western blots. Sample OAS001 was chosen to be 
used for these assays as it had the highest levels of anti-Ad5 antibodies of all the 
samples we had collected at the time (Figure 3–8A). OAS001 was shown to neutralise 
91 % and 96 % of Ad5 transduction in CHO-CAR cells at a concentration of 2.5 % 
and 10 %, respectively, determined as reduced virus-induced luciferase expression 
in these cells (Figure 3–9A). Intriguingly, OAS001 did not show any neutralisation of 
the Ad10 vector transduction at a concentration of 2.5 %, and exhibited only a modest 
27 % neutralisation at a concentration of 10 % (Figure 3–9B). Respectively, the 
OAS019 fluid was chosen as a representative sample for studying neutralisation of 
the Ad10 serotype, due to its high level of anti-Ad10 antibodies observed in ELISA 
(Figure 3–8B). While OAS019 was capable of neutralising 79 % and 93 % of Ad5 
transduction at concentrations of 2.5 % and 10 %, respectively (Figure 3–9A), it 
neutralised only 23 % of Ad10 vector transduction at a concentration of 10 % but had 
no neutralising effect at the lower 2.5 % ascites concentration in these cells (Figure 
3–9B). 
We then proceeded to assess the ability of anti-Ad antibodies present in the control 
serum and OAS001 to recognise the structural components of denatured Ad5 and 
Ad10 virions by Western blot. Heat-inactivated, whole virions of Ad5 and Ad10 
serotypes and the fiber-pseudotyped Ad5/kn10 vector (all generated in-house, see 
chapter 5) were run in an SDS-PAGE gel and blotted onto a nitrocellulose membrane. 
The membranes were then incubated with the OAS001 fluid, and bound anti-Ad 
antibodies detected by using an anti-human IgG-HRP conjugate. The Ad5 vector 
seemed to capture antibodies with two types of specificities from the control serum, 
seen as two very strong and distinct bands (Figure 3–9C). The larger of these bands 
was approximately the size of the fiber protein (~ 60 kDa), while the smaller band was 
approximately 23 kDa in size (Figure 3–9C). On the contrary, the Ad10 vector seemed 
to capture only negligible quantities of antibodies by this method, showing the 
strongest band of ~ 40 kDa for the fiber protein, and two fainter ones at ~ 60 kDa and 
~ 23 kDa (Figure 3–9C). However, the pseudotyped Ad5/kn10 was again able to 
detect fiber-specific antibodies from serum, albeit at lower levels compared to Ad5 
(Figure 3–9C). When the experiment was repeated using OAS001 fluid, same 
banding pattern was observed but the bands were seemingly fainter (Figure 3–9D). 
Both serum and OAS001 contained antibodies that recognised the most abundant 
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capsid protein, hexon (Figure 3–9C, D). Surprisingly, the band was considerably 
weaker than the band for anti-fiber antibodies. Other antibodies present in serum and 
ascites may be directed against proteins VI and VII or other small capsid proteins.
 129 
 
Figure 3–9. Adenovirus 5 (Ad5)- and Ad10-specific antibodies in serum and ovarian ascites. (A) Transduction efficiency of Ad5 and (B) Ad10 was measured by infecting 
CHO-CAR cells with 5000 particles/cell in the presence of control serum or ascites for 3 h and by quantifying luciferase expression 48 h later. For Western blots, viruses were heat-
inactivated at 56ºC for 30 min and run at 0.63, 1.25, 2.5 and 5 μg of protein / lane (1 μg of protein corresponding to 4 × 109 vp) on a 10 % Bis-Tris SDS-PAGE gel at 150 V for 1 h 
15 min. Proteins were transferred onto a nitrocellulose membrane in a semi-dry blotter and blocked in 5 % milk in TBS-T overnight at 4ºC. Membranes were incubated in a 1:500 
dilution of (B) serum from an adult volunteer or (C) OAS001 ascites for 2 h and in anti-human IgG-HRP conjugate (1:2000) at room temperature for 1 h. Bound antibodies were 
then detected with SuperSignal West Pico chemiluminescent substrate.  
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3.3 Discussion 
In this chapter, several model cancer cell lines were validated in in vitro assays for 
subsequent assessment of the generated recombinant Ad vectors. We identified a 
breast cancer cell line BT-20 as an excellent positive control cell line for the study of 
αvβ6 integrin-mediated vector transduction, due to its very low level of CAR and very 
high level of αvβ6 expression. Chinese hamster ovarian cell lines CHO-CAR and 
CHO-BC1 were selected as model cell lines for studying the CAR- and CD46-tropism 
of Ad vectors, respectively. These cell lines provide an excellent model for the 
unambiguous assessment of CAR and CD46 receptor tropisms, since they are devoid 
of the majority of common cell surface receptors that could contribute to cell 
transduction. CHO-K1 (CAR‒/CD46‒) and CHO-CAR (CAR+/CD46‒) cells were used 
for the in vitro assessment of the receptor tropism of vectors de-targeted from the 
native tropisms (described in chapter 4), CHO-CAR and CHO-BC1 cells were utilised 
for the in vitro assessment of different Ad serotypes and novel fiber-pseudotyped 
vector backbones from subgroup D (described in chapter 5). 
The ascites-derived and frequently utilised model cancer cell line ‒ SKOV3 ‒ was 
used as a representative EOC cell line in this project that is mainly focused on ovarian 
cancer. However, as SKOV3 cells were shown to be naturally devoid of αvβ6 integrin 
expression (Figure 3–1), a model cell line SKOV3-β6 was generated to represent an 
αvβ6-positive EOC for our purposes (Figure 3–3). Parental SKOV3 cells were 
transfected with a retrovirus vector pBabe puro β6 for stable expression of the β6 
integrin subunit that combines in cells with αv subunit, forming the αvβ6 integrin 
receptor on the cell surface. FACS yielded a representative cell population of highly 
αvβ6-positive cells that were propagated under strict puromycin selection, and used 
for in vitro assessment of αvβ6-targeted vectors (described in chapter 6). 
The second major part of this chapter describes the establishment of primary EOC 
ex vivo cultures from clinical ovarian ascites samples. Twenty samples were received 
over a period of two years in 2014‒2016 from female volunteers who at the time were 
undergoing chemotherapy treatment for advanced ovarian cancer at Velindre Cancer 
Centre in Cardiff. The samples were obtained as a side product of a routine 
paracentesis of i.p. ovarian ascites ‒ valuable clinical material that would otherwise 
have gone to waste. Successfully proliferating EOC ex vivo cultures were established 
from 65 % (13/20) of all ascites samples. A third of these cultures were shown to be 
positive for αvβ6 integrin expression, while the expression of the CSC marker CD44, 
Ad receptor CD46 and general cancer cell marker EGFR was ubiquitously high across 
all cultures. The level of CAR expression was highly variable, which reflects previous 
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observations of the unpredictable expression profile of this receptor in progressive 
cancers (Matsumoto et al., 2005, Wunder et al., 2012, Reeh et al., 2013). No 
connection between the chemotherapy treatment stage and the expression profile of 
specific receptors was observed in this thesis. EMT frequently occurs in advanced 
EOC; mesothelin and hyaluronic acid secreted by mesothelial cells enable EOC cell 
invasion into the peritoneum, facilitated by CD44, β-integrins and CA125 expressed 
on EOC cell surface [reviewed in (Kipps et al., 2013)]. 
Malignant ovarian ascites has extremely variable combinations of distinct cell 
types, such as lymphocytes, mesothelial cells, MΦ, adenocarcinoma cells, epithelial 
cells, fibroblasts and erythrocytes; high erythrocyte counts are sometimes observed 
if ascites has developed rapidly (reviewed in (Kipps et al., 2013)). Numerous detailed 
reports have described EOC cell culture from malignant ovarian ascites (Dunfield et 
al., 2002, Shepherd et al., 2007, Latifi et al., 2012, Ahmed and Stenvers, 2013, 
Thériault et al., 2013). O’Donnell and colleagues reported a 91 % success rate for the 
establishment of EOC cultures from 172 ovarian ascites samples from patients 
undergoing surgery (O'Donnell et al., 2014). Senescence commonly occurred 
between passage 2‒8, which is also in line with the observations in this thesis. In their 
study, the epithelial origin of cultured cells was verified by utilising a panel of markers 
including EpCAM, vimentin, pancytokeratin, CA125, MOC-31 and D2-40. However, 
the authors state that none of these are represented in all EOC cells, which is why 
the epithelial cell origin had to be determined from the presence of several different 
markers. In this present thesis, we did consider enrichment of EOC ex vivo cultures 
by magnetic separation using commercially available magnetic EpCAM (CD326) 
microbeads. However, this was not attempted as the initial cell numbers were already 
so low that the risk of remarkable cell loss was considered to be greater than the 
potential benefit.  
Ovarian ascites is known to be rich in various proteins that are also found in serum 
(Hemminki et al., 2002). We quantified the concentration of FX in ascites by 
performing FX-specific sandwich ELISA assays that were developed in-house. 
Concentration of FX was shown to vary greatly across the samples; in the majority 
the FX concentration being lower than the average concentration in serum (Table 3–
4 ). On the contrary, several ascites samples had higher ‒ up to 18-fold higher for 
OAS007 ‒ concentration of FX relative to serum. Sample OAS004 contained even 
more FX than that; its exact concentration however could not be measured due to the 
upper detection limit of the assay. It is well known in Ad vectorology that the presence 
of FX impacts the biodistribution of Ad5 vectors (Alba et al., 2009), and may 
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additionally shield the vector from natural IgM and complement attack (Xu et al., 
2013). It is therefore important to consider that the presence of FX in ascites has 
important implications when local i.p. delivery of Ad vectors into the peritoneal cavity 
is the desired route. A complete ablation of FX-binding mediated by anti-cancer Ad 
vectors (discussed in section 4.6) is an excellent solution for tackling the large 
concentration range of FX present in ascites. 
Like serum, malignant ovarian ascites contains high levels of anti-Ad antibodies 
(Hemminki et al., 2002) that can rapidly coat and neutralise the vector, rendering 
therapies ineffective. Therefore, we assessed the level of anti-Ad IgG antibodies 
present in ascites by performing direct ELISA assays, in order to establish a good 
overview of the range of antibody responses in clinical samples. The level of 
antibodies that recognised the Ad5 virion was generally very high in all samples ‒ 
similar or even higher than in the control serum obtained from a healthy male adult 
volunteer (Figure 3–8). The level of anti-Ad10 antibodies was lower than for anti-Ad5 
Abs across all ascites samples, with the exception of one sample (OAS019) that had 
very similar levels of both anti-Ad5 and anti-Ad10 Abs (Figure 3–7). The ascites 
sample OAS001 that has high levels of anti-Ad5, and intermediate levels of Ad10-
reactive antibodies, was selected as the representative example of a highly 
neutralising fluid for subsequent neutralisation assays for Ad5-based vectors. 
OAS019 was used as a highly neutralising fluid for assessment of Ad10-pseudotyped 
vectors. 
Additionally, we sought to evaluate the antigen-specificity of the ascites-derived 
anti-Ad antibodies by Western blot by allowing antibody binding to heat-inactivated 
and denatured viral particles of Ad5 and Ad10. We found that antibodies both in our 
serum control and ascites were primarily directed against the Ad5 fiber (Figure 3–9). 
The control serum showed a very strong anti-Ad5 band that was the size of the fiber 
trimer (~ 62 kDa), and a fainter band for smaller, possibly capsid, proteins. The pattern 
was similar but considerably fainter for the OAS001 fluid. Very faint bands for anti-
Ad10 antibodies were detected from both the control serum and OAS001; most of 
these antibodies seemed to be specific for the fiber (~ 40 kDa) and hexon (~ 120 kDa) 
proteins. We also evaluated the ability of the anti-Ad5 and anti-Ad10 antibodies to 
recognise the pseudotyped Ad5/kn10 vector. A substantial level of antibodies 
recognised these virions, although at slightly lower efficiency than the Ad5 virion. It 
was very surprising to find that the antibody levels against the hexon protein ‒ the 
structurally most abundant component of the virion capsid ‒ were very low in both 
samples. Furthermore, there does not seem to be notable cross-reactivity between 
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the two serotypes from distinct subgroups. The observations from our ELISA and 
Western blot assays indicates significant limitations of our detection methods. 
Although ELISA assays indicated high levels of anti-Ad10 antibodies in both serum 
and OAS001, the Ad10 virions did not recognise these antibodies in the Western blot 
analyses. This may well be due to the differences in the preparation of the antibody 
bait, ie. the virion. In ELISA assays the viruses were heat-inactivated and bound to 
plates as whole virions, while in the Western blots they were additionally denatured 
by boiling in lithium dodecyl sulphate buffer at 95ºC for 10 min. Disruption of the native 
conformation is therefore likely to have compromised the recognition of the individual 
capsid components, at least for the anti-Ad10 antibodies that may have an overall 
lower affinity to the antigens. It is also important to remember that while the ascites-
derived antibodies were able to recognise Ad5 and Ad10 virions in the described in 
vitro assays, it does not implicate their potential to neutralise an infection in vivo. 
Our observations are in line with the previous findings that native infection mainly 
elicits anti-fiber antibodies (Parker et al., 2009), while vaccine challenge leads to 
elicitation of anti-hexon antibodies (Sumida et al., 2005). The ascites donors in this 
study are not likely to have been treated with Ad-based vaccines, which could explain 
their low levels of anti-hexon antibodies. Binding of the fiber protein to its native 
receptor CAR has been suggested to enable viral spread by opening of tight junctions 
at the cellular interfaces (Walters et al., 2002). Ads are therefore thought to produce 
and shed excessive amounts of fiber proteins in the initial stages of infection, by 
means of enhancing epithelial permeability and viral spread, and facilitating 
basolateral-to-apical trafficking and viral escape from the apical surface. This could 
well explain the dominance of anti-fiber antibodies over anti-hexon antibodies in 
natural infections. Although the hexon is the largest and structurally most abundant 
component of the Ad virion capsid, excessive quantities of the fiber protein may be 
exposed to the innate immune system in the early stages of an acute Ad infection, 
steering the antibody production towards the fiber rather than the hexon protein. 
Interestingly, pseudotyping Ad5 with a knob domain from Ad10 restored recognition 
of anti-Ad5 antibodies both in serum and ascites. This may therefore indicate that 
these antibodies are primarily directed towards the fiber shaft rather than the 
immunodominant knob domain. Further studies are needed to dissect the intriguing 
nature of antibodies directed against Ad proteins, and their potential to cross-
neutralise serotypes from other subgroups. 
In this chapter we have established that malignant ovarian ascites has a complex 
composition that is very likely to influence the efficiency of anti-cancer treatments that 
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are based on the globally prevalent Ad serotype vector, Ad5. Phenotyping of a panel 
of suitable ovarian cancer cell lines, malignant ovarian ascites and ascites-derived 
EOC ex vivo cultures is important for the establishment of suitable model systems for 
subsequent in vitro and ex vivo assessment of Ad vectors. These evaluations are 
described in detail in the following chapters of this thesis. 
 
                                                                                                                                     
                                                                                                               
                                                                                                                              
                                                                                                               
 
 
 
 
CHAPTER 4. Results: In vitro assessment of de-
targeted vectors and production of 
recombinant proteins 
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CHAPTER 4. In vitro assessment of de-targeted vectors and 
production of recombinant proteins 
This chapter discusses the generation of basal Ad5 vector backbones for 
subsequent modification for cancer targeting purposes. We have incorporated 
combinations of point mutations in the three major capsid proteins ‒ fiber, hexon and 
penton. These sophisticated modifications successfully ablated all three central native 
tropisms of the Ad5 serotype, namely binding to CAR, FX and αvβ3/5 integrins. 
Vectors were rescued from BAC DNA and produced into high viral titres in permissive 
cell lines that express adenoviral genes and relevant cell surface receptors. In vitro 
assays that are commonly used in Ad vectorology, were utilised for the assessment 
of the altered tropism of these vectors. Additionally, the transduction efficiency was 
assessed in the presence of inhibitory factors and purified human FX. Recombinant 
6 x His-tagged knob proteins of serotypes Ad5 and Ad48 were produced in E.coli and 
used in competition inhibition assays for the evaluation of vector tropisms. 
4.1 Generated vectors 
A panel of recombinant vectors with a series of versatile de-targeting mutations 
were generated by AdZ homologous recombineering methods. The method had been 
previously developed in our laboratory by Dr Richard Stanton as a rapid means to 
overexpress transgenes (Stanton et al., 2008), and required only minor adjustments 
to suit our purposes. Selection for successful recombineering products and correct 
BAC clones was based on IPTG-induced blue/white selection in heat-inducible E. coli 
strain SW102. Colonies generally appeared 48−72 h after incubation at 32ºC. Blue 
(first step) and white (second step) colonies (Figure 4–1A) were picked from the agar 
plates and inoculated into LB medium with Kan and LB medium with Strep to verify 
that each colony was resistance to one and sensitive to the other (Figure 4–1B). The 
colonies that fulfilled these criteria, were grown into larger cultures and the bacterial 
DNA was extracted by a miniprep method. The mutated sequence was amplified by 
PCR and sequenced to verify the correct insertion. Viral BACs were then amplified 
and purified from maxiprep DNA cultures. T-REx-293 cells were transfected with 1 μg 
of each of the viral BAC DNAs, and viruses rescued from the cells ~ 10 days later 
when CPE was observed. CsCl gradient purification of the viruses was generally 
successful and yielded good viral titres. There were, however, big differences in the 
quality of the preparations, as well as the appearance and thickness of the mature 
virion bands. The mature virus particles formed a clearly visible grey band in the lower 
section of the gradient (Figure 4–1C). This was extracted in a maximum volume of 1 
mL using a 19-gauge needle. The virus preparation was dialysed O/N at 4ºC, 
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aliquoted out, and titered by microBCA assay for the physical viral titre (vp/mL) or by 
plaque assay for the infectious viral titre (pfu/mL). 
 
Figure 4–1. AdZ recombineering and virus purification. (A) Blue-white screening on agar plates, 
(B) verification of antibiotic resistance (left) and sensitivity (right), (C) virus banding pattern after the 
second step of CsCl gradient ultracentrifugation. 
 
The generated de-targeted vectors carry mutations that ablate their native 
interactions with CAR (KO1 mutation), penton base (RGE mutation) and FX (HVR7 
mutation). Fourteen basal replication-deficient vector backbones were generated by 
AdZ recombineering, 10 of which were rescued as functional virions and grown into 
high viral titres in T-REx-293 cells (Table 4–1). The viruses with combinations of two 
(KO1 and HVR7) or three mutations (Ad5.3D) did not form infectious virions, despite 
numerous transfection attempts. The infectivity of vectors containing the KO1-
mutation was facilitated by the addition of FX in the transfection medium; obviously, 
this was not feasible for the vectors with HVR7 mutation that are not capable of 
utilising FX for cell entry. This was likely a result of severely compromised fitness due 
to the lack of available entry receptor for these vectors. The de-targeted vectors were 
subsequently assessed on a panel of cancer cell lines to evaluate their transduction 
efficiency via native target receptors and entry pathways. Luciferase-expressing 
vectors were generated to be used in transduction assays in conjunction with a 
luciferase reporter gene assay kit, which was the main method of in vitro assessment 
of these vectors in this thesis. GFP-expressing versions of the vectors were generated 
for potential utilisation for cellular trafficking experiments, flow cytometry or 
immunofluorescent analysis. 
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Table 4–1. Basal and de-targeted replication-deficient Ad5 vectors. Viral genomes were 
generated by AdZ homologous recombineering methods, viruses were rescued in T-REx-293 cells, 
purified by two-step CsCl-purification and tittered by microBCA assay. CAR, coxsackie and adenovirus 
receptor; FX, coagulation factor 10; GFP, green fluorescent protein; HVR7, FX-binding mutation; KO1, 
CAR-binding mutation; Luc, luciferase; RGE, integrin-binding mutation; vp, viral particle. *, only genome 
was generated but no infectious virus was rescued. 
Virus 
CAR 
binding 
FX 
interaction 
Physical titre 
(vp/mL) 
Ad5.Luc + + 3.9 × 1012 
Ad5.GFP + + 1.0 × 1012 
Ad5.Luc.KO1 ‒ + 1.6 × 1012 
Ad5.GFP.KO1 ‒ + 7.6 × 1012 
Ad5.Luc.RGE + + 2.3 × 1012 
Ad5.GFP.RGE + + 4.6 × 1012 
Ad5.Luc.HVR7 + ‒ 4.3 × 1012 
Ad5.GFP.HVR7 + ‒ 4.3 × 1012 
Ad5.Luc.KO1.RGE ‒ + 2.9 × 1011 
Ad5.GFP.KO1.RGE ‒ + 3.7 × 1012 
Ad5.Luc.KO1.HVR7 ‒ ‒ * 
Ad5.GFP.KO1.HVR7 ‒ ‒ * 
Ad5.Luc.KO1.RGE.HVR7 (‘Ad5.3D’) ‒ ‒ * 
Ad5.GFP.KO1.RGE.HVR7 (‘Ad5.3D’) ‒ ‒ * 
 
4.2 Transfection efficiency in T-REx-293 cells 
The transfection efficiency of the Effectene transfection reagent was assessed in 
T-REx-293 cells that were used for the production and propagation of all Ad5 vectors 
in this thesis, except for the αvβ6-targeted vectors that were produced in HEK293-β6 
cells. Cells were transfected with 1 μL of pmaxGFP control plasmid according to the 
Effectene transfection protocol. Cells were then detached from the growth flasks by 
trypsin treatment 48 h later, washed in 5 % FBS in PBS and fixed in 4 % PFA for 10 
min. Of the transfected cells, ~ 45 % were shown to express GFP (Figure 4–2), which 
translates to transfection efficiency of approximately half of the treated cells. 
 
Figure 4–2. Transfection efficiency of T-Rex-293 cells by Effectene reagent. T-Rex-293 cells 
were infected with a green fluorescent protein (GFP)-expressing pmaxGFP control plasmid for 48 h in 
triplicate. Cells were then washed and fixed in 4 % paraformaldehyde, and 200 000 cells run in BD Accuri 
flow cytometer. Uninfected T-REx-293 cells (black curve) were used as a negative control for the assay. 
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4.3 Haemagglutination assays 
The ability of de-targeted viruses to agglutinate human erythrocytes was evaluated 
in standard haemagglutination assays. Ad5 binds to CAR on the surface of 
erythrocytes (Carlisle et al., 2009), which results in the formation of a characteristic 
red blood cell network on the surface of the well. In the absence of agglutination, the 
erythrocytes sediment to the bottom of the well, forming a tight erythrocyte cell pellet. 
In these assays, Ad5.Luc vector successfully agglutinated erythrocytes at all four 
concentrations tested (Figure 4–3, row 1), while the CAR-binding mutation KO1 
completely ablated Ad5 vector binding to erythrocytes at all doses (Figure 4–3, rows 
2 and 5). The integrin-binding mutation RGE (Figure 4–3, row 3) and the FX-binding 
mutation HVR7 (Figure 4–3, row 4) had no visible effect on the haemagglutination 
properties of these de-targeted Ad5 viruses. The haemagglutination patterns seen in 
this assay confirm that the CAR-binding mutation KO1 efficiently abolishes the ability 
of Ad5 to bind to its native receptor CAR. The same effect was seen for all viruses 
that have the KO1 mutation alone or in combination with other de-targeting mutations. 
 
Figure 4–3. Agglutination of human erythrocytes. 1 % erythrocyte suspension in PBS was mixed 
with descending concentrations of viral stocks in PBS and incubated at 37ºC for 2 h. PBS was used as 
a negative control and red blood cell lysis (RBC) buffer as a positive control for haemagglutination. ‒, 
no; +, low; ++, partial; +++, complete agglutination of erythrocytes. HVR7, coagulation factor 10 binding 
mutation; KO1, coxsackie and adenovirus binding mutation; RGE, αvβ3/5 integrin-binding mutation; vp, 
viral particle. 
 
4.4 Recombinant protein production & purification 
The purified and tittered basal, replication-deficient vectors were assessed for their 
binding and entry via CAR in luciferase transduction assays. Recombinant knob 
proteins were produced as described below, and used as blocking agents in 
competition inhibition assays. Protein expression pQE30 plasmids, that already had 
the knob sequences cloned in, were transformed into SG13009 E. coli cells by a heat 
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shock method. Colonies were picked and pre-cultures grown O/N at 37ºC. Protein 
production was induced in the SG13009 bacteria by addition of IPTG for 16 h at 250 
rpm in a shaking incubator at 20°C. Cell pellets were collected by high-speed 
centrifugation and lysed in lysozyme-containing buffer. A total volume of 50 mL of the 
lysate was bound to 0.5 mL of Ni-NTA agarose at 4ºC for 1 h, after which the agarose 
was loaded into a single-use plastic chromatography column and thoroughly rinsed 
with abundant wash buffer (5 x of the volume of the column = 100 mL).  
 
Figure 4–4. Example of knob protein elution fractions (Ad48 knob protein). Knob protein was 
eluted with increasing concentrations of imidazole. 14 μL of each elution fraction was mixed with 1 μL of 
DTT and 5 μL loading buffer, boiled at 95ºC for 10 min and run on a 10 % SDS-PAGE gel for 1 h 15 min 
at 150 V. The gel was stained with Coomassie for 30 min and de-stained overnight. (A) Elution fractions 
E1‒8 (a) Novex pre-stained protein marker, (b) lysed cells, (c) cleared lysate, (d) supernatant after Ni-
NTA binding.  
 
Recombinant proteins that were bound to the Ni-NTA agarose, were eluted as 1 
mL fractions and collected by hand. Individual fractions were analysed on a SDS-
PAGE gel to determine which fractions had the highest concentration of the purified 
protein with minimal impurities. The purest fractions were pooled (~ 10 mL total 
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volume) and the protein concentration determined by a standard BCA assay. All 
proteins were produced into high concentration, with the exception of CAR-ablated 
Ad5 knob that had a ~ 5-fold lower concentration compared to other knob proteins 
(Figure 4–5A). Both native and denatured (boiled at 95ºC for 10 min) aliquots of each 
produced protein were analysed on a SDS-PAGE gel to assess their ability to 
trimerise. All produced knob proteins were shown to form a structurally intact trimer, 
which was seen as a native trimeric (~ 63‒65 kDa) for the un-boiled and as a 
denatured monomeric form (~ 30‒35 kDa) for the boiled protein (Figure 4–5B). The 
differences in band strength are likely to reflect variation in protein titration by BCA, 
rather than the abundance of the protein. 
 
Figure 4–5. Recombinant 6 x His-tagged knob proteins. (A) Concentrations of the produced knob 
proteins. (B) Trimerisation assay. 14 µL of dialysed protein was mixed with 1 µL of DTT and 5 µL of 4 x 
SDS loading dye and incubated at room temperature (RT) or boiled at 95°C for 10 min. Samples were 
run on a pre-made Novex gel for 1 h 15 min at 100 V, the gel stained in Coomassie for 30 min and de-
stained overnight. A20, αvβ6-targeting peptide; kn, knob; wt, wild type; 477YT, CAR-binding mutation. 
 
4.5 Competition inhibition (luciferase) assays  
Basal de-targeted vectors were assessed in luciferase transduction assays for their 
CAR-tropism in CHO-CAR (CARhigh) cells. The in-house produced recombinant knob 
proteins (described in section 4.2) were used as blocking agents to inhibit cell entry 
via CAR. Transduction of the CAR-utilising Ad5.Luc vector was efficiently blocked at 
all three doses of kn5 protein (10, 20 and 40 μg/105 cells) but not by the negative 
control kn5.477YT (kn5.CAR‒) protein (Figure 4–6) in CHO-CAR cells. The CAR-
binding ablated Ad5.KO1 vector was completely unable to enter these cells due to 
lack of available entry receptor, and therefore blocking with knob proteins expectedly 
had no effect on transduction efficiency (Figure 4–6). Successful inhibition of CAR-
mediated entry of Ad5.Luc into CHO-CAR cells by the kn5 protein has also been 
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recently reported in our research publication (Uusi-Kerttula et al., 2016), and is 
therefore not discussed here in greater detail. 
 
Figure 4–6. Competition inhibition of Ad5 binding to coxsackie and adenovirus receptor 
(CAR). CHO-CAR cells were pre-blocked with recombinant knob proteins Ad5 knob (kn5) or kn5 with 
CAR-binding ablation mutation (kn5.CAR‒) at increasing concentrations of (A) 10, (B) 20 or (C) 40 μg/105 
cells prior to addition of Ad5.Luc or Ad5.KO1 viruses at 5000 viral particles/cell in triplicate for 1 h on ice. 
Luciferase expression expressed as relative light units (RLU)/mg protein. Data were analysed using one-
way ANOVA with Dunnett’s multiple comparisons test. ns, p > 0.05; *, p < 0.05; **, p < 0.01. 
 
4.6 The effect of FX on vector transduction efficiency 
While the CAR-mediated pathway is known to dominate in vitro cell entry, FX 
‘bridging’ pathway is the main entry route following systemic delivery of therapeutic 
Ad vectors. The effect of soluble FX on Ad transduction efficiency can be qualified by 
performing luciferase transduction assays in the presence of physical concentrations 
(10 μg/mL) of FX. The transduction-enhancing effect of FX can be neutralised by 
supplementing the medium with an anticoagulant found in snake venom, X-bp, that 
binds to FX and therefore prevents it from binding to Ad virions. To achieve as clean 
impact on the transduction efficiency as possible, assays were performed in CHO-K1 
cells that do not express CAR or other known Ad receptors. Addition of FX in the 
transduction medium increased Ad5.Luc transduction in CHO-K1 cells by 135-fold as 
compared to FX-free conditions, while the addition of FX together with three-fold molar 
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excess of X-bp again completely abolished transduction in these cells, back down to 
the transduction levels that were seen in the absence of FX (Figure 4–7A). In contrast, 
the well-described hexon mutation HVR7 successfully ablated binding to FX, as 
transduction efficiency of Ad5.HVR7 remained low despite the supplementation of the 
transduction media with FX, and independent on the presence of the anticoagulant X-
bp (Figure 4–7). The results demonstrate that Ad5 vector binding to FX can be 
efficiently abolished by introduction of the HVR7 mutations. 
 
Figure 4–7. The effect of coagulation factor X (FX) on vector transduction. (A) Ad5.Luc and (B) 
Ad5.HVR7 viruses were added at 5000 viral particles/cell for 3 h in serum-free medium alone or in 
medium supplemented with 10 μg/mL of FX with or without an anticoagulant X-bp in CHO-K1 cells. 
Luciferase activity was measured at 48 h post-infection and normalised to relative light units (RLU)/mg 
protein. Data were analysed using one-way ANOVA with Dunnett’s multiple comparisons test. ns, p > 
0.05; *, p < 0.05; **, p < 0.01. HVR7, five FX-binding mutations in hexon hypervariable region 7; Luc, 
luciferase.  
 
4.7 Discussion 
This chapter describes the design and generation of basal Ad5-based vector 
backbones for further development for cancer targeting and oncolytic purposes. De-
targeted, replication-deficient Ad vectors were generated by AdZ homologous 
recombineering methods and propagated into high viral titres in permissive T-REx-
293 cells that express the Ad E1 and E3 genes that are essential for viral replication. 
The de-targeted vectors were assessed in in vitro assays for their structural integrity, 
receptor usage and entry pathways. The main Ad entry pathways were successfully 
ablated by introduction of a series of well-described substitution/point mutations into 
the main capsid proteins fiber, hexon and penton. The luciferase-expressing vectors 
were comprehensively assessed in luciferase reporter gene assays by quantifying the 
amount of luciferase reporter gene expression in relative light units in a convenient 
96-well plate format. All vectors described in this chapter were generated in 
replication-deficient background. However, oncolytic and cancer-targeted versions of 
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some of these vectors have already been generated for further ex vivo and in vivo 
assessment (see chapters 6 and 7). 
The key interaction to be assessed was the knob-mediated binding of Ad5 to CAR 
‒ a receptor that is expressed in tight junctions on most polarised cell types (Coyne 
and Bergelson, 2005). The well-described ‘KO1’ mutation in the fiber knob AB loop 
(Smith et al., 2002) successfully abolished Ad5 binding and entry via the native Ad 
receptor, CAR. Successful ablation of binding interactions was comprehensively 
demonstrated in competition inhibition assays by using recombinant knob proteins as 
inhibitory agents prior to the addition of the viruses on the cells. Haemagglutination 
assay is an alternative method for studying the CAR interaction of Ad vectors. Human, 
but not murine, erythrocytes express CAR on the surface (Carlisle et al., 2009), which 
leads to Ad vector entrapment in the bloodstream and may change vector 
biodistribution (Seiradake et al., 2009). Although this has been proposed to limit vector 
bioavailability for its therapeutic target tissue, a recent study showed that Ad binding 
to erythrocytes is reversible in nature, and does not influence extravasation and organ 
transduction (Rojas et al., 2016). None of our CAR-binding ablated vectors were 
capable of agglutinating human erythrocytes, which again confirmed the functionality 
of the KO1 mutation. As expected, none of the other de-targeting mutations 
compromised the vector binding to CAR, since haemagglutination was as efficient as 
for the parental Ad5 vector. Due to the extensively ubiquitous expression of CAR 
across all nucleated tissues, including erythrocytes and platelets (Carlisle et al., 
2009), the ablation of CAR-binding is vital for the prevention of non-specific 
transduction of non-cancer tissues. The KO1 mutation is therefore an essential de-
targeting strategy in Ad vector design. 
As observed by Smith and colleagues (Smith et al., 2002), KO1 mutation is 
insufficient for abolishing in vivo liver transduction that is mediated by FX, and occurs 
between the hexon HVRs and HSPGs. Therefore, the second central modification is 
the mutation of the HVRs that are responsible for hexon binding to FX. We 
successfully showed that the extensively characterised ‘HVR7’ mutation (Alba et al., 
2009) ‒ a combination of five point mutations (Figure 1–21) ‒ fully hampered Ad5 
entry into cells via FX in vitro. We used hamster ovarian CHO-K1 cells as the main 
representative cell line for studying FX-tropism in this thesis. In these fully CAR-
deficient cells, FX provides a whole new cell entry pathway via HSPGs, which is also 
the main Ad entry pathway in vivo (Waddington et al., 2008, Alba et al., 2009). It is 
therefore an excellent, clean model system for studying the impact of FX on the vector 
transduction efficiency. The impact of the HVR7 mutation on the Ad5 vector tropism 
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was evaluated in luciferase transduction assays with physical concentrations of FX 
(10 μg/mL) supplemented in the assay medium. While the parental Ad5.Luc 
transduced CAR-negative CHO-K1 cells at ~ 140-fold improved efficiency in the 
presence of FX, the level of Ad5.HVR7 transduction in these cells was completely 
unchanged by the addition of FX in the transduction medium. The HVR7 is a 
combination of five mutations in the hexon, that has been fully validated in previous 
detailed studies by Alba and colleagues (Alba et al., 2009). The observations in this 
thesis show successful ablation of this key pathway for the generated recombinant 
vectors in vitro. Additionally, vector de-targeting from liver was evaluated in an in vivo 
biodistribution study following systemic delivery (discussed in chapter 7). 
The third receptor tropism of Ad5 is binding to αvβ3/5 integrins, which is the key 
event for viral internalisation (Wickham et al., 1993). Additionally, αvβ5 integrin has 
been shown to be essential for efficient Ad-mediated gene transfer in human airway 
epithelia (Goldman and Wilson, 1995). The penton base protein binds to αvβ3/5 
integrins (Wickham et al., 1993) via its highly conserved RGD motif (Neumann et al., 
1988, Zubieta et al., 2005). The RGD > RGE mutation in penton base is a well 
characterised mutation that in the early reports was shown to delay viral reproduction 
and the onset of viral DNA synthesis (Bai et al., 1993). RGE mutation has also been 
shown to dampen down innate anti-adenoviral immune responses, relative to the wild 
type Ad5 that triggers the production of pro-inflammatory cytokines via binding to 
splenic MΦs through the penton RGD motif, demonstrated using a RGD-deleted virus 
AdΔRGD (Shayakhmetov et al., 2005a, Di Paolo et al., 2009). The insertion of the 
penton RGE mutation in the HVR7-mutated Ad5 vector background has also been 
shown to decrease splenic transduction by 5-fold, and to markedly dampen down 
antiviral inflammatory responses (Bradshaw et al., 2012). The RGE mutation 
therefore seems to be a crucial addition in the de-targeting armature of vectors 
intended for in vivo delivery. We attempted to assess the RGE-containing virus 
binding to αvβ3/5 integrins by surface plasmon resonance (SPR) on several 
occasions, but unfortunately were not successful. However, we are confident that this 
modification is fully functional in the context of our viruses, as it is a well-known 
method in Ad vectorology. In further work we have evaluated the impact of the 
integrin-binding RGE mutation on the elicitation of innate cytokine responses following 
systemic vector delivery in wild type mice (section 7.1.5).  
In this chapter, a comprehensive panel of de-targeted vectors were generated to 
establish a reservoir of basal vectors that are readily modifiable for numerous 
therapeutic applications and cancer targeting. These replication-deficient vector 
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backbones represent a safe and highly flexible tool for the study of receptor 
interactions. They serve as a versatile platform for oncolytic modifications, in 
combination with cancer-targeting moieties for improved cancer-targeting. The 
modification of these vectors for selective targeting to αvβ6 integrin-expressing EOC 
is described both in replication-deficient (section 6.2.1) and oncolytic backgrounds 
(section 6.2.2). 
                                                                                                                                     
                                                                                                               
                                                                                                                              
                                                                                                               
 
 
 
 
CHAPTER 5. Results: In vitro assessment of novel 
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CHAPTER 5. In vitro assessment of novel species D vectors 
This chapter describes the production and characterisation of novel chimaeric 
vectors based on the Ad5 backbone with the fiber protein pseudotyped from species 
D serotypes. Species D Ads have significantly lower seroprevalence in the population 
than the most commonly used gene therapy vector Ad5 (Abbink et al., 2007). 
Furthermore, their receptor usage remains largely unknown, which gave us a 
secondary objective for their characterisation. We have previously generated a novel 
serotype Ad10, whose vectorisation has not been reported (data not shown). 
Additionally, a comprehensive panel of chimaeric vectors was generated by 
pseudotyping the Ad5 genomic backbone with the sequence of either the whole fiber 
protein or just the fiber knob domain from species D serotypes 10, 15, 24, 29, 48 and 
53. We attempted to evaluate the potential three-dimensional conformation of the 
knob domains of these serotypes. Amino acid sequence alignments with the Ad5 and 
Ad35 knob sequence was used to predict the likelihood of these vectors using CAR 
or CD46 as their primary entry receptors, respectively. These vectors were produced 
into high viral titres and assessed in a series of in vitro assays for their receptor 
tropisms for CAR and CD46 ‒ the central proteins known to be involved in host cell 
transduction. We were also interested in seeing whether fiber-pseudotyping 
influenced binding of hexon protein to FX. Furthermore, the ability of these novel 
pseudotyped vectors to evade pre-existing neutralising humoral immunity was 
assessed by utilising immune adult serum and malignant ovarian ascites as the 
source of anti-Ad nAbs. 
5.1 In silico assessment of species D serotype knob domains 
Species D Ads are a distinct group of viruses that are known to have variable cell 
and tissue tropisms from subgroup C, which includes the most commonly utilised 
gene therapy vector, Ad5. The detailed molecular level interaction of species D virus 
fiber protein and their primary entry receptors has not been crystallised yet, with the 
exception of Ad19p (Burmeister et al., 2004) and Ad37 interaction with sialyl-lactose 
receptors (Burmeister et al., 2004, Johansson et al., 2009). Members of subgroup D 
are also known to utilise CD46 (Chen et al., 2010, Li et al., 2012) and GD1a glycan 
(Nilsson et al., 2011) for cell entry. A great deal remains unknown of the receptor and 
tissue tropisms, infectivity and oncolytic potency of the genetically diverse (Figure 1–
5) and understudied species D serotypes. In this study, a panel of species D Ads were 
evaluated in silico to predict the structure of their fiber knob, based on these two 
publicly available, previously crystallised knob models from Protein Data Bank (PDB) 
(Berman et al., 2000). This formed a basis for pseudotyped species D vector 
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generation in Ad5 background and in vitro mapping of their binding to common cell 
surface receptors, CAR and CD46. 
5.1.1 ClustalW alignment of species D Ad knob sequences 
Fiber knob amino acid sequences for all 35 different species D serotypes were 
downloaded from the NCBI Protein database (NCBI, 2016), and aligned in BioEdit 
program (Hall, 1999) using the built-in ClustalW Multiple Alignment command. All of 
the knob amino acid sequences were shown to share two of the main CAR-binding 
residues S408 and P409 (Smith et al., 2002) with the Ad5 knob, while the third residue 
Y483 was conserved in all serotypes except Ad9, and the fourth key residue L491 
was highly divergent across serotypes (Figure 5–1A; highlighted in red). As for the 
CD46-tropism, four key CD46-binding residues have been previously determined for 
the CD46-binding species B Ad35 serotype (Wang et al., 2007). The sequence 
alignment showed all of the corresponding residues to be completely absent in all 
species D serotypes (Figure 5–1B; highlighted in blue), which suggested that these 
serotypes may not use CD46 as their primary target receptor for host cell entry. The 
findings based on the amino acid sequence therefore indicate that species D Ads do 
not utilise the CD46 receptor but may bind CAR, albeit likely at a lower affinity 
compared to Ad5, due to the conservation of two out of four key CAR-binding 
residues. Both the CAR- and CD46-tropism of the pseudotyped Ad5/species D 
chimaeras was further assessed in haemagglutination assays, luciferase transduction 
assays and competition inhibition assays in vitro (described in the following sections). 
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Figure 5–1. Amino acid sequence alignment of knob domains of all 35 species D adenovirus serotypes. (A) Key CAR-binding residues (Xia et al., 1994), the KO1 
mutation (Smith et al., 2002) and (B) CD46-binding residues as determined for Ad35 (Wang et al. 2007) in the fiber knob domain. Protein sequences were downloaded from 
National Center for Biotechnology Information (NCBI) website and aligned in BioEdit using ClustalW multiple alignment command using Ad5 knob sequence as a reference 
sequence. Sequences were further edited in Microsoft PowerPoint.  
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5.1.2 Predictive structural modelling of the knob domain 
Species D serotypes Ad10, -15, -24, -29, -48, -53 were chosen for further 
assessment based on their availability in our laboratory. The conformational structure 
of their fiber knob domain was visualised in a predictive SWISS-MODEL homology 
modelling software (Figure 5–2A). The majority of the species D fiber knobs have not 
yet been crystallised to a molecular detail, which is why the homology modelling was 
based on either of the published species D virus knob structures, Ad19p knob (PDB 
ID: 1UXB) or Ad37 (PDB ID: 2WGU). SWISS-MODEL software was run at an 
automated mode and the template was selected manually based on the highest 
possible sequence homology suggested by the software. All predicted models of the 
knob structure had a protruding loop structure whose amino acid sequence is 
PKPSNSKKY. The size of this loop seemed larger for Ad24 knob than for the other 
predicted knob structures. Structural modelling did not reveal major differences in the 
conformation of the fiber knob domain, relative to the Ad5 knob domain (Figure 5–
2B). However, in the absence of crystallisation data, the homology modelling only 
gives a sophisticated estimation of the 3D structure of these domains, and may not 
accurately reflect their true conformation in the context of the whole virion. 
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Figure 5–2. Predicted 3D structures of species D knob domains. (A) The models were based on either Ad19p or Ad37, depending on the structure with the highest 
degree of homology (indicated as a percentage). The sequence of the protruding loop structure: PKPSNSKKY. Colour indicates relative hydrophobicity: blue, hydrophobic; 
red, hydrophilic. (B) Ball view of species D knobs as seen from the top and from the side of the molecule. Immunodominant HI loop (Xia et al., 1994) highlighted in purple 
for Ad5; CAR-binding site highlighted in blue (Smith et al., 2002). 
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5.2 Generated pseudotyped vectors 
A panel of Ad5/species D pseudotyped vectors were generated by AdZ 
homologous recombineering methods. All vector genomes were based on the 
parental replication-deficient (ΔE1/E3) Ad5.Luc vector described in section 4.1. These 
vectors were generated by exchanging either the sequence of the whole fiber protein 
or the knob domain of the fiber protein with the respective sequences from species D 
serotypes. Nucleotide sequences with overlapping Ad5 homology arms were 
commercially synthesised and inserted into the Ad5.Luc sequence. Five whole fiber 
(Table 5–1A) and six fiber knob-pseudotyped Luc-expressing vectors (Table 5–1B) 
were generated, all of which were rescued as functional virions and produced into 
very high viral titres. CsCl-gradient ultracentifugation-purified stocks were titered by 
microBCA assays for their physical viral titre (vp/mL). In addition to the generation of 
novel pseudotyped vectors, Ad10 serotype with Luc or GFP reporter genes was 
vectorised by Dr James Davies as a novel vector backbone (Table 5–1C; unpublished 
data) for future assessment and modification for cancer-therapeutic purposes. 
Table 5–1. Generated a) whole fiber-pseudotyped (F) species D vectors, b) knob-pseudotyped 
(kn) species D vectors and c) serotype Ad10 vectors. Vectors were generated by homologous 
recombineering methods and produced into high viral titres in permissive T-REx-293 cells. The physical 
viral titre was determined using a microBCA protein kit, 1 μg of protein corresponding to a titre of 4 × 109 
viral particles (vp)/mL (Von Seggern et al., 1998). 
A  
Virus Physical titre (vp/mL) 
Ad5/F10.Luc 4.7 × 1012 
Ad5/F15.Luc 1.9 × 1012 
Ad5/F24.Luc 3.7 × 1012 
Ad5/F29.Luc 6.8 × 1012 
Ad5/F53.Luc 3.8 × 1012 
 
B  
Ad5/kn10.Luc 2.7 × 1012 
Ad5/kn15.Luc 1.3 × 1012 
Ad5/kn24.Luc 3.6 × 1012 
Ad5/kn29.Luc 1.6 × 1012 
Ad5/kn48.Luc 2.8 × 1012 
Ad5/kn53.Luc 2.3 × 1012 
 
C  
Ad10.GFP 3.2 × 1012 
Ad10.Luc 3.0 × 1012 
 
5.2.1 Verification of fiber integrity 
We then went on to assess the fiber integrity of these pseudotyped vectors by 
methods that are commonly utilised in Ad vector quality control. The pseudotyped 
vectors were assessed for fiber protein integrity by Western blot, using an Ad2 fiber-
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specific 4D2 mAb that recognises both the monomeric and trimeric forms of the fiber 
protein (Figure 5–3A). Additionally, the presence of all viral proteins was verified by a 
highly sensitive silver staining method (Figure 5–3B). The size of the Ad5 fiber is 
around 62 kDa, while species D fibers are ~ 40 kDa in size, as estimated using the 
ExPASY Bioinformatics Portal molecular weight calculator. This size difference can 
be seen as two distinct bands on the gel for viruses with the whole fiber (F) or just the 
knob (kn) domain replaced. Eight out of ten pseudotyped vectors were shown to 
exhibit a structurally intact fiber, based on the banding pattern on both the immunoblot 
and the protein silver staining (Figure 5–3). In contrast, both Ad5/F53 and Ad5/kn53 
vectors had two separate bands on the fiber Western blot image (Figure 5–3A), which 
suggest that the structural integrity of these vectors may be compromised, or rather 
that these stocks are a contaminated with Ad5. However, the genome of both of these 
vectors was confirmed to be correct by sequencing the BAC DNA following 
recombineering (data not shown). The Ad10 fiber protein could not be detected by 
using the anti-Ad2 fiber antibody (Figure 5–3B), which is likely due to the lack of cross-
reactivity between the species C and D fibers. However, a distinct, very strong band 
of the correct size (< 40 kDa) was observed for the Ad10 fiber in the silver staining 
(Figure 5–3C). The 4D2 antibody recognises the N-terminus (shaft) of the fiber protein 
that is in contact with the penton base protein. This domain is conserved throughout 
all pseudotyped vectors, while it is missing in the Ad10 vector. Therefore, the antibody 
efficiently recognises this sequence in the knob-pseudotyped vectors whose fiber 
shaft is derived from Ad5 (Figure 5–3A). However, recognition is less efficient for the 
whole fiber-pseudotyped vectors that only have a short sequence of Ad5 fiber at the 
N-terminus of their fiber protein, while the rest of the shaft is serotype-specific.  
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Figure 5–3. (A) Fiber protein Western blot of the species D pseudotypes and (B) Ad10 vectors. 
1 × 1010 viral particles in a total of 14 μL with 5 μL of loading buffer and 1 μL of DTT were loaded into 
each cell and run for 1 h 20 min at 150 V. The fiber protein was detected using an anti-Ad2 4D2 antibody. 
The image was developed in SuperSignal West Pico Chemiluminescent substrate for 10 min. (C) Silver 
staining of Ad5-based species D pseudotypes. 1 x 1010 viral particles in a total of 14 μL with 5 μL of 
loading buffer and 1 μL of DTT were loaded into each cell and run for 20 min at 120 V and 1 h at 150 V. 
The image was developed for 5 min and de-stained according to the Pierce SilverSnap kit instructions. 
 
5.3 In vitro evaluation of pseudotyped viruses 
Following the initial quality control, the generated novel pseudotyped vectors were 
also assessed in several different in vitro assay types. We sought to verify that the 
fiber pseudotyping had not compromised vector integrity and/or functionality. 
Additionally, the receptor tropism of these novel vectors and pseudotypes was 
assessed in a panel of cell lines expressing varying levels of the main Ad receptors. 
5.3.1 Haemagglutination assays 
Pseudotyped vectors were assessed for their ability to agglutinate human 
erythrocytes that express CAR on their surface (Carlisle et al., 2009). Using Ad5.Luc 
as a positive control virus, Ad10 was shown to be capable of agglutinating 
erythrocytes, albeit at lower efficiency than Ad5 (Figure 5–4). Two of the lower virus 
doses were not capable of agglutinating the erythrocytes, which indicates low affinity 
of Ad10 knob domain to CAR (Figure 5–4; row 3). None of the Ad5-based species D 
pseudotypes exhibited haemagglutination properties, with the exception of Ad5/kn53 
that showed full haemagglutination at all viral doses. Since this vector showed 
compromised fiber integrity in the Western blot as discussed in section 5.2.1, the 
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validity of this observation is debatable. The stock may be contaminated with Ad5, 
which would explain the haemagglutination profile. 
 
Figure 5–4. Haemagglutination assay on species D pseudotyped viruses. (A) Viruses were 
mixed with 1 % erythrocyte solution in PBS at four different concentrations of viral particles (vp). (B) 
Negative control in the assay was phosphate buffered saline (PBS), and positive control red blood cell 
lysis buffer. Haemagglutination grading: +++ complete; ++ midrange; + partial; − no haemagglutination. 
 
5.3.2 Transduction assays 
The receptor tropism of rare species D Ad serotypes is largely unknown to date. 
Whole fiber and fiber knob-pseudotyped vectors provide an excellent model system 
for studying receptor usage, as tropism is known to be determined by interactions 
between the fiber protein and cell surface receptors. To further elucidate the 
observations from haemagglutination assays, we sought to assess the receptor usage 
of the generated vectors in CHO-K1, CHO-CAR and CHO-BC1 model cell lines that 
have a clean receptor expression profile. We have previously validated luciferase 
transduction assays as a reliable method for studying CAR-tropism of Ad5.Luc and 
other vectors that utilise CAR in cellular entry (Uusi-Kerttula et al., 2016). 
Transduction assays performed in CHO-CAR cells indicated that CAR may not be 
involved in the cell entry of any of the Ad5-based vectors with whole fiber pseudotyped 
from species D serotypes (Figure 5–5A), as cell transduction levels were very similar 
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to the levels in CHO-K1 cells that do not express CAR at all. Statistically significant 
differences between CHO-K1 and CHO-CAR cells were observed for Ad5/F15 and 
Ad5/F29, but this may be reduced to variation around nothing, as the fold changes 
(CHO-K1 vs. CHO-CAR) raw RLU values are low for these viruses. In contrast, all 
knob-pseudotyped vectors, except Ad5/kn53, had significantly higher transduction 
efficiency in CHO-CAR as compared to CHO-K1 cells (Figure 5–5B). Interestingly, 
Ad5/kn10, Ad5/kn15 and Ad5/kn24 transduction in CHO-CAR was 4.7-, 3.2- and 3.3-
fold higher than Ad5.Luc transduction on these cells (Figure 5–5B). However, in this 
particular assay the raw RLU values for Ad5.Luc in CHO-CAR cells were ~ 10-fold 
lower than commonly observed for this virus in similar assays. This was considered 
common inter-assay variation since transduction levels returned to normal when the 
assay was repeated (Figure 5–9C). 
 
Figure 5–5. Transduction assays to assess CAR-tropism. (A) Whole fiber-pseudotyped virus 
transduction in CHO-K1 and CHO-CAR cells and (B) fiber knob-pseudotyped virus transduction in CHO-
K1 and CHO-CAR cells. Cells were infected with 5000 viral particles/cell for 3 h in serum-free medium. 
Luciferase activity was quantified at 48 h post-infection and normalised to relative light units (RLU)/mg 
protein in each well. Fold change indicates difference between CHO-K1 and CHO-CAR for the specific 
virus. Data were analysed in GraphPad Prism using two-tailed unpaired t test. n = 3; ns, p > 0.05; *, p < 
0.05; **, p< 0.01; ***, p < 0.001. Error bars represent standard deviation. 
 
We then went on to assess the CD46-tropism of the pseudotyped vectors. CHO-
BC1, a CHO-K1 cell line that expresses high levels of the BC1 isoform of the species 
B Ad receptor, CD46 (Gaggar et al., 2003), was used as a model cell line for these 
transduction assays. The Ad5/F35 vector (a kind gift from Prof Andrew H. Baker, 
University of Edinburgh) has the fiber pseudotyped from a CD46-utilising species B 
virus, and was used as a positive control, as previously reported (Uusi-Kerttula et al., 
2016). As expected, the transduction efficiency of Ad5/F35 was significantly higher in 
CHO-BC1 than in CHO-K1 or CHO-CAR cells (Figure 5–6A). None of the whole fiber-
pseudotyped viruses showed significantly increased transduction efficiency in CHO-
   
                                                                                                                   Chapter 5 
158 
 
BC1 as compared to CHO-K1 cells (Figure 5–6B). Similarly, none of the fiber knob-
pseudotyped viruses had an increased transduction efficiency in CHO-BC1 cells as 
compared to CHO-K1 cells (Figure 5–6C). However, Ad5/kn53 transduced CHO-BC1 
cells at 11-fold increased efficiency compared to the non-CD46-utilising Ad5.Luc. 
Despite the trend suggesting possible CD46 usage for Ad5/kn53, the difference 
between CHO-K1 and CHO-BC1 was not statistically significant (Figure 5–6C; p = 
0.0689). This particular virus also showed inconsistencies in the Western blot and 
haemagglutination assays discussed in the previous sections, which is why the 
validity of the observed CD46-binding may also be debatable as this stock may be 
contaminated with Ad5.Luc. Unfortunately, direct comparison of the transduction 
levels of Ad5/F35 and species D pseudotypes is not feasible, since the Ad5/F35 
vector expresses the β-Gal transgene, while all the other viruses are luciferase-
expressing. 
 
Figure 5–6. Transduction assays to assess CD46-tropism. (A) The CD46 receptor-utilising 
Ad5/F35 virus was used as a positive control, (B) whole fiber pseudotyped viruses and (C) fiber knob-
pseudotyped viruses for transduction assays in CHO-K1 and CHO-BC1 cells. Cells were infected with 
5000 viral particles/cell for 3 h at 37ºC in serum-free medium. Luciferase activity was quantified 48 h 
post-infection and normalised to relative light units (RLU)/mg protein in each well. Data were analysed 
in GraphPad Prism using two-tailed unpaired t test. n = 3; ns, not significant; p > 0.05. Error bars 
represent standard deviation. 
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5.3.3 Competition inhibition assays 
In order to further dissect the receptor tropism of the pseudotyped Ad5-based 
vectors, competition inhibition assays were performed in the described CHO model 
cell lines. Recombinant knob proteins were produced in house (section 4.2) and 
utilised as blocking agents along with validated function-blocking antibodies to 
competitively inhibit receptor binding. Vector receptor tropism was assessed in the 
CARneg control cell line CHO-K1 and the CARhigh CHO-CAR cell line. Cells were pre-
blocked with recombinant knob proteins to inhibit subsequent virus entry. All whole 
fiber-pseudotyped vectors seemed to be equally incapable of infecting CHO-K1 and 
CHO-CAR cells (Figure 5–7A, C, E, G, I). Thereby pre-blocking the cells with control 
kn5.CAR‒ or kn5 had no measurable effect on transduction efficiency. In contrast, the 
fiber knob-pseudotyped vectors showed slightly increased transduction in CHO-CAR 
as compared to CHO-K1 cell line and their whole fiber-pseudotyped counterparts 
(Figure 5–7B, D, F, H, J), which indicates that they may be able to use CAR for cell 
entry.  
Cell entry via CAR was significantly inhibited for Ad5/kn10 (p = 0.0048) and 
Ad5/kn15 (p = 0.0063) by pre-blocking the cells with kn5 protein (Figure 5–7B, D). 
Based on the observations from transduction assays in CHO-CAR cells, Ad5/kn24 
and Ad5/kn29 were expected to potentially use CAR for cell entry. However, blocking 
with kn5 did not result in significant reduction in transduction efficiency for either 
Ad5/kn24 or Ad5/kn29 by one-way ANOVA (p = 0.1454 and 0.2679, respectively). 
However, Ad5/kn24 transduction was significantly lower in the presence of the 
inhibitory kn5 protein than in ‘virus only’ conditions (p = 0.0172), when analysed by 
an unpaired t test. CAR-tropism of the pseudotyped Ad5/kn48 vector was assessed 
in competition inhibition assays in CHO-CAR cells using recombinant knob proteins 
as inhibitory agents. Ad5.Luc transduction was significantly inhibited by its own knob 
protein at three of the highest protein concentrations (Figure 5–8A). In contrast, Ad48 
knob significantly inhibited Ad5.Luc entry only at the highest protein concentration 
tested (Figure 5–8A). Conversely, Ad5 knob was capable of inhibiting Ad5/kn48 entry 
at significant levels at four out of six protein concentrations, while Ad48 knob inhibited 
Ad5/kn48 entry only at two of the highest protein concentrations (Figure 5–8B). This 
may indicate lower affinity of Ad48 knob for CAR, relative to Ad5. The tropism of 
Ad5/kn48 for CAR has been previously evaluated in a recent publication by our group 
(Uusi-Kerttula et al., 2016), and is therefore not discussed here in further detail. 
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Figure 5–7. Competition inhibition assays using species D pseudotypes. Cells were pre-blocked 
with 10 μg/105 cells of the proteins Ad5 knob (kn5) or Ad5 knob with 477YT CAR-binding mutation 
(kn5.CAR‒) for 30 min on ice. Cells were then infected with 5000 viral particles/cell for 1 h on ice and 
luciferase activity measured at 48 h post-infection. Values were normalised to relative light units 
(RLU)/mg protein. Data were analysed in GraphPad Prism using one-way ANOVA with Dunnett’s 
multiple comparison. n = 3; ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; error bars represent 
standard deviation. CAR, coxsackie and adenovirus receptor.  
 
 
Figure 5–8. Dose-response inhibition of CAR-mediated cell entry. CHO-CAR cells were pre-
incubated with varying concentrations of knob proteins for 30 min on ice and infected with luciferase-
expressing viruses at 5000 vp/cell for 1 h on ice in triplicate. Relative light units were measured at 48 h 
post-infection and normalised to total protein concentration in each well (RLU/mg). Data were analysed 
in GraphPad Prism using one-way ANOVA with Dunnett’s multiple comparison. n = 3; ns, p > 0.05; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001. Error bars represent standard deviation. 
 
5.3.4 Influence of FX on species D pseudotyped Ad5 vectors 
We then went on to assess the tropism of all whole fiber- and knob-pseudotyped 
Ad5 vectors in CHO-K1 (CARnegative), SKOV3 (CARintermediate) and CHO-CAR (CARhigh) 
cell lines, both in the absence and in the presence of 10 μg/mL of purified human FX 
(Figure 5–9). As expected, supplementation of the transduction medium with FX did 
markedly increase the transduction efficiency for all pseudotyped vectors that carry 
the Ad5 hexon protein. Since the pseudotyped vectors may bind CAR, the impact of 
FX on transduction efficiency was the less pronounced, the higher the CAR 
expression of the particular cell line. This meaning that background transduction 
levels are higher in cells that express CAR, which is why the relative increase in 
efficiency upon FX supplementation is less pronounced compared to cells that no not 
express CAR. Surprisingly, the effect was greatly more pronounced for the knob-
pseudotyped vectors than for their whole fiber-substituted counterparts. FX seemed 
to influence whole fiber-pseudotyped vector transduction less than it did for the 
parental Ad5, while the knob-pseudotyped vectors had very similar transduction 
patterns to Ad5. Ad5/kn53 was the only vector whose transduction efficiency was very 
similar both in the absence and presence of FX in all three cell lines (Figure 5–9). The 
native tropism of the Ad10 serotype has not been reported previously.  
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Sequence alignment of all seven hexon HVRs in Ad5 and Ad10 serotypes revealed 
Ad10 to have homologous amino acids in the HVR7 region with the FX-binding ‘HVR7’ 
mutation (Figure 5–10A) that has been described for Ad5 (Alba et al., 2009). In this 
seminal paper by Alba and colleagues, the subgroup D serotype Ad26 was 
designated as a non-FX-binder. This prompted the design of the HVR7 mutation 
based on the exact amino acids in the HVR7 of Ad26, whose corresponding residues 
are known to be critical for the FX binding of Ad5. We therefore sought to verify in 
vitro that the addition of physiological concentrations of FX in the medium would not 
impact the transduction efficiency of Ad10 in CHO-K1 cells that do not express either 
CAR or CD46 receptors, but are amenable to FX-mediated Ad5 uptake via HSPGs. 
As shown previously (Figure 4–7A), the transduction efficiency of Ad5.Luc vector was 
significantly enhanced by the addition of FX in the assay medium (Figure 5–10B), 
while its transduction was neutralised by the addition of neat ovarian ascites OAS019. 
On the contrary, the transduction efficiency of the novel Ad10 vector remained 
completely unchanged upon supplementation of the transduction medium with FX 
(Figure 5–10C). Additionally, transduction of Ad10 was significantly inhibited when 
cells were transduced in neat OAS019 ascites that was shown to contain anti-Ad10 
antibodies (Figure 3–7). We also sought to evaluate whether the depletion of FX from 
the transduction medium by the addition of the anti-coagulant X-bp would change the 
effect of OAS019 on vector transduction efficiency. In the case of Ad5, depletion of 
FX from OAS resulted in slightly more efficient neutralisation of the vector by OAS019 
fluid (Figure 5–10A). However, depletion of FX did not further improve neutralisation 
of Ad10 by OAS019 (Figure 5–10B). 
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Figure 5–9. Assessment of pseudotyped vector tropism for coagulation factor 10 (FX). (A) CHO-K1 hamster ovarian, (B) SKOV3 ovarian cancer and (C) CHO-CAR 
hamster ovarian cells were infected with 5000 viral particles / cell for 3 h in the absence of presence of 10 μg/mL human coagulation factor 10 (FX). Luciferase expression was 
quantified 48 h later as relative light units, and normalised to total protein / well (RLU/mg). Fold increase indicates the change relative to FX-free conditions (FX‒) for each virus. 
CAR, coxsackie and adenovirus receptor. 
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Figure 5–10. Adenovirus 10 (Ad10) binding to coagulation factor 10 (FX). (A) Amino acid sequence 
alignment of hexon hypervariable regions (HVR) in Ad5 and Ad10 serotypes. Sites for ‘HVR7’ FX-binding 
mutation in Ad5 shown in purple arrows (Alba et al., 2009); ‘original’ and ‘mutated’ amino acids involved 
in the point mutations are shown in bold black letters. CHO-K1 cells were transduced with (B) Ad5 and 
(C) Ad10 vectors at 5000 viral particles / cell for 3 h and luciferase activity measured 48 h later. Data 
shown as mean of triplicate values. Error bars represent standard error of the mean and fold change is 
relative to ‘virus only’ conditions for each virus. X-bp is an anticoagulant that was used to deplete FX 
from ovarian ascites (OAS) at a molar ratio of 3:1 (X-bp:OAS). ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, 
p < 0.001; ****, p < 0.0001. 
 
5.3.5 Neutralisation by ovarian ascites 
The capsid proteins are thought to be the main immunogenic determinants of Ad 
virion. The Ad5/species D pseudotyped vectors were generated in order to assess 
any potential to improve escape from pre-existing humoral immunity. The fiber-
pseudotyped vectors were assessed in vitro for their ability to resist neutralisation by 
ovarian ascites and to further refine the role of fiber protein in humoral immune 
recognition. CHO-CAR (CARhigh) cells were infected with 200 000 vp/cell for 3 h, and 
luciferase expression measured at 48 h p.i. Both Ad10 and Ad5/kn10 infected the 
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cells at similar efficiency compared to Ad5.Luc at this very high viral dose, while 
Ad5/F10 had ~ 1.4-fold lower transduction efficiency in these ascites-free conditions 
(Figure 5–11A, B; ‘virus only’). The lower transduction efficiency for Ad5/F10 
compared to Ad5/kn10 is in line with the observations from previous luciferase 
transduction assays in CHO-CAR cells (Figure 5–5). In the presence of OAS001, that 
has high levels of anti-Ad5 and moderate levels of anti-Ad10 antibodies (Figure 3–7), 
Ad5 vector was neutralised more efficiently at all ascites concentrations than any 
other vector (Figure 5–11A). The overall transduction efficiency of Ad5/F10 was very 
low, while Ad10 and Ad5/kn10 were capable of transducing the cells much more 
efficiently than Ad5 at all ascites dilutions (Figure 5–11A). In the presence of OAS019, 
that has high levels of both anti-Ad5 and anti-Ad10 antibodies (Figure 3–7), Ad10 had 
a superior transduction efficiency at all ascites concentrations as compared to all other 
vectors (Figure 5–11B). Additionally, both Ad5/F10 and Ad5/kn10 had greatly 
improved transduction at all ascites concentrations relative to Ad5 (Figure 5–11B). 
Overall, the Ad10 vector was capable of resisting neutralisation much better than Ad5 
or either of the pseudotyped Ad5/Ad10 vectors. 
Importantly, it is noteworthy that the RLU values were already at the maximal 
threshold for Ad5, Ad10 and Ad5/kn10 in ‘virus only’ conditions in this assay, since 
the cells were fully saturated with the very high viral load of 200 000 vp/cell. The 
transduction efficiency of these vectors may therefore in fact be higher than what 
could be detected in this assay. This obviously limits the interpretability of the 
observations. However, as we already used a very low volume of 10 μL of cell lysate 
for the assay, we did not feel comfortable with further reducing the assay volume. On 
the other hand, as the tropism of Ad10 for CAR was observed to be much lower than 
the affinity of Ad5 for CAR, we did not want to reduce the amount of virus in order to 
be able to observe the full neutralising effect of ovarian ascites. We therefore pushed 
the assay to its limits to see the differences in protection from neutralisation as clearly 
as possible.
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Figure 5–11. Neutralisation of Ad5/Ad10 pseudotyped vectors by ovarian ascites. Cells were infected with 200 000 viral particles/cell in the presence of ascending dilutions 
of ovarian ascites (OAS) from (A) patient 001 and (B) patient 019. Luciferase expression was measured as relative light units 48 h later and normalised to total protein per well 
(RLU/mg). Tables show fold change in transduction efficiency relative to Ad5 at each ascites dilution. Error bars represent standard error of the mean from duplicate 
measurements. 
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5.4 Discussion 
One of the main objectives of this thesis is the assessment of new Ad vector 
candidates that are based on rare Ad serotypes from subgroup D. Novel Ad10 and 
Ad5-based vectors with either the full length fiber or the fiber knob domain 
pseudotyped from species D serotypes were generated by AdZ homologous 
recombineering, produced to high viral titres in permissive T-REx-293 cells, and 
assessed for their receptor tropisms and entry pathways in vitro. Viral quality control 
‒ Western blot for the fiber protein and silver staining for all viral proteins ‒ confirmed 
all vectors (except Ad5/F53 and Ad5/kn53) to express structurally intact capsid 
proteins (Figure 5–3). The next step in the vector characterisation was the functional 
assessment of the generated vector backbones. 
Initially, haemagglutination assays were performed on the novel Ad10 vector and 
the complete panel of pseudotyped Ad5-based vectors using erythrocytes isolated 
from human blood (Figure 5–4). As described in section 4.2 for the de-targeted 
vectors, this assay is used routinely for the assessment of CAR-tropism of Ad 
serotypes, based on their binding to CAR that is expressed on the erythrocyte cell 
surface (Carlisle et al., 2009). While the CAR-binding vector Ad5 showed strong 
haemagglutination at all viral doses, Ad10 was capable of agglutinating erythrocytes 
only at the two of the highest viral doses. Surprisingly, Ad5/kn53 was the only 
pseudotyped vector that complete agglutinated the cells at all viral doses, while none 
of the other pseudotyped vectors showed any haemagglutination at any viral dose. 
We then proceeded to further assess the receptor tropism of Ad10 and the 
pseudotyped vectors in in vitro infectivity assays (Figure 5–5). Luciferase expression-
based transduction assays performed in CHO-CAR (CARhigh) cells indicated that 
Ad5/kn10 and Ad5/kn15 vectors may utilise CAR as their entry receptor. However, at 
low viral doses their transduction levels were low compared to Ad5, which indicates 
that these vectors may primarily use alternative, yet unidentified receptors for cell 
entry. However, when CHO-CAR cells were saturated with a very high viral load (200 
000 vp/cell) of Ad10 and Ad5/kn10, the transduction efficiency was comparable to 
Ad5 (Figure 5–11). Surprisingly, none of the Ad5-based vectors with a whole fiber 
pseudotyped from species D viruses seemed to use CAR (Figure 5–5) or CD46 
(Figure 5–6) for cell entry. Luciferase transduction (Figure 5–5) and competition 
inhibition assays (Figure 5–7) suggested that Ad5/kn10, -kn15 and -kn24, and 
possibly Ad5/kn29, may utilise CAR for cell entry, albeit less efficiently than Ad5. The 
Ad5/kn48 vector was confirmed to utilise CAR for cell entry, as the recombinant CAR-
binding kn5 protein successfully inhibited CAR-mediated transduction in CHO-CAR 
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cells (Figure 5–8). However, it was shown that the kn48 protein inhibited Ad5 entry 
into cells less efficiently than the kn5 protein, which suggests the CAR-affinity of Ad48 
to be lower than that of the Ad5 serotype. The CAR-tropism of Ad5/kn48 is further 
discussed in our recent research publication (Uusi-Kerttula et al., 2016). Although the 
haemagglutination assay suggested that Ad5/kn53 may use CAR for cell entry, the 
cell entry of this vector into CHO-CAR cells was not significantly inhibited by the CAR-
utilising Ad5 knob protein. Additionally, Ad5/kn53 was more efficient at transducing 
SKOV3 than the parental Ad5 (Figure 5–9), which suggests that the vector uses an 
alternative receptor, that is not expressed on CHO-CAR cells but is abundantly 
expressed on SKOV3 cells. However, this vector showed serious inconsistencies in 
the different assay types that suggest it may be an impure preparation contaminated 
with an Ad5 stock. 
Transduction levels of all pseudotyped vectors at the lower viral doses were 
relatively low in CHO-K1, CHO-CAR and CHO-BC1 cells, which may indicate that 
these vectors utilise a receptor that is absent in these cell types. It is likely that the 
vectors utilise CAR, and possibly CD46, as their auxiliary rather than primary 
receptors. Flexibility of the shaft domain is known to be essential for the internalisation 
step of the viral entry process. Pseudotyping the full amino acid sequence of the long 
Ad5 fiber with the sequence of a short species D serotype fiber has previously been 
shown to result in the generation of virions with compromised infectivity due to altered 
flexibility between the shaft and the knob domains, impairing the interactions between 
the penton base and αvβ3/5 integrins (Wu et al., 2003). This is in line with our 
observations of the drastically reduced infectivity for the whole fiber-pseudotyped 
vectors, and of the less pronounced impairment for the knob-pseudotypes, that may 
have a favourably flexible fiber protein. Additionally, fiber length has been shown to 
be crucial for Ad internalisation via CAR- and αv integrin-mediated pathways 
(Shayakhmetov and Lieber, 2000). The fiber proteins of the species D Ads studied in 
this thesis are considerably shorter (< 380 aa) than the Ad5 fiber (581 aa) (‘Protein’ 
search tool, (NCBI, 2016)), which may influence the infectivity of these serotypes. The 
pseudotyped vectors may also have altered intracellular processing, which may result 
in delayed endosomal release or even viral entrapment in the endosomes. An 
example of this is the species B serotype Ad35 that utilises CD46-mediated 
macropinocytosis, with delayed release from endocytic vesicles (Kälin et al., 2010). 
Therefore, the observed reduction in luciferase expression does not necessarily 
suggest reduced internalisation of the pseudotyped vectors, but may result from 
inaccessibility of the luciferase gene to the cellular translation machinery. The study 
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of receptor tropism by luciferase reporter gene assays is therefore not a 
straightforward indication of the receptor-binding capacity of the vectors. It is also 
noteworthy that the model cell lines used for the assessment of vector tropism are of 
hamster origin, and therefore do not simulate an infection in human cells. Further 
studies on the tropism of these vectors are needed in order to draw meaningful 
conclusions on their receptor tropism profile, based on transduction efficiency in a 
wider variety of distinctive cell types. SPR analysis by Biacore or related methods that 
assess receptor binding kinetics, will be highly valuable tools in the future. 
Furthermore, species D Ads are appealing vector candidates due to their low 
affinity to human FX (Waddington et al., 2008). This has important implications for the 
desirable avoidance of vector off-target sequestration by hepatocytes, with the view 
of minimising therapy-related toxicities. We (Figure 4–7) (Parker et al., 2006) and 
others (Shayakhmetov et al., 2005b, Waddington et al., 2008) have previously shown 
that the transduction efficiency of Ad5 vectors can be greatly improved by the addition 
of FX in the transduction medium (Figure 4–7), even in the absence of the primary 
cellular receptor, CAR. We performed sequence alignments of the Ad5 and Ad10 
hexon HVRs and showed that Ad10 and the non-FX-binder serotype Ad26 (Alba et 
al., 2009) have homologous residues within the five well-described residues that 
constitute the HVR7 mutation that was developed by Alba and colleagues in order to 
ablate the FX-binding of Ad5 (Figure 1–21). This finding strongly indicated lack of FX-
binding for the novel Ad10 vector, and prompted us to further verify the hypothesis in 
vitro. Supplementation of the transduction medium with physical concentrations of FX 
had absolutely no impact on the transduction efficiency of the novel vectorised Ad10 
serotype in CHO-K1 cells (Figure 5–10C), indicating that this serotype indeed does 
not bind FX. As discussed in section 4.7, CHO-K1 is a clean model for studying FX-
tropism, since the addition of FX enables the transduction of FX-binding Ad serotypes 
via HSPGs in this otherwise non-permissive cell line. 
We then went on to investigate whether pseudotyping with either the full fiber or 
just the fiber knob with corresponding regions from species D serotypes would have 
an impact on the FX-tropism of these vectors that carry the Ad5 hexon. Assays 
performed in CHO-K1, SKOV3 and CHO-CAR cells showed that the higher the CAR-
expression level of the cell line, the smaller influence FX supplementation had on 
vector transduction efficiency as compared to serum-free conditions (Figure 5–9). In 
the CAR-expressing CHO-CAR cells, the addition of FX had proportionally larger 
effect on the transduction efficiency of all pseudotyped vectors, than it had on Ad5. 
As seen in Figure 5–5, Ad5 transduces CHO-CAR cells already more efficiently than 
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the pseudotyped vectors, which is why FX supplementation does not improve its 
transduction efficiency as much as it does for the pseudotyped vectors that may be 
less able to use CAR as their entry receptor, as discussed earlier in this chapter. 
Taken together, collective observations from all performed in vitro assays showed 
divergent characteristics for both of the Ad5/53 vectors from all other pseudotypes. 
These vectors will need to be further validated and/or re-generated to exclude the 
possibility of cross-contamination. All of the pseudotyped Ad5 vectors have Ad5 
hexon protein, which is why FX was expected to have a similar impact on their 
transduction efficiency as it has on Ad5 transduction. The altered pattern seen in our 
studies may stem from reduced binding to FX, due to physical hindrances in the 
accessibility of FX to the hexon HVR7, resulting in reduced internalisation. Another 
explanation could be alternative intracellular processing of the virions and hampered 
translation of the luciferase gene, as discussed previously in this section.  
Species D Ads exhibit lower seroprevalence rates in human populations than the 
most commonly used gene therapy serotype, Ad5 (Abbink et al., 2007). The lower 
prevalence of these viruses in the human population may be due to the absence of a 
suitable cellular receptor in the human epithelia, leading to compromised cell entry 
and attenuated virulence in humans. Previously it has been proposed that anti-Ad 
antibodies are primarily directed towards the fiber protein, since pseudotyping Ad5 
with Ad45 fiber (Ad5/F45) helped to circumvent vector neutralisation (Parker et al., 
2009). It is important to seek alternative vector moieties as the high seroprevalence 
of Ad5 causes therapeutic vectors to be rapidly eliminated from the blood stream upon 
systemic delivery, leading to clinically inert vectors [reviewed in (Uusi-Kerttula et al., 
2015a)]. In this thesis, we have attempted to evaluate novel Ad candidates from the 
subgroup D, with the prospect that they could be more suitable vector backbones due 
to their avoidance of pre-existing humoral anti-Ad5 immunity. To this end, we 
performed neutralisation assays using the novel vectors Ad10, and two pseudotyped 
Ad5-based vectors Ad5/F10 and Ad5/kn10, to assess the depth and serotype-
specificity of pre-existing humoral immunity in ovarian ascites. Ad10 was better at 
resisting neutralisation by two different ascitic fluids (OAS001 and OAS019; Figure 3–
7), than either of the pseudotyped vectors or the Ad5 vector (Figure 5–11). Based on 
the presence of anti-Ad10 antibodies in OAS019, this fluid was expected to efficiently 
neutralise Ad10 and possibly Ad5/F10 and Ad5/kn10 too. As anti-Ad nAbs are thought 
to be directed against the fiber protein in natural infections (Cheng et al., 2010, 
Bradley et al., 2012a), it was surprising to find that the vectors with the Ad10 knob-
pseudotypes appeared protected from neutralisation, despite the presence of anti-
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Ad10 antibodies. However, it is noteworthy that the anti-Ad10 antibodies detected in 
our anti-Ad ELISA assays may be cross-reactive and/or non-neutralising IgG 
antibodies rather than nAbs. Regardless, the preliminary data from these in vitro 
assays showed promising potential for using Ad10 or Ad5/Ad10 pseudotyped 
backbones for improved circumvention of anti-Ad5 vector neutralisation. 
We hypothesise that there might be two competing interactions occurring between 
the Ad vectors and proteins present in ovarian ascites. On the one hand viruses can 
be efficiently neutralised by nAbs, while on the other hand their efficiency can be 
enhanced by the high affinity binding to FX that provides an alternative, CAR-
independent entry route into the target cells. FX has also been proposed to shield the 
virion from attack by natural IgM antibodies and the complement, thereby providing a 
protective shield from innate immune factors (Xu et al., 2013). In this thesis, depletion 
of FX from ascites further increased the neutralisation of the Ad5 vector but not of the 
Ad10 vector (Figure 5–10). Since we have shown that Ad10 does not have a 
measurable tropism for FX (Figure 5–10), and that it is much less readily neutralised 
by immune ovarian ascites, the observation is in line with the FX:Ad vs. Ad:nAb 
competition hypothesis. On the contrary for Ad5, in the absence of competition of FX 
for the virion, nAbs may better access the capsid proteins, coat the virion and prevent 
it from binding to its cellular entry receptors. It is however, important to consider that 
not only the affinity but also the relative abundance of FX versus anti-Ad nAbs is likely 
to contribute to the extent of neutralisation. 
Taken together, the novel Ad10 vector generated by our research group seems to 
have three advantages over the commonly used vector, Ad5: (1) low affinity to CAR 
that is ubiquitously expressed in healthy tissues but down-regulated in progressive 
cancers, and (2) lack of FX-binding, both of which may imply favourably decreased 
off-target delivery in vivo, as well as (3) improved resistance of neutralisation by 
immune ovarian ascites. Ad10 is therefore an appealing candidate for further 
modifications and functional studies, and can be a useful tool for further modification 
and utilisation for oncolytic alterations, in combination with cancer-targeting moieties. 
The work is undergoing in our laboratory to incorporate an αvβ6-targeting peptide in 
the highly promising Ad10, Ad5/F10 and Ad5/kn10 vector backbones. In this thesis 
we have also briefly visited the topic of re-targeting the Ad5/kn48 vector to αvβ6-
positive EOC in vitro, which is further discussed in section 6.2.1. 
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CHAPTER 6. In vitro assessment of αvβ6 integrin-targeted vectors 
The objective of this chapter was the generation of vectors selectively targeted to 
αvβ6 integrin receptor, whose expression is exclusively up-regulated in progressive 
epithelial cancers (Koopman Van Aarsen et al., 2008). This integrin presents an 
excellent tumour target candidate, since it is completely undetectable in healthy adult 
epithelia (Ahmed et al., 2002b). This section describes the generation of αvβ6 
integrin-targeted replication-deficient and replication-competent oncolytic vectors by 
AdZ homologous recombineering methods, and their functional assessment in 
ovarian and other model cancer cell lines in vitro. This chapter re-introduces the triple-
de-targeted Ad5.3D vector from chapter 4. We were intrigued by the possibility of 
generating a functional re-targeted Ad5.3D variant by engineering in a new tropism 
(A20 peptide) and producing this vector in the permissive HEK293-β6 cell line that 
expresses the αvβ6 receptor. A major part of this chapter is focused on the functional 
characterisation of the novel, exquisitely tumour-targeted Ad5 vector, Ad5.3D.A20. 
Generation of an αvβ6 integrin-expressing EOC model cell line for these studies, 
SKOV3-β6 puro, is described in section 3.1.3. EOC culture phenotyping and selection 
of αvβ6-positive cultures is further described in section 3.2.2. To better replicate the 
clinical scenario, vector transduction efficiency was also assessed in primary ovarian 
cancer ascites-derived EOC cell cultures ex vivo, in the presence of neutralising 
ovarian ascitic fluid.  
6.1 In silico assessment of recombinant knob domains 
Chapter 5 describes the generation of novel Ad5 vector backbones with species D 
serotype fibers. We then went on to evaluate the feasibility of the αvβ6-targeting 
peptide (A20) insertion in these pseudotyped backgrounds within the four different 
fiber knob loops ‒ CD, DG, HI and IJ ‒ that have been described for the most 
commonly used gene therapy vector, species C serotype Ad5. The impact of the 
targeting peptide insertion on the structural conformation of the knob domain was 
predicted in an automated homology-modelling software. Furthermore, the location 
for A20 insertion within the knob sequence was determined based on a sequence 
alignment of the domain and previously assessed insertion sites for serotypes Ad5 
(Coughlan et al., 2009a) and Ad48 (Coughlan et al., 2014). 
6.1.1 Sequence alignment of fiber knob loops for A20 peptide insertion 
The FMDV A20 peptide (NAVPNLRGDLQVLAQKVART) has previously been 
inserted into the Ad5 fiber knob domain within the HI loop in a replication-deficient 
vector background; the vector was shown to be able to target αvβ6+ cancer cells 
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(Coughlan et al., 2009a). A20 insertion has also been previously evaluated in the 
context of a recombinant Ad48 knob protein in knob loops CD, DG loop with a 13-aa 
deletion (Δ13aaDG.A20), HI and IJ (Coughlan et al., 2014), but has not been 
incorporated into a whole Ad5/kn48 virion before. In this thesis, the A20 peptide was 
additionally incorporated in Ad10 fiber knob within regions corresponding to Ad5 knob 
loops DG and HI. An additional virus was generated with a 5-aa deletion in DG loop 
(Δ5aaDG.A20) preceding the A20 insertion, whose length and location was selected 
based on the corresponding 13-aa deletion in the Ad48 knob that had been previously 
described by our group (Coughlan et al., 2014) (Figure 6–1). The sequence alignment 
shows the conservation stage of this location in all species D Ad knob domains. This 
information may be utilised for future re-targeting efforts of alternative species D 
serotypes. 
 
Figure 6–1. Rationale for the five amino acid deletion in DG loop of the Ad10 fiber knob for the 
A20 peptide sequence insertion. Knob sequences were downloaded from National Center for 
Biotechnology Information website and aligned in BioEdit using ClustalW multiple alignment tool. 
Sequences were further edited in Microsoft PowerPoint. 
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The fiber protein of species C Ad5 is 581 aa in length, while the fiber of the species 
D serotypes Ad10 and Ad48 is considerably shorter, 367 and 373 aa, respectively 
(NCBI, 2016). Sequence homology between Ad5 and Ad10 fibers is 36 % and 35 % 
between Ad5 and Ad48 fibers, whilst Ad10 and Ad48 fibers share a larger, 64 % 
homology. The knob domain itself has a homology of 49 % between Ad5 and Ad10, 
48 % between Ad5 and Ad48, and 59 % between Ad10 and Ad48 serotypes. A20 
peptide incorporation sites in the fiber knob domain were depicted in a sequence 
alignment for each of the three serotypes, Ad5, Ad10 and Ad48 (Figure 6–2), based 
on previously evaluated insertion sites (Coughlan et al., 2009a, Coughlan et al., 
2014). DG loop was the only site to accommodate a short deletion in addition to the 
A20 insertion. 
 
Figure 6–2. Insertion site for A20 peptide in fiber knob CD, DG, HI and IJ loops. FMDV A20 
peptide was genetically incorporated into locations that had been previously validated for Ad5 knob 
(Krasnykh et al., 1998, Coughlan et al., 2009a) and Ad48 knob (Coughlan et al., 2014). Amino acid 
deletion for incorporation into DG loop highlighted in black. A20, NAVPNLRGDLQVLAQKVART. 
 
6.1.2 Predictive structural modelling of the knob domain 
Trimeric fiber knob protein domains with a genetically inserted A20 peptide 
sequence were visualised by a predictive SWISS-MODEL structural homology 
modelling software. A20 insertion sites in each serotype were as follows: loop HI in 
Ad5; loops DG, Δ5aa.DG (+ 5-aa deletion) and HI in Ad10 knob; loops DG, Δ13aa.DG 
(+ 13-aa deletion) and HI in Ad48 knob. Predictive modelling indicated favourable 
spatial conformation the A20 peptide in loops DG and HI, as it was seen as a 
protruding loop structure projecting away from the core of the domain. In contrast, 
when A20 was inserted in loops CD and IJ, it seemed to have been buried deep in 
the domain, indicating that these locations are not likely to be feasible. It is however, 
crucial to keep in mind that these structures do not represent the whole virion, but 
merely a hypothetical prediction of the knob domain. Therefore, no conclusions on 
the viral fitness of the complete virions could be drawn based on these structures. 
However, these models were useful for matching the predicted structure to the 
success rate of rescuing the respective virions in a T-REx-293 human production cell 
line in vitro (described in section 6.2).
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Figure 6–3. Predictive structural modelling of species D adenovirus knob domains with an A20 targeting peptide insertion. (A) Ad5, (B) Ad10 and (C) 
Ad48 fiber knob with A20 peptide insertion in structural knob loops CD, DG, HI and IJ. Structures were based on either the Ad5 knob PDB model (ID: 1KNB) or species 
D structures Ad19p (PDB ID: 1UXB) or Ad37 (PDB ID: 2WGU), based on highest sequence homology. aa, amino acid; A20 sequence NAVPNLRGDLQVLAQKVART 
highlighted in green; immunodominant HI loop in Ad5 knob (Xia et al., 1994) highlighted in purple; Δ, amino acid (aa) deletion.
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6.2 Generated αvβ6 integrin-targeted vectors 
Vector genomes were generated as BACs by AdZ homologous recombineering. 
Infectious viruses were then rescued from the BAC genome and propagated into high 
viral titres in permissive T-REx-293 or HEK293-β6 puro cells, both of which express 
the Ad proteins E1 and E3. HEK293-β6 puro cell line stably expresses the target 
receptor for these vectors ‒ αvβ6 integrin ‒ under puromycin selection, and was 
utilised to further facilitate virus production (a kind gift from Dr Lynda Coughlan, 
University of Oxford). After successful transfection and generation of high titre stocks, 
the vectors were purified by two-step CsCl gradient ultracentrifugation, dialysed and 
titered by microBCA assay for their physical titre (vp/mL). 
6.2.1 Replication-deficient vectors 
A comprehensive panel of αvβ6 integrin-targeted vector genomes within several 
different basal backgrounds were generated in close collaboration with Dr James 
Davies, Cardiff University. The nucleotide sequence corresponding the A20 peptide 
sequence was inserted into the basal and de-targeted Ad5 vector BAC genomes 
(Table 6–1) that have also been modified to carry a series of native tropism-ablating 
mutations in the fiber, hexon and penton proteins (described previously in detail in 
chapter 4). Both Luc- and GFP-expressing versions of the viral vector backbones 
were generated as BACs. However, the production of several of the GFP-expressing 
vectors as infectious viruses was not attempted due to time limitations of this project. 
Unfortunately, we were unable to rescue viable, infectious virions from several of the 
vector backbones (Table 6–1; denoted as ‘BAC’), despite several transfection 
attempts in both T-REx-293 and HEK293-β6 puro cells. However, all successfully 
rescued vectors were produced into very high viral titres (Table 6–1), indicating 
feasible functioning of the production system. Pleasingly, we were able to generate 
the remarkably exciting basal Ad5.3D.A20 vector that is fully depleted of all native 
interactions (αvβ3/5 integrins, CAR, FX) and selectively re-targeted to a cancer 
marker, αvβ6 integrin. 
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Table 6–1. Recombinant αvβ6 integrin-targeted vectors in de-targeted backgrounds. Vector 
genomes were generated as bacterial artificial genomes (BAC) and produced in T-REx-293 or HEK293-
β6 cells. Viruses were purified by CsCl-gradient ultracentrifugation and titered by microBCA assay. A20, 
NAVPNLRGDLQVLAQKVART; CAR, coxsackie and adenovirus receptor; FX, human coagulation factor 
10; GFP, green fluorescent protein; HVR7, FX-binding mutation; KO1, CAR-binding ablation; Luc, firefly 
luciferase; RGE, αvβ3/5 integrin-binding mutation; vp, viral particle. 
Virus Known binding ligands Physical titre (vp/mL) 
Ad5.Luc.A20 CAR, αvβ3/5/6, FX 5.5 × 1012 
Ad5.GFP.A20 CAR, αvβ3/5/6, FX BAC 
Ad5.Luc.KO1.A20 αvβ3/5/6, FX 3.1 × 1012 
Ad5.GFP.KO1.A20 αvβ3/5/6, FX 3.8 × 1011 
Ad5.Luc.RGE.A20 CAR, αvβ6, FX 3.3 × 1012 
Ad5.GFP.RGE.A20 CAR, αvβ6, FX BAC 
Ad5.Luc.HVR7.A20 CAR, αvβ3/5/6 5.9 × 1012 
Ad5.GFP.HVR7.A20 CAR, αvβ3/5/6 BAC 
Ad5.Luc.KO1.RGE.A20 αvβ6, FX BAC 
Ad5.GFP.KO1.RGE.A20 αvβ6, FX 8.9 × 1010 
Ad5.Luc.KO1.HVR7.A20 αvβ3/5/6 BAC 
Ad5.GFP.KO1.HVR7.A20 αvβ3/5/6 5.8 × 1010 
Ad5.Luc.KO1.RGE.HVR7.A20 αvβ6 3.0 × 1012 
Ad5.GFP.KO1.RGE.HVR7.A20 αvβ6 BAC 
 
The A20 peptide sequence was also incorporated into the species D pseudotyped 
vector backgrounds (Table 6–2). We attempted to rescue the αvβ6-targeted 
Ad5/Ad10 pseudotyped vectors in both T-REx-293 and HEK293-β6 cells. Of these 
vectors only the Ad5/F10 and Ad5/kn10 pseudotyped vectors with A20 in DG loop 
with or without the 5-aa deletion could be rescued as infectious virions and produced 
into high viral titres (Table 6–2). These pseudotyped and re-targeted vectors took an 
average of two weeks to come through, which is about four days longer than for Ad5-
based vectors commonly. Unfortunately, despite 4‒5 individual transfection attempts 
in both T-REx-293 and HEK293-β6 cells, A20 insertion in pseudotyped Ad5/F10 or 
Ad5/kn10 in HI loop did not result in infectious virions. Similarly, rescue of Ad5/kn48 
with A20 peptide insertion in CD, HI and IJ loops was not successful despite several 
individual attempts. This is likely to be due to the compromised fitness of these virions, 
due to conformational disruptions by A20 insertion in these loops. The BAC genomes 
of Ad10.A20 vectors with A20 insertions (Table 6–2; ‘BAC’) have now been generated 
by homologous recombineering by Ms Jana Váňová, and their rescue as virions is 
currently undergoing in our laboratory. Unfortunately, the timescale of this project did 
not allow for the in vitro testing of these novel and exciting vector backbones.  
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Table 6–2 Generated αvβ6 integrin-targeted vectors in the species D pseudotyped 
background. BAC, bacterial artificial genome; CAR, coxsackie and adenovirus receptor; FX, coagulation 
factor 10; Luc, luciferase; vp, viral particle, ‒, no infectious virus could be rescued. 
Virus 
Predicted 
binding ligands 
Stage or titre (vp/mL) 
Ad10.Luc.DG.A20 αvβ6, CAR? BAC 
Ad10.Luc.Δ5aaDG.A20 αvβ6, CAR? BAC 
Ad10.Luc.HI.A20 αvβ6, CAR? BAC 
Ad5/F10.Luc.DG.A20 αvβ6, FX, CAR? 1.0 × 1012 vp/mL 
Ad5/F10.Luc.Δ5aaDG.A20 αvβ6, FX, CAR? 1.2 × 1012 vp/mL 
Ad5/F10.Luc.HI.A20 αvβ6, FX, CAR? ‒ 
Ad5/kn10.Luc.DG.A20 αvβ6, FX, CAR? 2.1 × 1012 vp/mL 
Ad5/kn10.Luc.Δ5aaDG.A20 αvβ6, FX, CAR? 1.6 × 1012 vp/mL 
Ad5/kn10.Luc.HI.A20 αvβ6, FX, CAR? ‒ 
Ad5/kn48.Luc.CD.A20 αvβ6, FX, CAR? ‒ 
Ad5/kn48.Luc.DGΔ13aa.A20 αvβ6, FX, CAR? 8.5 × 1011 vp/mL 
Ad5/kn48.Luc.HI.A20 αvβ6, FX, CAR? ‒ 
Ad5/kn48.Luc.IJ.A20 αvβ6, FX, CAR? ‒ 
 
6.2.2 Oncolytic vectors 
Wild type vectorised Ad5.Luc with intact E1 and E3 gene regions was further 
modified for oncolytic purposes by insertion of two mutations that render the vector 
cancer-selective and improve its lytic efficiency. Luciferase-expressing, oncolytic 
vector BAC genomes were all generated by Dr James Davies, Cardiff University, via 
introduction of de-targeting mutations and genetic A20 peptide sequence insertion 
within the knob HI loop. An Δ24 mutation, a 24-base pair deletion (dl922‒947) in the 
pRB binding domain of E1A (Fueyo et al., 2000), was included to restrict viral 
replication to cancer cells that have a deficient pRB pathway. Additionally, a T1 
mutation ‒ a single adenine insertion at position 445 within the ER retention domain 
of E3/19K ‒ was inserted to improve viral particle release from the ER (Gros et al., 
2008). These vectors were all rescued and produced into high viral titres in T-REx-
293 or HEK293-β6 puro cells (Table 6–3). In this thesis, the oncolytic vectors were 
assessed in vitro. In vivo studies for the assessment of the oncolytic activity of these 
vectors are currently underway at our collaborator Prof Richard Vile’s laboratory at 
Mayo Clinic, Rochester, Minnesota, USA. 
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Table 6–3. Generated oncolytic adenovirus vectors. Δ24, a 24-base pair deletion (dl922‒947) in 
the retinoblastoma protein (pRB) binding domain of E1A; Luc, luciferase transgene; T1, a single adenine 
insertion at position 445 within the endoplasmic reticulum (ER) retention domain of E3/19K; pfu, plaque 
forming unit; vp, viral particle. The vectors that were further assessed in this thesis, are abbreviated with 
an ‘O’ (oncolytic) to distinguish them from the replication-deficient versions of these vectors. 
 
Virus Abbreviation 
Physical titre 
(vp/mL) 
Infectious 
titre 
(pfu/mL) 
Ratio 
(vp:pfu) 
D
e
-t
a
rg
e
te
d
 
Ad5.Luc.Δ24  7.02 × 1011 2.67 × 1010 26 
Ad5.Luc.Δ24.T1 OAd5 1.12 × 1012 2.08 × 1010 54 
Ad5.Luc.Δ24.KO1  1.22 × 1012 7.20 × 108 1695 
Ad5.Luc.Δ24.T1.KO1 OAd5.KO1 1.11 × 1012 5.32 × 108 209 
Ad5.Luc.Δ24.HVR7  1.52 × 1012 6.06 × 1010 25 
Ad5.Luc.Δ24.T1.HVR7 OAd5.HVR7 1.06 × 1012 2.50 × 1010 42 
R
e
-t
a
rg
e
te
d
 
Ad5.Luc.Δ24.A20  1.74 × 1012 5.82 × 1010 30 
Ad5.Luc.Δ24.T1.A20 OAd5.A20 2.17 × 1012 9.15 × 1010 24 
Ad5.Luc.Δ24.KO1.A20  3.73 × 1011 2.44 × 1010 15 
Ad5.Luc.Δ24.T1.KO1.A20 OAd5.KO1.A20 1.72 × 1012 4.60 × 1010 37 
Ad5.Luc.Δ24.HVR7.A20  9.73 × 1011 4.40 × 1010 22 
Ad5.Luc.Δ24.T1.HVR7.A20 OAd5.HVR7.A20 1.50 × 1012 3.62 × 1010 41 
Ad5.Luc.Δ24.KO1.HVR7.A20  1.12 × 1012 4.16 × 1010 27 
Ad5.Luc.Δ24.T1.KO1.HVR7.A20  OAd5.KO1.HVR7.A20 5.78 × 1011 1.66 × 1010 35 
Ad5.Luc.Δ24.KO1.HVR7.RGE.A20   1.96 × 1012 1.07 × 1010 183 
Ad5.Luc.Δ24.T1.KO1.HVR7.RGE.A20  OAd5.3D.A20 1.51 × 1012 2.44 × 109 619 
 
6.3 In vitro assessment of αvβ6 integrin-targeted adenoviruses 
The generated replication-deficient vectors were assessed in representative in 
vitro assays for their ability to transduce αvβ6 integrin-positive cancer cells, and for 
their receptor tropism in haemagglutination assays. Furthermore, their selectivity for 
the αvβ6 integrin was assessed in competition inhibition assays using relevant 
inhibitory proteins and blocking antibodies. Additionally, the oncolytic vectors (OAd) 
were assessed for their in vitro oncolytic potency in cell viability assays over a 10-day 
time-course. The αvβ6 integrin-targeted vectors were also assessed for their ability to 
evade pre-existing humoral anti-Ad immunity in the presence of highly neutralising 
clinical ovarian ascites from patients with advanced ovarian cancer.  
6.3.1 Haemagglutination assays 
CAR-tropism of the αvβ6-targeted vectors was assessed in haemagglutination 
assays using whole human blood as described in section 4.3. Haemagglutination 
pattern was determined visually by grading from no agglutination (‒) to complete 
agglutination (+++). Interestingly, the presence of A20 peptide in the context of 
Ad5.A20, Ad5.RGE.A20 and Ad5.HVR7.A20 vectors was shown to partially 
compromise CAR-binding, although these viruses do not carry the KO1 mutation that 
ablates CAR-binding (Figure 6–4; rows 1, 3 and 4). The effect was most pronounced 
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for the Ad5.RGE.A20 vector that had only partial agglutination at the highest dose, 
low agglutination at second highest dose, but no agglutination at two of the lowest 
doses (Figure 6–4; row 3). As expected, the parental Ad5.RGE completely 
agglutinated erythrocytes due to its native CAR-binding [see previously (Figure 4–3)]. 
No haemagglutination was observed at any dose for viruses that have both the KO1 
mutation and the A20 peptide, including the triple de-targeted virus Ad5.3D.A20. 
Ad5/kn48.Δ13DG.A20 vector exhibited an altered CAR-tropism due to the A20 
peptide insertion, as compared to the pseudotyped Ad5/kn48 vector that did not 
agglutinate erythrocytes at any viral dose (Figure 5–4 and Figure 6–4; row 9). 
 
Figure 6–4. Haemagglutination assay on the αvβ6 integrin-targeted vectors. (A) Viruses were 
mixed with 1 % erythrocyte solution in PBS at four different concentrations and incubated for 2 h at 37ºC. 
(B) Negative control in the assay was PBS, and positive control red blood cell (RBC) lysis buffer. PBS, 
phosphate buffered saline; vp, viral particle. Haemagglutination grading: +++ complete; ++ midrange; + 
partial; − no haemagglutination (Nicol et al., 2004). 
 
6.3.2 Re-targeting in αvβ6-positive cell lines and primary EOC cultures 
The generated αvβ6-targeted viruses were assessed in selected model cell lines 
that express varying levels of αvβ6 integrin and CAR (Table 3–1). As all of the 
assessed vectors express the Luc reporter transgene, the relative cell transduction 
efficiency of each vector could easily be assessed by performing in vitro luciferase 
assays in a 96-well plate format. A model cell line SKOV3-β6 puro (section 3.1.3) was 
generated as an αvβ6-positive control cell line for the assessment of αvβ6-targeted 
vectors. Four established primary EOC ex vivo cultures that were shown to be positive 
for αvβ6 (Figure 3–6), were included as a clinically representative counterpart for the 
vector assessment, to better represent a clinical scenario. We also used the breast 
cancer cell line BT-20 as a positive control cell line due to its high level of αvβ6 and 
low level of CAR expression. 
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Figure 6–5. αvβ6 integrin-targeted vector transduction in breast (BT-20) and (B) ovarian 
cancer cells (SKOV3-β6). Cells were infected with 5000 viral particles/cell in triplicate for 3 h and 
luciferase expression quantified 48 h later. Relative light units (RLU) were normalised to total protein in 
each cell (RLU/mg). Data were analysed in GraphPad Prism using one-way ANOVA with Dunnett’s 
multiple comparisons post hoc test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
We have previously reported that Ad5.KO1.HI.A20, Ad5.HI.A20 and 
Ad5/kn48.Δ13aaDG.A20 vectors transduced αvβ6high/CARlow BT-20 breast cancer 
cells at 160-, 270- and 180-fold increased efficiency relative to Ad5.Luc (Uusi-Kerttula 
et al., 2016). Additionally, αvβ6-mediated cell entry of these viruses was significantly 
inhibited both by a function-blocking anti-αvβ6 antibody 10D5 and a recombinant 
Ad48.Δ13aaDG.A20 knob protein, but not by control IgG antibody or kn5.CAR‒ 
recombinant protein, in these cells. In this thesis we also evaluated the ability of the 
triple de-targeted and αvβ6-re-targeted Ad5.3D.A20 vector to transduce the BT-20 
and SKOV-β6 cells. The Ad5.3D.A20 vector was shown to transduce BT-20 cells at 
~ 300-fold increased efficiency relative to Ad5.Luc (Figure 6–5). Similarly, all A20 
vectors, regardless of de-targeting mutations, transduced SKOV3-β6 cells at highly 
efficient levels that were similar to the Ad5.A20 vector (Figure 6–5). Additionally, we 
assessed the efficiency of these vectors to transduce clinical αvβ6+ EOC cell cultures 
ex vivo. While Ad5.Luc had the highest efficiency of all vectors in the αvβ6low/CARmed 
EOC003 cells, the overall efficiency of all αvβ6-targeted vectors was very low in these 
cells (Figure 6–6A). On the contrary, all αvβ6-targeted vectors transduced the 
αvβ6high/CARmed EOC004 cells at up to ~ 70-fold improved efficiency relative to 
Ad5.Luc that cannot utilise αvβ6 for cell entry (Figure 6–6B). The pattern seen in 
αvβ6low/CARmed EOC016 cells was similar to the transduction efficiency observed in 
EOC003 cells that express only low levels of the αvβ6 integrin (Figure 6–6C).  
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Figure 6–6. Transduction efficiency in αvβ6-expressing primary ex vivo epithelial ovarian 
cancer (EOC) cultures. Cells were infected with 5000 viral particles/cell in triplicate for 3 h and luciferase 
expression quantified 48 h later. Relative light units were normalised to total protein in each cell 
(RLU/mg). Data were analysed in GraphPad Prism using one-way ANOVA and Dunnett’s multiple 
comparison post hoc test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
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6.3.3 Competition inhibition assays for verification of vector tropism for αvβ6 
A panel of αvβ6-targeted, Ad5-based viruses were assessed in competition 
inhibition assays in representative cell lines to verify the central involvement of αvβ6 
receptor in cell entry. We have previously shown that transduction of all basal Ad5 
vectors carrying the A20 targeting peptide, as well as the pseudotyped 
Ad5/kn48.Δ13aaDG.A20 vector, was significantly inhibited by both a function-blocking 
anti-αvβ6 antibody 10D5 and a recombinant kn48.Δ13aaDG.A20 protein in BT-20 
(αvβ6high/CARlow) cells (Uusi-Kerttula et al., 2016). Using the observations from the 
αvβ6+ BT-20 breast cancer cell line as a positive reference (Figure 6–7A), αvβ6 
integrin-blocking assays were additionally performed in SKOV3-β6 ovarian cancer 
cells, following a second round of cell sorting into highly αvβ6-positive cell populations 
by FACS (Figure 6–7B). αvβ6-mediated vector transduction was shown to be 
successfully blocked for both αvβ6-re-targeted A20 viruses, Ad5.A20 (p = 0.0029) and 
Ad5.3D.A20 (p = 0.001) in SKOV3-β6 cells, as compared to the ‘virus only’ conditions 
for each virus (Figure 6–7B). 
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Figure 6–7. Competition inhibition of αvβ6 integrin-mediated cell entry. (A) BT-20 breast cancer and (B) SKOV3-β6 ovarian cancer cells were pre-incubated with normal 
mouse IgG control, recombinant knob proteins or function-blocking antibodies for 30 min on ice, and viruses added at 5000 virus particles/cell for 2 h on ice. Transgene expression 
was quantified 48 h later. Error bars indicate the difference to the corresponding virus in non-inhibited, serum-free conditions (‘virus only’). Statistical analysis was performed 
using one-way ANOVA and Dunnett’s multiple comparisons post hoc test; * p < 0.05, ** p < 0.01, *** p < 0.001.  
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6.3.4 Oncolytic vector transduction in vitro 
The generated αvβ6 integrin-targeted oncolytic vectors were assessed in 
luciferase assays for their in vitro transduction efficiency to ensure they were capable 
of transducing αvβ6+ cells at equal efficiency to their replication-deficient 
counterparts. As predicted, the OAd5 vector transduced both SKOV3 and SKOV3-β6 
cells at equal efficiency, due to the equal levels of CAR-expression in these two cell 
lines (Figure 6–8). On the contrary, all αvβ6-targeted OAds, with the exception of 
OAd5.HVR7.A20 vector, showed increased transduction in SKOV3-β6 cells as 
compared to the non-αvβ6-expressing parental cell line SKOV3 (Figure 6–8). Most 
importantly, the OAd5.3D.A20 vector exhibited the largest increase of all tested 
viruses in SKOV3-β6 cells relative to SKOV3 cells (> 5-fold increase). We also 
assessed the transduction efficiency at 72 h post-infection. However, a large 
proportion of SKOV3-β6 cells had already died ‒ presumably due to oncolytic activity 
‒ and therefore luciferase expression could not be reliably quantified at this later time-
point (data not shown). Inversely, very low levels of luciferase expression were 
detected at an earlier time-point, at 24 h post-infection (data not shown). 
 
Figure 6–8. Oncolytic vector transduction efficiency in epithelial ovarian cancer cell lines. 
SKOV3 and SKOV3-β6 ovarian cancer cells were infected at 5000 viral particles/cell for 3 h, transgene 
expression quantified 48 h later, and normalised to relative light units/total protein (RU/mg). Error bars 
indicate statistical difference between the two cell lines for each virus. Statistical analysis was performed 
using unpaired, two-tailed T test; ns, p > 0.05; * p < 0.05; ** p < 0.01; *** p < 0.001. 
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6.3.5 Cytotoxicity of oncolytic vectors 
Cell viability assays were utilised to evaluate the cell killing efficiency of the 
oncolytic vectors by a colorimetric MTS assay. Cells were infected in the same 
manner as in regular luciferase transduction assays, but plates were incubated in 
closed humidified containers to prevent the medium from evaporating during the 
lengthy time-course. At time-points 24, 48, 72, 96, 120, 144, 168, 192, 216 and 240 h 
(10 days) post-infection, following the addition of assay reagent, the proportion of live 
SKOV3 cells (Figure 6–9A) and SKOV3-β6 (Figure 6–9B) in each infection well was 
quantified, and normalised to the absorbance in the ‘cells only’ control wells (% cell 
viability). Additionally, BT-20 breast cancer cells were assessed as a representative 
cell line of αvβ6high/CARlow cells (Figure 6–9C). The uninfected control cells remained 
healthily confluent throughout the duration of the experiment.  
At the earliest time-point of 24 h, no cell death was observed for any of the three 
viruses at any viral dose in either cell line (Figure 6–9). At a dose of 1000 vp/cell, 
SKOV3 cells were not remarkably affected by any virus at any time-point, and retained 
close to 100 % viability until day 10 (Figure 6–9A; top panel). At a higher viral dose of 
5000 vp/cell, OAd5 vector had killed up to 50 % SKOV3 cells by day 5 (Figure 6–9A; 
middle panel). However, these cells appeared to have acquired resistance to all of 
the viruses, as they grew back by day 6, and only slowly started dying off again 
towards the end of the time-course. Similar, but more pronounced pattern was 
observed at a viral dose of 25 000 vp/cell, as cells acquired full viability on day 6, 
despite having had only ~ 20 % viability on day 5 (Figure 6–9A; bottom panel). The 
triple de-targeted OAd5.3D.A20 vector was not capable of killing SKOV3 cells at 
doses 1000 and 5000 vp/cell (Figure 6–9A; top and middle panel, respectively). 
However, the vector unexpectedly killed these cells at equal efficiency to OAd5 and 
OAd5.A20 when the cells were saturated with a high dose of 25 000 vp/cell (Figure 
6–9A; bottom panel). The SKOV3-β6 cells seemed to be overall much more sensitive 
to the oncolytic treatment by all three vectors than their parental SKOV3 cells (Figure 
6–9B). Close to 100 % cell death was observed at all viral doses for all three vectors 
by the end of the time-course, on day 10. Oncolysis by OAd5 was shown to be the 
most efficient at viral doses of 1000 and 5000 vp/cell (Figure 6–9B; top and middle 
panel, respectively), while all three viruses were equally efficient at cell killing at the 
highest viral dose of 25 000 vp/cell (Figure 6–9B; bottom panel).  
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Figure 6–9. Cytotoxicity of oncolytic vectors. (A) SKOV3 and (B) SKOV3-β6 epithelial ovarian 
cancer cells were infected with 1000, 5000 or 25 000 viral particles (vp)/cell and (C) BT-20 breast cancer 
cells at 25 000 vp/cell for 3 h. 20 μL of assay reagent (5 % total concentration) was added into each well, 
and absorbance measured at λ490 nm following a 2 h incubation at 37ºC in the dark. Cell viability (%) 
was quantified by a colorimetric MTS assay, relative to the viability of uninfected cells. 
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We also assessed oncolytic activity in the positive control cell line BT-20 to 
demonstrate efficacy in the absence of CAR expression. The Ad5.3D.A20 vector had 
superior cytotoxicity over the OAd5 and OAd5.A20 vectors at the last two time points, 
72 h and 103 h (Figure 6–9C). At the assay endpoint, the viability of cells infected with 
OAd5, OAd5.A20 and OAd5.3D.A20 was 68.4, 46.2 and 35.6 %, respectively. 
6.3.6 Neutralisation by ovarian ascites 
Transduction efficiency of the αvβ6-targeted replication-deficient vectors was also 
assessed in the presence of highly neutralising cell-free ascites OAS001 (see Figure 
3–9 for antibody titres). Cell line BT-20 and EOC004 primary culture were used as 
model cultures for this assay due to their high level of αvβ6 and low level of CAR 
expression. All αvβ6-targeted vectors were shown to transduce BT-20 cells with high 
efficiency at up to 10 % concentration of ascites, the Ad5.3D.A20 vector having 
superior protection from neutralisation compared to all other vectors (Figure 6–10A). 
The other two A20 peptide-carrying vectors had a similar but slightly lower 
transduction efficiency in these cells (Figure 6–10A; open symbols). Vector 
transduction in EOC004 cells again showed that Ad5.3D.A20 was able to transduce 
these cells with high efficiency, resisting neutralisation at up to 5 % concentration of 
ascites (Figure 6–10B). Similar to BT-20 cells, all non-αvβ6-tropic vectors without the 
A20 targeting moiety were completely unable to transduce these cells (Figure 6–10B). 
Despite improved protection, the A20 peptide did not fully help the vectors to evade 
neutralisation, as each of them, including the Ad5.3D.A20, were completely 
neutralised in the presence of 40 % and higher concentrations of ascites in both cell 
cultures (Figure 6–10). Regardless, the A20 targeting moiety enabled efficient vector 
transduction and remarkably increased vector protection from neutralisation by 
immune ovarian ascites.
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Figure 6–10. αvβ6-targeted vector transduction efficiency in the presence of neutralising ascites. (A) BT-20 breast cancer and (B) primary epithelial ovarian cancer 
cells from patient 4 (EOC004) were transduced with 200 000 viral particles/cell in the presence of descending two-fold dilutions of cell-free ovarian ascites (OAS001). Luciferase 
activity was measured 48 h post-infection and relative light units normalised to total protein concentration in each well (RLU/mg). ‘virus’ denotes transduction level in ascites-free 
conditions. 
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6.4 Discussion 
The epithelial-specific integrin αvβ6 is an intriguing cancer marker due to its 
negligible expression levels in healthy adult epithelium (Ahmed et al., 2002b). It is 
rapidly up-regulated during epithelial re-modelling events such as foetal development, 
injury, wound healing and neoplasia (Breuss et al., 1995, Thomas et al., 2006). αvβ6 
is known to be involved in cancer progression by functioning as a key up-stream 
activator of TGF-β1 (Hezel et al., 2012), thereby enhancing cell motility and migration, 
angiogenesis and EMT, among other mechanisms [reviewed in (Khan and Marshall, 
2016)]. It is the main native cellular entry receptor for two positive-strand RNA viruses 
that belong to the Picornaviridae family: FMDV (Miller et al., 2001) that infects pharynx 
and soft palate of hooved cattle (Monaghan et al., 2005), and of coxsackievirus A9 
(CAV-9) that causes respiratory illnesses, infections of the central nervous system 
and myocarditis (Williams et al., 2004, Heikkilä et al., 2009). Both viruses bind αvβ6 
with high affinity via the RGD motif located in the C-terminal extension of their capsid 
protein VP1. αvβ6 has also been suggested to function as a gH/gL receptor of HSV 
by promoting viral endocytosis (Gianni et al., 2013). αvβ6 is constitutively expressed 
in the tongue and interdigital skin epithelium in cattle (Monaghan et al., 2005) but is 
absent in healthy oral epithelia in humans (Thomas et al., 2006). To date, none of the 
Ad serotypes have been shown to use αvβ6 integrin as their native receptor for host 
cell entry. 
This chapter describes the generation, production and functional evaluation of 
Ad5-based vectors targeted to cancer cells that express αvβ6 integrin. The vectors 
have been rendered αvβ6-specific by a genetic incorporation of an A20 peptide 
(NAVPNLRGDLQVLAQKVART) from the capsid protein VP1 of FMDV that has a 
natively high affinity to this receptor (DiCara et al., 2007, Dicara et al., 2008). The 
αvβ6-targeted vectors were successfully grown into high viral titres and assessed for 
their transduction efficiency in suitable cell lines in vitro and in primary EOC cultures 
ex vivo. We have shown that these vectors are efficiently targeted to cellular αvβ6 
integrin in both αvβ6+ cell lines (Figure 6–5) and in αvβ6+ primary EOC ex vivo 
cultures (Figure 6–6). Based on the observations from competition inhibition assays, 
the A20 peptide indeed does efficiently target the vectors to αvβ6 in cells that express 
high levels of the receptor, since cell entry could be efficiently inhibited by previously 
described function-blocking agents, an anti-αvβ6 antibody 10D5 (Weinreb et al., 
2004) and recombinant kn48.Δ13aaDG.A20 protein (Uusi-Kerttula et al., 2016) 
(Figure 6–7). On the contrary, when cellular CAR level is medium or high, and the αvβ6 
level low, the αvβ6-mediated cell entry is outcompeted by CAR-mediated entry for 
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vectors that have natively high affinity to CAR. This observation on the strong affinity 
of Ad5 to CAR underlines the necessity for the accommodation of the CAR-binding 
mutation KO1 into therapeutic vectors in order to avoid non-specific sequestration by 
non-target cells. The combination of KO1 mutation and A20 insertion gave rise to 
vectors that are capable of selectively entering cells with high αvβ6 integrin 
expression. 
We also performed haemagglutination assays to further elucidate the vector 
tropism for CAR, based on the observations that erythrocytes express CAR and can 
therefore trap vectors to the blood stream (Carlisle et al., 2009), possibly impacting 
off-target delivery. Surprisingly, the A20 peptide remarkably decreased vector binding 
to CAR, even in the absence of the CAR-binding ablation, KO1 mutation (Figure 6–
4). Although the A20 peptide is incorporated in a different knob loop (HI loop) than the 
KO1 mutation (AB loop), the spatial conformation of the bulky heterologous peptide 
may physically hinder the access of the CAR-binding residues to the receptor. 
Predictive 3D models created in SWISS-MODEL software (Figure 6–3) did not reveal 
major structural disruptions brought on by the A20 insertion. It is however, important 
to acknowledge that in the absence of high resolution crystallisation data, the models 
are nothing but a ‘best guess’ of the knob structure. Furthermore, the 3D predictions 
did not reliably predict the success of A20 peptide insertion in various different knob 
loops in the knobs of species D serotype vectors either. Despite the favourable-
looking structure of the protruding A20 loop in the HI loop of Ad10 and Ad48 knob 
domain (Figure 6–3), these viruses could not be rescued as functional virions (Table 
6–2). The only exception was Ad48.IJ.A20, whose A20 peptide insertion in Ad48 knob 
loop IJ did not appear structurally favourable in the predictive 3D model, nor did it 
produce a functional virion in vitro. Although Ad vectors are known to be a very flexible 
vector backbone that are known to tolerate large insertions and deletions, it is never 
easy to predict which modifications allow the production of functional virions without 
compromising viral fitness. In this thesis we have shown that both fiber pseudotyping 
and heterologous peptide incorporation can result in highly unpredictable tropisms 
and significantly alter vector functionality. 
In this chapter we describe the generation and assessment of a panel of bi-
functional vectors that are both de-targeted from native interactions, and 
simultaneously re-targeted to αvβ6-expressing cancer cells. Our lead candidate 
vector is Ad5.3D.A20, that has shown simultaneous de-targeting from all native 
interactions (αvβ3/5 integrins, CAR and FX) and efficient re-targeting to αvβ6 integrin 
in vitro and ex vivo. Importantly, cell viability assays showed promising oncolytic 
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activity in the SKOV3-β6 EOC cell line (αvβ6+/CAR+). However, as the Ad5 vector is 
able to enter these due to their CAR-expression, it had superior oncolytic efficacy over 
both of the OAd5.A20 and OAd5.3D.A20 vectors, both in SKOV3 and SKOV3-β6 cells 
(Figure 6–9). Promisingly, the OAd5.3D.A20 showed superior oncolysis in breast 
cancer cell line BT-20 to the non-αvβ6-targeted OAd5 that was not capable of entering 
these cells due to the lack of an entry receptor. This vector presents an exciting 
candidate for anti-cancer vector targeting to αvβ6-positive ovarian cancer and other 
cancer types that express high levels of αvβ6, such as cervical or skin cancer that 
have been shown to have close to 100 % expression of αvβ6 (Koopman Van Aarsen 
et al., 2008). The replication-deficient version of the Ad5.3D.A20 vector was further 
assessed in vivo in a biodistribution study, whose outcomes are discussed in chapter 
7. The oncolytic efficacy of the OAd5.3D.A20 vector will be assessed in an in vivo 
survival study in immunocompromised SKOV3-β6 ovarian cancer xenograft model in 
NOD/SCID mice in spring 2017.  
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CHAPTER 7. In vivo vector biodistribution and generation of an 
ovarian cancer model 
This chapter describes the in vivo characterisation of replication-deficient, αvβ6 
integrin-targeted vectors in wild type non-tumour-bearing B6 albino mice. Vectors 
were administered i.v. and biodistribution in the main off-target organs ‒ liver, spleen, 
lungs, heart and ovaries ‒ was evaluated at 72 h post-infection by the quantification 
of luciferase expression and viral genome copy number by qPCR. Additionally, we 
were interested in assessing the breadth of innate antiviral inflammatory responses 
elicited by the vectors bearing de-targeted mutations in the capsid proteins (described 
in chapter 4), since the literature suggests they should have improved toxicological 
profiles. We have also generated and optimised an i.p. SKOV3-β6 ovarian cancer 
xenograft model in immunocompromised NOD/SCID mice to represent the clinical 
scenario of an advanced intraperitoneally metastasised EOC. The model will be 
utilised for subsequent assessment of oncolytic vector efficacy in a survival study. 
Due to the time limitations, the results from the efficacy study are not discussed in this 
thesis. 
7.1 Biodistribution study in wild type mice 
In this study the biodistribution and tissue tropism of replication-deficient, de-
targeted and αvβ6-targeted Ad5-based vectors was studied in wild type female B6 
albino mice. Mice were allowed to acclimatise for a week, and then challenged with a 
single i.v. injection of 1 × 1011 vp of replication-deficient Ad vectors diluted in a total 
volume of 100 μL of PBS / mouse on day 0. All animals tolerated the virus challenge 
very well, and no treatment-related adverse effects or changes in appearance or 
behaviour were observed. The animals were observed daily, and then sacrificed on 
day 3 by inhalation of CO2. 
7.1.1 Temporal and spatial luciferase expression by IVIS imaging 
Tropism in peripheral tissues following intravascular delivery of the luciferase-
expressing replication-deficient viral vectors was monitored by non-invasive, semi-
quantitative IVIS imaging from live animals at 72 h following systemic delivery. Mice 
were injected i.p. with 200 μL of D-luciferin, rapidly anaesthetised by inhalation of 
isoflurane, and imaged within 5 min of D-luciferin administration one group (n = 5) at 
a time. Luminescence signal (total photons/second/cm2/steradian) was normalised on 
a single representative scale for all images to exclude the negligible levels of 
background luminescence and to limit saturation of the highly luminescent (red) 
areas. Luciferase expression from the viral vectors was variable between treatment 
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groups, and clearly focused within the area of liver and spleen. No luminescence was 
detected in the control group (PBS) animals, while mice treated with the parental 
Ad5.Luc vector had the visibly highest level of luminescence of all treatment groups 
(Figure 7–1). 
 
Figure 7–1. Adenovirus vector biodistribution in live mice at 72 h following systemic delivery. 
Mice were anaesthetised by inhalation of isoflurane, and administered intraperitoneally with 200 μL of D-
luciferin at 15 mg/mL and imaged after 5 min with 1 min exposure in Xenogen IVIS 200 luminescence 
imager. Images were adjusted in Living Image software on a normalised scale 
(photons/second/cm2/steradian). Colours indicate the relative luminescence intensity. 
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Large differences were observed in the total number of photons emitted by the live 
animals in each group (Figure 7–2). The mice injected with the Ad5.KO1 or Ad5.A20 
(p = 0.0224) vectors had overall ~ 10-fold lower levels of luciferase activity compared 
to the animals injected with Ad5.Luc, while mice treated with Ad5.KO1.A20 had similar 
luminescence levels to the Ad5.Luc animals. Both FX-binding -ablated vectors, 
Ad5.HVR7 and Ad5.HVR7.A20, had ~ 10-fold lower average levels of luciferase 
activity as compared to Ad5.Luc. In contrast to all other treatment groups, mice 
infected with the Ad5.3D.A20 vector exhibited extremely low luciferase activity that 
was close to the background luminescence levels (PBS group) and significantly lower 
(p = 0.0006) than luminescence in the Ad5.Luc group. The highest level of 
luminescence in the mice in the Ad5.3D.A20 group was seen in the tail, which was 
the site of vector administration. 
 
Figure 7–2. Total luminescence signal in live mice. The animals were anaesthetised at 72 h post-
infection one group at a time, and imaged in Xenogen IVIS 200 imager within 5 min of intraperitoneal D-
luciferin injection. Luminescence was recorded for each individual mouse as total photons / second in 
each treatment group, and presented on a log10 scale with the mean of control (PBS) group subtracted 
from all values. Data were analysed by Kruskal‒Wallis test and multiple comparisons by Dunn’s post hoc 
test in GraphPad Prism. Error bars represent standard error of the mean; n = 5/group; *, p < 0.05; **, p 
< 0.01; ***, p < 0.001; ****, n < 0.0001; ns, no statistical significance relative to Ad5.Luc group. Baseline 
luminescence for the PBS group is shown as a dotted line. 
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7.1.2 Ex vivo organ luminometry 
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Figure 7–3. Luciferase expression by adenoviral vectors in individual organs. Organs were 
harvested immediately post-mortem and placed in 12-well plates with 2 mL of D-luciferin reagent at 300 
μg/mL. Luminescence signal was detected by the Xenogen IVIS 200 imager with 1 min exposure time. 
The scale was normalised across treatment groups to minimise background luminescence and saturated 
pixels. 
 
Liver, lungs, spleen, heart and ovaries were harvested from mice in groups A, B 
and H (n = 5), while only liver, lungs and spleen were harvested from mice in groups 
C, D, E, F and G (n = 3) post-mortem. Organs were analysed for ex vivo luciferase 
expression to correlate with the pattern seen in in vivo imaging. Intact organs were 
placed on 12-well plates with 1 mL of PBS, 1 mL of D-luciferin added on the top (final 
concentration: 300 μg/mL), and imaged immediately (Figure 7–3). In general, the 
majority of luciferase activity was localised in the liver in all treatment groups, and no 
measurable luminescence was detected in the spleens or other organs by this 
method. We also observed the organs for any possible abnormalities in size or shape. 
Mouse #1 in Ad5.KO1 group had an enlarged spleen (image not shown) but no 
increased luciferase activity was detected in this organ. 
As expected, all harvested organs from mice infected with Ad5.Luc had very high 
levels of luciferase activity (Figure 7–4). The mice infected with the Ad5.3D.A20 vector 
had significantly decreased luminescence in all harvested organs as determined by 
multiple comparisons test relative to Ad5.Luc in the same organs (Figure 7–4A‒E). 
Additionally, the transduction mediated by Ad5.KO1, Ad5.A20, Ad5.HVR7 and 
Ad5.HVR7.A20 was decreased in liver, spleen and lungs, although statistically 
significant difference was not observed relative to Ad5.Luc, potentially due to high 
variability of the data (Figure 7–4A, B, C). Mice infected with Ad5.KO1.A20 had a 
surprisingly high level of luminescence in liver, spleen and lungs ‒ only slightly lower 
than the luminescence in the Ad5.Luc group (Figure 7–4A, B, C). This was 
unexpected, since the level of transduction in both Ad5.KO1 and Ad5.A20 groups was 
lower than in the Ad5.Luc group. Ovaries and heart were harvested only from the 
PBS, Ad5.Luc and Ad5.3D.A20 groups; the Ad5.3D.A20 vector showed significantly 
reduced luminescence signal as compared to Ad5.Luc in both of these organs (Figure 
7–4D, E).
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Figure 7–4. Total 
luminescence in 
individual organs ex vivo. 
(A) Livers, (B) spleens, (C) 
lungs, (D) ovaries and (E) 
hearts were harvested 
immediately post-mortem 
and placed on 12-well 
plates with 300 μg/mL final 
volume of D-luciferin (2 mL 
in PBS). Organs were 
imaged in Xenogen IVIS 
200 imager with 1 min 
exposure and adjusted in 
Living Image software. 
Data were analysed by 
Kruskal‒Wallis test and 
multiple comparisons by 
Dunn’s post hoc test in 
GraphPad Prism. n = 3 or 
5/group; *, p < 0.05; **, p < 
0.01; ***, p < 0.001; ****, n 
< 0.0001; the absence of 
asterisk indicates no 
statistically significant 
difference was observed 
compared to Ad5.Luc 
group. Baseline 
luminescence (PBS group) 
shown as a dotted line. 
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All groups showed decreased luminescence intensity in all harvested organs, as 
compared to Ad5.Luc (Table 7–1). Of all challenge groups, Ad5.3D.A20 exhibited the 
largest differences, most remarkably in liver transduction. On the contrary, the 
smallest differences relative to Ad5.Luc were observed in the Ad5.KO1 challenge 
group, consistent with the redundancy of CAR utilisation by systemically administered 
Ad5. 
Table 7–1. Fold decrease in total luminescence (photons/second) relative to Ad5.Luc. The 
mean luminescence intensity of Ad5.Luc was divided by the mean luminescence in each organ in 
respective groups. ‒, organ not harvested from this group. 
Fold decrease vs. Ad5.Luc  Organ 
Group Liver Spleen Lungs Ovaries Heart 
Ad5.KO1 45 33 36 ‒ ‒ 
Ad5.A20 650 1200 841 ‒ ‒ 
Ad5.KO1.A20 39 2.3 1.2 ‒ ‒ 
Ad5.HVR7 641 694 807 ‒ ‒ 
Ad5.HVR7.A20 152 5500 407 ‒ ‒ 
Ad5.3D.A20 13300 9230 3700 1100 573 
 
7.1.3 Viral genome quantification by qPCR 
Total DNA was extracted from a small section of the harvested organs; 40 ng of 
DNA was then subjected to qPCR. Purified stocks of each virus were used for 
preparation of dilutions for generation of control standard curves. Overall, the highest 
viral copy numbers were observed in the liver, while the viral genome copy number 
was more than 100-fold lower in the spleen and lungs, and lower in the heart and 
ovaries (Figure 7–5). The liver-de-targeted FX-binding ablated vectors ‒ Ad5.HVR7 
and Ad5.HVR7.A20 ‒ showed a dramatic ~ 7000- and ~ 13 000-fold decrease in viral 
genome copy number in the liver, as compared to the parental Ad5 (Figure 7–5A), but 
did not reach statistical significance (p = 0.4708 and p = 0.1836, respectively). The 
αvβ6-re-targeted vectors Ad5.A20 and Ad5.3D.A20 exhibited a dramatic decrease in 
copy number relative to the parental Ad5 ‒ Ad5.3D.A20 showing 7-log (p = 0.0002) 
and 5-log decrease (p = 0.0023) in the liver and lungs, respectively (Figure 7–5A, C), 
while Ad5.A20 had a 6-log (p = 0.0149) and 300 000-fold decrease (p = 0.0009) in 
the respective organs (Figure 7–5A, C). Genome copy number of the Ad5.3D.A20 
vector was reduced down to baseline levels (PBS group) in the heart and ovaries. 
Unexpectedly, the Ad5.KO1.A20 vector showed very high copy number levels in liver, 
spleen and lungs (Figure 7–5A, B, C). 
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Figure 7–5. Quantitative PCR (qPCR) for adenovirus genome copy number following systemic 
vector delivery. Total DNA was extracted from (A) liver, (B) spleen, (C) lungs, (D) heart and (E) ovaries 
(~ 10 mg of spleen, ~ 25 mg of other organs) and 40 ng subjected to qPCR using hexon-specific primers. 
Data in (A‒C) were analysed by Kruskal‒Wallis test and multiple comparisons by Dunn’s post hoc test; 
two-tailed unpaired T test was performed in (D‒E) in GraphPad Prism. Error bars represent standard 
error of the mean; n = 5/group; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, n < 0.0001; the absence of 
asterisk indicates no statistically significant difference was observed compared to Ad5.Luc group (black 
bars). 
7.1.4 Immunohistochemistry on paraffin tissue sections 
Formalin-fixed paraffin-embedded liver tissue sections were stained by 
immunohistochemical methods to visualise the localisation of viral particles within the 
tissues. After re-hydration in a series of xylene and ethanol washes, antigen retrieval 
by proteinase K treatment and hydrogen peroxide quenching, the sections were 
blocked in normal 2.5 % horse serum for 1 h. After washing with PBS, sections were 
incubated with primary rabbit antibodies O/N at 4ºC and a secondary α-rabbit IgG-
HRP conjugate for 30 min. DAB substrate was added for 3 min, and sections 
counterstained in haematoxylin for a brief 15 s as a standard 60 s wash stained the 
tissues too dark. After a serial de-hydration in ethanol and xylene washes, the 
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sections were mounted and images taken under a light microscope at 10 x, 20 x and 
40 x magnification.  Using a rabbit IgG as a control antibody, we could optimise the 
protocol to yield as low background staining as possible. Liver tissues were shown to 
express very high levels of CAR, as the whole tissue section acquired a brown tone; 
the strongest staining was observed in the structures lining the cell membranes 
(Figure 7–6A). As expected, no expression of αvβ6 integrin was observed in the livers 
(Figure 7–6A). Livers from mice infected with Ad5 and Ad5.3D.A20 vectors showed 
remarkably variable staining patterns. The representative mouse #5 from the Ad5 
treatment group had strongly stained infected cells throughout the section, while no 
infected cells could be found in the liver of the Ad5.3D.A20-infected animal #5 (Figure 
7–6B). Data from other animals in these or other treatment groups is not shown here. 
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Figure 7–6. Immunohistochemical staining of paraffin-embedded mouse liver sections. Formalin-fixed and paraffin-embedded liver sections were stained for (A) 
haematoxylin/eosin (H & E), rabbit control IgG (1 μg/mL), α-CAR antibody (1:100) or α-αvβ6 antibody (1:10). (B) Liver sections from mouse #5 infected with Ad5 vector and mouse 
#5 infected with Ad5.3D.A20 vector were stained with anti-Ad5 antibody (1 μg/mL) and imaged at 10 x, 20 x and 40 x magnification. Sections were blocked in normal 2.5 % horse 
serum for 1 h at room temperature, stained with primary antibodies O/N at 4ºC, incubated with horse anti-rabbit IgG-HRP for 30 min, counterstained with haematoxylin for 15 s, 
and developed in DAB substrate for 3 min. Images were acquired in Leica DMC 2900 light microscope.
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7.1.5 Cytokine screening 
100 μL of blood was collected from each mouse at 6 h and 24 h post-treatment 
from the submandibular vein via a cheek puncture. Plasma was separated from whole 
blood by centrifugation and cytokine screening performed from by Dr Angela 
Bradshaw at University of Glasgow, UK. Twenty-three different cytokines and 
chemokines were assessed from 30 μL of plasma in duplicate using an automated 
bead-based Luminex multiplex array (Figure 7–7). Analyte concentrations are in 
shown as picograms per μL of sample, and were further normalised to total protein 
concentration in each sample (pg/mg). Furthermore, the mean of the control (PBS) 
group was subtracted from each value to directly reflect the Ad vector-driven 
response. At 6 h post-injection, overall highest concentrations of all cytokines were 
observed for MCP-1, followed by G-CSF and eotaxin (Figure 7–7; images 1/4 and 
2/4). Large intra-group variation was observed in the cytokine concentrations, which 
is why only very few statistically significant differences were observed between 
treatment groups at the 6 h time-point. The Ad5.KO1 vector was the only one to elicit 
significantly lower levels of IL-12p70 as compared to the Ad5 vector (p = 0.0472). 
Conversely, the Ad5.HVR7.A20 vector was the only one to elicit significantly higher 
levels of MIP-1α relative to Ad5 (p = 0.0477) (Figure 7–7; image 2/4); no statistically 
significant differences were observed for any of the other analytes at the 6 h time-
point. 
At 24 h post-injection, the overall levels of all chemokines and chemokines were 
remarkably lower than at the 6 h time-point; for instance, the level of MCP-1, whose 
concentration was the highest at 6 h, had decreased > 100-fold (Figure 7–7; image 
4/4). The Ad5.3D.A20 vector elicited significantly higher levels of IFN-γ and IL-6 (both 
p = 0.0436) (Figure 7–7; image 3/4), while Ad5.HVR7 elicited significantly higher 
levels of IL-13, relative to Ad5 (p = 0.0436) (Figure 7–7; image 4/4). The level of IL-
β1 was significantly lower for Ad5.KO1 (p = 0.0288) (Figure 7–7; image 3/4), while 
the level of RANTES was significantly lower for Ad5.3D.A20 (p = 0.0118) relative to 
Ad5 (Figure 7–7; image 4/4). Additionally, vectors Ad5.KO1, Ad5.A20 and 
Ad5.3D.A20 showed significant reduction of KC (p = 0.0026, p = 0.0394, p = 0.0026, 
respectively), and MCP-1 (p = 0.0288, p = 0.0260, p = 0.0390, respectively) relative 
to the Ad5 vector at the 24 h time-point (Figure 7–7; image 4/4).
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Figure 7–7. Cytokine screen at 6 h and 24 h following systemic delivery of replication-deficient vectors. 40 μL of mouse plasma was subjected to automated magnetic 
bead-based Luminex array in duplicate. Eosinophil chemoattractant (eotaxin), granulocyte colony-stimulating factor (G-CSF); granulocyte-macrophage colony-stimulating factor 
(GM-CSF); interferon γ (IFN-γ); interleukin (IL) -1α, -1β, -2, -3, -4, -5, -6, -9, -10, -12p40, -12p70, -13, -17; keratinocyte chemoattractant (KC); monocyte chemotactic protein 1 
(MCP-1); macrophage inflammatory protein 1 (MIP-1) α and β; chemokine ligand 5 (RANTES); tumour necrosis factor α (TNF-α). Horizontal line inside the box shows the median; 
‘+’ shows the mean, and each dot is an individual animal; n = 5 animals/group. The mean of control (PBS) group was subtracted from all values; the number below each box 
shows the fold change relative to the mean of Ad5 group (black box). Cytokine concentration (pg) was normalised to total protein in the sample (mg) by BCA assay. Data were 
analysed using non-parametric Kruskal‒Wallis test with Dunn’s multiple comparisons post hoc test in GraphPad Prism; *, p < 0.05; **, p < 0.01.
4/4 
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7.2 Generation of an ovarian cancer model in immunocompromised mice 
A small pilot study was performed in immunocompromised NOD/SCID mice to 
evaluate tumour growth rate, and to optimise a treatment schedule and final endpoint 
for a subsequent oncolytic efficacy study. 1 × 107 SKOV3-β6 cells in PBS were 
implanted i.p. in eight mice on day 0. Mice were monitored daily and weighed every 
seven days to record the development of tumour mass and build-up of malignant 
ascites. Mice were sacrificed at pre-determined time-points and tumours harvested. 
7.2.1 Tumour growth rate and development of ascites 
Two mice were sacrificed at days 7, 14, 21 and the final two mice on days 48 and 
49. No weight changes were observed over the course of the study. The last two mice 
were sacrificed due to high tumour burden and build-up of ascites; this was the pre-
determined endpoint of the study. Tumour size increased gradually during the study 
(Figure 7–8). On days 7 and 14 all mice carried a small tumour at the size of tumour 
cell implantation, as well as a larger tumour on the side of the pancreas. The mice 
that were sacrificed on day 14, additionally had a few very small micro tumours 
between the lobes of the liver. By day 21 both large tumours had grown, and the micro 
tumour mass within the liver lobes had increased in both volume and number, and 
had spread to a larger area. The last two mice were very ill on the day of euthanasia. 
These animals had a visibly extended stomach, tumour growth throughout the 
peritoneum, purple colour of the skin on the stomach; they were also moving slowly 
and looking pale. Additionally, in these mice the tumour at the injection site was so 
large that it was even palpable through the skin. We also monitored the build-up of 
malignant ascites within the course of tumour growth. The mice that were sacrificed 
at days 7, 14 and 21 were not found to have any ascites in the peritoneum. On the 
contrary, the last two severely ill mice had a volume of 2.6 mL of bloody ascites at the 
time of euthanasia.  
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Figure 7–8. Tumour growth in the intraperitoneal SKOV3-β6 ovarian cancer model. Eight female 
NOD/SCID immunocompromised mice were implanted with 1 × 107 cells in 100 μL PBS by an 
intraperitoneal injection on day 0. Tumour growth and ascites build-up was monitored by sacrificing two 
mice at each time-point: days 7, 14, 21 and 48/49 (endpoint) and by harvesting every individual solid 
tumour from each mouse. 
 
7.2.2 Expression of CAR and αvβ6 in the harvested tumours 
The expression levels of CAR and αvβ6 integrin receptors were assessed by flow 
cytometry. It is important to verify that the retrovirus-transfected SKOV3-β6 tumour 
cells maintain an adequate level of αvβ6 expression even in the non-selective 
peritoneal environment (ie. no puromycin) of live mice. The harvested tumours were 
pooled together from each mouse and homogenised though a cell strainer. The 
recovered cells were washed in 1 % FBS/PBS and stained with primary anti-CAR and 
anti-αvβ6 antibodies and secondary goat anti-mouse IgG AlexaFluo647 conjugate. 
Gating was performed with in vitro grown SKOV3-β6 cells, and 10 000 events 
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recorded for cells from each mouse. The expression of αvβ6 decreased by 1.4 %, 6.4 
%, 12.0 % and 6.4 % over the time of 7, 14, 21 and 48/49 days, respectively (Figure 
7–9). The level of CAR expression, however, remained virtually unchanged 
throughout the study. 
 
Figure 7–9. Expression of coxsackie and adenovirus receptor (CAR) and αvβ6 integrin in 
SKOV3-β6 cancer model over time. Tumour cells were pooled together from each mouse immediately 
after euthanasia, and stained for CAR and αvβ6 surface markers. 10 000 cells/animal were analysed in 
FACSAria flow cytometer and images edited in FACSDiva software. Mean % shows the average 
expression of CAR (red) and αvβ6 (green) at each time-point. 
 
7.3 Discussion 
The first objective of this chapter was the assessment of the biodistribution profile 
of αvβ6-targeted replication-deficient vectors with single, double or triple de-targeting 
mutations in wild type mice. We used the inbred albino B6 mouse strain due to its 
white coat colour, which allowed better luciferase signal detection using the IVIS 
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imager, compared to the widely used laboratory strain C57BL/6 that has a black coat. 
These two strains are genotypically equal, except for the albino phenotype as a result 
of a spontaneous mutation in the tyrosinase gene. Live mouse imaging produced 
noteworthy luminescence data with inter-group variation (Figure 7–1). As expected, 
and in accordance with previous observations, Ad5.Luc mediated saturating level 
luminescence signal within the upper abdominal area where liver and spleen are 
located. All other treatment groups had lower luminescence originating from this area. 
Groups Ad5.A20 and Ad5.3D.A20 had and 784- and 19 100-fold lower number of total 
photons (p = 0.0046 and p < 0.0001, respectively). Despite visibly lower luminescence 
signal observed relative to Ad5.Luc, other groups did not quite reach statistical 
difference (Ad5.HVR7, p = 0.0625; Ad5.HVR7.A20, p = 0.0523), presumably due to 
wider intra-group variability (Figure 7–2). The total luminescence of mice in 
Ad5.KO1.A20 group was unexpectedly high compared to Ad5.KO1 and Ad5.A20 
groups that had greatly lower luminescence than Ad5.Luc. The finding suggests that 
the combination of KO1 mutation and A20 peptide may somehow be capable of 
rescuing liver and/or spleen uptake via a yet unknown mechanism that we cannot 
explain ‒ warrants further investigation. 
We then examined individual organs for luminescence signal emitted by the viral 
vectors that had been taken up by the tissues. All harvested tissues seemed to have 
taken up large amounts of the parental Ad5.Luc virus, which had stronger signals than 
any other treatment group in all organs (Figure 7–3). In contrast, the triple de-targeted 
and αvβ6-re-targeted vector Ad5.3D.A20 exhibited a greatly reduced tropism relative 
to the parental Ad5.Luc. It was the only vector whose transduction was significantly 
lower in all harvested tissues as compared to Ad5.Luc (Figure 7–4). While the KO1 
mutation and the HVR7 mutation alone reduced luciferase signal in the liver by 45- 
and 641-fold, respectively, and in the spleen by 33- and 694-fold, respectively, the 
combination of these two, together with the αvβ3/5 integrin-binding ablation mutation 
RGE and the A20 targeting peptide, efficiently de-targeted the vector from these 
organs (13 300-fold reduction in the liver and 9230-fold reduction in the spleen, 
relative to Ad5.Luc) (Table 7–1). The luminescence signal in the Ad5.3D.A20 group 
was significantly lower in both heart (1100-fold decrease) and ovaries (573-fold 
decrease) than in the Ad5.Luc group (both p < 0.01) ‒ these organs were not 
harvested from the other treatment groups (Figure 7–4 and Table 7–1).  
The presence of viral vectors was also evaluated by qPCR from a piece of each 
harvested tissue ‒ the liver, spleen, lungs, heart and ovaries (Figure 7–5A). Very high 
levels of Ad5 were confirmed in all harvested organs. Overall, the highest genome 
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copy numbers were quantified in the liver, followed by a ~ 100-fold reduction in the 
spleen and lungs, and considerably less in the heart and ovaries, consistent with 
previous findings that the majority of Ad5 ends up in the liver within hours of systemic 
administration (Smith et al., 2002, Green et al., 2004). The liver-de-targeted, FX-
ablated vectors Ad5.HVR7 and Ad5.HVR7.A20 showed a significant ~ 7000- and ~ 
13 000-fold decrease in liver transduction relative to the parental vector Ad5.Luc, 
respectively (Figure 7–5). Intriguingly, the triple-de-targeted Ad5.3D.A20 vector 
showed significantly altered biodistribution compared to all other viruses. The genome 
copy numbers of this vector were significantly lower than the levels of Ad5.Luc in all 
harvested organs, with a substantive and significant 7-log decrease in the liver (Figure 
7–5A) and 5-log decrease in the lungs (Figure 7–5C). Unexpectedly, the combination 
of KO1 mutation and A20 peptide insertion seemed to rescue vector transduction, as 
the genome copy numbers of this vector were higher than for either of the parental 
vectors, Ad5.KO1 or Ad5.A20 (Figure 7–5A‒C). In fact, the Ad5.A20 vector exhibited 
significantly lower genome copy numbers (6-log, 7887-fold and 300 000-fold decrease 
in the liver, spleen and lungs, respectively) compared to the Ad5.Luc vector, showing 
similar transduction pattern to the fully de-targeted vector, Ad5.3D.A20 (Figure 7–5A‒
C). 
We then went on to further verify the presence of Ad5.Luc vector and the absence 
of the Ad5.3D.A20 vector particles in the liver by performing a series of IHC staining 
procedures on formalin-fixed paraffin-embedded tissue slides. First, we confirmed the 
expression of CAR in the liver, as seen as an intense staining throughout the tissue, 
and particularly focused at the borders lining the cellular junctions (Figure 7–6A). 
Second, we confirmed the lack of expression of αvβ6 integrin in these tissues (Figure 
7–6A), as expected. Liver sections from mouse number #5 in Ad5.Luc group and 
mouse #5 in Ad5.3D.A20 group were stained using an antibody that recognises all Ad 
capsid proteins (immunogen: purified Ad5). Clear differences were observed in the 
staining pattern; sections from Ad5-infected mice demonstrating strong staining 
throughout the tissue, whilst little or no staining was observed in the sections from the 
Ad5.3D.A20-infected animals (Figure 7–6), confirming the observations from 
luminescence imaging and qPCR. Ad5.3D.A20 vector appears to be efficiently de-
targeted from all major off-target sites for the native Ad5 virus, as confirmed by all 
three distinct analyses ‒ luminescence, qPCR and IHC-P. Ad5.3D.A20 represents an 
exciting candidate for therapeutic applications, and warrants further investigation. 
The secondary objective of this study was the evaluation of the breadth of innate 
anti-viral immune responses. Following systemic delivery, Ads are known to elicit high 
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levels of cytokines and chemokines, primarily via recognition of viral RNA and DNA 
sequences by the inflammasome (Muruve et al., 2008) and cytosolic defensins (Smith 
et al., 2010). Additionally, the RGD motif in the Ad penton protein has been previously 
shown to be involved in the activation of immune cells ‒ DCs and MΦs (Worgall et 
al., 2004, Schoggins and Falck-Pedersen, 2006, Di Paolo et al., 2009) ‒ as well as 
innate cytokines, such as IL-1α, IFN-γ, IP-10, TNF-α and MIP-1 (Schoggins and 
Falck-Pedersen, 2006, Di Paolo et al., 2009). In this study, we showed that the 
parental Ad5.Luc had activated 21 out of 23 cytokines quantified in this assay by the 
6 h time-point, whilst levels returned to baseline by 24 h post-injection (Figure 7–7). 
No IL-4 or IL-17 was detected in any treatment group at either time-point. Levels of 
different analytes were highly variable between treatment groups; no trend was 
observed for any vector for having elicited consistently lower or higher levels of 
specific analytes. The inclusion of the RGE mutation in the penton base protein has 
previously been shown to reduce the production of innate inflammatory markers in 
vivo (Bradshaw et al., 2012). Following i.v. delivery of the AdRGE vector in non-MΦ-
depleted animals, in addition to decreased splenic uptake of the vector, significantly 
decreased levels of IL-12, IL-5, IL-6, IL-1α, IL-1β, IP-10 and MCP-1, relative to Ad5, 
were observed (Bradshaw et al., 2012). Additionally, in their study the levels of IL-12, 
IL-6 and IL-1α were significantly reduced in these animals, relative to the AdT* vector 
with an FX-binding mutation, whilst in MΦ-depleted animals, the levels of IL-12, IP-
10, IFN-γ and MCP-1 were significantly reduced for AdT*RGE compared to AdT*. We 
were therefore interested in assessing the impact of these de-targeting mutations on 
the breadth of immune response in our biodistribution study following systemic 
delivery of the triple-de-targeted, replication-deficient Ad5.3D.A20 vector. 
Disappointingly, however, Ad5.3D.A20 vector did not appear to show any overall 
decreased activation of innate immunity in this study. At 6 h following vector injection, 
no significant decrease was observed for any analyte as compared to Ad5. On the 
contrary, the levels of RANTES, KC and MCP-1 were significantly lower than for Ad5 
at the 24 h time-point (Figure 7–7; image 4/4). However, the overall levels of these 
analytes were very low, which is why the observed variation may be negligible, and 
drawing any solid conclusions at this time-point is challenging. In their seminal paper, 
Di Paolo and colleagues suggested the central involvement of IL-1α on anti-Ad 
immunity (Di Paolo et al., 2009). In our study, the Ad5 and Ad5.HVR7.A20 vectors 
activated equal levels of IL-1α, while the Ad5.KO1.A20 elicited 1.8-fold increased 
levels compared to Ad5; the levels of this cytokine were negligible in all other 
treatment groups (Figure 7–7).  
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Activation of innate immune mediators may be dependent on the genetic 
background of the experimental mouse strain [for alloantigens of common strains, see 
(BioLegend, 2017)]. Bradshaw and colleagues utilised an outbred MF1 strain for their 
investigations on innate anti-Ad immunity (Bradshaw et al., 2012), while Di Paolo and 
colleagues used various knockout strains, all of which were based on the inbred 
C57/BL6 genetic background (Di Paolo et al., 2009) In our study, we used an inbred 
B6 albino strain that is coisogenic to the C57/BL6 strain. Outbred animals are 
genetically diverse with polymorphic MHC alleles, in contrast to inbred strains that 
have homozygous MHC haplotypes (C57/BL6 strain: H-2b). The differences in 
cytokine production may also depend on inherent differences in the polarised Th1 and 
Th2 subpopulations of helper T cells in each mouse strain. While the Th1 arm ‒ that 
produces IFN-γ, TNF-α, IL-2, IL-12 ‒ is involved in fighting off viral infections (among 
other cell-mediated immune functions) and Th2 ‒ that produces IL-4, IL-5, IL-6, IL-9, 
IL-10 and IL-13 ‒ drives humoral immunity, the arms can also down-regulate each 
other [reviewed in (Romagnani, 2000, Kidd, 2003)]. The use of outbred mice may 
therefore be preferable, since they better represent the clinical scenario where study 
participants have highly variable genetic backgrounds with an unpredictable influence 
on the study outcome. 
These preliminary in vivo studies form an important part of the functional 
assessment of these replication-deficient vectors that offer a safe and clean system 
for the assessment of Ad vector tropism and biodistribution. We demonstrate that the 
biodistribution of de-targeted vectors was altered in comparison to the parental 
Ad5.Luc that does not carry any de- or re-targeting mutations. When studying 
biodistribution profile of human viruses in mouse models, it is important to recognise 
the limitations of the models and how they do not accurately represent the clinical 
scenario. One of the key differences is that human, but not murine, erythrocytes 
express CAR on the cell surface (Carlisle et al., 2009). To better reflect this difference 
in receptor distribution, and the resulting change in biodistribution, we manipulated 
our vectors to be devoid of CAR-interaction by the introduction of the KO1 mutation. 
However, as Ad5 is known to preferentially transduce cells via the FX:HSPG bridging 
interaction rather than the CAR-mediated pathway in vivo (Waddington et al., 2008, 
Alba et al., 2009), we incorporated an HVR7 mutation in the hexon protein, that was 
shown to significantly abolish the FX-mediated pathway in vitro and to drastically 
decrease liver transduction in vivo. Additionally, we set out to explore whether the 
expression of αvβ6 may be different in mice than in humans, where it is found only at 
negligible levels in healthy epithelia. Reassuringly, the luciferase expression pattern 
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observed in the biodistribution did not show any altered tropisms for the αvβ6-targeted 
vectors to any unexpected off-target sites (Figure 7–1). The observations indicate that 
αvβ6 is not expressed in healthy mouse tissues, as the A20 peptide did not detectably 
alter vector biodistribution or direct the vector to any organs that have not previously 
been unidentified for Ad5-based vectors. Evidently, we only quantified viral genome 
copy numbers in organs that have previously been known to be involved in Ad5 
tropism, and therefore cannot rule out sequestration by other sites. However, as most 
of the luciferase signal originated from the area of liver and spleen in the IVIS imaging, 
we could not justify further exploration of other organs. 
The third objective of this chapter was the generation of an i.p. ovarian cancer 
xenograft model in immunocompromised mice. Previous studies have shown that in 
a SKOV3 ovarian ascites i.p. model using a dose of 1 × 107 cells/animal, the mice 
start building up ascites around day 40. From the onset of ascites build-up, the 
animals will generally have to be sacrificed within a week due to their very poor health 
(personal communication with Ianko Iankov, Mayo Clinic, MN, USA). We chose this 
cell dose based on communication with research groups that had been working on 
the same cell line. We showed that the cell dose was optimal for generation of a 
severely ill model within 40 days. The study endpoint was reached on day 49, when 
the last mouse had to be sacrificed due to excess tumour burden and ill health. 
Previous studies have shown that the cells slowly lose αvβ6 expression in vivo, over 
longer time periods (personal communication with Dr Lynda Coughlan, University of 
Oxford). We therefore assessed the expression of αvβ6 integrin from tumour cells 
harvested at each study time-point. No obvious decrease was observed in the levels 
of αvβ6 or CAR during the duration of the study. This is reassuring since the absence 
of a suitable cell receptor would severely compromise the efficacy of therapeutic Ad 
vectors.  
Based on the observations from this preliminary pilot study, we have established a 
protocol for a follow-up study that will assess the oncolytic efficacy of αvβ6-targeted 
vectors in the SKOV3-β6 ovarian cancer xenograft model. Mice will be treated with 
three doses (1 × 1010 vp each) of the oncolytic vectors OAd5, OAd5.A20 and 
OAd5.3D.A20 on days 14, 16 and 18 post-tumour implantation. The primary outcome 
of this study will be overall survival. The study is scheduled for spring 2017, and will 
be carried out at Dr Richard Vile’s laboratory (Department of Molecular 
Medicine/Immunology at Mayo Clinic, Rochester, MN, USA). 
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CHAPTER 8. Final discussion 
The cancer field is in a flux with the clinical maturation of immunotherapies and 
precision medicine approaches manifesting in significant changes to cancer treatment 
in the coming years. Immunotherapies are revolutionising the field, and their usage is 
rapidly becoming the mainstream in the treatment of aggressive immunological 
cancers such as melanoma. Sequencing of the cancer exome has produced a wealth 
of genomic data that has yet to be dissected into a clinically meaningful information. 
Growing knowledge on cancer antigens and neoantigens in individual cancer types, 
and at the population level, will help tailor the therapies towards targeted and 
personalised therapies. Antigen cross-presentation is likely to be an important aspect 
in therapeutic design, since tumours are an ever-evolving environment of original 
malignant cells, TILs, cancer-initiating cells and the supporting TME. The key 
questions in cancer immunotherapies persist: how to successfully break the anti-
cancer immune tolerance and to enable long-lasting cures by re-programming the 
body for a permanent attack against malignant cells? Oncolytic cancer virotherapies 
are an appealing approach due to their dual functionality as direct tumour cell killers 
and systemic immune stimulators. 
The primary focus of this thesis lies on the development of Ad vectors for ovarian 
cancer-targeted virotherapies. Treatment options for ovarian cancer are evidently 
insufficient at present. The malignancy commonly presents with highly non-specific 
symptoms, which leads to delayed initial diagnosis, allowing the development of 
advanced stage disease that rapidly develops resistance to first-line platinum-based 
chemotherapies. Despite the new PARP inhibitors for Brca+ ovarian cancer, tumour 
relapse and progression commonly occur, causing ovarian cancer to be the deadliest 
of gynaecological cancers. Late disease stages are characterised with intraperitoneal 
build-up of malignant ascites that provides a highly pro-tumourigenic environment, 
facilitating tumour spread and metastasis. EOC cells that are shed from the surface 
of the ovarian epithelium, can reside in ascites as a resistant population with the ability 
of acquiring invasive properties and initiating new lesions. Any novel treatment 
strategy therefore needs to be able to radically eradicate these populations and CSCs. 
Currently, one of the most promising approaches is the combination of conventional 
treatment moieties ‒ re-bulking surgery, radiotherapy and chemotherapy ‒ with new 
innovations, such as immunotherapeutic mAbs and oncolytic virotherapies. The key 
dogma is combating cancer tolerance and ensuring efficient cell killing, by 
simultaneous elicitation of long-lasting cancer-specific immune memory. 
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Oncolytic Ad vectors can be developed as bespoke personalised in situ cancer 
vaccines ‒ capable of potent and selective oncolysis and replication within the tumour 
mass. Viral amplification bursts the infected cells, releasing the virus progeny that can 
infect surrounding tumour cells, theoretically multiplying the lytic effects, whilst acting 
as a factory for the production of therapeutic molecules in neighbouring cells. No other 
anti-cancer therapy can match this selectivity and power for therapeutic amplification. 
Release and display of viral-associated antigens and TAAs by the bursting cells can 
prime T-cells, eliciting a long-lasting tumour-specific immunological memory that will 
potentially protect the body from a subsequent tumour challenge later in life, as well 
as providing an immunological means for tumour killing at distant metastatic sites. 
Tumour cells could also be primed using focused ultrasound (Mo et al., 2012, Carlisle 
et al., 2013) or cytotoxic agents to weaken them for subsequent oncolysis and release 
of TAAs for immune recognition. Systemically administered oncolytic virotherapies 
have great potential to be used for tracing and attacking both primary and metastatic 
tumour cells that radio- or chemotherapies cannot reach, virtually in all sufficiently 
vascularised tissues of the body. Direct and local therapeutic vector delivery into the 
tumour location, such as the peritoneal cavity in ovarian cancer, provides an 
appealing alternative treatment route. By this approach, the therapeutic vector can 
spread within the peritoneum and reach both the primary tumour and peritoneal 
metastases, which would also allow at least partial circumvention of the efficacy-
limiting blood interactions. However, as systemic delivery remains the ‘Holy Grail’ of 
cancer virotherapies, vigorous development of therapeutic vectors, based on better 
understanding of the interactions that limit efficacious viral delivery and promote dose-
limiting toxicities, has substantially improved Ad-based vectors in recent years. To 
this end, we developed de-targeted vectors devoid of central interactions with viral 
receptors and blood factors, that may limit uptake in healthy tissues and act as a 
platform for targeted delivery to disease sites in vivo, through the incorporation of 
suitable elements into the viral capsid.  
We have extensively assessed the properties of malignant ovarian ascites and the 
potential hindrances for efficient vector treatment in this complex tumour environment. 
Valuable clinical ascites samples provided an excellent opportunity for the 
assessment of vector targeting in the ex vivo setting. Twenty ascites samples from 
Velindre Cancer Centre in Cardiff were assessed for multiple characteristics in vitro 
and ex vivo. We found that the concentration of FX was highly variable among the 
twenty samples, approximately half of the fluid samples having an FX concentration 
lower than that of a physical concentration in whole blood (8 μg/mL), and the other 
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half having up to 10-fold higher FX concentration than whole blood. The highly 
variable FX concentration may have important implications for Ad vector delivery via 
the i.p. route, since the high affinity of Ad5 to FX can promote off-target uptake into 
cells via HSPG receptors, and subsequent toxicity. To this end, we have approached 
the vector development with two strategies: (1) introduction of genetic FX-binding 
ablating HVR7 mutations in the viral hexon protein of Ad5 (Alba et al., 2009), and (2) 
generation of a novel Ad10 serotype vector backbone from species D, whose 
members have previously been shown to have natively low affinity to FX (Waddington 
et al., 2008). The HVR7-binding ablation mutation was shown to efficiently block the 
Ad5:FX -interaction for a panel of basal vectors both in vitro and in vivo following 
systemic vector delivery in wild type B6 albino mice. Additionally, a novel vector 
candidate that has not previously been vectorised – Ad10 – was shown to be devoid 
of FX binding, confirmed by in vitro transduction assays supplemented with 
physiological concentrations of FX. Additionally, this serotype has lower tropism for 
CAR relative to Ad5, and does not seem to utilise CD46 for cell entry. However, Ad10 
may utilise these receptors as auxiliary rather than primary cell entry receptors, and 
further studies are needed to elucidate the primary receptor interactions, tropism and 
oncolytic potential of this exciting new vector candidate. In line with previous 
observations, ovarian ascites also contains high levels of anti-Ad5, with lower but 
detectable levels of anti-Ad10 antibodies in the limited samples we tested. We also 
assessed the antigenicity of these antibodies, and found that most of them appear to 
be directed towards the viral Ad5 fiber protein, while the level of anti-hexon antibodies 
was lower. Additionally, the transduction of Ad5 vector was more readily neutralised 
by ascites than the rare species D serotype Ad10. 
While Ad5-based vectors primarily utilise the hexon:FX:HSPG pathway for cell 
entry following systemic delivery, their in vitro tropism is dictated by binding to CAR. 
This ubiquitously expressed receptor is found within cellular tight junctions co-
localised with ZO-1 [reviewed in (Coyne and Bergelson, 2005)], ubiquitous in human 
tissues. Importantly, it is commonly down-regulated in progressive cancers (Li et al., 
1999b, Pearson et al., 1999, Asaoka et al., 2000, You et al., 2001, Kim et al., 2002a, 
Kim et al., 2002b), which makes it a poor cancer target. Moreover, as CAR is 
expressed on erythrocytes and platelets (Carlisle et al., 2009), it has been proposed 
that the high affinity of Ad5 to this receptor may trap the vector in the bloodstream and 
limits its availability to the therapeutic target sites, although this appears controversial 
(Rojas et al., 2016). For the ablation of CAR-tropism, we manipulated our vectors to 
contain a KO1-mutation in the fiber AB loop, which was shown to abolish CAR-
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mediated cell entry, in line with previous literature (Smith et al., 2002). As the CAR-
interaction, orchestrated by the fiber knob domain, is a highly undesirable feature for 
a cancer vector, we have generated a panel of chimaeric vector backbones by 
pseudotyping the whole fiber or the fiber knob domain form six different Ad serotypes 
from subgroup D ‒ Ad10, -15, -24, -29, -48 and -53 ‒ to evaluate their potentially 
favourable tropism profiles. The receptor tropisms of these rare seroprevalence 
serotypes are largely unknown to date. None of the whole fiber-pseudotyped vectors 
seemed to utilise CAR for cell entry, while the knob-pseudotyped Ad5/kn10, -15, -24, 
-48 (and possibly Ad5/kn29) seemed to be able to use CAR, albeit at remarkably 
lower efficiency than the parental Ad5. While FX improved transduction efficiency of 
the knob-pseudotyped vectors, the poor efficiency of the whole fiber-pseudotypes in 
the tested cell lines may be explained by altered or delayed endosomal processing 
due to the rigidity and/or suboptimal length of the fiber. 
Successful anti-cancer Ad vector design involves complementation of refined de-
targeting approaches with selective re-targeting to markers that are exclusively 
cancer cell-specific. In this study, a comprehensive panel of Ad vectors re-targeted to 
αvβ6 integrin – an epithelial cancer-specific marker – were generated by using 
sophisticated homologous recombineering techniques. An A20 peptide from FMDV, 
that has natively high affinity to αvβ6 integrin, was genetically engineered into the viral 
fiber knob domain. A significant outcome of this project is the generation of a triple 
de-targeted and αvβ6-re-targeted vector Ad5.3D.A20, that has superior transduction 
in αvβ6+ cancer cell lines. The vector was shown to exclusively utilise αvβ6 receptor 
for host cell entry, and had completely ablated native interactions with FX, CAR and 
αvβ3/5 integrins, as a result of the well-documented de-targeting mutations ‒ HVR7, 
KO1 and RGE, respectively. To our knowledge, we are the first ones to report the 
successful generation of an infectious vector with fully ablated native tropisms and 
simultaneous cancer re-targeting. It is noteworthy that we were unable to rescue the 
control virus, Ad5.3D, whose viral fitness is likely to be severely hampered due to 
ablation of all central viral tropisms. By incorporation of the targeting peptide A20, we 
were able to rescue infectious virions in HEK293-β6 puro cells with stable expression 
of the αvβ6 integrin. Both replication-deficient and oncolytic versions of this vector 
were shown to be selectively targeted to αvβ6+ ovarian cancer cell lines in vitro and 
αvβ6+ primary ovarian ascites-derived EOC cells ex vivo. Furthermore, the 
Ad5.3D.A20 showed improved protection from neutralisation by immune ovarian 
ascites, and promising oncolytic activity in αvβ6+ cells. 
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The pioneering vector ‒ Ad5.3D.A20 ‒ generated in this thesis has proved superior 
to its parental Ad5 vector in preliminary in vitro and ex vivo studies. As a logical next 
step, we sought to rule out the possibility of any unexpected tropisms or uptake by 
previously undocumented off-target sites following systemic delivery of the 
Ad5.3D.A20 vector in non-tumour-bearing B6 albino mice that are not known to 
express αvβ6. Ad5.3D.A20 had an extensively altered tropism profile compared to the 
parental Ad5 vector in the primary off-target sites ‒ liver, spleen and lungs. Both in 
vivo IVIS imaging and ex vivo imaging of individual organs showed remarkably 
decreased luciferase transgene expression; luminescence intensity was ~ 20 000-fold 
lower in live mice, ~ 14 000-fold lower in the liver, ~ 10 000-fold lower in the spleen 
and ~ 4000-fold lower in the lungs of the Ad5.3D.A20-infected mice than of the Ad5-
infected mice. The viral genome copy number of Ad5.3D.A20 was seven logs lower 
than that of Ad5 in the liver, and four logs lower in the spleen. The absence of 
Ad5.3D.A20 vector in the liver was confirmed by IHC staining. It is not clear where 
these virions are trafficked upon systemic delivery. We are developing a means of 
tracing virions using PET imaging and zirconium-89 labelling in collaboration with Dr 
Stephen Paisey (Wales Research and Diagnostic PET Imaging Centre, Cardiff 
University). Dual tracing using both PET and IVIS could more accurately establish 
viral fate in the early stages following systemic delivery. Future investigations could 
also involve studying biodistribution of the Ad5.3D.A20 vector in MΦ-depleted 
(clodronate liposome-treated) mice to dissect the possibility of liver MΦ involvement 
in the early stages of infection. 
In this thesis, we used the ovarian-ascites derived SKOV3 as a representative 
EOC line. SKOV3 has been shown to exhibit high level of p53 mutations (Yaginuma 
and Westphal, 1992). For this reason, it is an excellent ovarian cancer model cell line 
since approaching 100 % of HGS-OCs have been shown to have mutations in TP53 
in high-throughput genomic analyses of the cancer genome (Bell et al., 2011). We 
have established i.p. tumour xenografts with SKOV3 cells modified to express a 
cancer specific integrin, αvβ6. This model will be used for the assessment of the 
oncolytic efficacy of αvβ6-targeted OAds at Prof Richard Vile’s laboratory at Mayo 
Clinic, Rochester, MN, USA in spring 2017. However, studying human cancer in an 
immunocompromised mouse model hardly represents the disease observed in 
humans, which is why better models are urgently required to assess the 
immunological aspect of oncolytic virotherapies. In this project, we were very lucky to 
receive extremely valuable ascites samples from ovarian cancer patients who were 
undergoing chemotherapy for an advanced disease at a local cancer hospital in 
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Cardiff. In this thesis, ex vivo culture of clinical ovarian ascites-derived EOC cells in 
the presence of autologous ascitic fluid was the most closely representative of the 
clinical scenario, although it is obvious that these model systems are lacking in many 
aspects of the TME, including blood supply and immune suppression. Better means 
are needed to address the maturation of the immune response, both against the virus 
and any virally encoded immunological transgenes. The utilisation of clinical samples 
gave us an advantage for being one step closer to potential clinical assessment of 
these therapies. Further vector development in improved model systems, such as 3D 
spheroids and organoid cultures in collaboration with local experts (CardiffUni, 2016), 
is likely to provide closer insight into the suitability of these vectors for cancer 
therapies. Furthermore, we are in the process of establishing collaborations for the 
utilisation of patient-derived xenograft (PDX) models for oncolytic vector assessment. 
This thesis describes a novel and exciting approach for oncolytic anti-cancer Ad 
vector design for ovarian cancer targeting. We chose the αvβ6 integrin as the cellular 
cancer-specific target due to the well-characterised nature of the A20 peptide and 
αvβ6 interaction, and the cancer-specificity of αvβ6. This receptor, however, is not 
restricted to ovarian cancer, and therefore the Ad5.3D.A20 has great potential for use 
in a multitude of cancer types. Most remarkably, 92 % of cervical cancers and 84 % 
of skin cancers have been shown to express αvβ6 (Koopman Van Aarsen et al., 
2008), and therefore may represent better targets. Future studies could potentially 
consist of screening suitable cancer types, and the development of clinically relevant 
model systems. Ad5.3D.A20 could form a useful platform for a wider range of 
targeting applications beyond the αvβ6:A20 interaction, where a suitable 
peptide:receptor interaction is documented.  
Vectors intended for cancer virotherapy require transcriptional control, in addition 
to the transductional targeting approach described in this thesis. The OAds generated 
in this study have been modified to selectively replicate in cells with a defective pRB 
pathway, which comprises most cancers (Sherr, 1996). The inclusion of tumour-
specific promoters and/or miRNA binding sites could further prevent expression of 
therapeutic transgenes in off-target tissues. Additionally, the vector may be armed 
with therapeutic molecules for stimulation of anti-cancer immunity, such as the 
checkpoint inhibitor anti-CTLA4 and anti-PD-1 mAbs, whose efficacy has been 
demonstrated in countless clinical studies for multiple indications in the recent years. 
These vectors are currently being developed in our laboratory, and warrant further 
assessment for their immune-oncolytic potential both in ovarian cancer and other 
cancer types. There is vast potential for arming the OAds with virtually any moieties 
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that can be converted into therapeutically active agents, once within the TME. 
Multimodal approach to cancer eradication in combination with radio- and 
chemotherapy is likely to pave the way in effective cancer eradication. Targeting the 
exciting cancer marker, αvβ6 integrin, with oncolytic vectors in innovative 
combinations together with biological agents, therapeutic antibodies and 
radiotherapy, has unleashed potential whose clinical adaptation and anti-cancer 
efficacy remains to be seen in the near future. 
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